0001193125-13-442024.txt : 20131114 0001193125-13-442024.hdr.sgml : 20131114 20131114153608 ACCESSION NUMBER: 0001193125-13-442024 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20130930 FILED AS OF DATE: 20131114 DATE AS OF CHANGE: 20131114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Q Therapeutics, Inc. CENTRAL INDEX KEY: 0001366541 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 203708500 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-52062 FILM NUMBER: 131219641 BUSINESS ADDRESS: STREET 1: 615 ARAPEEN DRIVE STREET 2: SUITE 102 CITY: SALT LAKE CITY STATE: UT ZIP: 84108 BUSINESS PHONE: (801) 582-5400 MAIL ADDRESS: STREET 1: 615 ARAPEEN DRIVE STREET 2: SUITE 102 CITY: SALT LAKE CITY STATE: UT ZIP: 84108 FORMER COMPANY: FORMER CONFORMED NAME: Q Holdings, Inc. DATE OF NAME CHANGE: 20111208 FORMER COMPANY: FORMER CONFORMED NAME: Grace 2, Inc. DATE OF NAME CHANGE: 20060619 10-Q 1 d601481d10q.htm 10-Q 10-Q
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549 

 

 

FORM 10-Q

 

 

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2013

OR

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission file number: 000-52062

 

 

Q THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Delaware   20-3708500

(State or Other Jurisdiction of

Incorporation or Organization)

  

(I.R.S. Employer

Identification Number)

615 Arapeen Drive, Suite 102

Salt Lake City, UT

   84108
(Address of Principal Executive Offices)   (Zip Code)

(801) 582-5400

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name, Former Address and Former Fiscal Year, If Changed Since Last Report)

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “non-accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer   ¨    Accelerated filer   ¨
Non-accelerated filer   ¨  (Do not check if a smaller reporting company)    Smaller reporting company   x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

As of November 14, 2013, there were 24,936,833 shares of Common Stock, $0.0001 par value per share, issued and outstanding.

 

 

 

Table of Contents

Q Therapeutics, Inc.

(A Development Stage Company)

TABLE OF CONTENTS

 

PART 1 – FINANCIAL INFORMATION

   

Item 1. Financial Statements (Unaudited)

   

Condensed Consolidated Balance Sheets (Unaudited)

      1   

Condensed Consolidated Statements of Operations (Unaudited)

      2   

Condensed Consolidated Statements of Cash Flows (Unaudited)

      3   

Notes to Condensed Consolidated Financial Statements (Unaudited)

      5   

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

      10   

Item 3. Quantitative and Qualitative Disclosures about Market Risk

      13   

Item 4. Controls and Procedures

      13   

PART II – OTHER INFORMATION

   

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

      14   

Item 6. Exhibits

      14   

Signatures

      15   

Table of Contents

Q Therapeutics, Inc.

(A Development Stage Company)

PART I

Item 1. Financial Statements

Condensed Consolidated Balance Sheets (Unaudited)

 

     September 30,     December 31,  
     2013     2012  

Assets

     

Current assets:

     

Cash

    $ 330,365      $ 794,207   

Receivables, net of allowance of $28,800 as of September 30, 2013 and December 31, 2012

      15,667        477,802   

Prepaid financing costs, net

      188,333        —     

Prepaid expenses and other

      2,800        10,366   
  

 

 

    

 

 

  

Total current assets

      537,165        1,282,375   

Property and equipment, net

      30,222        16,044   

Other assets

      7,513        7,513   
  

 

 

    

 

 

  

Total assets

    $ 574,900      $ 1,305,932   
  

 

 

    

 

 

  

Liabilities and Stockholders’ Equity (Deficit)

     

Current liabilities:

     

Accounts payable

    $ 2,236,896      $ 1,203,365   

Accrued liabilities

      69,781        9,685   

Accrued compensation

      232,522        87,892   

Notes payable

      500,000        —     
  

 

 

    

 

 

  

Total current liabilities

      3,039,199        1,300,942   
  

 

 

    

 

 

  

Stockholders’ equity (deficit):

     

Common stock, $0.0001 par value: 100,000,000 shares authorized; 24,936,833 and 24,761,832 shares outstanding as of September 30, 2013 and December 31, 2012, respectively

      2,494        2,476   

Additional paid-in capital

      20,790,758        20,494,792   

Accumulated deficit

      (23,257,551 )      (20,492,278 ) 
  

 

 

    

 

 

  

Total stockholders’ equity (deficit)

      (2,464,299 )      4,990   
  

 

 

    

 

 

  

Total liabilities and stockholders’ equity (deficit)

    $ 574,900      $ 1,305,932   
  

 

 

    

 

 

  

See accompanying notes to condensed consolidated financial statements.

 

1

Table of Contents

Q Therapeutics, Inc.

(A Development Stage Company)

Condensed Consolidated Statements of Operations (Unaudited)

 

     For the Three Months Ended
September 30,		     For the Nine Months Ended
September 30,		     Cumulative
From		  
     2013     2012     2013     2012     Inception  

Grant revenues

    $ —        $ —        $ 12,286      $ 7,229      $ 1,102,545   

License fees and other revenues

      12,000        —          12,000        —          294,900   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Total operating revenues

      12,000        —          24,286        7,229        1,397,445   

Cost of revenues

      4,800        —          4,800        —          4,800   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Gross profit

      7,200        —          19,486        7,229        1,392,645   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Operating expenses:

           

Research and development

      1,371,644        283,141        1,642,591        764,810        12,615,483   

General and administrative

      326,649        317,961        1,078,239        1,049,249        10,197,474   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Total operating expenses

      1,698,293        601,102        2,720,830        1,814,059        22,812,957   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Operating loss

      (1,691,093 )      (601,102 )      (2,701,344 )      (1,806,830 )      (21,420,312 ) 
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Other income (expense):

           

Interest income

      —          1,023        —          3,212        187,616   

Interest expense

      (66,158 )      (2,136 )      (66,808 )      (5,580 )      (2,178,222 ) 

Other income, net

      991        769        2,879        2,130        153,367   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Total other income (expense), net

      (65,167 )      (344 )      (63,929 )      (238 )      (1,837,239 ) 
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Loss before provision for income taxes

      (1,756,260 )      (601,446 )      (2,765,273 )      (1,807,068 )      (23,257,551 ) 

Provision for income taxes

      —          —          —          —          —     
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Net loss

    $ (1,756,260 )    $ (601,446 )    $ (2,765,273 )    $ (1,807,068 )    $ (23,257,551 ) 
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Weighted average number of common shares outstanding—basic and diluted

      24,839,007        24,685,193        24,807,040        24,679,417     

Net loss per common share—basic and diluted

    $ (0.07 )    $ (0.02 )    $ (0.11 )    $ (0.07 )   

See accompanying notes to condensed consolidated financial statements.

 

2

Table of Contents

Q Therapeutics, Inc.

(A Development Stage Company)

Condensed Consolidated Statements of Cash Flows (Unaudited)

 

     For the Nine Months Ended
September 30,		     Cumulative
From		  
     2013     2012     Inception  

Cash flows from operating activities:

       

Net loss

    $ (2,765,273 )    $ (1,807,068 )    $ (23,257,551 ) 

Adjustments to reconcile net loss to net cash used in operating activities:

       

Depreciation and amortization

      9,624        14,088        401,271   

Original debt discount

      —          —          450,000   

Accretion of debt costs and beneficial conversion feature

      61,667        —          1,298,930   

Stock-based compensation

      76,316        95,912        508,117   

Debt issued for services

      —          110,360        90,000   

Common stock issued for services

      175,000        10,000        331,750   

Preferred stock issued for services

      —          —          44,750   

Warrants issued for services

      44,668        —          57,754   

Provision for losses on receivables

      —          (2,282 )      (43,677 ) 

Decrease (increase) in:

       

Receivables

      462,135        26,839        28,010   

Prepaid expenses and other assets

      7,566        (5,465 )      (10,313 ) 

Increase (decrease) in:

       

Accounts payable and other liabilities

      1,093,627        (73,110 )      2,705,796   

Accrued compensation

      144,630        10,919        232,522   
  

 

 

    

 

 

    

 

 

  

Net cash used in operating activities

      (690,040 )      (1,619,807 )      (17,162,641 ) 
  

 

 

    

 

 

    

 

 

  

Cash flows from investing activities:

       

Purchase of property and equipment

      (23,802 )      (2,363 )      (431,273 ) 
  

 

 

    

 

 

    

 

 

  

Cash flows from financing activities:

       

Proceeds from issuance of notes payable

      250,000        —          5,507,562   

Payments on short-term note payable

      —          (15,000 )      (90,000 ) 

Issuance of preferred stock for cash

      —          —          8,671,747   

Issuance of common stock for cash

      —          190,000        3,821,137   

Proceeds from exercise of common stock options

      —          1,800        11,600   

Proceeds from exercise of preferred stock warrants

      —          —          2,233   
  

 

 

    

 

 

    

 

 

  

Net cash provided by financing activities

      250,000        176,800        17,924,279   
  

 

 

    

 

 

    

 

 

  

Net (decrease) increase in cash

      (463,842 )      (1,445,370 )      330,365   

Cash as of beginning of the period

      794,207        2,741,519        —     
  

 

 

    

 

 

    

 

 

  

Cash as of end of the period

    $ 330,365      $ 1,296,149      $ 330,365   
  

 

 

    

 

 

    

 

 

  

Supplemental disclosure of cash flow information:

       

Cash paid for interest

    $ 866      $ —        $ 8,537   

Non cash financing activities:

       

Debt discount related to bridge financing

    $ 250,000      $ —        $ 250,000   

See accompanying notes to condensed consolidated financial statements.

 

3

Table of Contents

Q Therapeutics, Inc.

(A Development Stage Company)

 

Condensed Consolidated Statements of Cash Flows (Unaudited) Continued

 

Supplemental disclosure of noncash investing and financing activities for the period from March 28, 2002 (date of inception) to September 30, 2013:

 

  •   The Company issued 219,658 shares of common stock in exchange for technology valued at $220.

 

  •   The Company converted $1,050,000 of notes payable and $29,691 of accrued interest to 482,008 shares of Series A2 preferred stock.

 

  •   The Company converted $3,740,000 of notes payable and $370,346 of accrued interest to 1,787,104 shares of Series B preferred stock.

 

  •   The Company recorded a debt discount of $1,237,263 related to preferred stock warrants issued with debt and the beneficial conversion feature.

 

  •   The Company converted $900,000 of bridge notes payable and $16,644 of accrued interest to 916,644 shares of common stock.

 

  •   The Company converted 250,000 shares of Series A1 preferred stock, 2,022,190 shares of Series A2 preferred stock, and 4,102,654 shares of Series B preferred stock to 13,791,231 shares of common stock.

 

  •   Two stockholders forfeited, and the Company retired, 200,000 shares of common stock with a net impact on equity of $19 as a result of untimely payments on their notes.

See accompanying notes to condensed consolidated financial statements.

 

4

Table of Contents

Q Therapeutics, Inc.

(A Development Stage Company)

Notes to Condensed Consolidated Financial Statements (Unaudited)

1. Organization

Q Therapeutics, Inc. (Q) conducts its operations through its wholly owned subsidiary, Q Therapeutic Products, Inc. (Q Products) and its wholly owned subsidiary, NeuroQ Research, Inc (collectively, Q Therapeutics or the Company). Q Therapeutics is a Salt Lake City, Utah-based biopharmaceutical company that is developing human cell-based therapies intended to treat degenerative diseases of the brain and spinal cord, the primary components of the central nervous system (CNS). Q Products was incorporated in the state of Delaware on March 28, 2002, and merged with Q Acquisition, Inc., a Delaware corporation and a wholly owned subsidiary of Grace 2, Inc., on October 13, 2011. Grace 2, Inc. was incorporated on October 27, 2005. On November 2, 2011, Grace 2 changed its name to Q Holdings, Inc., and on December 10, 2012, it changed its name to Q Therapeutics, Inc.

The technology upon which these potential therapies is based was developed by Q’s co-founder Mahendra Rao, M.D., Ph.D., a leader in glial stem cell biology, during his tenure at the University of Utah and as Head of the Stem Cell Section at the National Institutes of Health (NIH). Dr. Rao was one of the first scientists to identify and seek patent coverage on stem cells and their progeny cells found in the CNS. After licensing Dr. Rao’s technology from the University of Utah and NIH, Q commenced operations in the spring of 2004 to develop cell-based therapeutic products that can be sold as “off-the-shelf” pharmaceuticals.

2. Significant Accounting Policies

The following significant accounting policies are followed by the Company in preparing its consolidated financial statements:

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of Q Therapeutics have been prepared in accordance with the instructions to Form 10-Q and, therefore, do not include all information and notes necessary for a complete presentation of financial position, results of operations, and cash flows in conformity with U.S. generally accepted accounting principles (US GAAP). This report on Form 10-Q should be read in conjunction with the Company’s annual report on Form 10-K for the year ended December 31, 2012.

The accompanying unaudited condensed consolidated balance sheets, statements of operations, and statements of cash flows reflect all normal recurring adjustments that are, in the opinion of management, necessary for a fair presentation of the Company’s financial position, results of operations and cash flows. The results of operations for the nine-month period ended September 30, 2013 are not necessarily indicative of the results to be expected for the full year ending December 31, 2013.

Basis of Consolidation

The accompanying unaudited condensed consolidated financial statements include the accounts of Q and its wholly owned subsidiary, Q Products, and Q Products’ wholly owned subsidiary, NeuroQ Research Inc. The Company is a development stage company engaged in the discovery, research, development and eventual commercialization of products as potential treatments for debilitating and fatal diseases of the CNS. All significant intercompany amounts have been eliminated.

Development Stage and Liquidity

For the period from March 28, 2002 (date of inception) through September 30, 2013, the Company has not generated significant revenues and has been developing its products. Therefore, the Company is considered to be in the development stage in accordance with the provisions of Accounting Standards Codification (ASC) Topic 915, Development Stage Entities. Cumulative amounts are presented for the period from March 28, 2002 (date of inception) through September 30, 2013. Historically, the Company has been dependent on government grants and debt and equity raised from investors to sustain its operations. The Company expects to continue to fund its operations through similar sources of capital. There can be no assurance that such capital will be available on favorable terms or at all. If it is unable to raise additional capital, the Company will likely be forced to curtail desired development activities, which will delay the development of its product candidates. The Company’s products have not been approved by the U.S. Food and Drug Administration (FDA) for commercial sale; therefore, the Company has not generated revenues from commercial therapeutic product sales. The Company has incurred losses and used cash for operating activities since inception. As of September 30, 2013, the Company had an accumulated deficit of $23,257,551.

Given the current pace of pre-clinical and clinical development of its product candidates, management believes that the Company has sufficient resources to fund the Company’s operations through at least December 31, 2013. However, the Company will require additional cash resources during the first quarter of 2014. The Company is working to raise capital through the sale of common stock and filed a registration statement on June 20, 2013 with the Securities and Exchange Commission registering the offering and sale of 5,000,000 shares of its common stock with warrants to purchase up to 1,250,000 shares of common stock. The Company has not raised any capital through the sale of common stock during 2013.

 

5

Table of Contents

Q Therapeutics, Inc.

(A Development Stage Company)

Notes to Condensed Consolidated Financial Statements Continued

 

Use of Estimates

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Accordingly, actual results could differ from those estimates. Key estimates include allowances for doubtful accounts receivable, useful lives for property and equipment, valuation allowances for net deferred income tax assets, and valuations for stock-based compensation awards. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances.

Revenue Recognition and Grants Receivable

The Company periodically applies for research grants, including as a sub-recipient to grants funded by government agencies through research universities. Grant revenues are recognized as associated expenses are incurred and are billed in conjunction with the terms of the grants. The Company records its grants receivable in accordance with the provisions of the grant agreements. The Company’s grants receivable are considered past due when payment has not been received within 30 days of the invoice date, although certain institutions customarily do not pay within 30 days of the invoice date. The amounts of the specific reserves are estimated by management based on various assumptions including the age of the individual receivable, as well as changes in payment schedules and histories. Grants receivable balances are charged off against the allowance for doubtful accounts when management determines the potential for recovery is remote. Recoveries of receivables previously charged off are recorded when payment is received. For the nine months ended September 30, 2013, revenues were derived from two customers.

In December 2012, the Company was notified of a sub-award as part of grant funding awarded to The Johns Hopkins University (JHU) from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health. The sub-award for the 2012-2013 grant plan year is $631,383. In May 2013, JHU applied for, and was granted a six-month extension for completing the analysis and remitting data and expenses. As of September 30, 2013, $491,588 has been invoiced under the sub-award and $3,667 is included in the grants receivable balance. The balance outstanding is expected to be paid upon the completion of the extension.

Stock-Based Compensation

The Company calculates the estimated fair value of its stock options and warrants on the grant date using the Black-Scholes option-pricing model. The Company recognizes stock-based compensation expense as services are provided, which is generally over the vesting period of the individual equity instruments. Expense related to stock options issued in lieu of cash to non-employees for services performed are measured at the fair value of the options on the date they are earned.

The volatility assumption used in the Black-Scholes option-pricing model is based on the volatility of publicly traded companies in the same industry segment as the Company. The expected lives of the options and warrants granted represent the periods of time that the options granted are expected to be outstanding. The risk free rates for periods within the contractual lives of the options and warrants are based on the U.S. treasury securities constant maturity rate that corresponds to the expected terms in effect at the time of grant. Stock-based compensation is included in general and administrative expense in the statements of operations.

Net Loss Per Common Share

Basic net income or loss per common share (Basic EPS) is computed by dividing net income or loss by the weighted average number of common shares outstanding. Diluted net income or loss per common share (Diluted EPS) is computed by dividing net income or loss by the sum of the weighted average number of common shares outstanding and the dilutive potential common share equivalents then outstanding. Potential dilutive common share equivalents consist of shares issuable upon the exercise of outstanding stock options and warrants to acquire common stock.

Due to the fact that for all periods presented the Company has incurred net losses, potential dilutive common share equivalents as of September 30, 2013 and 2012, totaling 16,107,458 and 15,072,509, respectively, are not included in the calculation of Diluted EPS because they are anti-dilutive. Therefore, basic net loss per common share is the same as diluted net loss per common share for the three and nine months ended September 30, 2013 and 2012.

Recent Accounting Pronouncements

The Company has reviewed accounting pronouncements that become effective subsequent to September 30, 2013 and does not believe the future adoption of those pronouncements will have a material impact on the Company’s financial position, results of operations or liquidity.

 

 

6

Table of Contents

Q Therapeutics, Inc.

(A Development Stage Company)

Notes to Condensed Consolidated Financial Statements Continued

 

3. Accrued Compensation

Accrued compensation consists of the following:

 

     September 30, 2013      December 31, 2012  

Accrued wages

    $ 162,531       $ 17,046   

Accrued vacation

      69,991         70,846   
  

 

 

     

 

 

  

Total accrued compensation

    $ 232,522       $ 87,892   
  

 

 

     

 

 

  

Starting in March 2013, certain of the Company’s executives agreed to defer part, if not all, of their salaries until additional funding is obtained.

4. Notes Payable

Between August 12 and September 30, 2013, the Company received $250,000 in cash proceeds resulting from a bridge financing by a group of note holders, some of which are also stockholders that are considered affiliates, as evidenced by promissory notes (Notes). The Notes were issued at 50% of face value, bear interest at the rate of 8% per annum, and are due in full beginning February 5, 2014. Notes payable as of September 30, 2013 are $500,000. To date, the Company has recorded interest relating to the note of $65,942, of which almost all pertains to the amortization of the debt discount with an additional $188,333 of debt discount costs to be amortized over the remaining term of the note. As of September 30, 2013, no payments towards principal or interest had been made.

The effective interest rate related to this financing is approximately156%.

5. Stockholders’ Equity

Common Stock

During the nine months ended September 30, 2013, the Company issued 75,001 shares of its common stock with an estimated fair value of $75,001 to an investor and public relations firm in lieu of cash for services rendered during the period. In September 2013, the Company issued 100,000 shares of its common stock with an estimated fair value of $100,000 related to a licensing agreement with a collaborative partner. As of September 30, 2013, 24,936,833 shares of common stock are outstanding.

Stock Options

The following summarizes the outstanding common stock options and related activity for the nine months ended September 30, 2013:

 

            Weighted  
     Number of      Average Exercise  
     Options      Price Per Share  

Outstanding as of December 31, 2012

      3,865,440       $ 0.34   

Granted

      —           —     

Exercised

      —           —     

Forfeited

      —           —     
  

 

 

     

Outstanding as of September 30, 2013

      3,865,440         0.34   
  

 

 

     

Exercisable as of September 30, 2013

      3,388,773         0.25   
  

 

 

     

On December 18, 2012, the Board of Directors approved, subject to stockholder approval, the addition of 3,000,000 shares to the 2011 Equity Incentive Compensation Plan (the Plan). On May 6, 2013, stockholders representing 69% of the issued and outstanding voting common stock of the Company accepted the Board of Directors’ recommendation and provided their written consent to approve these additional 3,000,000 shares of common stock of the Company to the pool of shares reserved for issuance under the Plan, increasing

 

7

Table of Contents

Q Therapeutics, Inc.

(A Development Stage Company)

Notes to Condensed Consolidated Financial Statements Continued

 

the number of shares from 1,877,529 to 4,877,529 shares. As of September 30, 2013, options to purchase 3,987,529 shares of common stock under the Plan were available for future grant. The following summarizes information about stock options outstanding as of September 30, 2013:

 

        Weighted            
        Average   Weighted       Weighted
    Numbers of   Remaining   Average   Number of   Average
Exercise   Options   Contractual   Price   Options   Price

Price

  

Outstanding

  

Life (Years)

  

Exercise

  

Exercisable

  

Exercise

$0.06 – $0.08   902,600   5.58   $0.08   902,600   $0.08
$0.15 – $0.19   2,072,840   5.70   0.17   2,072,840   0.17
$1.00   890,000   8.34   1.00   413,333   1.00
 

 

      

 

  
  3,865,440   6.28   0.34   3,388,773   0.25
 

 

      

 

  

As of September 30, 2013, the aggregate intrinsic value of outstanding and exercisable stock options was $2,549,625.

Stock-based compensation for the three months ended September 30, 2013 and 2012 was $25,439 and $40,445, respectively. Stock-based compensation for the nine months ended September 30, 2013 and 2012 was $76,316 and $95,912, respectively. As of September 30, 2013, the Company had $219,439 of unrecognized stock-based compensation expense related to non-vested awards that will be recognized over a weighted-average period of 2.3 years.

Warrants

In October 2012, the Company entered into a service agreement with an investor relations and public advisory firm. As part of the agreement, the service provider was entitled to receive up to 250,000 warrants to purchase common stock at prices ranging from $1.25 to $2.75 per share with a term of two years. The warrants are immediately exercisable upon issuance. On January 1, 2013, the first tranche of 62,500 warrants was issued with an exercise price of $1.25. On April 1, 2013, the second tranche of 62,500 warrants were issued with an exercise price of $1.75. On July 1, 2013, the third tranche of 62,500 warrants were issued with an exercise price of $2.25.

As of September 30, 2013, 12,242,018 warrants to purchase common stock had been issued with exercise prices ranging from $.046 to $2.25 per share and terms ranging from two to seven years. The weighted average warrant exercise price is $1.40 and the weighted average remaining life is 4.7 years.

6. Commitments and Contingencies

Supplier Agreements

In March 2010, the Company entered into a service agreement with an outside research firm to support the Company’s preclinical Good Laboratory Practice (GLP) safety studies.

In November 2012, the Company and the supplier amended the terms of their original agreement via a Letter of Understanding and increased the total purchase commitment with the supplier to approximately $2,600,000 with an expected completion by year-end 2013. Upon conclusion of the supplier’s final project report, any outstanding balance will be converted into a note payable accruing interest at 8% until July 31, 2015. Any outstanding amounts thereafter shall accumulate interest at 10% through March 31, 2016. Should the Company be successful in obtaining additional financing, the amendment calls for a percentage of the funds raised to immediately pay down the outstanding balance. As of September 30, 2013, the amount owed under this agreement totaled $2,136,730 and is included in accounts payable. The supplier also was granted, upon successful completion of the clinical study, a right of first negotiation on any future preclinical GLP safety to toxicology studies.

 

8

Table of Contents

Q Therapeutics, Inc.

(A Development Stage Company)

Notes to Condensed Consolidated Financial Statements Continued

 

Advisory Agreements

In February 2013, the Company entered into an agreement to engage a financial advisory firm for a minimum term of six months. The agreement was revised in May 2013. The financial advisory firm is entitled to a commission equal to 7% of the total proceeds raised by the Company from its financing efforts payable in cash; and if warrants are issued as part of the placement of securities, an issuance of warrants equivalent to 1% of the aggregate number of warrants purchased in the offering, collectively not to exceed 8%. Additionally, the Company shall reimburse reasonable out-of-pocket expenses. To date, no placement of securities has occurred.

In July 2013, the Company entered into a business consulting services agreement effective through December 31, 2015. Under the agreement, the Company issued an initial payment of a warrant to purchase 75,000 shares of common stock at a strike price of $1.01 per share, with a five-year life and a cashless exercise option. The business consulting firm is entitled to receive additional warrants for up to 100,000 shares of common stock with similar terms.

7. Related Party Transactions

Between August 12 and September 30, 2013, the Company received $250,000 in cash proceeds resulting from a bridge financing by a group of note holders, which included both an officer and an affiliate. The officer has since transferred ownership of the note to an affiliate.

 

9

Table of Contents

Q Therapeutics, Inc.

(A Development Stage Company)

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS

The following discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations and intentions. Our actual results and the timing of events could differ materially from those anticipated as a result of a number of factors, including those set forth under the Risk Factors, Cautionary Notice Regarding Forward-Looking Statements and Business sections in our 2012 Annual Report on Form 10-K filed with the Securities and Exchange Commission. The following discussion of our financial condition and results of operations should be read with our unaudited consolidated financial statements and the related notes included elsewhere in this Form 10-Q. We use words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions to identify forward-looking statements.

Company Overview

Q Therapeutics, Inc. conducts its operations through its wholly owned subsidiary, Q Therapeutic Products, Inc. (Q Products) and its wholly owned subsidiary, NeuroQ Research, Inc. (collectively, Q or the Company). Q Therapeutics is a Salt Lake City, Utah-based biopharmaceutical company that is developing human cell-based therapies intended to treat degenerative diseases of the brain and spinal cord, the primary components of the central nervous system (CNS). Q Products was incorporated in the state of Delaware on March 28, 2002, and merged with Q Acquisition, Inc., a Delaware corporation and a wholly owned subsidiary of Grace 2, Inc., on October 13, 2011. Grace 2, Inc. was incorporated on October 27, 2005. On November 2, 2011, Grace 2 changed its name to Q Holdings, Inc., and on December 10, 2012, it changed its name to Q Therapeutics, Inc.

The technology upon which these therapies are based was developed by Q’s co-founder, Mahendra Rao, M.D., Ph.D., a global leader in glial stem cell biology, during his tenure as a Professor at the University of Utah and as Head of the Stem Cell Section at the National Institutes of Health. Q is managed by an experienced team of biotechnology executives with demonstrated start-up success and advised by leaders in the neurology and stem cell therapeutics fields.

Every year, hundreds of thousands of people suffer with debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig’s disease), Multiple Sclerosis (MS), Transverse Myelitis (TM) and Spinal Cord Injury (SCI). Traditional drugs tend to fail to treat the nerve damage caused by these diseases due to the multifactorial nature of these diseases and the inability of most drugs to address all of these factors. Q is developing a new and non-traditional approach targeted to improve the health of people suffering from neurodegenerative diseases: a human cell-based product called Q-Cells®.

Q-Cells are healthy human glial cells. The role of glial cells in the brain and spine is to support and protect neurons, which form the signal transmission lines of the central nervous system. Glial cells perform many functions including forming an insulating “myelin sheath” around neuronal axons providing the necessary growth factors needed to maintain a healthy nervous system, and removing compounds that are toxic to neurons. Many neurodegenerative diseases arise when glial cells are damaged or destroyed, causing neurons to malfunction and eventually die. Q-Cells technology aims to treat neurodegenerative diseases by supplementing the damaged or missing glia in the central nervous system with new, healthy cells that can help maintain and/or restore neuron function to a more robust state.

The diseases targeted by Q’s products are not well treated with current drug therapies. At best, patients suffering from these diseases can, in some cases, only hope to slow their inexorable progression and the associated disabilities. A handful of companies are exploring the possibility of harnessing the power of stem or progenitors cells to treat these conditions, although no clear leader has emerged. In addition to utilizing its proprietary cellular products as therapeutic products, Q may evaluate novel ways to utilize these cells to screen for new drugs (such as small molecule compounds) that could also provide treatments for neurological diseases.

Q believes that a worldwide market exists for those companies whose cell-based treatments become commercial products. Q’s patent protected technology represents an opportunity to build on the recent advancements in the cell therapy field and bring to market a therapeutic approach that will change the way medicine is practiced in treating many disabling and fatal conditions of the central nervous system.

 

10

Table of Contents

Q Therapeutics, Inc.

(A Development Stage Company)

 

Results of Operations for the Three Months Ended September 30, 2013 compared to the Three Months Ended September 30, 2012:

For the period from March 28, 2002 (date of inception) through September 30, 2013, we have not generated significant revenues and have been focused on developing our products for therapeutic use for commercial sale. Q is considered to be a development stage company.

We have not generated revenues in excess of expenses and have been dependent on government grants and debt and equity raised from investors to sustain our operations. Our products have not yet been approved by the FDA for commercial sale, and as a result we have not generated revenues from therapeutic product sales. We have incurred losses and used cash in operating activities since inception. As of September 30, 2013, the Company had an accumulated deficit of $23,257,551 and negative working capital of $2,502,034.

Revenues

The Company has generated minimal revenues through (1) research grants from foundations and government agencies such as the National Institutes of Health (NIH), (2) granting rights to the Company’s technology to other entities, and (3) sales of its product for research purposes.

Grant revenues for the three months ended September 30, 2013 and 2012 were $0. A sub-award was approved in December 2012 for a total of $631,383 for the 2012-2013 grant budget year. To date, approximately $491,588 has been billed to NIH. We anticipate grant revenues to increase as we identify new opportunities for grants that are available and specific to our research of cell-based therapies.

License fees and other revenues for the three months ended September 30, 2013 and 2012, were $12,000 and $0, respectively. The increase was due to a sale of non-commercial products to a collaborative research partner.

Cost of Revenues

Cost of revenues for the three months ended September 30, 2013 and 2012 were $4,800 and $0, respectively. The increase is due to the cost of products sold to a collaborative research partner.

Research and Development Expenses

Q anticipates that development activities and costs will remain approximately the same as it advances the work necessary to complete our future Investigational New Drug (IND) submission. This includes Good Laboratory Practices (GLP) animal safety studies, injection device studies, manufacturing activities and working with clinical and regulatory consultants. Should additional financing be obtained, we may also increase research and development activities to evaluate use of our proprietary products in other disease indications, including working with outside collaborators.

Research and development expenses for the three months ended September 30, 2013, were $1,371,644, an increase of $1,088,503, or 384.4%, from $283,141 for the three months ended September 30, 2012. The increase is primarily due to the costs associated with the near completion of our safety studies.

General and Administrative Expenses

The following table details the general and administrative expenses incurred by the Company for the three months ended September 30, 2013 and 2012:

 

     For the Three Months               
     Ended September 30,               
     2013      2012      Change     %  

Salaries and benefits

    $ 131,989       $ 152,547       $ (20,558 )      -13.5 % 

Legal and professional fees

      118,120         84,583         33,537        39.6 % 

Facility and office related

      43,358         35,950         7,408        20.6 % 

Stock-based compensation

      25,439         40,445         (15,006 )      -37.1 % 

Travel and entertainment

      7,176         3,969         3,207        80.8 % 

Depreciation

      567         467         100        21.4 % 
  

 

 

     

 

 

     

 

 

    

Total general and administrative expenses

    $ 326,649       $ 317,961       $ 8,688        2.7 % 
  

 

 

     

 

 

     

 

 

    

 

 

11

Table of Contents

Q Therapeutics, Inc.

(A Development Stage Company)

 

Results of Operations for the Nine Months Ended September 30, 2013 compared to the Nine Months Ended September 30, 2012:

Revenues

Grant revenues for the nine months ended September 30, 2013 and 2012 were $12,286 and $7,229, respectively. The increase was primarily due to being the recipient of a sub-award of an NIH grant issued to The Johns Hopkins University. License fees and other revenues for the nine months ended September 30, 2013 and 2012, were $12,000 and $0, respectively. The increase was due to a sale of non-commercial products to a collaborative research partner.

Cost of Revenues

Cost of revenues for the nine months ended September 30, 2013 and 2012 were $4,800 and $0, respectively. The increase is due to the cost of products sold to a collaborative research partner.

Research and Development Expenses

Research and development expenses for the nine months ended September 30, 2013 were $1,642,591, an increase of $877,781, or 114.8%, from $764,810, for the nine months ended September 30, 2012. The increase is primarily due to the costs associated with the completion of our safety studies. We anticipate our research and development expenses will remain approximately the same as we continue our ongoing safety studies and until additional financing can be obtained.

General and Administrative Expenses

The following table details the general and administrative expenses incurred by the Company for the nine months ended September 30, 2013 and 2012:

 

     For the Nine Months              
     Ended September 30,              
     2013      2012     Change     %  

Salaries and benefits

    $ 451,418       $ 446,850      $ 4,568        1.0 % 

Legal and professional fees

      390,057         350,070        39,987        11.4 % 

Facility and office related

      139,278         132,982        6,296        4.7 % 

Stock-based compensation

      76,316         95,912        (19,596 )      -20.4 % 

Travel and entertainment

      19,570         24,339        (4,769 )      -19.6 % 

Depreciation

      1,600         1,378        222        16.1 % 

Bad debt expense

      —           (2,282 )      2,282        -100.0 % 
  

 

 

     

 

 

    

 

 

    

Total general and administrative expenses

    $ 1,078,239       $ 1,049,249      $ 28,990        2.8 % 
  

 

 

     

 

 

    

 

 

    

The increase in general and administrative expenses is primarily due to the preparation, review and filing of its Registration Statement on Form S-1 with the SEC on June 20, 2013. We anticipate general and administrative expenses to remain at approximately the same levels, or decrease as necessary due to our cash constraints, until further financing becomes available.

Liquidity and Capital Resources

For the nine months ended September 30, 2013, net cash used in operating activities totaled $690,040 compared to $1,619,807 for the nine months ended September 30, 2012. Cash outflows decreased in 2013 primarily due to the payment arrangement with a vendor for our safety studies, payment of professional services with Company securities in lieu of cash, and deferral in payment of executive salaries.

For the nine months ended September 30, 2013, net cash used in investing activities related to the purchase of lab and computer equipment totaled $23,802 compared to $2,363 for the nine months ended September 30, 2012.

For the nine months ended September 30, 2013, net cash provided by financing activities was $250,000 compared to $176,800 for the nine months ended September 30, 2012. Cash provided by financing activities was from the bridge financing that was completed in September 2013. Financing activities in 2012 related to cash proceeds of $190,000 from the private placement of the Company’s securities and the exercise of stock options for $1,800, offset by the repayment of a $15,000 note payable in the first nine months of 2012.

 

12

Table of Contents

Q Therapeutics, Inc.

(A Development Stage Company)

 

As of September 30, 2013, the Company had negative working capital of $2,502,034. Of the amount included in accounts payable, $2,136,730 is owed to a vendor and is not payable until the current project is completed, which is expected to be in the fourth quarter of 2013. Upon completion of the project, the Company will have the option to convert a portion of the balance owed to this vendor into equity with a note payable issued for the balance due by March 31, 2016.

Between August 12 and September 30, 2013, the Company received $250,000 in cash proceeds from a bridge financing. We believe that our current levels of cash, when combined with (1) our expected cash flows from grant revenues, and (2) reductions to our current operating expenses, will be sufficient to meet our liquidity needs through at least December 31, 2013; however, we will require additional cash resources during the first quarter of 2014 in order to continue the Company’s current operations. We will need additional cash resources in the future if we pursue opportunities for investment, acquisition, strategic cooperation or other similar actions. To satisfy future cash requirements, we expect to seek funding through government grants, the issuance of debt or equity securities and/or the obtaining of a credit facility. Any future issuance of equity securities would cause dilution for our stockholders. Any incurrence of indebtedness will increase our debt service obligations and may cause us to be subject to restrictive operating and financial covenants. It is possible that we will be unsuccessful securing future government grants and financing may not be available to us in amounts or on terms that are favorable to the Company or not available at all.

Recent Accounting Pronouncements

The Company has reviewed recently issued, but not yet effective, accounting pronouncements and does not believe the future adoption of any such pronouncements will have a material impact on the Company’s financial position, results of operations or liquidity.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Significant Accounting Policies

Significant accounting policies are those policies which are both important to the presentation of a company’s financial position and results of operations and require management’s most subjective or complex judgments. Often estimates are required to be made about matters that are inherently uncertain. No significant changes to our accounting policies occurred during the periods presented. For a further discussion of our significant accounting policies, see our Annual Report on Form 10-K for the year ended December 31, 2012.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

None.

Item 4. Controls and Procedures.

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our filings under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the periods specified in the rules and forms of the SEC. This information is accumulated and communicated to our executive officers to allow timely decisions regarding required disclosure. Our Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based upon that evaluation, our Chief Executive Officer and the Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of September 30, 2013.

No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934) occurred during the quarter ended September 30, 2013 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

 

13

Table of Contents

Q Therapeutics, Inc.

(A Development Stage Company)

 

PART II

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

In July, the Company issued a warrant to purchase 75,000 shares of its common stock at a strike price of $1.01 per share. The warrant has a five-year life, and provides for a cashless exercise option. The issuance of the securities was made to one party in a private offering exempt from registration in reliance on Section 4(2) of the Securities Act of 1933, as amended.

In September 2013, the Company issued 100,000 shares of its common stock with an estimated fair value of $100,000 related to a licensing agreement with a collaborative partner. The issuance of the securities was made to one party in a private offering exempt from registration in reliance on Section 4(2) of the Securities Act of 1933, as amended.

On October 15, 2013, the Company entered into an amendment of an agreement with an investor relations firm which extended the original service term through September 30, 2013. In lieu of cash, the investor relations firm received an additional 25,000 shares of common stock for services rendered from July 1, 2013 through September 30, 2013 as described below:

 

  •   8,333 shares of common stock issued on July 1 and August 1of 2013, and

 

  •   8,334 shares of common stock issued on September 1 of 2013.

The issuance of the securities was made to one party in a private offering exempt from registration in reliance on Section 4(2) of the Securities Act of 1933, as amended. Additionally, the Company agreed to issue up to 250,000 warrants between January 1, 2013 and October 1, 2013 based on achievement of time-based objectives, with exercise prices ranging between $1.25 and $2.75. Warrants to purchase 62,500 shares of common stock were issued and immediately vested on January 1, 2013 with an exercise price of $1.25. Warrants to purchase 62,500 shares of common stock were issued and immediately vested on April 1, 2013 with an exercise price of $1.75. Warrants to purchase 62,500 shares of common stock were issued and immediately vested on July 1, 2013 with an exercise price of $2.25.The warrants have a two-year life. The issuance of the securities was made to one party in a private offering exempt from registration in reliance on Section 4(2) of the Securities Act of 1933, as amended.

Item 6. Exhibits.

Index to Exhibits

 

Exhibit

  

Description

  10.1(1)   Form of Promissory Note
  31.1(1)   Certification of the Company’s Principal Executive Officer pursuant to 15d-15(e) under the Securities and Exchange Act of 1934, as amended, with respect to the registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2013.
  31.2(1)   Certification of the Company’s Principal Financial and Principal Accounting Officer pursuant to 15d-15(e) under the Securities and Exchange Act of 1934, as amended, with respect to the registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2013.
  32.1*   Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Principal Executive Officer ) and (Principal Financial Officer and Principal Accounting Officer).
101.INS   XBRL Instance Document
101.SCH   XBRL Taxonomy Extension Schema
101.CAL   XBRL Taxonomy Extension Calculation Linkbase
101.DEF   XBRL Taxonomy Extension Definition Linkbase
101.LAB   XBRL Taxonomy Extension Label Linkbase
101.PRE   XBRL Taxonomy Presentation Linkbase

 

(1) Filed herewith.
* Furnished herewith.

 

14

Table of Contents

Q Therapeutics, Inc.

(A Development Stage Company)

 

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 14, 2013   By: /s/ DEBORAH A. EPPSTEIN
 

Name: Deborah A. Eppstein, PhD

Title: Chief Executive Officer, President

(Principal Executive Officer)

Date: November 14, 2013   By: /s/ STEVEN J. BORST
 

Name: Steven J. Borst

Title: Vice President, Chief Financial Officer

(Principal Financial Officer

and Principal Accounting Officer)

 

15

EX-10.1 2 d601481dex101.htm EX-10.1 EX-10.1

Exhibit 10.1

THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO DISTRIBUTION OR RESALE.

Q THERAPEUTICS, INC.

PROMISSORY NOTE

 

$[                    ]

   

Salt Lake City, UT

            , 2013

1. Principal and Interest. Q Therapeutics, Inc., a Delaware corporation (the “Company”), for value received, hereby promises to pay to the order of [            ] or its assigns (the “Holder”) in lawful money of the United States, the principal amount of [            ] ($            ), together with interest (computed on the basis of a 360-day year) accrued on the unpaid principal of this Note at the rate of 8.00% per annum commencing on the date hereof with simple interest accruing. The initial purchase price of this Note shall be an amount equal to fifty percent (50.0%) of the original face or principal amount of this Note, as referenced above.

Unless the entire outstanding principal amount of this Note, together with all accrued but unpaid interest hereon, is converted in full in accordance with the provisions of Section 2 hereof, this Note, together with all accrued but unpaid interest thereon, is due and payable (a) on the first to occur of (i) that date which is 180 days subsequent to the date of execution of this Note; (ii) the occurrence of a Liquidity Event, as defined below (the first of such events to occur, the “Maturity Date”), or (b) on demand by written notice following an Event of Default. The Company shall, on the Maturity Date or, if earlier, within three (3) business days of receipt of the written notice referred to in the immediately preceding sentence (the “Payment Date”), pay the outstanding principal and all accrued and unpaid interest on this Note (as well as any other amounts payable hereunder) as of the Maturity Date or the Payment Date, as applicable. A “Liquidity Event” shall mean any of the following: (A) the consummation by the Company of a Qualified Financing as defined herein below, (B) the sale by the Company of all or substantially all of its assets, or (3) the acquisition by a third party of all of the outstanding equity interests of the Company or the consolidation or merger of the Company with or into any other corporation or other entity or person, or any other corporate reorganization, in which the shareholders of the Company immediately prior to such consolidation, merger or reorganization, own fifty percent (50%) or less of the Company’s voting power immediately after such consolidation, merger or reorganization.

The Company shall have one option to extend the Maturity Date of this Note for an additional 180 days by notifying the holder of this note in writing at least 10 business days prior to the original Maturity Date and paying an extension fee. The extension fee shall be an amount equal to 25.0% of the then outstanding principal and interest payable in the form of a note in a form similar to this Note (the new note shall not have an option to extend the Maturity Date). For the avoidance of doubt, in no case shall this Note’s Maturity Date exceed a date that is 360 days from the date hereof.

2. Optional Conversion. In the event of the closing by the Company of a Qualified Financing (as defined below) on the Maturity Date, should the Company and a majority of the Note Holders negotiate and mutually agree on terms converting this Note into a Qualified Financing (“Optional Conversion Terms”), the Company and Holder agree to convert all of the outstanding principal of, and accrued interest on, this Note into the shares of stock of the Company or its successor or affiliated entity issued and sold to the investors in the Qualified Financing (“QF Conversion Securities”) on the Optional Conversion Terms. A “Qualified Financing” shall mean the closing of an equity investment in the form of the Company’s capital stock occurring after the date hereof in which the Company receives from one or more investors (which investors may include the Holder) with gross proceeds to the Company of at least $3,000,000 (not including any debt conversion or cancellation of indebtedness unless allowed by investors in the Qualified Financing). Upon conversion of this Note in accordance with this Section 2, then the Holder shall become party to a purchase agreement and all related agreements, each in customary form, along with the investors participating in such Qualified Financing.

3. No Usury. This Note is hereby expressly limited so that in no event whatsoever, whether by reason of deferment or advancement of loan proceeds, acceleration of maturity of the loan evidenced hereby, or otherwise, shall the amount paid or agreed to be paid to the Holder hereunder for the loan, use, forbearance or detention of money exceed the maximum interest rate permitted by the laws of the State of Delaware or otherwise. If at any time the performance of any provision involves a payment exceeding the limit of the price that may be validly charged for the loan, use, forbearance or detention of money under applicable law, then automatically and retroactively, ipso facto, the obligation to be performed shall be reduced to such limit, it being the specific intent of the Company and the Holder hereof that all payments under this Note are to be credited first to interest as permitted by law, but not in excess of (i) the agreed rate of interest hereunder, or (ii) that permitted by law, whichever is the lesser, and the balance toward the reduction of principal.

4. Attorneys’ Fees. If the indebtedness represented by this Note or any part thereof is collected in any judicial proceedings or if this Note is placed in the hands of attorneys for collection after default, the Company agrees to pay, in addition to the principal and interest payable hereunder, reasonable attorneys’ fees and costs incurred by the Holder, as well as any and all interest that has accrued on the outstanding principal after the commencement of bankruptcy, receivership or other judicial proceedings.

5. Transfer.

(a) The rights and obligations of the Company and the Holder of this Note will be binding upon and inure to the benefit of the successors, assigns and transferees of the parties hereto.

(b) Notwithstanding the provisions of the legend appearing on the face of this Note, the Holder may, prior to payment in full hereof, and with the Company’s consent or approval at its sole discretion, surrender this Note at the principal office of the Company for transfer or exchange of all or any portion of this Note; provided, however, that such transferee to which all or a portion of this Note is transferred (i) shall be an accredited investor, as such term is defined in Rule 501 promulgated under the Securities Act of 1933, as amended (the “Securities

 

2

Act”), and (ii) shall agree in writing to be subject to the terms hereof to the same extent as if it were an original Holder. Within a reasonable time after notice to the Company by the Holder of its intention to make such exchange and without expense to the Holder, the Company shall issue in exchange therefor another note or notes for the same aggregate principal amount as the unpaid principal amount of the Note so surrendered, having the same rate of interest, containing the same provisions, and subject to the same terms and conditions as the Note so surrendered. Each such new Note shall be made payable to such person or persons, or transferees, as the Holder of such surrendered Note may designate in writing.

6. Notices. Any notice or other communication required or permitted hereunder shall be in writing and shall be faxed or delivered to each party to the facsimile number or its address set forth below (or to such other facsimile number or address as the recipient of any notice shall have notified the other in writing). All such notices and communications shall be effective (a) when delivered by Federal Express or other overnight courier service of recognized standing; or (b) when delivered by hand, upon delivery; and (c) when faxed, upon confirmation of receipt.

 

If to the Holder, to:   
   Ph
If to the Company, to:   

Q Therapeutics, Inc.

615 Arapeen Drive, Ste. 102

Salt Lake City, UT 84108

Ph (801) 582-5400

Fx (801) 582-5401

Attention: Chief Financial Officer

 

With a copy to:

P. Christian Anderson, Esq.

Ballard Spahr LLP

One Utah Center, Suite 800

Salt Lake City, UT 84111

Ph (801-517-6826

Fx (801) 531-3001

7. Event of Default.

(a) General. If an Event of Default (as defined below) occurs, the Holder may, by notice to the Company, declare the principal amount then outstanding of, and the accrued interest and all other amounts payable on, this Note to be immediately due and payable. The Company agrees to give the Holder of this Note written notice of the occurrence of an Event of Default promptly (setting forth in reasonable detail all facts related thereto).

 

3

(b) Definition. For purposes of this Note, an “Event of Default” is any of the following occurrences:

(i) The Company shall fail to pay the outstanding principal and all accrued and unpaid interest and all other amounts payable on this Note on the Maturity Date; or

(ii) The Company shall have breached any covenant in this Note (other than a payment default described in Section 7(b)(i)), and, with respect to breaches capable of being cured, such breach shall not have been cured within five (5) days following notice of such breach to the Company by the Holder; or

(iii) Any representation or warranty subject to a materiality qualification made by the Company herein or any other document referred to herein shall prove to have been incorrect in any respect, or any representation or warranty not subject to a materiality qualification made by the Company herein or in any other such document shall prove to have been incorrect in any material respect; or

(iv) The Company shall be involved in financial difficulties as evidenced (i) by its commencement of a voluntary case under Title 11 of the United States Bankruptcy Code as from time to time in effect, or by its authorizing, by appropriate proceedings of its Board of Directors or other pleading admitting or failing to deny the material allegations of a petition filed against it commencing an involuntary case under said Title 11, or seeking, consenting to or acquiescing in the relief therein provided, or by its failing to controvert timely the material allegations of any such petition, (ii) by the entry of an order for relief in any involuntary case commenced under said Title 11, which order is not rescinded within 60 days of the date of entry of such order, (iii) by its seeking relief as a debtor under any applicable law, other than said Title 11, of any jurisdiction relating to the liquidation or reorganization of debtors or to the modification or alteration of the rights of creditors, or by its consenting to or acquiescing in such relief, (iv) by the entry of an order by a court of competent jurisdiction (A) finding it to be bankrupt or insolvent, (B) ordering or approving its liquidation, reorganization or any modification or alteration of the rights of its creditors, or (C) assuming custody of, or appointing a receiver or other custodian for, all or a substantial part of its property, or (v) by its making an assignment for the benefit of, or entering into a composition with, its creditors, or appointing or consenting to the appointment of a receiver or other custodian for all or a substantial part of its property; or

(v) The Company shall take any action authorizing, or in furtherance of, any of the foregoing.

In case any one or more Events of Default shall occur and be continuing, the Holder may proceed to protect and enforce its rights by an action at law, suit in equity or other appropriate proceeding, whether for the specific performance of any agreement contained herein or for an injunction against a violation of any of the terms hereof, or in aid of the exercise of any power granted hereby or by law or otherwise. In case of a default in the payment of any principal of or premium, if any, or interest on this Note, the Company will pay to the Holder such further amount as shall be sufficient to cover the reasonable cost and expenses of collection, including, without limitation, reasonable attorneys’ fees, expenses and disbursements. No course of dealing and no delay on the part of the Holder in exercising any right, power or remedy shall operate as a

 

4

waiver thereof or otherwise prejudice the Holder’s rights, powers or remedies. No right, power or remedy conferred by this Note upon the Holder shall be exclusive of any other right, power or remedy referred to herein or now or hereafter available at law, in equity, by statute or otherwise.

8. Waivers and Amendments. The Company hereby waives presentment, demand for performance, notice of non-performance, protest, notice of protest and notice of dishonor. No delay on the part of the Holder in exercising any right hereunder shall operate as a waiver of such right or any other right. Any term of this Note may be amended or waived only with the written consent of the Company and the Holder. Notwithstanding the foregoing, in the event that at any time prior to date that this Note is paid in full or converted into QF Conversion Securities, the Company issues any additional convertible bridge notes on terms more favorable to the holders thereof than contained in this Note, than the terms and conditions of this Note shall automatically be deemed to be revised to correspond to such more favorable terms.

9. Governing Law. This Note is being delivered in, and shall be governed by and construed in accordance with, the laws of the State of Delaware, without regard to conflicts of laws provisions thereof.

10. Fractional Shares. No fractional shares will be issued in connection with any conversion hereunder; in lieu of such fractional shares, the Company shall pay to the Holder in cash that amount of the unconverted principal balance of, or accrued interest on, this Note.

11. Prepayment. The Company may prepay all or any portion of this Note without the prior approval of the Holder.

12. Miscellaneous. In the event any one or more of the provisions of this Note shall for any reason be held to be invalid, illegal or unenforceable, in whole or in part or in any respect, or in the event that any one or more of the provisions of this Note operate or would prospectively operate to invalidate this Note, then and in any such event, such provision(s) only shall be deemed null and void and shall not affect any other provision of this Note and the remaining provisions of this Note shall remain operative and in full force and effect and in no way shall be affected, prejudiced, or disturbed thereby.

13. Arbitration. Any dispute arising under or in connection with any matter of any nature (whether sounding in contract or tort) relating to or arising out of this Agreement, shall be resolved exclusively by arbitration. The arbitration shall be in conformity with and subject to the applicable rules and procedures of the American Arbitration Association. All parties agree to be (1) subject to the jurisdiction and venue of the arbitration in the State of Utah, (2) bound by the decision of the arbitrator as the final decision with respect to the dispute, and (3) subject to the jurisdiction of the District Courts of the State of Utah for the purpose of confirmation and enforcement of any award.

[Remainder of Page Intentionally Blank]

 

5

Q THERAPEUTICS, INC.,

a Delaware corporation

By:  

 

Name:  

 

Its:  

 

By:  

 

Name:  

 

Its:  

 

 

6

EX-31.1 3 d601481dex311.htm EX-31.1 EX-31.1

EXHIBIT 31.1

Q Therapeutics, Inc.

(A Development Stage Company)

Certification of the Company’s Principal Executive Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and Securities and Exchange Commission Release 34-46427

I, Deborah A. Eppstein, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Q Therapeutics, Inc. for the fiscal quarter ended September 30, 2013.

2. Based on my knowledge, this report does not contain any untrue statement of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 14, 2013   By:   /s/ DEBORAH A. EPPSTEIN
  Name:   Deborah A. Eppstein, PhD
  Title:   Chief Executive Officer, President
    (Principal Executive Officer)
 EX-31.2 4 d601481dex312.htm EX-31.2 EX-31.2

EXHIBIT 31.2

Q Therapeutics, Inc.

(A Development Stage Company)

Certification of the Company’s Principal Financial Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and Securities and Exchange Commission Release 34-46427

I, Steven J. Borst, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Q Therapeutics, Inc. for the fiscal quarter ended September 30, 2013.

2. Based on my knowledge, this report does not contain any untrue statement of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 14, 2013   By:   /s/ STEVEN J. BORST
  Name:   Steven J. Borst
  Title:   Chief Financial Officer, VP Corporate Development
    (Principal Financial Officer and Principal Accounting Officer)
 EX-32.1 5 d601481dex321.htm EX-32.1 EX-32.1

EXHIBIT 32.1

Q Therapeutics, Inc.

(A Development Stage Company)

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Deborah A. Eppstein, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Form 10-Q of Q Therapeutics, Inc. for the quarter ended September 30, 2013,fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Form 10-Q fairly presents in all material respects, the financial condition and results of operations of, Q Therapeutics, Inc.

 

Date: November 14, 2013   By:   /s/ DEBORAH A. EPPSTEIN
    Deborah A. Eppstein, PhD
    Chief Executive Officer, President
    (Principal Executive Officer)

I, Steven J. Borst, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Form 10-Q of Q Therapeutics, Inc. for the quarter ended September 30, 2013,fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Form 10-Q fairly presents in all material respects, the financial condition and results of operations of, Q Therapeutics, Inc.

 

Date: November 14, 2013   By:   /s/ STEVEN J. BORST
    Steven J. Borst
    Chief Financial Officer, VP Corporate Development
    (Principal Financial Officer and Principal Accounting Officer)

 

* This certification shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.
EX-101.INS 6 qhoi-20130930.xml XBRL INSTANCE DOCUMENT 0001366541 2013-09-30 0001366541 2013-01-01 2013-09-30 0001366541 2013-11-14 0001366541 2012-12-31 0001366541 2013-07-01 2013-09-30 0001366541 2012-07-01 2012-09-30 0001366541 2012-01-01 2012-09-30 0001366541 2002-03-29 2013-09-30 0001366541 qhoi:SeriesA1PreferredStockConvertedToCommonStockMember 2002-03-29 2013-09-30 0001366541 qhoi:SeriesA2PreferredStockConvertedToCommonStockMember 2002-03-29 2013-09-30 0001366541 qhoi:SeriesBPreferredStockConvertedToCommonStockMember 2002-03-29 2013-09-30 0001366541 qhoi:CommonStockIssuedPreferredStockMember 2002-03-29 2013-09-30 0001366541 qhoi:NotesPayableConvertedToSeriesA2PreferredStockMember 2002-03-29 2013-09-30 0001366541 qhoi:AccruedInterestConvertedToSeriesA2PreferredStockMember 2002-03-29 2013-09-30 0001366541 qhoi:NotesPayableConvertedToSeriesBPreferredStockMember 2002-03-29 2013-09-30 0001366541 qhoi:AccruedInterestConvertedToSeriesBPreferredStockMember 2002-03-29 2013-09-30 0001366541 qhoi:BridgeNotesPayableConvertedToCommonStockMember 2002-03-29 2013-09-30 0001366541 qhoi:AccruedInterestConvertedToCommonStockMember 2002-03-29 2013-09-30 0001366541 qhoi:SeriesA2PreferredStockIssuedNotesPayableAccruedInterestMember 2002-03-29 2013-09-30 0001366541 qhoi:SeriesBPreferredStockIssuedNotesPayableAccruedInterestMember 2002-03-29 2013-09-30 0001366541 qhoi:CommonStockIssuedBridgeNotesPayableAccruedInterestMember 2002-03-29 2013-09-30 0001366541 us-gaap:SubsidiariesMember 2013-01-01 2013-09-30 0001366541 us-gaap:StockOptionMember 2013-09-30 0001366541 us-gaap:StockOptionMember 2012-12-31 0001366541 us-gaap:StockOptionMember 2013-01-01 2013-09-30 0001366541 qhoi:ExercisePrice006008Member 2013-09-30 0001366541 qhoi:ExercisePrice015019Member 2013-09-30 0001366541 qhoi:ExercisePrice100Member 2013-09-30 0001366541 qhoi:ExercisePrice006008Member 2013-01-01 2013-09-30 0001366541 qhoi:ExercisePrice015019Member 2013-01-01 2013-09-30 0001366541 qhoi:ExercisePrice100Member 2013-01-01 2013-09-30 0001366541 qhoi:SupplierAgreementsMember 2013-01-01 2013-09-30 0001366541 qhoi:AdvisoryAgreementsMember 2013-01-01 2013-09-30 0001366541 qhoi:AdvisoryAgreementsMember us-gaap:MinimumMember 2013-01-01 2013-09-30 0001366541 qhoi:AdvisoryAgreementsMember us-gaap:MaximumMember 2013-01-01 2013-09-30 0001366541 2012-09-30 0001366541 2011-12-31 0001366541 2002-03-28 0001366541 qhoi:EquityIncentiveCompensationPlanMember 2013-01-01 2013-09-30 0001366541 qhoi:EquityIncentiveCompensationPlanMember 2013-09-30 0001366541 qhoi:EquityIncentiveCompensationPlanMember us-gaap:MinimumMember 2013-09-30 0001366541 qhoi:EquityIncentiveCompensationPlanMember us-gaap:MaximumMember 2013-09-30 0001366541 qhoi:January12013Member qhoi:FirstTrancheMember 2013-01-01 2013-09-30 0001366541 qhoi:April12013Member qhoi:SecondTrancheMember 2013-01-01 2013-09-30 0001366541 qhoi:ServiceAgreementMember 2013-01-01 2013-09-30 0001366541 us-gaap:MaximumMember qhoi:ServiceAgreementMember 2013-01-01 2013-09-30 0001366541 qhoi:January12013Member qhoi:FirstTrancheMember 2013-09-30 0001366541 qhoi:April12013Member qhoi:SecondTrancheMember 2013-09-30 0001366541 us-gaap:MinimumMember qhoi:ServiceAgreementMember 2013-09-30 0001366541 us-gaap:MaximumMember qhoi:ServiceAgreementMember 2013-09-30 0001366541 us-gaap:WarrantMember 2013-09-30 0001366541 us-gaap:WarrantMember us-gaap:MinimumMember 2013-09-30 0001366541 us-gaap:WarrantMember us-gaap:MaximumMember 2013-09-30 0001366541 us-gaap:WarrantMember 2013-01-01 2013-09-30 0001366541 us-gaap:WarrantMember us-gaap:MinimumMember 2013-01-01 2013-09-30 0001366541 us-gaap:WarrantMember us-gaap:MaximumMember 2013-01-01 2013-09-30 0001366541 us-gaap:ParentCompanyMember 2013-01-01 2013-09-30 0001366541 qhoi:InvestorPublicRelationsFirmMember 2013-01-01 2013-09-30 0001366541 qhoi:LicensingAgreementWithCollaborativePartnerMember 2013-01-01 2013-09-30 0001366541 qhoi:July12013Member qhoi:ServiceAgreement-ThirdTrancheWarrantsIssuedMember 2013-09-30 0001366541 qhoi:July12013Member qhoi:ServiceAgreement-ThirdTrancheWarrantsIssuedMember 2013-01-01 2013-09-30 0001366541 qhoi:BusinessConsultingServicesAgreementMember 2013-01-01 2013-09-30 0001366541 qhoi:BridgeFinancingMember qhoi:OfficerAffiliateMember 2013-01-01 2013-09-30 0001366541 us-gaap:MinimumMember qhoi:BridgeFinancingMember qhoi:OfficerAffiliateMember 2013-01-01 2013-09-30 0001366541 us-gaap:MaximumMember qhoi:BridgeFinancingMember qhoi:OfficerAffiliateMember 2013-01-01 2013-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:USD qhoi:unit Q Therapeutics, Inc. 0001366541 10-Q 2013-09-30 false --12-31 No No Yes Smaller Reporting Company Q3 2013 24936833 330365 15667 2800 537165 30222 7513 574900 2236896 69781 232522 3039199 2494 20790758 23257551 -2464299 574900 794207 477802 10366 1282375 16044 7513 1305932 1203365 9685 87892 1300942 2476 20494792 20492278 4990 1305932 28800 28800 0.0001 0.0001 100000000 100000000 24936833 24761832 12000 12000 1371644 326649 1698293 -1691093 66158 991 -65167 -1756260 -1756260 24839007 -0.07 283141 317961 601102 -601102 1023 2136 769 -344 -601446 -601446 24685193 -0.02 12286 12000 24286 1642591 1078239 2720830 -2701344 66808 2879 -63929 -2765273 -2765273 24807040 -0.11 7229 7229 764810 1049249 1814059 -1806830 3212 5580 2130 -238 -1807068 -1807068 24679417 -0.07 1102545 294900 1397445 12615483 10197474 22812957 -21420312 187616 2178222 153367 -1837239 -23257551 -23257551 9624 61667 76316 175000 44668 462135 7566 1093627 144630 -690040 23802 250000 250000 -463842 866 8537 -1445370 330365 14088 10000 -2282 26839 -5465 -73110 10919 -1619807 2363 15000 190000 176800 401271 450000 1298930 508117 90000 331750 44750 57754 -43677 28010 -10313 2705796 232522 -17162641 431273 5507562 90000 8671747 3821137 11600 2233 17924279 250000 2022190 4102654 13791231 220 219658 1237263 19 200000 1050000 29691 3740000 370346 900000 16644 482008 1787104 916644 P30D 631383 491588 3667 25439 16107458 15072509 16107458 15072509 162531 69991 17046 70846 3865440 3865440 3388773 0.34 0.34 0.25 0.06 0.08 0.15 0.19 1.00 902600 2072840 890000 3865440 3388773 0.25 0.08 0.17 1.00 902600 2072840 413333 0.08 0.17 1.00 0.34 P5Y6M29D P5Y8M12D P8Y4M2D P6Y3M11D 2600000 .08 .10 2136730 P6M .07 .01 .08 1296149 2741519 3000000 .69 1877529 4877529 3987529 40445 2549625 1.25 2.75 250000 62500 1.25 62500 1.75 12242018 .046 2.25 P4Y8M12D 1.40 219439 P2Y3M18D 5000000 1250000 0 2002-03-28 2005-10-27 500000 4800 4800 4800 95912 1800 250000 250000 2 .50 .08 2014-02-05 65942 0 1.56 75001 75001 100000 100000 62500 2.25 250000 2013-08-12 2013-09-30 75000 1.01 P5Y 100000 P2Y P2Y P7Y 7200 7229 1392645 19486 110360 <!--StartFragment--> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt;"><b>1. Organization</b></p> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;">Q Therapeutics, Inc. (Q)&#160;conducts its operations through its wholly owned subsidiary, Q Therapeutic Products, Inc. (Q Products) and its wholly owned subsidiary, NeuroQ Research, Inc (collectively, Q Therapeutics or the Company). Q Therapeutics is a Salt Lake City, Utah-based biopharmaceutical company that is developing human cell-based therapies intended to treat degenerative diseases of the brain and spinal cord, the primary components of the central nervous system (CNS). Q Products was incorporated in the state of Delaware on March&#160;28, 2002, and merged with Q Acquisition, Inc., a Delaware corporation and a wholly owned subsidiary of Grace 2, Inc., on October&#160;13, 2011. Grace 2, Inc. was incorporated on October&#160;27, 2005. On November&#160;2, 2011, Grace 2 changed its name to Q Holdings, Inc., and on December&#160;10, 2012, it changed its name to Q Therapeutics, Inc.</p> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt;">The technology upon which these potential therapies is based was developed by Q&#8217;s co-founder Mahendra Rao, M.D., Ph.D., a leader in glial stem cell biology, during his tenure at the University of Utah and as Head of the Stem Cell Section at the National Institutes of Health (NIH). Dr.&#160;Rao was one of the first scientists to identify and seek patent coverage on stem cells and their progeny cells found in the CNS. After licensing Dr.&#160;Rao&#8217;s technology from the University of Utah and NIH, Q commenced operations in the spring of 2004 to develop cell-based therapeutic products that can be sold as &#8220;off-the-shelf&#8221; pharmaceuticals.</p> <!--EndFragment--> <p style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt;"><b>2. Significant Accounting Policies</b></p> <p style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;"><b>The following significant accounting policies are followed by the Company in preparing its consolidated financial statements:</b></p> <p style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;"><b>Basis of Presentation</b></p> <p style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;">The accompanying unaudited condensed consolidated financial statements of Q Therapeutics have been prepared in accordance with the instructions to Form 10-Q and, therefore, do not include all information and notes necessary for a complete presentation of financial position, results of operations, and cash flows in conformity with U.S. generally accepted accounting principles (US GAAP). This report on Form 10-Q should be read in conjunction with the Company&#8217;s annual report on Form 10-K for the year ended December&#160;31, 2012.</p> <p style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt;">The accompanying unaudited condensed consolidated balance sheets, statements of operations, and statements of cash flows reflect all normal recurring adjustments that are, in the opinion of management, necessary for a fair presentation of the Company&#8217;s financial position, results of operations and cash flows. The results of operations for the nine-month period ended September&#160;30, 2013 are not necessarily indicative of the results to be expected for the full year ending December&#160;31, 2013.</p> <p style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt;"><b>Basis of Consolidation</b></p> <p style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;">The accompanying unaudited condensed consolidated financial statements include the accounts of Q and its wholly owned subsidiary, Q Products, and Q Products&#8217; wholly owned subsidiary, NeuroQ Research Inc. The Company is a development stage company engaged in the discovery, research, development and eventual commercialization of products as potential treatments for debilitating and fatal diseases of the CNS. All significant intercompany amounts have been eliminated.</p> <p style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt;"><b>Development Stage and Liquidity</b></p> <p style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;">For the period from March&#160;28, 2002 (date of inception) through September&#160;30, 2013, the Company has not generated significant revenues and has been developing its products. Therefore, the Company is considered to be in the development stage in accordance with the provisions of Accounting Standards Codification (ASC) Topic 915,&#160;<i>Development Stage Entities</i>. Cumulative amounts are presented for the period from March&#160;28, 2002 (date of inception) through September&#160;30, 2013. Historically, the Company has been dependent on government grants and debt and equity raised from investors to sustain its operations. The Company expects to continue to fund its operations through similar sources of capital. There can be no assurance that such capital will be available on favorable terms or at all. If it is unable to raise additional capital, the Company will likely be forced to curtail desired development activities, which will delay the development of its product candidates. The Company&#8217;s products have not been approved by the U.S. Food and Drug Administration (FDA) for commercial sale; therefore, the Company has not generated revenues from commercial therapeutic product sales. The Company has incurred losses and used cash for operating activities since inception. As of September&#160;30, 2013, the Company had an accumulated deficit of $23,257,551.</p> <p style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt;">Given the current pace of pre-clinical and clinical development of its product candidates, management believes that the Company has sufficient resources to fund the Company&#8217;s operations through at least December&#160;31, 2013. However, the Company will require additional cash resources during the first quarter of 2014. The Company is working to raise capital through the sale of common stock and filed a registration statement on June&#160;20, 2013 with the Securities and Exchange Commission registering the offering and sale of 5,000,000 shares of its common stock with warrants to purchase up to 1,250,000 shares of common stock. The Company has not raised any capital through the sale of common stock during 2013.</p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;">&#160;</p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><b>Use of Estimates</b></p> <p style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;">The preparation of financial statements in conformity with US&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Accordingly, actual results could differ from those estimates. Key estimates include allowances for doubtful accounts receivable, useful lives for property and equipment, valuation allowances for net deferred income tax assets, and valuations for stock-based compensation awards. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances.</p> <p style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt;"><b>Revenue Recognition and Grants Receivable</b></p> <p style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;">The Company periodically applies for research grants, including as a sub-recipient to grants funded by government agencies through research universities. Grant revenues are recognized as associated expenses are incurred and are billed in conjunction with the terms of the grants. The Company records its grants receivable in accordance with the provisions of the grant agreements. The Company&#8217;s grants receivable are considered past due when payment has not been received within 30 days of the invoice date, although certain institutions customarily do not pay within 30 days of the invoice date. The amounts of the specific reserves are estimated by management based on various assumptions including the age of the individual receivable, as well as changes in payment schedules and histories. Grants receivable balances are charged off against the allowance for doubtful accounts when management determines the potential for recovery is remote. Recoveries of receivables previously charged off are recorded when payment is received. For the nine months ended September&#160;30, 2013, revenues were derived from two customers.</p> <p style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt;">In December 2012, the Company was notified of a sub-award as part of grant funding awarded to The Johns Hopkins University (JHU) from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health. The sub-award for the 2012-2013 grant plan year is $631,383. In May 2013, JHU applied for, and was granted a six-month extension for completing the analysis and remitting data and expenses. As of September&#160;30, 2013, $491,588 has been invoiced under the sub-award and $3,667 is included in the grants receivable balance. The balance outstanding is expected to be paid upon the completion of the extension.</p> <p style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt;"><b>Stock-Based Compensation</b></p> <p style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;">The Company calculates the estimated fair value of its stock options and warrants on the grant date using the Black-Scholes option-pricing model. The Company recognizes stock-based compensation expense as services are provided, which is generally over the vesting period of the individual equity instruments. Expense related to stock options issued in lieu of cash to non-employees for services performed are measured at the fair value of the options on the date they are earned.</p> <p style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt;">The volatility assumption used in the Black-Scholes option-pricing model is based on the volatility of publicly traded companies in the same industry segment as the Company. The expected lives of the options and warrants granted represent the periods of time that the options granted are expected to be outstanding. The risk free rates for periods within the contractual lives of the options and warrants are based on the U.S. treasury securities constant maturity rate that corresponds to the expected terms in effect at the time of grant. Stock-based compensation is included in general and administrative expense in the statements of operations.</p> <p style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt;"><b>Net Loss Per Common Share</b></p> <p style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;">Basic net income or loss per common share (Basic EPS) is computed by dividing net income or loss by the weighted average number of common shares outstanding. Diluted net income or loss per common share (Diluted EPS) is computed by dividing net income or loss by the sum of the weighted average number of common shares outstanding and the dilutive potential common share equivalents then outstanding. Potential dilutive common share equivalents consist of shares issuable upon the exercise of outstanding stock options and warrants to acquire common stock.</p> <p style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt;">Due to the fact that for all periods presented the Company has incurred net losses, potential dilutive common share equivalents as of September&#160;30, 2013 and 2012, totaling 16,107,458 and 15,072,509, respectively, are not included in the calculation of Diluted EPS because they are anti-dilutive. Therefore, basic net loss per common share is the same as diluted net loss per common share for the three and nine months ended September&#160;30, 2013 and 2012.</p> <p style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt;"><b>Recent Accounting Pronouncements</b></p> <p style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;">The Company has reviewed accounting pronouncements that become effective subsequent to September&#160;30, 2013 and does not believe the future adoption of those pronouncements will have a material impact on the Company&#8217;s financial position, results of operations or liquidity.</p> <!--StartFragment--> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><b>3. Accrued Compensation</b></p> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;">Accrued compensation consists of the following:</p> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 12pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p> <table cellpadding="0" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; border-collapse: collapse; font-size: 10pt;" width="76%" border="0" cellspacing="0" align="center"> <tr> <td width="63%"/> <td valign="bottom" width="12%"/> <td/> <td/> <td/> <td valign="bottom" width="12%"/> <td/> <td/> <td/></tr> <tr style="font-family: 'Times New Roman'; font-size: 8pt;"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom" style="border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);" align="center" colspan="2"><b>September&#160;30,&#160;2013</b></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom" style="border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);" align="center" colspan="2"><b>December&#160;31,&#160;2012</b></td> <td valign="bottom">&#160;</td></tr> <tr bgcolor="#cceeff" style="font-family: 'Times New Roman'; font-size: 10pt;"> <td valign="top"> <p style="margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: 'Times New Roman';">Accrued wages</p></td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">162,531</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,046</td> <td valign="bottom">&#160;&#160;</td></tr> <tr style="font-family: 'Times New Roman'; font-size: 10pt;"> <td valign="top"> <p style="margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: 'Times New Roman';">Accrued vacation</p></td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">69,991</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">70,846</td> <td valign="bottom">&#160;&#160;</td></tr> <tr style="font-size: 1px;"> <td valign="bottom"/> <td valign="bottom">&#160;&#160;</td> <td valign="bottom"> <p style="border-top-width: 1px; border-top-style: solid; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td valign="bottom"> <p style="border-top-width: 1px; border-top-style: solid; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td>&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom"> <p style="border-top-width: 1px; border-top-style: solid; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td valign="bottom"> <p style="border-top-width: 1px; border-top-style: solid; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td>&#160;</td></tr> <tr bgcolor="#cceeff" style="font-family: 'Times New Roman'; font-size: 10pt;"> <td valign="top"> <p style="margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: 'Times New Roman';">Total accrued compensation</p></td> <td valign="bottom"><font style="font-size: 8pt;">&#160;&#160;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">232,522</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom"><font style="font-size: 8pt;">&#160;&#160;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">87,892</td> <td valign="bottom">&#160;&#160;</td></tr> <tr style="font-size: 1px;"> <td valign="bottom"/> <td valign="bottom">&#160;&#160;</td> <td valign="bottom"> <p style="border-top-width: 3px; border-top-style: double; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td valign="bottom"> <p style="border-top-width: 3px; border-top-style: double; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td>&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom"> <p style="border-top-width: 3px; border-top-style: double; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td valign="bottom"> <p style="border-top-width: 3px; border-top-style: double; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td>&#160;</td></tr></table> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt;">Starting in March 2013, certain of the Company&#8217;s executives agreed to defer part, if not all, of their salaries until additional funding is obtained.</p> <!--EndFragment--> <!--StartFragment--> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt;"><b>4. Notes Payable</b></p> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;">Between August&#160;12 and September&#160;30, 2013, the Company received $250,000 in cash proceeds resulting from a bridge financing by a group of note holders, some of which are also stockholders that are considered affiliates, as evidenced by promissory notes (Notes). The Notes were issued at 50% of face value, bear interest at the rate of 8%&#160;per annum, and are due in full beginning February&#160;5, 2014. Notes payable as of September&#160;30, 2013 are $500,000. To date, the Company has recorded interest relating to the note of $65,942, of which almost all pertains to the amortization of the debt discount with an additional $188,333 of debt discount costs to be amortized over the remaining term of the note. As of September&#160;30, 2013, no payments towards principal or interest had been made.</p> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt;">The effective interest rate related to this financing is approximately156%.</p> <!--EndFragment--> <p style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt;"><b>5. Stockholders&#8217; Equity</b></p> <p style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;"><b>Common Stock</b></p> <p style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;">During the nine months ended September&#160;30, 2013, the Company issued 75,001 shares of its common stock with an estimated fair value of $75,001 to an investor and public relations firm in lieu of cash for services rendered during the period. In September 2013, the Company issued 100,000 shares of its common stock with an estimated fair value of $100,000 related to a licensing agreement with a collaborative partner. As of September&#160;30, 2013, 24,936,833 shares of common stock are outstanding.</p> <p style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt;"><b>Stock Options</b></p> <p style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;">The following summarizes the outstanding common stock options and related activity for the nine months ended September&#160;30, 2013:</p> <p style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p> <table cellpadding="0" style="border-collapse: collapse; font-size: 10pt;" width="76%" border="0" cellspacing="0" align="center"> <tr> <td width="72%">&#160;</td> <td valign="bottom" width="8%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="8%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="font-size: 8pt;"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom" colspan="2">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom" align="center" colspan="2"><b>Weighted</b></td> <td valign="bottom">&#160;</td></tr> <tr style="font-size: 8pt;"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom" align="center" colspan="2"><b>Number of</b></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom" align="center" colspan="2"><b>Average&#160;Exercise</b></td> <td valign="bottom">&#160;</td></tr> <tr style="font-size: 8pt;"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom" style="border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);" align="center" colspan="2"><b>Options</b></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom" style="border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);" align="center" colspan="2"><b>Price Per Share</b></td> <td valign="bottom">&#160;</td></tr> <tr bgcolor="#cceeff" style="font-size: 10pt;"> <td valign="top"> <p style="margin-left: 1em; text-indent: -1em; font-size: 10pt;">Outstanding as of December 31, 2012</p></td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">3,865,440</td> <td nowrap="nowrap" valign="bottom">&#160;&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.34</td> <td nowrap="nowrap" valign="bottom">&#160;&#160;</td></tr> <tr style="font-size: 10pt;"> <td valign="top"> <p style="margin-left: 3em; text-indent: -1em; font-size: 10pt;">Granted</p></td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">&#8212;&#160;&#160;</td> <td nowrap="nowrap" valign="bottom">&#160;&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">&#8212;&#160;&#160;</td> <td nowrap="nowrap" valign="bottom">&#160;&#160;</td></tr> <tr bgcolor="#cceeff" style="font-size: 10pt;"> <td valign="top"> <p style="margin-left: 3em; text-indent: -1em; font-size: 10pt;">Exercised</p></td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">&#8212;&#160;&#160;</td> <td nowrap="nowrap" valign="bottom">&#160;&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">&#8212;&#160;&#160;</td> <td nowrap="nowrap" valign="bottom">&#160;&#160;</td></tr> <tr style="font-size: 10pt;"> <td valign="top"> <p style="margin-left: 3em; text-indent: -1em; font-size: 10pt;">Forfeited</p></td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">&#8212;&#160;&#160;</td> <td nowrap="nowrap" valign="bottom">&#160;&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">&#8212;&#160;&#160;</td> <td nowrap="nowrap" valign="bottom">&#160;&#160;</td></tr> <tr style="font-size: 1px;"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom"> <p style="border-top-width: 1px; border-top-style: solid; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td valign="bottom"> <p style="border-top-width: 1px; border-top-style: solid; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td>&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td></tr> <tr bgcolor="#cceeff" style="font-size: 10pt;"> <td valign="top"> <p style="margin-left: 1em; text-indent: -1em; font-size: 10pt;">Outstanding as of September 30, 2013</p></td> <td valign="bottom"><font style="font-size: 8pt;">&#160;&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">3,865,440</td> <td nowrap="nowrap" valign="bottom">&#160;&#160;</td> <td valign="bottom"><font style="font-size: 8pt;">&#160;&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">0.34</td> <td nowrap="nowrap" valign="bottom">&#160;&#160;</td></tr> <tr style="font-size: 1px;"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom"> <p style="border-top-width: 3px; border-top-style: double; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td valign="bottom"> <p style="border-top-width: 3px; border-top-style: double; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td>&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td></tr> <tr style="font-size: 10pt;"> <td valign="top"> <p style="margin-left: 1em; text-indent: -1em; font-size: 10pt;">Exercisable as of September 30, 2013</p></td> <td valign="bottom"><font style="font-size: 8pt;">&#160;&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">3,388,773</td> <td nowrap="nowrap" valign="bottom">&#160;&#160;</td> <td valign="bottom"><font style="font-size: 8pt;">&#160;&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">0.25</td> <td nowrap="nowrap" valign="bottom">&#160;&#160;</td></tr> <tr style="font-size: 1px;"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom"> <p style="border-top-width: 3px; border-top-style: double; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td valign="bottom"> <p style="border-top-width: 3px; border-top-style: double; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td>&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td></tr></table> <p style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt;">On December&#160;18, 2012, the Board of Directors approved, subject to stockholder approval, the addition of 3,000,000 shares to the 2011 Equity Incentive Compensation Plan (the Plan). On May&#160;6, 2013, stockholders representing 69% of the issued and outstanding voting common stock of the Company accepted the Board of Directors&#8217; recommendation and provided their written consent to approve these additional 3,000,000 shares of common stock of the Company to the pool of shares reserved for issuance under the Plan, increasing&#160;<font style="font-size: 10pt;">the number of shares from 1,877,529 to 4,877,529 shares. As of September&#160;30, 2013, options to purchase 3,987,529 shares of common stock under the Plan were available for future grant. The following summarizes information about stock options outstanding as of September&#160;30, 2013:</font></p> <p style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p> <table cellpadding="0" style="border-collapse: collapse; font-size: 8pt;" width="100%" border="0" cellspacing="0" align="center"> <tr> <td width="16%">&#160;</td> <td valign="bottom" width="1%">&#160;</td> <td width="16%">&#160;</td> <td valign="bottom" width="1%">&#160;</td> <td width="16%">&#160;</td> <td valign="bottom" width="1%">&#160;</td> <td width="16%">&#160;</td> <td valign="bottom" width="1%">&#160;</td> <td width="16%">&#160;</td> <td valign="bottom" width="1%">&#160;</td> <td width="15%">&#160;</td></tr> <tr style="font-size: 8pt;"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="center"><b>Weighted</b></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td></tr> <tr style="font-size: 8pt;"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="center"><b>Average</b></td> <td valign="bottom">&#160;</td> <td valign="bottom" align="center"><b>Weighted</b></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="center"><b>Weighted</b></td></tr> <tr style="font-size: 8pt;"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="center"><b>Numbers of</b></td> <td valign="bottom">&#160;</td> <td valign="bottom" align="center"><b>Remaining</b></td> <td valign="bottom">&#160;</td> <td valign="bottom" align="center"><b>Average</b></td> <td valign="bottom">&#160;</td> <td valign="bottom" align="center"><b>Number of</b></td> <td valign="bottom">&#160;</td> <td valign="bottom" align="center"><b>Average</b></td></tr> <tr style="font-size: 8pt;"> <td valign="bottom" align="center"><b>Exercise</b></td> <td valign="bottom">&#160;</td> <td valign="bottom" align="center"><b>Options</b></td> <td valign="bottom">&#160;</td> <td valign="bottom" align="center"><b>Contractual</b></td> <td valign="bottom">&#160;</td> <td valign="bottom" align="center"><b>Price</b></td> <td valign="bottom">&#160;</td> <td valign="bottom" align="center"><b>Options</b></td> <td valign="bottom">&#160;</td> <td valign="bottom" align="center"><b>Price</b></td></tr> <tr style="font-size: 8pt;"> <td valign="bottom" style="border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);" align="center"> <p style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt;" align="center"><b>Price</b></p></td> <td valign="bottom">&#160;</td> <td valign="bottom" style="border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);" align="center"> <p style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt;" align="center"><b>Outstanding</b></p></td> <td valign="bottom">&#160;</td> <td valign="bottom" style="border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);" align="center"> <p style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt;" align="center"><b>Life (Years)</b></p></td> <td valign="bottom">&#160;</td> <td valign="bottom" style="border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);" align="center"> <p style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt;" align="center"><b>Exercise</b></p></td> <td valign="bottom">&#160;</td> <td valign="bottom" style="border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);" align="center"> <p style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt;" align="center"><b>Exercisable</b></p></td> <td valign="bottom">&#160;</td> <td valign="bottom" style="border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);" align="center"> <p style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt;" align="center"><b>Exercise</b></p></td></tr> <tr bgcolor="#cceeff" style="font-size: 10pt;"> <td nowrap="nowrap" valign="bottom" align="center">$0.06&#160;&#8211;&#160;$0.08</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">902,600</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">5.58</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">$0.08</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">902,600</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">$0.08</td></tr> <tr style="font-size: 10pt;"> <td nowrap="nowrap" valign="bottom" align="center">$0.15&#160;&#8211;&#160;$0.19</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">2,072,840</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">5.70</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">0.17</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">2,072,840</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">0.17</td></tr> <tr bgcolor="#cceeff" style="font-size: 10pt;"> <td valign="bottom" align="center">$1.00</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">890,000</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">8.34</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">1.00</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">413,333</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">1.00</td></tr> <tr style="font-size: 1px;"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top-width: 1px; border-top-style: solid; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top-width: 1px; border-top-style: solid; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td></tr> <tr style="font-size: 10pt;"> <td valign="bottom">&#160;</td> <td valign="bottom"><font style="font-size: 8pt;">&#160;</font></td> <td valign="bottom" align="right">3,865,440</td> <td valign="bottom"><font style="font-size: 8pt;">&#160;</font></td> <td valign="bottom" align="right">6.28</td> <td valign="bottom"><font style="font-size: 8pt;">&#160;</font></td> <td valign="bottom" align="right">0.34</td> <td valign="bottom"><font style="font-size: 8pt;">&#160;</font></td> <td valign="bottom" align="right">3,388,773</td> <td valign="bottom"><font style="font-size: 8pt;">&#160;</font></td> <td valign="bottom" align="right">0.25</td></tr> <tr style="font-size: 1px;"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top-width: 3px; border-top-style: double; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top-width: 3px; border-top-style: double; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td></tr></table> <p style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt;">As of September&#160;30, 2013, the aggregate intrinsic value of outstanding and exercisable stock options was $2,549,625.</p> <p style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt;">Stock-based compensation for the three months ended September&#160;30, 2013 and 2012 was $25,439 and $40,445, respectively. Stock-based compensation for the nine months ended September&#160;30, 2013 and 2012 was $76,316 and $95,912, respectively. As of September&#160;30, 2013, the Company had $219,439 of unrecognized stock-based compensation expense related to non-vested awards that will be recognized over a weighted-average period of 2.3 years.</p> <p style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt;"><b>Warrants</b></p> <p style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;">In October 2012, the Company entered into a service agreement with an investor relations and public advisory firm. As part of the agreement, the service provider was entitled to receive up to 250,000 warrants to purchase common stock at prices ranging from $1.25 to $2.75 per share with a term of two years. The warrants are immediately exercisable upon issuance. On January&#160;1, 2013, the first tranche of 62,500 warrants was issued with an exercise price of $1.25. On April&#160;1, 2013, the second tranche of 62,500 warrants were issued with an exercise price of $1.75. On July&#160;1, 2013, the third tranche of 62,500 warrants were issued with an exercise price of $2.25.</p> <p style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt;">As of September&#160;30, 2013, 12,242,018 warrants to purchase common stock had been issued with exercise prices ranging from $.046 to $2.25 per share and terms ranging from two to seven years. The weighted average warrant exercise price is $1.40 and the weighted average remaining life is 4.7 years.</p> <p style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt;"><b>6. Commitments and Contingencies</b></p> <p style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;"><b>Supplier Agreements</b></p> <p style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;">In March 2010, the Company entered into a service agreement with an outside research firm to support the Company&#8217;s preclinical Good Laboratory Practice (GLP) safety studies.</p> <p style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt;">In November 2012, the Company and the supplier amended the terms of their original agreement via a Letter of Understanding and increased the total purchase commitment with the supplier to approximately $2,600,000 with an expected completion by year-end 2013. Upon conclusion of the supplier&#8217;s final project report, any outstanding balance will be converted into a note payable accruing interest at 8% until July&#160;31, 2015. Any outstanding amounts thereafter shall accumulate interest at 10% through March&#160;31, 2016. Should the Company be successful in obtaining additional financing, the amendment calls for a percentage of the funds raised to immediately pay down the outstanding balance. As of September&#160;30, 2013, the amount owed under this agreement totaled $2,136,730 and is included in accounts payable. The supplier also was granted, upon successful completion of the clinical study, a right of first negotiation on any future preclinical GLP safety to toxicology studies.</p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt;">&#160;</p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><b>Advisory Agreements</b></p> <p style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;">In February 2013, the Company entered into an agreement to engage a financial advisory firm for a minimum term of six months. The agreement was revised in May 2013. The financial advisory firm is entitled to a commission equal to 7% of the total proceeds raised by the Company from its financing efforts payable in cash; and if warrants are issued as part of the placement of securities, an issuance of warrants equivalent to 1% of the aggregate number of warrants purchased in the offering, collectively not to exceed 8%. Additionally, the Company shall reimburse reasonable out-of-pocket expenses. To date, no placement of securities has occurred.</p> <p style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt;">In July 2013, the Company entered into a business consulting services agreement effective through December&#160;31, 2015. Under the agreement, the Company issued an initial payment of a warrant to purchase 75,000 shares of common stock at a strike price of $1.01 per share, with a five-year life and a cashless exercise option. The business consulting firm is entitled to receive additional warrants for up to 100,000 shares of common stock with similar terms.</p> <!--StartFragment--> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt;"><b>7. Related Party Transactions</b></p> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;">Between August&#160;12 and September&#160;30, 2013, the Company received $250,000 in cash proceeds resulting from a bridge financing by a group of note holders, which included both an officer and an affiliate. The officer has since transferred ownership of the note to an affiliate.</p> <!--EndFragment--> <!--StartFragment--> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;"><b>Basis of Presentation</b></p> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;">The accompanying unaudited condensed consolidated financial statements of Q Therapeutics have been prepared in accordance with the instructions to Form 10-Q and, therefore, do not include all information and notes necessary for a complete presentation of financial position, results of operations, and cash flows in conformity with U.S. generally accepted accounting principles (US GAAP). This report on Form 10-Q should be read in conjunction with the Company&#8217;s annual report on Form 10-K for the year ended December&#160;31, 2012.</p> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt;">The accompanying unaudited condensed consolidated balance sheets, statements of operations, and statements of cash flows reflect all normal recurring adjustments that are, in the opinion of management, necessary for a fair presentation of the Company&#8217;s financial position, results of operations and cash flows. The results of operations for the nine-month period ended September&#160;30, 2013 are not necessarily indicative of the results to be expected for the full year ending December&#160;31, 2013.</p> <!--EndFragment--> <!--StartFragment--> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt;"><b>Basis of Consolidation</b></p> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;">The accompanying unaudited condensed consolidated financial statements include the accounts of Q and its wholly owned subsidiary, Q Products, and Q Products&#8217; wholly owned subsidiary, NeuroQ Research Inc. The Company is a development stage company engaged in the discovery, research, development and eventual commercialization of products as potential treatments for debilitating and fatal diseases of the CNS. All significant intercompany amounts have been eliminated.</p> <!--EndFragment--> <!--StartFragment--> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt;"><b>Development Stage and Liquidity</b></p> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;">For the period from March&#160;28, 2002 (date of inception) through September&#160;30, 2013, the Company has not generated significant revenues and has been developing its products. Therefore, the Company is considered to be in the development stage in accordance with the provisions of Accounting Standards Codification (ASC) Topic 915,&#160;<i>Development Stage Entities</i>. Cumulative amounts are presented for the period from March&#160;28, 2002 (date of inception) through September&#160;30, 2013. Historically, the Company has been dependent on government grants and debt and equity raised from investors to sustain its operations. The Company expects to continue to fund its operations through similar sources of capital. There can be no assurance that such capital will be available on favorable terms or at all. If it is unable to raise additional capital, the Company will likely be forced to curtail desired development activities, which will delay the development of its product candidates. The Company&#8217;s products have not been approved by the U.S. Food and Drug Administration (FDA) for commercial sale; therefore, the Company has not generated revenues from commercial therapeutic product sales. The Company has incurred losses and used cash for operating activities since inception. As of September&#160;30, 2013, the Company had an accumulated deficit of $23,257,551.</p> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt;">Given the current pace of pre-clinical and clinical development of its product candidates, management believes that the Company has sufficient resources to fund the Company&#8217;s operations through at least December&#160;31, 2013. However, the Company will require additional cash resources during the first quarter of 2014. The Company is working to raise capital through the sale of common stock and filed a registration statement on June&#160;20, 2013 with the Securities and Exchange Commission registering the offering and sale of 5,000,000 shares of its common stock with warrants to purchase up to 1,250,000 shares of common stock. The Company has not raised any capital through the sale of common stock during 2013.</p> <!--EndFragment--> <!--StartFragment--> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><b>Use of Estimates</b></p> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;">The preparation of financial statements in conformity with US&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Accordingly, actual results could differ from those estimates. Key estimates include allowances for doubtful accounts receivable, useful lives for property and equipment, valuation allowances for net deferred income tax assets, and valuations for stock-based compensation awards. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances.</p> <!--EndFragment--> <!--StartFragment--> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt;"><b>Revenue Recognition and Grants Receivable</b></p> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;">The Company periodically applies for research grants, including as a sub-recipient to grants funded by government agencies through research universities. Grant revenues are recognized as associated expenses are incurred and are billed in conjunction with the terms of the grants. The Company records its grants receivable in accordance with the provisions of the grant agreements. The Company&#8217;s grants receivable are considered past due when payment has not been received within 30 days of the invoice date, although certain institutions customarily do not pay within 30 days of the invoice date. The amounts of the specific reserves are estimated by management based on various assumptions including the age of the individual receivable, as well as changes in payment schedules and histories. Grants receivable balances are charged off against the allowance for doubtful accounts when management determines the potential for recovery is remote. Recoveries of receivables previously charged off are recorded when payment is received. For the nine months ended September&#160;30, 2013, revenues were derived from two customers.</p> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt;">In December 2012, the Company was notified of a sub-award as part of grant funding awarded to The Johns Hopkins University (JHU) from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health. The sub-award for the 2012-2013 grant plan year is $631,383. In May 2013, JHU applied for, and was granted a six-month extension for completing the analysis and remitting data and expenses. As of September&#160;30, 2013, $491,588 has been invoiced under the sub-award and $3,667 is included in the grants receivable balance. The balance outstanding is expected to be paid upon the completion of the extension.</p> <!--EndFragment--> <!--StartFragment--> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt;"><b>Stock-Based Compensation</b></p> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;">The Company calculates the estimated fair value of its stock options and warrants on the grant date using the Black-Scholes option-pricing model. The Company recognizes stock-based compensation expense as services are provided, which is generally over the vesting period of the individual equity instruments. Expense related to stock options issued in lieu of cash to non-employees for services performed are measured at the fair value of the options on the date they are earned.</p> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt;">The volatility assumption used in the Black-Scholes option-pricing model is based on the volatility of publicly traded companies in the same industry segment as the Company. The expected lives of the options and warrants granted represent the periods of time that the options granted are expected to be outstanding. The risk free rates for periods within the contractual lives of the options and warrants are based on the U.S. treasury securities constant maturity rate that corresponds to the expected terms in effect at the time of grant. Stock-based compensation is included in general and administrative expense in the statements of operations.</p> <!--EndFragment--> <!--StartFragment--> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt;"><b>Net Loss Per Common Share</b></p> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;">Basic net income or loss per common share (Basic EPS) is computed by dividing net income or loss by the weighted average number of common shares outstanding. Diluted net income or loss per common share (Diluted EPS) is computed by dividing net income or loss by the sum of the weighted average number of common shares outstanding and the dilutive potential common share equivalents then outstanding. Potential dilutive common share equivalents consist of shares issuable upon the exercise of outstanding stock options and warrants to acquire common stock.</p> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt;">Due to the fact that for all periods presented the Company has incurred net losses, potential dilutive common share equivalents as of September&#160;30, 2013 and 2012, totaling 16,107,458 and 15,072,509, respectively, are not included in the calculation of Diluted EPS because they are anti-dilutive. Therefore, basic net loss per common share is the same as diluted net loss per common share for the three and nine months ended September&#160;30, 2013 and 2012.</p> <!--EndFragment--> <!--StartFragment--> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt;"><b>Recent Accounting Pronouncements</b></p> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;">The Company has reviewed accounting pronouncements that become effective subsequent to September&#160;30, 2013 and does not believe the future adoption of those pronouncements will have a material impact on the Company&#8217;s financial position, results of operations or liquidity.</p> <!--EndFragment--> <!--StartFragment--> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;">Accrued compensation consists of the following:</p> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 12pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p> <table cellpadding="0" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; border-collapse: collapse; font-size: 10pt;" width="76%" border="0" cellspacing="0" align="center"> <tr> <td width="63%"/> <td valign="bottom" width="12%"/> <td/> <td/> <td/> <td valign="bottom" width="12%"/> <td/> <td/> <td/></tr> <tr style="font-family: 'Times New Roman'; font-size: 8pt;"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom" style="border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);" align="center" colspan="2"><b>September&#160;30,&#160;2013</b></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom" style="border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);" align="center" colspan="2"><b>December&#160;31,&#160;2012</b></td> <td valign="bottom">&#160;</td></tr> <tr bgcolor="#cceeff" style="font-family: 'Times New Roman'; font-size: 10pt;"> <td valign="top"> <p style="margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: 'Times New Roman';">Accrued wages</p></td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">162,531</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,046</td> <td valign="bottom">&#160;&#160;</td></tr> <tr style="font-family: 'Times New Roman'; font-size: 10pt;"> <td valign="top"> <p style="margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: 'Times New Roman';">Accrued vacation</p></td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">69,991</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">70,846</td> <td valign="bottom">&#160;&#160;</td></tr> <tr style="font-size: 1px;"> <td valign="bottom"/> <td valign="bottom">&#160;&#160;</td> <td valign="bottom"> <p style="border-top-width: 1px; border-top-style: solid; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td valign="bottom"> <p style="border-top-width: 1px; border-top-style: solid; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td>&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom"> <p style="border-top-width: 1px; border-top-style: solid; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td valign="bottom"> <p style="border-top-width: 1px; border-top-style: solid; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td>&#160;</td></tr> <tr bgcolor="#cceeff" style="font-family: 'Times New Roman'; font-size: 10pt;"> <td valign="top"> <p style="margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: 'Times New Roman';">Total accrued compensation</p></td> <td valign="bottom"><font style="font-size: 8pt;">&#160;&#160;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">232,522</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom"><font style="font-size: 8pt;">&#160;&#160;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">87,892</td> <td valign="bottom">&#160;&#160;</td></tr> <tr style="font-size: 1px;"> <td valign="bottom"/> <td valign="bottom">&#160;&#160;</td> <td valign="bottom"> <p style="border-top-width: 3px; border-top-style: double; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td valign="bottom"> <p style="border-top-width: 3px; border-top-style: double; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td>&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom"> <p style="border-top-width: 3px; border-top-style: double; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td valign="bottom"> <p style="border-top-width: 3px; border-top-style: double; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td>&#160;</td></tr></table><br class="Apple-interchange-newline"/> <!--EndFragment--> <!--StartFragment--> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;">The following summarizes the outstanding common stock options and related activity for the nine months ended September&#160;30, 2013:</p> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 12pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p> <table cellpadding="0" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; border-collapse: collapse; font-size: 10pt;" width="76%" border="0" cellspacing="0" align="center"> <tr> <td width="72%"/> <td valign="bottom" width="8%"/> <td/> <td/> <td/> <td valign="bottom" width="8%"/> <td/> <td/> <td/></tr> <tr style="font-family: 'Times New Roman'; font-size: 8pt;"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom" colspan="2">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom" align="center" colspan="2"><b>Weighted</b></td> <td valign="bottom">&#160;</td></tr> <tr style="font-family: 'Times New Roman'; font-size: 8pt;"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom" align="center" colspan="2"><b>Number of</b></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom" align="center" colspan="2"><b>Average&#160;Exercise</b></td> <td valign="bottom">&#160;</td></tr> <tr style="font-family: 'Times New Roman'; font-size: 8pt;"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom" style="border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);" align="center" colspan="2"><b>Options</b></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom" style="border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);" align="center" colspan="2"><b>Price Per Share</b></td> <td valign="bottom">&#160;</td></tr> <tr bgcolor="#cceeff" style="font-family: 'Times New Roman'; font-size: 10pt;"> <td valign="top"> <p style="margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: 'Times New Roman';">Outstanding as of December 31, 2012</p></td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">3,865,440</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.34</td> <td valign="bottom">&#160;&#160;</td></tr> <tr style="font-family: 'Times New Roman'; font-size: 10pt;"> <td valign="top"> <p style="margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: 'Times New Roman';">Granted</p></td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">&#8212;&#160;&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">&#8212;&#160;&#160;</td> <td valign="bottom">&#160;&#160;</td></tr> <tr bgcolor="#cceeff" style="font-family: 'Times New Roman'; font-size: 10pt;"> <td valign="top"> <p style="margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: 'Times New Roman';">Exercised</p></td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">&#8212;&#160;&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">&#8212;&#160;&#160;</td> <td valign="bottom">&#160;&#160;</td></tr> <tr style="font-family: 'Times New Roman'; font-size: 10pt;"> <td valign="top"> <p style="margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: 'Times New Roman';">Forfeited</p></td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">&#8212;&#160;&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">&#8212;&#160;&#160;</td> <td valign="bottom">&#160;&#160;</td></tr> <tr style="font-size: 1px;"> <td valign="bottom"/> <td valign="bottom">&#160;&#160;</td> <td valign="bottom"> <p style="border-top-width: 1px; border-top-style: solid; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td valign="bottom"> <p style="border-top-width: 1px; border-top-style: solid; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td>&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom"/> <td valign="bottom"/> <td valign="bottom"/></tr> <tr bgcolor="#cceeff" style="font-family: 'Times New Roman'; font-size: 10pt;"> <td valign="top"> <p style="margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: 'Times New Roman';">Outstanding as of September 30, 2013</p></td> <td valign="bottom"><font style="font-size: 8pt;">&#160;&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">3,865,440</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom"><font style="font-size: 8pt;">&#160;&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">0.34</td> <td valign="bottom">&#160;&#160;</td></tr> <tr style="font-size: 1px;"> <td valign="bottom"/> <td valign="bottom">&#160;&#160;</td> <td valign="bottom"> <p style="border-top-width: 3px; border-top-style: double; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td valign="bottom"> <p style="border-top-width: 3px; border-top-style: double; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td>&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom"/> <td valign="bottom"/> <td valign="bottom"/></tr> <tr style="font-family: 'Times New Roman'; font-size: 10pt;"> <td valign="top"> <p style="margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: 'Times New Roman';">Exercisable as of September 30, 2013</p></td> <td valign="bottom"><font style="font-size: 8pt;">&#160;&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">3,388,773</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom"><font style="font-size: 8pt;">&#160;&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">0.25</td> <td valign="bottom">&#160;&#160;</td></tr> <tr style="font-size: 1px;"> <td valign="bottom"/> <td valign="bottom">&#160;&#160;</td> <td valign="bottom"> <p style="border-top-width: 3px; border-top-style: double; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td valign="bottom"> <p style="border-top-width: 3px; border-top-style: double; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td>&#160;</td> <td valign="bottom">&#160;&#160;</td> <td valign="bottom"/> <td valign="bottom"/> <td valign="bottom"/></tr></table><br class="Apple-interchange-newline"/> <!--EndFragment--> <!--StartFragment--> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;">The following summarizes information about stock options outstanding as of September&#160;30, 2013:</p> <p style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 12pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p> <table cellpadding="0" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; border-collapse: collapse; font-size: 8pt;" width="100%" border="0" cellspacing="0" align="center"> <tr> <td width="16%"/> <td valign="bottom" width="1%"/> <td width="16%"/> <td valign="bottom" width="1%"/> <td width="16%"/> <td valign="bottom" width="1%"/> <td width="16%"/> <td valign="bottom" width="1%"/> <td width="16%"/> <td valign="bottom" width="1%"/> <td width="15%"/></tr> <tr style="font-family: 'Times New Roman'; font-size: 8pt;"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="center"><b>Weighted</b></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td></tr> <tr style="font-family: 'Times New Roman'; font-size: 8pt;"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="center"><b>Average</b></td> <td valign="bottom">&#160;</td> <td valign="bottom" align="center"><b>Weighted</b></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="center"><b>Weighted</b></td></tr> <tr style="font-family: 'Times New Roman'; font-size: 8pt;"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="center"><b>Numbers of</b></td> <td valign="bottom">&#160;</td> <td valign="bottom" align="center"><b>Remaining</b></td> <td valign="bottom">&#160;</td> <td valign="bottom" align="center"><b>Average</b></td> <td valign="bottom">&#160;</td> <td valign="bottom" align="center"><b>Number of</b></td> <td valign="bottom">&#160;</td> <td valign="bottom" align="center"><b>Average</b></td></tr> <tr style="font-family: 'Times New Roman'; font-size: 8pt;"> <td valign="bottom" align="center"><b>Exercise</b></td> <td valign="bottom">&#160;</td> <td valign="bottom" align="center"><b>Options</b></td> <td valign="bottom">&#160;</td> <td valign="bottom" align="center"><b>Contractual</b></td> <td valign="bottom">&#160;</td> <td valign="bottom" align="center"><b>Price</b></td> <td valign="bottom">&#160;</td> <td valign="bottom" align="center"><b>Options</b></td> <td valign="bottom">&#160;</td> <td valign="bottom" align="center"><b>Price</b></td></tr> <tr style="font-family: 'Times New Roman'; font-size: 8pt;"> <td valign="bottom" style="border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);" align="center"> <p style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: 'Times New Roman';" align="center"><b>Price</b></p></td> <td valign="bottom">&#160;</td> <td valign="bottom" style="border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);" align="center"> <p style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: 'Times New Roman';" align="center"><b>Outstanding</b></p></td> <td valign="bottom">&#160;</td> <td valign="bottom" style="border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);" align="center"> <p style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: 'Times New Roman';" align="center"><b>Life (Years)</b></p></td> <td valign="bottom">&#160;</td> <td valign="bottom" style="border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);" align="center"> <p style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: 'Times New Roman';" align="center"><b>Exercise</b></p></td> <td valign="bottom">&#160;</td> <td valign="bottom" style="border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);" align="center"> <p style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: 'Times New Roman';" align="center"><b>Exercisable</b></p></td> <td valign="bottom">&#160;</td> <td valign="bottom" style="border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);" align="center"> <p style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: 'Times New Roman';" align="center"><b>Exercise</b></p></td></tr> <tr bgcolor="#cceeff" style="font-family: 'Times New Roman'; font-size: 10pt;"> <td valign="bottom" align="center">$0.06&#160;&#8211;&#160;$0.08</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">902,600</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">5.58</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">$0.08</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">902,600</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">$0.08</td></tr> <tr style="font-family: 'Times New Roman'; font-size: 10pt;"> <td valign="bottom" align="center">$0.15&#160;&#8211;&#160;$0.19</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">2,072,840</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">5.70</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">0.17</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">2,072,840</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">0.17</td></tr> <tr bgcolor="#cceeff" style="font-family: 'Times New Roman'; font-size: 10pt;"> <td valign="bottom" align="center">$1.00</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">890,000</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">8.34</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">1.00</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">413,333</td> <td valign="bottom">&#160;</td> <td valign="bottom" align="right">1.00</td></tr> <tr style="font-size: 1px;"> <td valign="bottom"/> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top-width: 1px; border-top-style: solid; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td valign="bottom">&#160;</td> <td valign="bottom"/> <td valign="bottom">&#160;</td> <td valign="bottom"/> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top-width: 1px; border-top-style: solid; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td valign="bottom">&#160;</td> <td valign="bottom"/></tr> <tr style="font-family: 'Times New Roman'; font-size: 10pt;"> <td valign="bottom"/> <td valign="bottom"><font style="font-size: 8pt;">&#160;</font></td> <td valign="bottom" align="right">3,865,440</td> <td valign="bottom"><font style="font-size: 8pt;">&#160;</font></td> <td valign="bottom" align="right">6.28</td> <td valign="bottom"><font style="font-size: 8pt;">&#160;</font></td> <td valign="bottom" align="right">0.34</td> <td valign="bottom"><font style="font-size: 8pt;">&#160;</font></td> <td valign="bottom" align="right">3,388,773</td> <td valign="bottom"><font style="font-size: 8pt;">&#160;</font></td> <td valign="bottom" align="right">0.25</td></tr> <tr style="font-size: 1px;"> <td valign="bottom"/> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top-width: 3px; border-top-style: double; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td valign="bottom">&#160;</td> <td valign="bottom"/> <td valign="bottom">&#160;</td> <td valign="bottom"/> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top-width: 3px; border-top-style: double; border-top-color: rgb(0, 0, 0);">&#160;</p></td> <td valign="bottom">&#160;</td> <td valign="bottom"/></tr></table><br class="Apple-interchange-newline"/> <!--EndFragment--> 188333 EX-101.SCH 7 qhoi-20130930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000010 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 000100 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000200 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000300 - Statement - Condensed Consolidated Statements of Stockholders’ Equity link:presentationLink link:calculationLink link:definitionLink 000400 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000405 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 010100 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 010900 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 011100 - Disclosure - Related-Party Transactions link:presentationLink link:calculationLink link:definitionLink 011200 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 020200 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 040200 - Disclosure - Significant Accounting Policies (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 040900 - Disclosure - Commitments and Contingencies (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 041100 - Disclosure - Related-Party Transactions (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 041200 - Disclosure - Subsequent Events (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 010200 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 010300 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 010400 - Disclosure - Accrued Compensation link:presentationLink link:calculationLink link:definitionLink 010500 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 010600 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 010700 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 011000 - Disclosure - Benefit Plans link:presentationLink link:calculationLink link:definitionLink 030200 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 030300 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 040300 - Disclosure - Property and Equipment (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 040301 - Disclosure - Property and Equipment (Components of Property and Equipment) (Details) link:presentationLink link:calculationLink link:definitionLink 040201 - Disclosure - Significant Accounting Policies (Useful Lives of Property and Equipment) (Details) link:presentationLink link:calculationLink link:definitionLink 030400 - Disclosure - Accrued Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 040500 - Disclosure - Notes Payable (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 030600 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 040600 - Disclosure - Income Taxes (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 040700 - Disclosure - Stockholders' Equity (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 030700 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 040701 - Disclosure - Stockholders' Equity (Summary of Outstanding Common Stock Options and Related Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 040702 - Disclosure - Stockholders' Equity (Stock-Based Compensation Award Weighted Average Assumptions) (Details) link:presentationLink link:calculationLink link:definitionLink 040703 - Disclosure - Stockholders' Equity (Summary of Stock Options Outstanding) (Details) link:presentationLink link:calculationLink link:definitionLink 040704 - Disclosure - Stockholders' Equity (Summary of Stock Warrants Exercisable) (Details) link:presentationLink link:calculationLink link:definitionLink 041000 - Disclosure - Benefit Plans (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 040100 - Disclosure - Organization (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 040401 - Disclosure - Accrued Compensation (Schedule of Accrued Compensation) (Details) link:presentationLink link:calculationLink link:definitionLink 040400 - Disclosure - Accrued Compensation (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 qhoi-20130930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 qhoi-20130930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 qhoi-20130930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Series A1 Preferred Stock [Member] Equity Components [Axis] Series A2 Preferred Stock [Member] Series B Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital Additional Paid-In Capital [Member] Defict Accumulated During Development Stage [Member] Deficit Accumulated During Development Stage Accumulated Deficit [Member] Notes Receivable Maximum [Member] Range [Axis] Minimum [Member] Plan Name [Axis] Document and Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Well-known Seasoned Issuer Entity Voluntary Filer Entity Current Reporting Status Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Condensed Consolidated Balance Sheets [Abstract] Assets Current assets: Cash Cash as of beginning of the period Cash as of end of the period Prepaid expenses and other Total current assets Assets, Current Property and equipment, net Net book value Other assets Total assets Assets [Default Label] Liabilities and Stockholders' Equity (Deficit) Current liabilities: Accounts payable Accrued liabilities Note payable Notes payable Total current liabilities Liabilities, Current Notes payable Total liabilities Liabilities Commitments and contingencies Stockholders' equity (deficit): Common stock; $0.0001 par value: 100,000,000 shares authorized; 24,936,833 and 24,761,832 shares outstanding as of September 30, 2013 and December 31, 2012, respectively Additional paid-in capital Total stockholders' equity (deficit) Balance, beginning of period Balance, end of period Stockholders' Equity Attributable to Parent Total liabilities and stockholders' equity (deficit) Liabilities and Equity Common stock, par value (in Dollars per Share) Common stock, shares authorized (in Shares) Common stock, shares issued (in Shares) Common stock, shares outstanding (in Shares) Condensed Consolidated Statements of Operations [Abstract] Grant revenues Grant revenue from sub-award, included in grant receivable balance License fees and other revenues Total operating revenues Revenues Operating expenses: Research and development Research and development expense General and administrative Total operating expenses Operating Expenses Operating loss Operating Income (Loss) Other income (expense): Interest expense Interest Expense Other income, net Total other income (expense), net Nonoperating Income (Expense) Loss before provision for income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest Provision for income taxes Net loss Net loss Weighted average number of common shares outstanding - basic and diluted (in Shares) Net loss per common share - basic and diluted (in Dollars per Share) Statement [Table] Statement [Line Items] Balance, beginning of period (in Shares) Balance, end of period (in Shares) Shares, Outstanding Common stock issued for cash Common stock issued for cash (in Shares) Common stock issued for services ($1 per share) Common stock issued for services Stock issued in lieu of cash for services Common stock issued for services ($1 per share), share Common stock issued for services (in Shares) Stock issued in lieu of cash for services (in Shares) Common stock forfeited Common stock forfeited, share Exercise of common stock options Exercise of common stock options (in Shares) Number of Options, Exercised (in Shares) Condensed Consolidated Statements of Cash Flows [Abstract] Cash flows used in operating activities: Cash flows from operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Original debt discount Accretion of debt costs and beneficial conversion feature Accretion of Deb tCosts and Beneficial Conversion Feature Stock-based compensation Stock-based compensation expense Debt issued for services Debt issued for services Series B preferred stock issued for services Preferred stock issued for services Preferred stock issued for services Provision for losses on accounts receivable Provision for losses on receivables Decrease (increase) in: Other receivable Receivables Prepaid expenses and other assets Increase (decrease) in: Accounts payable Increase (Decrease) in Accounts Payable Accrued liabilities Increase (Decrease) in Accrued Liabilities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash flows used in investing activities: Cash flows from investing activities: Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Cash flows from financing activities: Proceeds from issuance of notes payable Note payable, cash proceeds Payments on short-term note payable Repayments of Notes Payable Issuance of preferred stock for cash Issuance of common stock for cash Sale of common stock, capital raised Proceeds from exercise of common stock options Proceeds from exercise of preferred stock warrants Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Net (decrease) increase in cash Cash and Cash Equivalents, Period Increase (Decrease) Supplemental disclosure of cash flow information: Cash paid for interest Supplemental disclosure of noncash investing and financing activities for the period from March 28, 2002 (date of inception) to September 30, 2013: The Company issued 219,658 shares of common stock in exchange for technology valued at $220 Non-cash common shares issued in exchange for technology value. Common shares issued in exhange for technology, value Common shares issued in exchange for technology (in Shares) Non-cash common shares issued in exchange for technology shares. Stockholders' Equity [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Related Party Transactions [Abstract] Related-Party Transactions Subsequent Events [Abstract] Subsequent Events Development Stage and Liquidity, Policy Use of Estimates, Policy Stock-Based Compensation, Policy Net Loss Per Common Share, Policy Stock Options Outstanding Percentage of acquisition (in Percent) Percentage of shares issued and outstanding owned by Q Therapeutics stockholders (in Percent) Anti dilutive losses (in Shares) Units sold from private placement (in Units) Net proceeds from private placement Issuance cost for private placements Number of shares initially provided for reservation Common shares authorized and reserved (in Shares) Common shares available to issue Total number of shares approved by Board of Directors for issuance Shares authorized for issuance (in Shares) Issued shares to be acquired Unrecognized stock based compensation Warrants, weighted average remaining life (in Duration) Outstanding stock options, aggregate intrinsic value Aggregate intrinsic value of stock options exercised Number of Options Outstanding, begining balance (in Shares) Number of Options Outstanding, ending balance (in Shares) Number of Options Outstanding (in Shares) Number of Options, Granted (in Shares) Number of Options, Forfeited (in Shares) Weighted Average Exercise Price Per Share, Outstanding, begining balance (in Dollars per Share) Weighted Average Exercise Price Per Share, Outstanding, ending balance (in Dollars per Share) Weighted Average Exercise Price (in Dollars per Share) Weighted Average Exercise Price Per Share, Granted (in Dollars per Share) Weighted Average Exercise Price Per Share, Exercised (in Dollars per Share) Weighted Average Exercise Price Per Share, Forfeited (in Dollars per Share) Expected stock price volatility (in Percent) Expected dividend yield (in Percent) Exercise Price, lower limit Exercise Price, stock options, lower limit (in Dollars per Share) Exercise Price, upper limit Exercise Price, stock options, upper limit (in Dollars per Share) Weighted average remaining contractual life years Number of Options Exercisable Number of Options, Exercisable, ending balance (in Shares) Weighted Average Exercise Price, Exercisable Weighted Average Exercise Price Per Share, Exercisable, ending balance (in Dollars per Share) Initial payment for license Exercise price for common stock warrants Total contract price Accrued interest Operating leases future minimum payments due, 2012 Operating leases future minimum payments due, 2013 Lease expense under operating leases Note receivable Unsecured note payable Annual interest rate Note payable, annual interest rate (in Percent) Note payable, maturity date (in Date) Statement of Stockholder's Equity [Abstract] Statement Class Of Stock [Axis] Equity Component [Domain] Class Of Stock [Domain] Notes Receivable [Member] Common stock issued for technology Common stock issued for technology (in Shares) Conversion of notes payable, including accrued interest Conversion of debt, shares issued (in Shares) Subscription receivable $2.30 per share Subscription receivable $2.30 per share (in Shares) Offering and sale of common stock (in Shares) Common stock issued at inception, $0.001 per share Exercise of series A2 preferred stock warrants for cash Exercise of series A2 preferred stock warrants for cash (in Shares) Proceeds from debt allocated to preferred stock warrants and beneficial conversion feature Organization Organization [Abstract] Date of incorporation (Date) Significant Accounting Policies [Abstract] Basis of Consolidation, Policy Merger with Public Company, Policy Concentrations of Credit Risk, Policy Cash Equivalents, Policy Revenue Recognition and Grants Receivable, Policy Property and Equipment, Policy Impairment of Long-Lived Assets, Policy Leases, Policy Income Taxes, Policy Uncertain Tax Positions, Policy Research and Development Costs, Policy Recent Accounting Pronouncements, Policy Subsequent Events, Policy Schedule of Useful Lives of Property and Equipment Property and Equipment [Abstract] Property and Equipment Accrued Compensation [Abstract] Accrued Compensation Schedule of Accrued Compensation Income Taxes [Abstract] Income Taxes Schedule of Income Tax Benefit Reconcilliation Schedule of Deferred Tax Assets and Liabilities Stockholders' Equity Schedule of Stock Option Awards, Valuation Assumptions Summary of Stock Options Outstanding Summary of Stock Warrants Exercisable Schedule Of Property Plant And Equipment [Table] Property Plant And Equipment By Type [Axis] Property Plant And Equipment Type [Domain] Computers and Software [Member] Leasehold Improvements [Member] Office Equipment and Furniture [Member] Property Plant And Equipment [Line Items] Useful lives, property and equipment (in Duration) Property and equipment, gross Less accumulated depreciation and amortization Accrued compensation Total accrued compensation Federal income tax at statutory rates State income tax at statutory rates Research and development credits Change in valuation allowance Other Income tax benefit, total Current: Accruals and reserves Change in valuation allowance, current Long-term: Net operating loss carryforwards, long-term Depreciation and amortization, long-term Research and devlopment credits, long-term Valuation allowance, long-term Total deferred income tax assets, long-term Total deferred tax assets, current Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Award Type [Axis] Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Summary of Outstanding Common Stock Options and Related Activity Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Risk-free interest rate (in Percent) Schedule Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Table] Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Axis] Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Domain] Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] Number of Options Outstanding, exercise price range (in Shares) Weighted Average Remaining Contractual Life (Years) (in Duration) Weighted Average Price Exercise, exercise price range, stock options outstanding (in Dollars per Share) Number of Options Exercisable, exercise price range (in Shares) Weighted Average Price Exercise, exercise price range, options exercisable (in Dollars per Share) $0.06 - $0.08 [Member] $0.15 - $0.19 [Member] Exercise Price $1.00 [Member] Date of agreement and plan of merger, "Merger Agreement" (Date) Effective date of acquisition (Date) Cash equivalents Period of no payment, grant receivable considered as past due (in Duration) The period of no payment received on grants receivable at which the company considers them to be past due. Sub-award received to help fund manufacturing and pre-clinical safety studies for Q-Cells Grant revenue invoiced under sub-award Grant revenue invoiced under sub-award. Concentration Risk [Table] Concentration Risk By Type [Axis] Concentration Risk Type [Domain] One Supplier [Member] Concentration Risk [Line Items] Percent of research and development purchases (in Percent) Impairment of property and equipment and other long-lived assets Tax years subject to federal and state tax examination (Date) Notes Payable [Abstract] Notes Payable Unsecured note payable, total Repayment of unsecured note and related interest Net operating loss carryforwards Operating loss carryforwards, expiration date (Date) Tax Credit Carryforward [Table] Tax Credit Carryforward [Axis] Tax Credit Carryforward Name [Domain] Research and Development [Member] Tax Credit Carryforward [Line Items] Tax credit carryforward, amount Tax credit carryforward, expiration date (Date) Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table] Subsidiary Sale Of Stock [Axis] Sale Of Stock Name Of Transaction [Domain] Private Placement [Member] Range [Domain] Subsidiary Sale Of Stock [Line Items] Aggregate proceeds, net of debt issuance costs Preferred stock, shares authorized (in Shares) Preferred stock, shares issued (in Shares) Conversion of preferred stock, common shares issued (in Shares) Preferred Stock [Member] Warrants issued for services Common stock issued for asset purchase agreement (in Shares) Accounts payable and other liabilities Compensation accrued Accrued compensation Deficit accumulated during the development stage Accumulated deficit Accumulated deficit Executive compensation due upon one year anniversary of reverse merger Accrued wages Accrued vacation Payments of stock issuance costs Plan Name [Domain] Stock option plan expense Unrecognized stock-based compensation expense related to non-vested awards Unrecognized stock-based compensation expense related to non-vested awards, weighted-average period of recognition (in Duration) Share-based compensation arrangement by share-based payment award, number of additional shares authorized (in Shares) Additional shares authorized (in Shares) Class Of Warrant Or Right [Table] Class Of Warrant Or Right [Axis] Class Of Warrant Or Right [Domain] Warrants, outstanding (in Shares) Class Of Warrant Or Right [Line Items] Benefit Plans [Abstract] Benefit Plans Company elective contribution to 401(k) retirement plan Note payable to officer and company in which officer is a general partner Related party notes payable, interest rate (in Percent) Note receivable from minority stockholders Proceeds from related party note receivable, total Entity Public Float Long Term Purchase Commitment [Table] Long Term Purchase Commitment By Category Of Item Purchased [Axis] Long Term Purchase Commitment Category Of Item Purchased [Domain] Research and Development Arrangement [Member] Long Term Purchase Commitment [Line Items] Purchase commitments entered into Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Type Of Arrangement [Axis] Arrangements And Nonarrangement Transactions [Member] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangement [Member] Purchase Commitment [Member] Significant purchase commitment remaining amount committed Note payable interest rate applicable through July 31, 2015, for note payable created through conversion of any outstanding balance under purchase commitment upon conclusion of supplier's final project report (in Percent) Note payable interest rate applicable through July 31, 2015, for note payable created through conversion of any outstanding balance under purchase commitment upon conclusion of supplier's final project report. Note payable interest rate applicable after July 31, 2015 through March 31, 2016, for note payable created through conversion of any outstanding balance under purchase commitment upon conclusion of supplier's final project report (in Percent) Note payable interest rate applicable after July 31, 2015 through March 31, 2016, for note payable created through conversion of any outstanding balance under purchase commitment upon conclusion of supplier's final project report. The company received proceeds of $1,237,263 from debt related to preferred stock warrants and their benficial conversion feature Proceeds from debt related to preferred stock warrants and their beneficial conversion feature. Debt discount related to preferred stock warrants issued with debt and the beneficial conversion feature Two stockholders forfeited, and the Company retired, 200,000 shares of common stock with a net impact on equity of $19 as a result of untimely payments on their notes Two stockholders forfeited and the Company retired 200,000 shares of common stock with a net impact on equity of $19 as a result of untimely payments on their notes Common stock retired, net impact on equity Basis of Presentation, Policy Entities [Table] Legal Entity [Axis] Entity [Domain] Q Therapeutics, Inc. [Member] Q Therapeutic Products, Inc. [Member] Entity Information [Line Items] Grants receivable, sub-award Stock options exercisable, aggregate intrinsic value Warrants [Member] Percent of warrants purchased to be issued to firm (in Percent) If warrants are issued as part of the placement of securities, the percentage of the aggregate number of warrants purchased to be issued to advisory firm. Percentage of proceeds financial advisory firm entitled to (in Percent) Percentage of proceeds financial advisory firm entitled to. Minimum term of agreement (in Duration) Expiration date of operating lease (Date) Operating lease, minimum future lease payments Supplier Agreements [Member] Advisory Agreements [Member] Operating Leases Number of shares of common stock retired during during the period as a result of untimely payments. Common stock retired (in Shares) Stock Options [Member] Receivables, net of allowance of $28,800 as of September 30, 2013 and December 31, 2012 Receivables, allowance for doubtful accounts Interest income Depreciation and amortization Significant Accounting Policies Conversion Of Stock [Table] Conversion Of Stock By Unique Description [Axis] Conversion Of Stock Name [Domain] Conversion Of Stock [Line Items] Series A1 Preferred stock converted to common stock [Member] Series A2 Preferred stock converted to common stock [Member] Series B Preferred stock converted to common stock [Member] Conversion of stock, shares converted (in Shares) Conversion of stock, shares issued (in Shares) Debt Conversion [Table] Debt Conversion By Unique Description [Axis] Debt Conversion Name [Domain] Debt Conversion [Line Items] Notes payable converted to Series A2 preferred stock [Member] Accrued interest converted to Series A2 preferred stock [Member] Notes payable converted to Series B preferred stock [Member] Accrued interest converted to Series B preferred stock [Member] Bridge notes payable converted to common stock [Member] Accrued interest converted to common stock [Member] Debt conversion, original debt amount Common stock issued for preferred stock [Member] Series A2 preferred stock issued for notes payable and accrued interest [Member] Series B preferred stock issued for notes payable and accrued interest [Member] Common stock issued for bridge notes payable and accrued interest [Member] Maximum shares of common stock called by warrants (in Shares) Maximum number of shares of common stock called by warrants. Percent of issued and outstanding voting capital stock to approve share increase (in Percent) Percent of issued and outstanding voting capital stock to approve share increase. Share-based compensation arrangement by share based payment award options outstanding and exercisable intrinsic value Share-based compensation arrangement by share based payment award options outstanding and exercisable intrinsic value. Aggregate intrinsic value of outstanding and exercisable stock options Amount owed under agreement, included in accounts payable Amount owed under agreement, included in accounts payable. Option Grant [Member] Monthly cash retainer Service agreement - First tranche of warrants issued [Member] Service agreement - Second tranche of warrants issued [Member] Exercise price of warrants (in Dollars per Unit) Schedule Of Share Based Goods And Nonemployee Services Transaction [Table] Share Based Goods And Nonemployee Services Transaction By Supplier [Axis] Share Based Goods And Nonemployee Services Transaction Supplier [Domain] Share Based Goods And Nonemployee Services Transaction [Line Items] Warrants approved for issuance (in Warrants) Number of warrants issued (in Warrants) Shares of common stock called by options, authorized under the Plan (in Shares) Equity Incentive Compensation Plan [Member] Award Date [Axis] Award Date [Domain] January 1, 2013 [Member] April 1, 2013 [Member] Service agreement [Member] Weighted average warrant exercise price (in Dollars per Unit) The weighted-average price as of the balance sheet date of warrants issued. Subsequent Event [Table] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event [Line Items] Subsequent event (Date) Subsequent event, number of common shares issued (in Shares) Subsequent events, number of common shares issued. Subsequent event, common stock issued (in Dollars per Share) Subsequent event, common stock issued. Subsequent event, shares called by warrants, additional shares approved for issuance (in Shares) Subsequent event, shares called by warrants, additional shares approved for issuance. Offering and sale of common stock, capital raised Grace 2, Inc. [Member] Cost of revenues Non cash financing activities: Debt discount related to bridge financing Cash proceeds received from bridge financing. Number of customers revenues derived from (in Customers) Number of customers revenues derived from. Note payable, interest recorded Note payable, percentage of face value at issuance (in Percent) Note payable, percentage of face value at issuance. Note payable, nominal effective interest rate (in Percent) Note payable, payments toward principal or interest Investor and Public Relations Firm [Member] Licensing Agreement with Collaborative Partner [Member] July 1, 2013 [Member] Service agreement - Third tranche of warrants issued [Member] Business Consulting Services Agreement [Member] Warrant issued, life of common stock called for, cashless exercise option (in Duration) Warrant issued, cashless exercise option, number of shares of common stock called by warrant (in Shares) Warrant issued, cashless exercise option, number of shares of common stock called by warrant. Warrant issued, cashless exercise option, common stock called for, strike price (in Dollars per Share) Warrant issued, cashless exercise option, common stock called for, strike price. Additional warrants authorized for issuance, maximum number of shares of common stock (in Shares) Additional warrants authorized for issuance, maximum number of shares of common stock. Schedule Of Related Party Transactions By Related Party [Table] Related Party Transactions By Related Party [Axis] Related Party [Domain] Related Party Transaction [Axis] Related Party Transaction [Domain] Related Party Transaction [Line Items] Officer and Affiliate [Member] Bridge Financing [Member] Related party transaction, cash proceeds received Related party transaction, date (in Date) Agreement with Vendors to Issue Stock in Lieu of Cash [Member] Promissory Notes Amended and Converted [Member] Public Offering [Member] Subsequent event, stock to be issued, aggregate value of units Subsequent event, stock to be issued, aggregate value of units. Subsequent event, stock to be issued for interest accrued Subsequent event, stock to be issued for interest accrued. Subsequent event, net proceeds Subsequent event, net proceeds. Subsequent event, common stock called by warrants, additional shares approved, exercise price (in Dollars per Share) Subsequent event, common stock called by warrants, additional shares approved, exercise price per share. Warrants issued to purchase shares of common stock, term (in Duration) Warrants issued to purchase shares of common stock, term. Gross profit Gross profit Prepaid financing costs, net Note payable, prepaid financing costs to be amortized over remaining term EX-101.PRE 11 qhoi-20130930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8
Significant Accounting Policies (Narrative) (Details) (USD $)
 3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Dec. 31, 2012
Significant Accounting Policies [Abstract]          
Deficit accumulated during the development stage $ 23,257,551   $ 23,257,551   $ 20,492,278
Offering and sale of common stock (in Shares)     5,000,000    
Maximum shares of common stock called by warrants (in Shares)     1,250,000    
Offering and sale of common stock, capital raised     0    
Period of no payment, grant receivable considered as past due (in Duration)     30 days    
Number of customers revenues derived from (in Customers)     2    
Sub-award received to help fund manufacturing and pre-clinical safety studies for Q-Cells     631,383    
Grant revenue invoiced under sub-award 491,588   491,588    
Grants receivable, sub-award $ 3,667   $ 3,667    
Anti dilutive losses (in Shares) 16,107,458 15,072,509 16,107,458 15,072,509  
EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0#ZP-;3N@$``-<0```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F%U/@S`4AN]-_`^DMP9* M4>#T;*N M@@486RJ9$A;%)`"9*5'*:4H^)B]AGP36<2EXI22D9`66C(:7%X/)2H,-?+6T M*2FFYL[?FBG5/)OQ*=`DCGLT4]*!=*%K>I#AX`ER M/J]<\+STC]2KA1B'QEN\86I;97'H/0 M3H5FYG>!3=V;WQI3"@C&W+A77GL,NJSHES*S3Z5FT>$F'90JS\L,A,KFM=^! MR&H#7-@"P-55U(Y1S4NYY3Z@WRZVM!W8F4&:]VL;G\B1(.&X1L)Q@X3C%@E' M#PG''1*./A*.>R0<+,8"@L51&19+95@\E6$Q58;%51D66V58?)5A,5:&Q5D3 M+,Z:8''6!(NS)EB<-?DO9W4^-@)MKW__.MHV1W*+=:L*[)G_-=9-CRD7W(!X M=\8'[+,#_.Q]B,/'S[%1VOH@;N#T7=@F[:8ZU+X1&%?"+FMW9=:=H@_QIPON MA69HC@D$B`YMVAY+#+\!``#__P,`4$L#!!0`!@`(````(0"U53`C]0```$P" M```+``@"7W)E;',O+G)E;',@H@0"**```@`````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````````````````````````````````C)+/ M3L,P#,;O2+Q#Y/OJ;D@(H:6[3$B[(50>P"3N'[6-HR1`]_:$`X)*8]O1]N?/ M/UO>[N9I5!\<8B].P[HH0;$S8GO7:GBMGU8/H&(B9VD4QQJ.'&%7W=YL7WBD ME)MBU_NHLHN+&KJ4_"-B-!U/%`OQ['*ED3!1RF%HT9,9J&74"T\ MU<%J"`=[!ZH^^CSYLK$SO+=N5#9@NIS]NHFD++28,5 M\YS3$$ MX4UD^&'!Q0]47P```/__`P!02P,$%``&``@````A`$ MM^X'F$1-0E,[V-Y'__U,UZ4M=-HEZ!*P0^271Z\4>;'ZVC?)!SI?6Y,)&*0B M09/;HC9E)MXVSP\SD?B@3:$;:S`3!_1BM;R_6[Q@HT/\R%=UZY,8Q?A,5"&T MCU+ZO,*]]@/;HHEOMM;M=8A+5\I6YSM=HE1I.I'N,H987L5,UD4FW+J(YV\. M;3SY_]AVNZUS?++Y^QY-N'&$_+1NYRO$$(-J5V+(1+?EY?'-;!`5"WE;#`R9 MU<"0E,,-!T@Z:M(G'1\.331;EZB?-86#.SED;A3T":-SZ9E'MW4RK@**S919 MS902`XI9#2A2#C<<(.FH<9]T0FS%>';-<2F/3](OW!FB$]1K8^D*YTREVSK5 M$DPHOZCXDV3])ZF4DL/=:$C?<&>*3!2PHR'9J!&W;T:4;WIM,UT%_5U48TH, M<*L!4H[BGB44.4P`=\?D-``#__P,`4$L#!!0`!@`(````(0`< MX90&SP(``%4(```/````>&PO=V]R:V)O;VLN>&ULE)9-4]LP$(;OG>E_\/A> M_!&@P)`PY:-3+C33I'#4"&L3:Y"E5)()Z:_O6FG,QDXSZ*WJU^^ZS=BZO MWBH5O8)UTNAAG!VE<02Z,$+J^3#^.?WZZ2R.G.=:<&4T#.,5N/AJ]/'#Y=+8 MEV=C7B(4T&X8E]XO+I+$%254W!V9!6A5,*GA<5Q3QQ>*!5YCW MFXHCQ9V_$]*#&,8G&)HE;#VP]>*ZE@I7SP?I($Y&;9%C&PF8\5KY*9:W44>_ M\N,\/VU^V5CQ*&'IWC]]"MVK]?N2X,M;%R_Q\JR.+(7$F_L MO_:E M*$R-?=%S-D9C"TDK0(3>S_[B?L;0)L_H$1G/19W MM8!-&TNW"J(\9ST4=YBZ0X/2G.WED#UP:Y&&5V"WX+E4-)>,(H5!9]+W.X-F MM#.:4;PPZ`CM=&92E"!J!8SJ4."R_9SV*J,Z6_`=0BY1(SK-Z[BE#X-.7;N: M-:FKBML5,S.J0Q',>Q3OUZ$(YA1!##H)[9TJ:G1.*<2@H_//L0HVT<(HB7F@ M.0E4X*>GX*K`;V)S:3XJP;UD\X]@]`<``/__`P!02P,$%``&``@````A`*K2 M8BM]!@``/QL``!@```!X;"]W;W)KY6VI-.I_OQ3!/2H$U"!'2[^]_?&$/P#`G0/K0- M_C!XOC,>3\S3IQ_GD_$]*ZN\N&Q,MK1,([OLBGU^>=V8__R=+'S3J.KTLD]/ MQ27;F#^SROST_.LO3^]%^:TZ9EEM@(5+M3&/=7U=KU;5[IB=TVI97+,+C!R* M\IS6\+%\7577,DOWS4WGTXI;EEB=T_QB*@OK[XGP%$R_Y*:]_-D9-X[Q;?WF]%&7Z<@*_ M?S`GW76VFP\#\^=\5Q95<:B78&ZE)CKT.5@%*[#T_+3/P0,INU%FAXWYF:T3 M;INKYZ=&H'_S[+W2_C>J8_'^6YGOO^:7#-2&.,D(O!3%-XE^VY:_'&L+M@D?2L?7^9Y15.U`4S"RY*RWMBA-,`'X; MYURF!BB2_FC^ON?[^K@Q;;%T/\R5WS`BFBMP-_.BC=W*BOE5J-2E-;I\U-9O!N0>C#QZIK*1&9K M,-S)HYRY"?9(+Q!*&ODLK6Q,SS1`B@J"_/W9]9]6WR$NNQ8)[R`!1K8=(J,@ MS4;=A=XLP[?$'='=DJ@+\/LV$V'=[EF!TS?/(2BZY_<3HG-0PM+![CFANJ`_ MA]\>TTQ^.R0$F7TT1(B1>$A0(\D0Z8T@AVWLL`RU#>MIW'%Y$W"ZGKWYQM%0 M(8Z&N$2*22*:).))(ADCD!`PU?F1E_#&!)'[A+*Q>Z%"Q@28)")%^,W:89S[ M`C\CUL<]SLG22?1AQBSN.GT,D.]0@N;[+F'BNX/G%2I$M/.VK'ZQJ56@QF%Z M-_GZB:E%/F$AGK20Z!9XX`3:))#O4-_F^RYAXCN9>:B0Q[ZK\3'?=0O<&49= M'[\3=7V8V8'G/(HZ5.;YGDN8>$ZR,52(\MSQ-;U5T-7PF./C!N))`\E#`RCB MLHO3=K?Q4B=AXK='LETARF\/.CD\O%7#8W[K!EC@#):Y/GXGX/HP!)R+1P$/ M/N*XA$F-I[NW0D8\VTX2T2013Q+)&($BSV!GFQ_ZAB:Q)R4V;)EVN=L>$PXI MAEN$<-]F#MWQ$0$6N!L0)$:()QR?D31+$,&X8*[C]WL2ED'V0[-7`%/=D[[9 M>>3A80%M62)$,,OSN4V,Q`1Q`DZ?DQ"$0?WS^HA@&623 M-%\&U5(A&4B40J:8-AM$X/.@#X&J@@@1EMR6<;V($,&AH/@VD3M&"/.98[E$ MJ@0AT#HP'KA]X<(ZR!YIO@ZJHT(Z$!="IABEPX*)@%E#(1!S7PF$<,]B-EU= M,7F4;XF!7`EF.'.X_*9VDQV+`>7L`V)(&E=)CT0\9(H9*Y/32#2-Q--(,HI@ M'63_-#\I5+>%DJ)?=4WFA_(+-F@UJH/>M,'*(%)&TR;B%NDJD1;F9A8)&F>^ M)UC?QF`!9!\U7P#5=2$!:&?(],YL(:!"DPUUBPG.['YNS>PC#`CA6\1$C`G7 M]4GM2##`&=19_F@MR'YJO@2J^T(2D/F'K.OAY&E`0'>Y+1KV!*EI43NL8LM] MCXS'>)S1LIF@<>;:MGA4$65+-=]QU8`AQWO#;?+K3=I"N$Q[=$-LF2*52"&6YSUW/=?CM' M8O`/=8T-C;M&FJAAR^BED*[3[0PFFL'$,YADG,%B?*AWY,/>T>]55DNC9=0I MQX+=S0S,W,T,C-S/#,S19R4MHV=LO[WA!)%- MFU8ZYITHPFG_0!.R^X(%47&+[["6@UZ;`HPD9XR!&<^4 M[RT>MSE**?5>0IVXG[/R-=MFIU-E[(HW^<[!!O]N5V_O0SYS>?C MP^L16\,A.%Q?W6Z`UQ?7]#7[(RU?\TMEG+(#/,I:>I"MI7H!HC[4Q;4Y_W\I M:GAQT?Q[A!=5&9R\6TN`#T51=Q_D`VZOOI[_!P``__\#`%!+`P04``8`"``` M`"$`*R*#(=0$``"E%```&0```'AL+W=O9[O$FK M;5JPBJ[\3\K][^N??UJ>6?W&#Y0V'GBH^,H_-,UQ$00\.]`RY2-VI!5\LV-U MF3;PMMX'_%C3="N-RB*(PW`2E&E>^>AA40_QP7:[/*,O+#N5M&K024V+M`'^ M_)`?^<5;F0UQ5Z;UV^GX+6/E$5QL\B)O/J53WRNSQ8]]Q>IT4T#>'U&29A?? M\LV5^S+/:L;9KAF!NP")7N<\#^8!>%HOMSED(,KNU72W\I^BQ3-)_&"]E`7Z M-Z=GWGGM\0,[_UKGV]_SBD*UH4^B`QO&W@3TQU9\!,;!E?6K[,"?M;>EN_14 M-'^Q\V\TWQ\::/<8,A*)+;:?+Y1G4%%P,XK'PE/&"B``O[TR%Z,!%4D_Y-]S MOFT.*Y],1N-I2"*`>QO*F]=Q<@)_E9.8C))X/)T- M\!(@(YG@2]JDZV7-SAY,#<3DQU3,8+0`SY?,D$>;ZZU4(4?AY$EX6?E3WX,L M./3G?4U(O`S>H::9PCPC!GZWF*A%!,"FI00TNI3<1;Y$%F`1611=4'G&#[IA M-!$C##'#B,R3FSV]A!-&T+U.$H20-@UD@)BD@QFW"(,!0+J)"@8$9O-^PL)H MY4.6;1D)25K_R``Q$VS$;#).DK!%&`P@W\<9"".;@L?.2!F+JL0CCI%,DH`0_MX"821'7YFA4>,:@*9S:93/2@&`_&4 ML%:POP#"R&8PMQ@@YE*`6/?("#\WP]^?/@&VPG9F"^N.F&[O;T2.8-@?SUQ: M]>V@`@TA(73)*G__%D:H9L8:)EK/L!`*=&E`>&,!(B%9CS-`H3,9:*E3#!#4 M,M`S:HQ`Y-#"`35`H3,8=+9,,4`0KL$\C"?A#2F*A&@]7@5A90TDT>.F.""H M.PPDN;&,XK%NT^C?1FEET[#U2(%ZF^$0Q`'-<"FB;K0PL9^*"M0=`STIYCY8FCCL;!"A\,'`=Q[->LQ4"P:K M8^Q0Q_XYD%;6)%X)DP)=>A#=*$/\)6F45C8#6Y@4J&6@I\1H1"STZV%1D%86 M@RMA4B#<%Y(K84#0 M3)[:]8'*F$,1RMZ$_O#2RMX$^QFA0#B'LWD(/^VAVN3P)6TDCF/CU7%%@;I] M(,F-E20.@>S?!FEEET)'P)E4H/N=^)(T$I_D*+@GL9.XF;H`@&N/VTO:5ZBN4]4_L% M7!(=TSW](ZWW><6]@N[`-!Q-00UKO&;"-PT[RJN:#6O@>DB^/,!U((4+CW`$ MX!UCS>6-N,AJ+QC7_P,``/__`P!02P,$%``&``@````A`#@Z\?]C`P``A`L` M`!D```!X;"]W;W)K&ULG%9;;YLP%'Z?M/^`_%[` MD`N)0JIV5;=*FS1-NSP[8()5P,AVFO;?[Q@3($[2TKYP_<[G[UQ\?%;7SV7A M/%$A&:]BA%T?.;1*>,JJ;8S^_+Z_BI`C%:E24O"*QNB%2G2]_OQIM>?B4>:4 M*@<8*AFC7*EZZ7DRR6E)I,MK6L&?C(N2*'@56T_6@I*T,2H++_#]F5<25B'# ML!1C.'B6L83>\617TDH9$D$+HD"_S%DM#VQE,H:N).)Q5U\EO*R!8L,*IEX: M4N24R?)A6W%!-@7X_8PG)#EP-R\G]"5+!)<\4R[0>4;HJ<\+;^$!TWJ5,O!` MA]T1-(O1#5[>XAGRUJLF0'\9WB?5]DX&?PDEI1G:%^L7WWRC;Y@K2/06/M&/+].6.R@0B"C1N,-5,"2]` M`%R=DNG2@(B0Y^:^9ZG*8Q3.W.G<#S'`G0V5ZIYI2N0D.ZEX^<^`<$ME2(*6 M!.XM"9ZZDV`ZCT:P>$91X^`=462]$GSO0-7`FK(FN@;Q$IBU9Q/09'1TOEYR M%7S4)#>:)49SY("YA/P\K4,N.:B.HFP%[B!<=OU%@,",40(9M!2'LBM<5:",K!H%O*3"8F2F!:#:=3'K$ M40QF'U&@C6P%?1&9&!C,,`;1!0E0KN\/@C:R)?0%9B08S!@)^H"P=M_;>=!& MMH30RH/!C)&P^(@$;61+F%@2#&9$*6"HO/='H;&R-?0;SF2B!;4BPBB:S_M( M'=4CUNW)2H5NA*]OB<;*%F'WA1:T:#:%[X9]H(X56'U/MX6WBP&;?G?4F8*Y ME8H6-*8VIH8I-K9&!$+;65GP^Z1#34<E'% MF38YHB;.],FP;T%M81K0FS5QIDV.4'"F3X9VGX1Y20?KH"#HMXZI2C,,F5FA MI&)+O]"BD$["=WK0P5#,W==N"+L)FC&J^P$S4$VV]`<16U9)IZ`9F/KN')P7 M9HHR+XK7S22RX0JFG^8QAVF7PGGNNP#..%>'%SVG=?/S^C\```#__P,`4$L# M!!0`!@`(````(0!?,(%XS@D``+T^```9````>&PO=V]R:W-H965T8`0:+G9EGQU82HVW+ ML)Q.][_?HD@I9HFILCWST)F8'X^D(Q9YJ%CWO_S8;0??RV.]J?8/PW@4#0?E M?E6M-_N7A^&?_U-?YL-!?5KNU\MMM2\?AC_+>OC+X[__=?]>';_5KV5Y&H#" MOGX8OIY.A[OQN%Z]EKME/:H.Y1Y:GJOC;GF"7X\OX_IP+)?KIM-N.TZB:#K> M+3?[H56X.UZB43T_;U:EJ%9ONW)_LB+'\VJV-55\^G M$SQ7#\>-\8]->F?*_/_G]0 MOU;O^KA9_[;9E^`VW"=S!YZJZIM!?UV;CZ#SN-=;-7?@C^-@73XOW[:G_U;O M_RDW+Z\GN-T3N")S87?KGZ*L5^`HR(R2B5%:55LX`?AWL-N8H0&.+'\T/]\W MZ]/KPS"=CB:S*(T!'SR5]4EMC.1PL'JK3]7N;PO%3LJ*)$XDA;-W[<"YQU'V]G1#X+,1`+?>B'PU*@]# MZ`\WMX9A^_TQF:?WX^\PU%:.R?O,9.$C18N8@65T1?O!AV[L=Y$MT791]@/X MMSN5:>3WT2UB*@%LZ+R`@7?N17C0MY=L8'/)[8%S^\'Y@1/_N$6?F*++$7T$ MB<@^@454'T$BND^D'R9YGD`17NZ)@1^&(-YYG\PSWX3<,E"5'3/QB8(EA"7F MS4"+9Y,H^CCY9MQ(#X!FU*[.V]/42/CGH*ES\/R!"SGWQ]1/"M,N/79,)]^G MR?IQXCS[()Y]-PN MVB8#^S8MT'W*+>)LFF0IGE'.V[,HR]!8$^?MLVD:3_W;(,_;%Y-%_'%9S4!3 MY^V3:!['Z#YJ"X!!@9OD.0-KP[DSEPTDT\EW"-9)_Q)RRX3/H+F(@B4$2TB6 M4"RA*<+S"A::Z[TRG;!7Z';GEJ&\8@EA"3LDS=R$IGC)*BB6T!3A.66"^=GR M3M>;@;%#>/JV#.402PA+?.X0JZ!80E.$Y]#"=^BRNC.=L%.H\G/+4$ZQA&`) MR1**)31%>%[%L+*=#Z?+S&IZ8;=PY3F(LHM'A$/LT(K-PH\6#,F+*![1).); M9L+FQ148VVA*)R@'D599'0(13H6RBA51_*EH$O&M,JGT$0^Q$!D^(^E,^>QC%'T:3B.^8R;'7.V;3 MK^\8VO+E<1N1S2.6&)[!^?-=T;6'MAM-[8H."4O(KOU3"=4A80G=M8F6B+/.,?.<0V$/N>]0J2 M2LW.,Q81[E!$0;(:RFD04X,F$=\Q$W"O=\S&8M^Q7D&VV=F6PJQ7D&U[J!1< M0;9(6$+&;?NG$JI#PA*Z:P])>%8E@83/%V33"Z^0R(K<0<0M+7A$\(CD$<4C MFD1\SU#$ORR+)8&HWULA'41ZQJ9TX50^+TC^,(I'-(GXCD%175^0B>F%1QDN M2`=E]L%I?X7LVD.E8`NR0TPUP9]8T$"67?NG$JI#PA*Z:P])^%:AH$]'U200 M\!=XJ^T@P#!JT@>43RB2<3W"B[IAF%E>N%AA5?&Q$*D9RPBG(K;;4GT22O7HEN<.(@=7&_Q#Y^F\ZB/)`FWN)7\HQ2.: M1'S7`@&?#ZM)/^"G>%N7.XATC0_XO(KD$<4CFD1\STP\OCJN)C94TW'506U% MXJ6MZ-J)8=:&=UM06$+R$JI#PA*Z:P^=A6^5R<;76V43];E5*?XS39ZPL;O@ M$<$CDD<4CV@2\3PSY7>]9TTOM$K.T>R2.X@J21X1`:3_Z#``H9RF>$23B._: M32$_#85\'%D=9(LR&TT6_G_R"PHC1=@04V(7:,JNPZ>:JD,NU-1= MAY"F[^Y-&X*TOR%((V16[B!R3%H=`A&\BN01Q2.:1'S/T,[@LFUGVM\AI%%O M1++QOW`ZI&=6Q:9=\UP6+^&2%U$\HDG$MPQ.]X:IS_1"4]^B9YF%VGUG[T%0 MVK:':L'5;(N8^DI&6$+R$JI#PA*Z:P^=A6_53=N"M+\M2".4VG,'P=4&OA/3 M6%'PB.`1R2.*1S2)^)[=M$5(`UN$_LK:#_=HN2N<#F&K""!IA'1D`$*(XA%- M(KYK-VT1TOX6(>D799O_;3G@K%HX$=(R6D+R$JI#PF>AN_90/?A6H9T!_3`H M[>\(T@@_#'(084'!(X)')(\H'M$DXGL5V!KP3[+3T-8`/]=P4+NP90OXJR/Z M0YQ#"%L%KR)Y%<6K:%+%\RP+;`UXSYI>_OJ81O@9AX/L=W:3>-'_JJ8C*,M8 M$!M(^_PYP[B/2,W1`( MIV(G17A:%XC[_($4CV@2\3V#2\)Q_X+IS/1"TUF,XWYF(=(S%A%.96)GQ6@T M19.`Y`^C>$23B._83:G?>-IS#*=^![GQL9C/)@FZVL(AA*F"5Y&\BN)5-*GB M>W93ZL_ZJ3^-T:R;.X@PI.`1P2.21Q2/:!+Q/;LI\V?]S-][8R-WD!UG\7P6 M&F=MI@\%;KL7YU6D0XB;HW@53:KXGJ'P?]GSGBRP"<`OJ>0.(BZEX!'!(Y)' M%(]H$O$]"VP"S#-?)I\%-@'XS:`<7L,UDYX=9UEXG%F$L%7P*M(AA(KB57\JBW&[KP:IZ,V_\IO"-BN[3[FWDKXEY`1)]GL=W M1?-*+_I'#\N7\O?E\66SKP?;\AD.%<&SK^'@:%\_MK^< MJD/SKNI3=8+7AIO_?877Q$MX230:`?Q<5:?V%W.`[L7SQ_\#``#__P,`4$L# M!!0`!@`(````(0#NBR,Q<0,``!8+```9````>&PO=V]R:W-H965TOA(^$H54A:K;I$V:IGT\.^`D5@$CVVG: M?[]KG%#LK!%='I*`CP_GGGM]N:O;YZ9VG@@7E+49"EP?.:0M647;789^_7RX M29$C)&XK7+.69.B%"'2[_OAA=63\4>P)D0XPM")#>RF[I>>)U8>&M)*3<))C27H M%WO:B3-;4TZA:S!_/'0W)6LZH-C0FLJ7GA0Y3;G\LFL9QYL:XGX.YK@\<_<7 M%_0-+3D3;"M=H/.TT,N8%]["`Z;UJJ(0@;+=X62;H;M@600A\M:KWJ#?E!S% MZ+\C]NSXB=/J*VT)N`UY4AG8,/:HH%\J=0LV>Q>['_H,?.=.1;;X4,L?[/B9 MT-U>0KHCB$@%MJQ>[HDHP5&@<<-(,96L!@'P[314E08X@I_[WR.MY#Y#L]B- M$G\6`-S9$"$?J*)$3GD0DC5_-"@X46F2\$0"OR>2('+G892D[V&9G5C@]\R2 M3)7BZ;!ZE^ZQQ.L59T<'2@^$BPZK0@Z60'RV1PQ2FP$J>2 MJ]3F^L9823@\ID<4UQ"&$+!LNA`%AOH9.Y`FYI-SC9F/,)&)**XA#&U`,EV; M`F<(XAZR$R;6DW.-275^(Q\^EK0Q((K\)(I?C36DP=$92U-5-X.C?3V/:I,M M,385Y!H3:8V^:T50O+ELJ(O_1YW:9*NSDZLQ@SH_-=47;Z\;^N"QG?A"KT-VA^)X-=90IMZ:HVYR79D"F\KF=L_0D+@7UA>< M77%7`(:PQ7N$*;`I+$P69JIRC='*XF@Q?RUTW4'T^@3+`JC[L6?3SD*_R]*8 M6N;D)Y`6&:3I;#8SHRBN(0S_`M6;1YF=J%)W=*.KI%;7SWOJ#)V.K"U0,TSQ M4?7L]RO4G=Y4:.4RA_E$%<3IW`9N9'4=-<"\!=`NZO%$OW@;PG>D('4MG)(= MU.@10'T/=X>QZ*Z?BKQA`::2#N_(-\QWM!5.3;:PU7<3Z&E&PO=V]R:W-H965TY=4^)O_\_7AS2RS1)E66 M%+QB,7EE@GS9_/[;^L2;)W%@K+6`H1(Q.;1MO7(252V2-*Q(6M`O#GDM MSFQE:D)7)LW3L;Y)>5D#Q38O\O95D1*K3%??]Q5ODFT!>;_019*>N=7#&_HR M3QLN^*ZU@@CB;M2K0OSD[B=%[ M2QSXZ6N39S_RBD&UH4^R`UO.GR3T>R8_@F#G3?2CZL"OQLK8+CD6[5_\](WE M^T,+[0X@(YG8*GM]8"*%B@*-[062*>4%"(!7J\SE:$!%DA?U_Y1G[2$F?F@' MD>M3@%M;)MK'7%(2*SV*EI?_(8AV5$CB=23POR.A@;WP@NC6@,5!12K!AZ1- M-NN&GRR8&EA3U(F<0;H"YG-FJ*//];U4(4=):7\3^RC`3' M!+A[\?YBV?/BRHA9C#!!CY@D")!Q@K+F/LSDY41E$.!&['[@]ORH`#$&"F#J MQ@HNKRS!6N[!T#I<&3&WJO5>Z,J_7MLD]W"ZLIHW%Z(O2Y!1NH2AK2@!,0%J M<&UWF+^)`!C2<>J&`F24+L#O,T0!B.D%#"6:K"_/!&W#76^^#-*77VC+(Z9K M`?7#R'^G!/(JZMKH=R`3$=*(/MP!BO8U M<8`@U%K0@<8B_"#J09,YH-*H/BX#[6TJ8YAT[(>BCDDWB9&MMN/P$OUY,^R= MJ2;-$\V26=, M\VTS$#0T8]A+TZ'43--P'F;<,QSV7M<,8_OT/F6?*NK:SNA`!LWP9NQSZ8>=,QL&;,4H# M!3-&&0XNB..@J&,R[H0?#@?-5`:@=*LTD"&C]%X,IU0G`T'8"ZH.#^TX#C/XP>_:`-YQWIX?Y$6NOV!O_@<``/__ M`P!02P,$%``&``@````A`(K45J_<`@``1`@``!D```!X;"]W;W)K&ULE%7+;MLP$+P7Z#\0O$=O^07+0=(@;8$6*(H^SC1%241$ M42#I./G[+D6;D9TT47R01&EV=F=V3:XO'T2+[IG27'8%CH,((]916?*N+O#O M7[<7"XRT(5U)6MFQ`C\RC2\W'S^L]U+=Z88Q@X"ATP5NC.E78:AIPP31@>Q9 M!U\JJ00QL%1UJ'O%2#D$B39,HF@6"L([[!A6:@J'K"I.V8VD.\$ZXT@4:XF! M^G7#>WUD$W0*G2#J;M=?4"EZH-CREIO'@10C05=?ZTXJLFU!]T.<$7KD'A;/ MZ`6G2FI9F0#H0E?H<\W+*506^BE?7<83#S7HPZ`]G>SUZ M1KJ1^\^*E]]XQ\!MZ)/MP%;*.PO]6MI7$!P^B[X=.O!#H9)59->:GW+_A?&Z M,=#N'!198:OR\89I"HX"39#DEHG*%@J`*Q+93& M`$=;ILTMMY08T9TV4OQUH/A`Y4B2`PG<#R1Q'F1)/E],8`E=18/`&V+(9JWD M'L'40$[=$SN#\0J8K;(,:G)U>*W_DPH:+_"4 M'C#7#@-7CXD](H1J?$E0QKBDETT^9K9@F]F:;DNY=B_&:9*7TZ3O26/!T+51 M\>ELZ7E=9H?)1IC<(TX$`F0LT'J>PDR^+M0&%1C4>?O2>>3Y704.LQ@:D.01 M_#S@I`!H\+B`UQ-;\'GBI\ZYQ`XS0?KL/9DM^"W3'69"9AC.L>9IIMN@<^U/ MX^2T.TP^F)[%V?)I[D\\MV?!Z(_VNN<6?)XW];UT>1UF@O+E>S);\%N>.\R$ MS+`GGXB>9OH0=:[^W/4#Z&A[GLV]/U.P[437O-&I9!:%1,(=Q5^X4<`LC^V$GW4H#N_?PV,!I MS6`_B@(`5U*:X\*>,_[\W_P#``#__P,`4$L#!!0`!@`(````(0#[8J5ME`8` M`*<;```3````>&PO=&AE;64O=&AE;64Q+GAM;.Q93V_;-A2_#]AW('1O;2>V M&P=UBMBQFZU-&\1NAQYIF9984Z)`TDE]&]KC@`'#NF&7`;OM,&PKT`*[=)\F M6X>M`_H5]DA*LAC+2](&&];5AT0B?WS_W^,C=?7:@XBA0R(DY7';JUVN>HC$ M/A_3.&A[=X;]2QL>D@K'8\QX3-K>G$COVM;[[UW%FRHD$4&P/I:;N.V%2B6; ME8KT81C+RSPA,S*A/D%# M3=+;RHCW&+S&2NH!GXF!)DV<%08[GM8T0LYEEPETB%G;`SYC?C0D#Y2'&)8* M)MI>U?R\RM;5"MY,%S&U8FUA7=_\TG7I@O%TS?`4P2AG6NO76U=VJ^>?__J M^5/TZOF3XX?/CA_^=/SHT?'#'RTM9^$NCH/BPI???O;GUQ^C/YY^\_+Q%^5X M6<3_^L,GO_S\>3D0,F@AT8LOG_SV[,F+KS[]_;O')?!M@4=%^)!&1*);Y`@= M\`AT,X9Q)2"M.69EN`YQC7=70/$H`UZ?W7=D M'81BIF@)YQMAY`#W.&<=+DH-<$/S*EAX.(N#UO5D" M53,+2L?VW9`X8NXS'"LY1ZMAUC_J"2SY1Z!Y%'4Q+33*D M(R>0%HMV:01^F9?I#*YV;+-W%W4X*]-ZAQRZ2$@(S$J$'Q+FF/$ZGBD".S1P1%H$B)Z9B1)?7B?-AOZ'&(K MA\1JCX_M\+H>SHX;.1DC56#.M!FC=4W@K,S6KZ1$0;?785;30IV96\V(9HJB MPRU769O8G,O!Y+EJ,)A;$SH;!/T06+D)QW[-&LX[F)&QMKOU4>86XX6+=)$, M\9BD/M)Z+_NH9IR4Q>Q,O M91&\\!)0.YF.+"XF)XO14=MK-=8:'O)QTO8F<%2&QR@!KTO=3&(6P'V3KX0- M^U.3V63YPINM3#$W"6IP^V'MOJ2P4P<2(=4.EJ$-#3.5A@"+-2[\JIB4OR!5BF'\/U-%[R=P!;$^UA[PX7988*0SI>UQH4(. M52@)J=\7T#B8V@'1`E>\,`U!!7?4YK\@A_J_S3E+PZ0UG"35`0V0H+`?J5`0 ML@]ER43?*<1JZ=YE2;*4D(FH@K@RL6*/R"%A0UT#FWIO]U`(H6ZJ25H&#.YD M_+GO:0:-`MWD%//-J63YWFMSX)_N?&PR@U)N'38-36;_7,2\/5CLJG:]69[M MO45%],2BS:IG60',"EM!*TW[UQ3AG%NMK5A+&J\U,N'`B\L:PV#>$"5PD83T M']C_J/"9_>"A-]0A/X#:BN#[A28&80-1?F#R`Y+<BZ\(6*V)TJ[4E:JJW7UVS`!6 ML`?93DB^?<_X#+9G3%C(0X+COP^_'HOWHC+I.F<^_ M[2I99\\'\/N=^EE^MMU=3,R715[+1F[;&9CS$'3J<^(E'EA:+38%>*#"[M1B MNW2_TOF:,==;+;H`_2C$J1F]=IJ]//U1%YN_BDI`M"%/*@//4KXHZ;>-^A<\ M[$V>?NHR\'?M;,0V>SVT_\C3GZ+8[5M(=P`>*0043`S8X&RE,L# M`,!OIRQ4:4!$LO?N[ZG8M/NER\-9$!%.0>X\BZ9]*I1)U\E?FU:6/U%$M2DT MPK01#O3Z/INQ.*!!^&LK'A)U#CYF;;9:U/+D0-7`>S;'3-4@G8-EY1F'^%SV M#%Q2SWQ5#W6/@KJ!=+RM6++PWB""N9:D%R2F8CU5<-)+/,#K&<'S,>-U-B4& M'URG9^.T-]OAIRCQ1Y+`5*RO*0PT>)_;T91XZ8+M`8V9;YRB).YBRCGAH4TV M%D2)STC46S#`P+LQF,JK_VG%GO.J'K(`>6\>8X>2L`.$R@N'M^_NK\?W_2B* MR>"AP0*8"80::6 MW&B"7,^D$EMD5@6E*$$R3A@;"@@#-KY/0^(/E6!@)?=@*;&%%?=YP("A!+&B M@-KE]>EM`XK":+T]6)W:PIK,665QZ>I$1GXR*3!M!164DR#A0TA-.FL97$\E MQ0$.`ZGO*-\J[E1K+G<=IO.JQ,134_GF2J,XP\?3UK<7@=9@:!CC89Q8?;(V M))01/A[))IX:S;?CX2`W\(:T8,E1U"!>F$2QQ;\V!$D8?]*A5`WEV\EPA!MD M5K6GG<5SU3'.@DF7&HHXBI/!.3-J=RT"]:'+:M11_^NHC5=!0-2/V5R M59IT=RT#.MT&_I`233>>][#@$YI8+;W69OJ&);#F>P],O+NV`L61;C2L5>ZI MUEP.C6Y8-'-98N)9JT%]"(D@.[^8*],=X=L[@HZ7`/.380=H1O-^-+AI`MZU M).AT2_CVEM`:/5%(E)`HL#1K2P/TT6?=P>[:%YW:W!>^55RIUB#@@VK=*`CL MN6*)B)\P%@UN&#%D=RV-3FTB!E9[IEIS1O1#GTUZQ-#X23+8,.'4$AA-OMN. M-W"4M*>,':)4:_"3>G!I[QJ*RWL7#YQX'CMF._$]JW=%U3@'L856(3/5+#4> M-_&BE3\?,KM^;FKTQ*3BHLUQZ`48L9:*@K?K'/_\<7>5 M8:0T:0M2BY;E^(4I?#W_^&&V%?)158QI!`ZMRG&E=3?U?44KUA#EB8ZU<*<4 MLB$:AG+MJTXR4MBBIO:C($C]AO`6.X>I?(^'*$M.V:V@FX:UVIE(5A,-_*KB MG=J[-?0]=@V1CYONBHJF`XL5K[E^L:88-71ZOVZ%)*L:@IYDG_L0'I_FLX)#`M!U)5N;X)IPN4^S/9[8_OSC;JE?72%5B M^UGRXH&W#)H-TV0F8"7$HY'>%^8O*/9/JN_L!'R3J&`EV=3ZN]A^87Q=:9CM M!`*97-/BY98I"@T%&R]*C!,5-0#`-VJX61G0$/)L?[>\T%6.X]1+QD$<@ARM MF-)WW%AB1#=*B^:W$X4[*V<2[4QBH-_=C[PH2\(D_;>+[XALP%NBR7PFQ1;! MHH%GJHZ8)1A.P=DD&YU-!I%,S8TILJ6@5C`;3_,DFOE/T$&ZDRQ.)0/%\E01 M!P<3'_`.C)!\R!C#'/Z]^WM&4P1]QNC(&!_L;8R%DXQ>2_J*Y5N*'B(\YW)$ M4Y1C>,81<=0'6#A)9GL<95EP[)"-L#Q_OX<'&2_',T4#O&2`YR03BQ=^NAK0 M+\_>[L'!4& M6G1V"Z^$AA/'7E;P@F&POP,/Q*40>C\P9^/AE37_`P``__\#`%!+`P04``8` M"````"$`%@ZIU"(L```QE0``%````'AL+W-H87)E9%-T&UL[)W; M;AM)MJ;O!YAW2!@NV`8H66?+W=6UH9)LEVN[;-FRI[#1F(L4F9*RBV2RF:1D M->:BWF'F9H"]`3^+'Z6>9+Y_142>DZ*KO7MF@`;Z8)&9<5CG]:\5P6__Y>-D M'%TG\SS-IG^ZM[VY=2]*IL-LE$XO_W3OP_OG&X?WHGP13T?Q.)LF?[IWF^3W M_N6[__I?OLWS1<2[T_Q/]ZX6B]D?'C_.AU?)),XWLUDRY9N+;#Z)%_PYOWR< MS^9)/,JODF0Q&3_>V=HZ>#R)T^F]:)@MIPOFW3DXN!WT_QI]%,V M75SE/#I*1LUOSY+99K2[-8AVMK9WFU^^SJXWH^V][B_O6$;TYZ/S?#&/AXO_ MWASV0?,#OXEWR66J5]C:ZWB2-)]Z\#9Z?Y7,XUFR7*3#?,"FAYO-A_Q0Q]!G M'H]Y9)1\C/XUN6T^]V!KBPT?'.SO;3>_*C;V_G;67L3VUL;;WC=.DWF:B2FC MZ"1>M%X^@FTC8]WS<7S9'.7!13S.6^\<+^=S-A,]3_,A&_JW))[WCO]@8V-[ M9V.WM2-/E)^3\7CCEVEV,XW.DCA'@D?1RSQ?)O/64EYGS8_\&/\M&R^GBWA^ MRX+&[1?]4V'1[Y)9-E^@/='9(EXL\^:@#_XM:7WFA[#AHV.H>)G-V^P[F\1C MYH_*&8ZSR2R>MIX,*\HFDXQ]+[+A+X/H["J>)WGT9KDP;6:!S9450N#I[CG[ M'-UKK?C!VY;F-%\WMG6_W*5XQQER.\WA#__*LW$Z@@ZCZ/MX'$^'"#E*^>81_SX[B>X_:FTC&:+>VZ;!.\TO`Y?B/&>X/[2^CO.KYF?ODF&2 M7L?GXP3]FR:+*+N(8$1V8^OBC_L[AX/#K:THSO45UF613,[A4S`Q9K1.&,5] MVK.RTWDRB]-1=)%.&5CR,\SRA9NRN:3P;/(12YO#59G%;(&E:#[Y/EN@04.O M4&[7S6=.YQCL.195HR1_7:8SZ:OMM?GH&\W!1D6\YG=NJN[O`MG':7R>CM-% MFK1I?S0T7Y!'L_A6U&Z.S_?S)1)1&:/OD2%Z`6'B18=O>)TM(%C/''5RK9C) ME.HJ&X]PG`^,:-#OX2BY2(?IXE%;KIPJYE+%/T;WMS9EBEG$/+J.Q\OD#]'V MUM:`S_3?*'>:&B\75]D\_5LR^F.TLS=XNGLP.-S=-2;QYY.#;?[<"0]GI5I_ MH1P.(LS"+!DNTNMDW#(E1R.4#2HB1)+.C70:#>-9BE!UT'XY68Y-:3T=FH\X MZAH1>DG7_4Z%$T:`+QMC3=-RBH$D:DCPM/%8YN5.4[/>P/U10+9J$P?;+NALE!J4H10]AT4DV'L=SI!QE-;O?,I+UMUL29Z,X MC['>JU7YTPIZW^TT\O*4B8R.6=`W+-M4=RUSO[LRUMO>/5SY?346;#N+;I?4 MN]I^1K^P"&^>7"?39=O]OTJ',N/115(UY>AE]^-.C62SH1)^HN^Y8_R'/%+? M]R_F68Z,S+.+=-&4+L\#1@\^IF73WB4Y@=GPRA1RQ%K'F3F.YE`ODBDK19#Q M+O%HDDXMX)6Y:3[9W%B8NOE9)-%#/T;;)+^<+A(LWR)R M3S9'*;[V`S2_=Y[0O=OI*OUF.A?3^<(K<>,\0?D3,>4Z5486R1;XO2SBCVW9 MP7FO^>2#SY\^?VINXS7Q3!<1?T[2RRO%7S&I87R91-.E12^($W0UP^.\5%7Q M-Z+S.$^'3B#2\5+OKS`&86XS4]51H[Z!UK%K:QB88Z*\Z#D1W%H&QIZ^L*]KHYZBOHAJ%D=G4`P68*G*;>4N#SQ3@;"`%[`>.]@9A)UI-JCR,@!<)SY/Y M-4:PIWSO.G\^0B(7D<.;^XSBL_QW,9YWR=9^O*)KW!8$,U^!%2A"9I MB?M!/C#N*(+[UR,XW6%,>T=@3Y88!&MH7+%@OR<0?^DG4CRZ8LIFO%T9MQ)N M-?39,DE$> MF7)+)D->-UV5*9S&MSY@(08C3E]LX$XFD=[I2RZ$.X2Q4>&:H$H)1-;FEJKO M!!,I'3.MZ7H!$:UL)_F8S(>IHV'M]6PF=6_I6__;S07?>+5I+KB0#UAVG8[0 MQ//;2DY;,J+KQ9K`>KVQC*--&!,IEW&?@Z%-IXJ$D!3\K?P)D%1S@LH;0%*K MGSU;SF9CBTAE.K&:Z#KF3B^)Z)'<`6H,UT`X(61+GVTRE\^;`W>Q1G-)K[$= M;KPBZ2\)U!K3C&8PX=@A#&0#J+5F9_AI+@O8ZVH].& M+7)N7L$;O*M9C3__9!A6"]TF#PZ!P1L0,%O,GU^ETR1Z25Z7KWH>8?$I;.YX M7\Z^8MMA\3M?8?%^K.^_PE`U[GG)D^`VA68-.K;HXH=;093757_E@S7/Q9)> MZR[%%*#"UU7LM&<=WY2S#")@JTK4&4_Z8DZ%?VG(PTK&F\EPTKFS-NWZMUAA MQ+1&(LM(/:I8+&,]WHP(8`CE+*68.H M-BSV+[.A7)61X8M/'EENL'*HU\ERGKVE-N5`(1LC>CADX@`M-Z9CM7AT_"-\ MF5'$>K197XX2LBB.SN+Q(GH5_\)S.+%!]&$17_D$\SS-9OB,23RTZJ@EJ#84 MP\9*+_'#ADHI-+Q:3F*"+94#77K*U-15Y0*E2*`&YNX6)&ODR3?6EG2<6-NXC^M.(NKO%%NS"(0T4N M`L13(,I3BN0*2]Y&/U!\@;%Y6(XTEM%#G8TUN0H_PZ6DK!;[-<=X;S*PJK;. M$]6P.E%D+_(@][^]NO_SI&. MC0L\(J4C&'B%Z,WCZ%V<#:*?-D\V!]'IE?U?'(WIF.`9!."2A'R,""`QDN`( MR5<4/(A&R[D)-[+..I2A(+VL)/HP173IZ:`J!>>D-(Z_>?0#H^HS/76F$8\U MXIFTE+WYUU];5L.<+Z?DZ0N0/!-_WAT3WCY\_?('I/9DOOGY$PNW?2+N8=2+ M=`ZLF@]34882IOA%)L@?%Z[&F"?)+R3)HAS$8)T"&)F\V*`K:++"5+%3AC*B M4RR3)%V$$TFT?)1G,SJZ(+>B*"@(7;0(JS)25S(&2^]7D(8]R4+)E=#_`K\J MQC3HX,RH#?'(=O:T+<_=METQF=+:G7$V@S3$`)VCR0BN:G2__?KOV<7%!DO: MH"]F?/';K_\1U>U9WFKU.$LOIREHG/I%/'ZC/9]2+H?B. ME[]M]-R\AR$7F/OL1BO**PN-705+'\_\0B,9,/>TTPQCIW,$XBZQ",51O2&E MQ\>5#0$^-S5]0(0,A&FED]^#0YO$G@+Q(V:=V*A6K+69S]!:X;U3/U.0Y@`*UX(VW MTE;S*>1F%`30=.#B;,$+P_%RQ+K1V0K^8,KM(I@I6&2>RPLI\X@ET$`90J4J MI-"B2T+.LN`@>&0YAN)\78J_'!V=8D3>7\$HN`V")A-0$@!0;8FBH##J'!,!F?,O MRZFS4P4%CQW[3-OCZ72)7+1'^U>CA0A^JUXBY^U+3Q&:15KJ]N42#*L41(A`72HN8C.MI7+H!1&H2L^U)<3$KUR^N"JV=2%P$7BEM"MQQE7+I!"QP[%+_BS'/B$ID:08/8 MK;(P;%*BFO9"6LH@1*JJ*_G,21)8.$S\8R6T4E#NT'9QD]Q;/40P7\H@N#)6 MDU,S3G?1`4RO^B)+FL/Z'3!1M=?).*5`K;B[)0LGE8V<&1DT]2L:5LFFFO#: M7$VKV#*3/"_?%H`T(O9NQ-2G;AVJX-*,P!ZJ(Z87/EF!$]6MAK*_D4B/FD?R M_!#IY%H#P4UE@Z^IV`&)`':7C)%BN65(Z)8W-576.L'@"TENT\LQB:M1FSP? ME2X!.M)7/!_EF)V1Q346A#X\.CM^%+W'E`VCI]O[@U"VAJKZSRG_DSZFU_=O MPF[I'=ZZQU^DFH[>$YJ4M_7)_#GFQ3URC)21Y^O3BW@B^V%O[N@#ZUI.W`

6'Y0>X_U.BPD M1[GIBR("I[3H,AK?S.;%GV*,A>C33*75)2LGX;78/5^2\OF'B7BP*NA!?!TS M'JV*VO)%?$W&KC_(1R:LF^#+'/AF])*""*%;K@#3'J`A0%O'DQ?==7[L.G%M MHG'Z"XUYF@_CI\0$`A$*0"!L7I);A:"JBF7)9N!351MF!&YP:ZRK/HS-K9@! M[7]DC;=YC=@67053X<);^6,S*/%,ZLVRR&\E&!8)/L]H"1?+3^;+R^BHTO4# MI1X^/SEZ9'ZY]`%1'H^3/VJ`+B/4-G2%<3/AJ8RC$7R[?#!N-G9]0^S!8!;U MQ=)1Z@KY6N_28GXK\<%`+WMR,X2=KM4#&RNIT/]8A8L,U,S:&M9:))&!;/9) MRO/=W]D=[.P_&>SO;WO7@VFI'&EX@<:["$]AH!1K)C3&?&:R,1P3]:&=1O/B MC[48/:C$B7!TG&+QT"K%E4T]SY<7Z@31Y)@;KT1(H^EX#DWS#SO4("Y"EC8N)JV4+,LU^!A$"W!@0]_7<9SP0*0AU[SO9HP M2Q%OLODOZU0+.NB-MN*_M8GF M^:.V_U9<]0$[R,3/P)FHI;K;,2PJB2YL5J&`B*TGIV>=/ M+T@SH:E)4%X5=0@P$:RL1A2;V#@BLS]QO1%.!V+(3R(F3KB\4IRW@I9IO6MW MMUK$ M4?FG[&,`*MQ)"6%W'6W-4#5T/@UD?=7R/,;6N<=Q+2RO?32!Z&WIQ*'HFG8O MJ*6.[G/7`\8:U`-*WZ0GM\N.BI?=*Z;7'3UKD6#V4<-O"-A%UE"U8N?2=T`, M'Q\9L:E=RD>(]GQY#9(ES+_HV6I(&*;-VUWS[3AZ=8S1"H$>D>G(1BA`W.9WSJ/_.>L1!>S6*+^>)@RUKDYC3 M;`^NY6,V0@(VD_L

<;"@=J-+,8.]AF"\CWKE(F2 M/%B:4P9#`+2YH$<60):0E2^A5-2G:II+\=/`PB2\H10L1-N9,UV!0VP3EZ\R M!__O*D'F+P+YE`&.E@(F)3!>EPL)%#P91F)5=AS-+9VAK-2&BV8-4`_>V'J* MTV'=)L]X5]GJ"'@6MS4UE:C6E/2Z9`^E`/'20B;4FS:C=^XSZ1#[+I>G?#ZY MEK&!8;7506@--)(S2G0B6[!"*IN17B`JC,;^G'DQ:RP&S@CM]+'3 M)ED8,T,RUCR/[7G/6#]F5R#J/V0SPKR\6@U[^.,/'T@^U,BM.=N%+@UMP!@5 M-@NI3])<=",SE72<+>8940,EL-'42LWAMFR_2=0Q/!C!KL'V*E'SVP MFGRDQ%:<(L`7JA`@8FEVP.'QK:HDVA6"E2[L*\Q";!\%B[HRO[F_]W1[L']X M:/F461]O7LBD"L=5[EQ3W=\='!P\D30[)6;-&"FMJ&W\O+8Y`@9HO7KB@%$< M#N`X?X[RZ`REE6DU9-@S9L1SJJ!)2RC/U+:V`>3+6!)%2&)>4I%LT2^'LBL<<`38B:*('SAS/#=1Z(PH'ZGN!R@=H2 M]2I>!["F/Z8E%N]Y[SICU<*<>;)($(I3&QKY;C9)XA4]6DBH5RJ#LMO9\IP: M+F:;-A'9,4DN347LV&M'KLX'J(Q1Q1GDR:5Y?EBHL22O!'!.%`J-<'&T9U#8 MNW2PD+Q@-<@&Y)05NS&:XZR+&%(%T`$,"&.$UXQLH=`"J]"_BG:ZU^>]V:N$9,0YW4O(,$B#I%FJW8B9!Y0;*W M4.I]:\MP6\(?LNL9M5ZHF-G6"]JYF!#:)RX!]#)%KF@:;12@1FXVPZU$'`LV MHVG>O!J9VM?/P(7(M6!S@!&,_"6(TI)+-=J_TI&Q4_02_@NB.%,+;=->8=&( MN90887"5#\$`(5[B@L3,L`V]&#UTCSX[Q;$AK=J0G>$"V;.H2C:I8QR^%@=O M?L>1,9I(_#FQCG';ZPL/_\X5DMH'-_![%FOS-VG64..+&GJ*<7K?MLB?J!(=SL4BK($.D5ABB-QZD2W/>%0F:MC7 MFMHC[+'ZPN!YF%J"W)*Q$]R75XP+=--IC118[0=!B;WEP&:)-L?.$M4!5C'7 M@:R<5/Z"[6/=V'E'[&FL\)&C;CB09&X?#+:WG@SV]@_M6^I&6T]V!OM;3^LG MW`F9V#;QI=1!$$41?P1G[LOG%6'#L`UCP`GMT#D++$JZ$?AGAB[@UA@#KV[= M2H9BB4YFSMF?C<$:`HG:6BEZZPVR98RH^+A6>%Z0J,55L@=9^DH=[G2>36FL MXH8*R6S3@+QOL%4I1G+#FI7U+E5Z`42JC;&&5"IBUI/T0U-CE3U ML764(>;BCP=%;/,72ZPWNQ\Y%^346`!48V(K=5C_32R+3TJ"GI5'(41'+Z&6 M;Y>XVAT],&8T0ZVW15%(:5=3:.C@`II4['IF10,6@7_7&WVC0NEB9OE2`GN, MCW?]15M6JT_J<\>1X#I?A&*W;TFJ`?CV2.OP?%C]#=EY2Z3N]^WC.E931T>/ MA=UC$GLZ5W?;'.F,FWI,)/'=5FWWF5,`.#Q-JE+`*;FA&73"8($S6#*U]H$B M6K()VG5A`HG5XVR#97QTSX#%@XP@JU(!H(6REA=R4E0].Q>JTA%6OL8,XKN[ MKSJI?;E"2"ALU!YMTN+[9'&C-K2CY25A(RVQ.V85ZASV]*FHAI((0P2H2OD* M`<2T>!QU<\<+\45TBDGU+9>.6X?05`^,R>DRB@W0;,I^(W_K!VU1%H=<^/JD M##+W0/F4P#_D;(B^,G$F`9?%H0`%S@[I,./D?CIAB-DR[(BEJ8;"S4DV&5UF M1AOK,2/1-WH;4.%3#2S4_M8W6AN^S>K_2P"Q;'*)3K-?2*S'%>VVC.@N_?[`_>+H'SL*_7?MR/)[H>@CO MR"6D10P,;%><)]<+D@PKW5N##]+NZEF`%169O[]]>#C8W=W5"_6'W5%R%G0. ME]W0,*Q()X$>F-S6K`.T?CXM?"7R0(G>PW=:M\`?@5^X]'2&Q<=E%C2YHGO0 MH(D)B57+=,NYE1ZJ>,DX7DE605))78I3FOQA=>^/5CH:WV[O'WS3&MJ2`R_- M#Z)GQ%O--J'%=UW/K%!X>N6K;^##>L;%O%E"H+#NVT:G[@EYD$2$G:\52=0% MSVO/$Y4@MT-4"M>ZRX\(20GPUA/R^WX()(.GW`%4A98$."X91K['Y@Q$>40# M%:MA`PJ,"BB`DK@S$94:EXM0#4$K3%Z'M?,[\E2!ZB(%Z[YI[H]6&;+++4 M06O0X/,G[:^\#,C;((L!N9#N M"0U,.T\5?>P5?[A'5AJU8#]XK^A1V1T\/72C]=BY^B*!G[![94>>G(-/&CU6 M]YZ%=YJVVCF*<_C>@$ZJDM`;L[4,E[=#365R=DL&I/G-NQ`(-;\(EJ'Y^7$) MF3:_,F/6_+!BPII?O4HO@/]T8V?>NN^M8C*:K^DBPX//GW[[]7]^_J1_'W8\ ML+U?/K#]M/G`D9G2PFZ53?_>.ER2CUTJ^B8R(VH1M%)456I\06,39_#-MIFV M%WB_"F3WP8+VG@X.=O:[/6)7H:0.O>!B=:>P`@WJ@-)V78E5+MDT6J"4'8@C M=1KL[3ZU#^_O;0WV]D@#!#=C$C%?8\!Z"^56S;M6>-:8]LG!8'?[P$W[E*A? MIKH^[1TT#Q9-VGM@LLQG(J`^:[+XR^74L/M:40!J#2*N"H:`357$L- MQHS$*G315D:UI(`SJ!Y)W@B7C[E`3F9K9W/72J3MFO+//1?2O"R.J2KT:Y2: M,;*65R)=1*$AFBQ;-(I,IPA/RYBT$JC&(_K;E7@J3C5+-_-%:EG+(NIS,NU# M5B%72E^Q^DBG?-I"/2JL`X(H^Z:*J;]"!E[4;/BL,)(UCP1-51@D6"/PX/X% MGYK?W][B>1BUAGEB?N3/*/RW%S(^2!!#Q_ M_QP[\*1EAU8H)H*[0_Z^M7U8TJQ7$(J,M[K7.CF;,K*YM7?@901A$<;A9$1" M+@%I/+]`5I@^5V]636B:-2`O14UFDC_#S#WN3-;XB$10^>*^P1(6&,LW\<+> MYI,>U<=BT;Y@V+4-*,>(^+LNLZ;'6?DPY:C0L+DB"S_@&,:73&GW+Z70]*AH M_6JN"BM5@)5T#8LD3#%39+FVC9(_Q*#(VJ/&G%>PK%ELXC8KG:^LC&KH]PQ+ M$QK'7ZAC_Y7+167)3E6,54;T\,6KTT>`G1<)M=-\0=-?1_S>)JT6`G4J0$Y"A,._#W,I2'R1PF'<$0=-`3O@)NR ME1OLPQ"%S>B#ZG%8(&I*UG+C=E3,5)0;*)S-,\N+7`NN8$0.Z5=RN=#H$APD M@Y+3RGUZ-S45EEJ@B,+$18@"N\(/''[C46EGPOP!5ZS:46.NT*('4:"@':5' M\=4I5QQ3J`V\O?4-C'+M_":PA#_.TJ,49^[(K@@I`J=E3:J53OBNJ4K*Q([/SOE]P,H,)N@ M,ICDRZ="-8U_=1K4&MHMLH^ICM!QMUJ?DA^%*&>E&0NP=P?05K=D+"R80_D2 M=YB4S90UN5I898TC%/7`BB?4\64V%!/0[>8[%1UERS%%594J9180O-!#YQ[K MFP0_PRJ+4,R.SX>3&90NR;M9ZI,"+S`9D$+[HH@318Q#50O-2H4#2\R)Q;C6"(/@8JA MRJX$[6&[V$-`&C+=OML=1=W(+C9F0#6T#/A<0@%I*($(]N_>N'4<9%@M'>EJ MA58X*)G".X4R.E?K'>;*,!A?X2I`YE*XRI)!L(8!#BP,(M;V@[<;K1P@F$A/C;H3-.;[K(8V%&0W%"#E,! MK`J94E;M3R#5?_&@N1E;9CBT*85O9WWO7#_AQBGYUFWTGM@_5]P"?M:,L/R3 ME%R;3ZZ(])ZHUWI,WC/J>*\YP_^SU597\2O:7;A_QEB(4!_N[7^-PYC\/ M^)M^BOD&92CJ-18=E6U!-&-\C0/^=IQ?T8EU0OU?/^#_G[@<,LM_'O#W>:\U M%EM7`AD0";UK1E30;\7FLC>VR$B"KPAGD^50W*_5F$T#_?GG`?]_'O"GN9X8 MQ_()+T."$83*NY/9SMO)Y?TC#_A_(!)&7I_E_CARM]]9?/=NW8.>?0.XJ@,^ M$C>N.#344/N>?TTDWMEHWO?"NSOZ2_O>PV^TNBBCA^]5SVE7I3@18V?V1+.N M%UNA1Z7\&YIQ^@>WO@>[.O%-!9B!6D5336B@L(PMQ(A'3HA:`_QJ__`-6:%A;1W%E[1WKN3,2[:)`_R\.ZEH,,J\" M,^.H?-ED5;V&`]CRLG5"XTW7%0^UM&[%K=\_Q32A`8A8:F?Q5^U-(6@H.I!$ MD7^M&.S.E9#V.X?J8;>FU)[2<0V0#.O*!KV!/]_H;K$G;Q8]2L"708T>GB7B:W8 MAC[->&U=MZ>^X;73K*QZ-8"FDCH\=L#9FMO5+.6C=9RX[.W5L4#A+0:,2120 M50'*+4&H#^L,7?_UXMB96GB=@'<9L?J.'5-)Z/CI4(DO M^'NCY[8LK`E1N6/@\",WKL-6B%*[P7;U$%.:LO7[4R5@5FXN4*2/$>8K&PVT MW;ZI3XBL]:Z-OAQ95T;72FM%P[++RDL/?H?D>\RX`HC0W1[]U_ZAN9@6G;8 M<\L"/`O0I_53R)L5K]MVQ0/_\YI)WD3`0J9?&H4.W*-W[&4L`V5%Q+$RM'JUW.TY MN8L.PS46=&7I%I2F(/[DRTD5V6I3-7RYQLMA_;W4"N%:&!-A7G_"8G3?%=IH MVUPITQT3%\.%Q30W^,!W7#0_=R;.-U+W;O6H*"QA\G]W\UYS[@]?K0WM/V_D M4GH[6MB(X(H;FE8+L3>>T6XAQ(>=0NR.EJQLC>[C<%FE"PE$^;/3J_R3=]F6 MH_GR)`%QM>J9]NI#;V005"&9"BVD+L"/GQ!/6N6%S]<4!/N_V;JBR0`7A MJ@=8![-H>6:'I-OVW,[>K$4@]+%I$YIRXB:)*NM014M&O`@MO\XZ?&;7QSO3 MPE9X5,$:*NB"-2R10MUJ+[^>%@(O\)R=A+=;Y'9=MUQ@TITI)_8 M=%>1*Q.M/D=N8)T>1S3`\E?WIX!XMCPJ80OO,"GEH#64_-F+7 MYW[96R%06/D;;1VS/0]G.E;I6.N]J+;AQ/4__;[M^H4K&1_0\6"=5&N,5/AZ MW]W.O2[^\H'3^O&907VMG[([35G=$%5V5S-7*\Q2U`:\O;?@=#1WX.F4V\@W M;%0GL_-$>5/.W]EO4OX=UBH)>N-B8S./JVQ!2V"+TR)8]O+FG.HY#J<*O6C: M@8^0R^!BNS.X:,WL-#VH!=:C8RO^N%5Q`".KH.@6\]RIH6WC5Y>RCDF_B'[K M[2(<3/)[-.QRO?7;T9AH([)C,;TA#1?#W968U3>B;G&."X0`I!F1 M/3CTB]PK%MFY1@62O8WB7X@LA5[F`I_)>Y?W*B,L>2^PY'3I?].Z7,G*F*=X M7IA^6#F897%HI4F)UQ4H%&A9#P*J&&9)X$VSC(EPZ%DS`"`T!P\,LYY6!U!L MKMZG\#P(!IW(H;VYKV^9`CU"5C2LE4MWO:T,4NF1#IVP#UQ[9+,[VL2^+R]8 M;[.NJ[FVU6)#KN<^=##__T>!([N)NMJD7+0HVJG-XGXC2E.U-N2FW'3T]O:* M<\B/$"YKP2VFO,/CG![\U)S6<];W=`=\/S3*`AO76X"1_*(U5V:X3S!6[6:- M!,\/6\/]@CA;40A4O81)K?WQ[UG-'6G>]Z$C%4_$16.U`6[7$E1[7]ZXZ0JV:MVL.,FIYPTH? MZWINM[E;@PI[]F%S]+6[WB'+WBLVY;D"IY#/$M71X]V#$^AW%USE]DZZ:^L] MB(+/WCOZ7_O<&27>HNOS*%RG4^CZ(/(_V/L\',FH?-4=7@<`H=58N]*SA;=F MUHYKK:6N<;=1Z_,%S_;M!\$*]&POV_CQA'_OT"_`\%KBP2H+8FB+,FQ')QDLSW@>@UZ+EJ@*0I*HFS&?*@4=9$3 M]+MW9OF:E?A86BNMBR9"SB*EG?G-'2^KFVYWO:5^<:..&P43O779US0D6 MX=(-'B?Z7Q^LBY&N;6([6-I>&#@3_<79Z-_>_OI7-YOXQ7,^/SE.K`&)8#/1 MG^)X?=WI;!9/CF]O+L.U$\`GJS#R[1@.H\?.9ATY]G*#@WRO8W2[5QW?=@,] MH7#M+T2(^';TO%U?+$)_;^X!U%W/M!<9;79P M0-YW%U&X"5?Q)9#KA*N5NW`.48X[XPY0NKT)MK[EQQMM$6Z#>*(;^2DM^>3# M>3BUU:V[WHOR6D#3S#'2+_G MNV`F/-E).)R7SQS19#*-$`8G4Q_/4)E\$,G&D_4RV3^4R,3Q&C3S.D9_'"\F M1;UYQ/=LB"']+I=5"LUV(F8C6==X'#LTG6 MM_K64*IDG"\>V@T9]BV9JFQ@:+T?WIU-G?*954F7IN%S10`&G%PMNA"Z-?$] MM/!U#C\Y\X1V&HLQJES29Z$G*S=R7GAB7IQCG)A7[H#H:*=37\;FL.20:J6, M38^57:<3AWK#B47BG(',)G*#EA6C&RCS7,_+J_R^B74PG+F]@05'[$2!!0=: M^O[A90U5<`!K(W2=3O*]AF\_1O9+SV"UH-B`3>BY2T3Q.&.U=UK[S*[NK=D] MXTN0B:*H(&I9L^$)B-Y/QS/Y2&?CL6RBA@4OR43?#_`EF:@%_\VDZ30-)%,6 MR)R>%KNX5NY>#L?C\:AW-1J-QF:_9YI,R?/4H]U@Z>P<7#Y+4],A@@$@&/=' MXRL#@'3-$6-U5@1]`#`<#$:#WM@PX7^6R4Z/0+9.![IJJQ($BJQ*$"BR*ENN M=21D_C12H`FD.%8)`D56)0@4674H.0,/E5N5(%!D58)`D559>2PQ5J$CK#A6 M"0)%5B4(%%E56O&99N"QQC%6[M8_E"[G7>HKH$;4;;/@1(=!SB1UAZ(#V4$KI.83',%,S2PM.`!\ M(G,)P1$R9"RZ\:(RDA%B,I(!@C*2$:(R0NB4!5>FR66XA2O#^P:VK%&WRU9B MK?VEG"`!7N(QC6,.]=DXI$2CC6-$=9HI#_++06Q,#7RQBK5$TH81AW(V#"B1 MLF&$J(R\WY1*G+<3,#V7(-G3-_?UU\$`1LG`#,]>$DSS$UZ022[)"+MON;B- MY(G40*'==)7)L*>F0QF:F:23(\RU"\?S/N/L]_=5/N%"7^GV9K^YCX#NL,Z8G9+Z+PMA9Q&P?#KO<486G7X&GEQ(2P7,,?[."/^A)6!_' M\(?.2ZD102]*^8-S"?.7Z0_0L\CT`2:@3EV'1R8"6%]G",`(*A#@#JDTL,$] M52"`=4N&`!RT0`!P:KSBF#CHD6P&/E"P!/ZG8@DY)I.28WE"*:O2+_"OD=+B MTN]1:B;Y%AR]4#,HU,)=8AQ"DP%:F&`'"40""&@`T7ZC$HFH&I M-RB:@BD$;@X^8TQ0;^!F2$48`(^2J"CJA!XW8YQ1#02"J@Q)O,%0E2(I!E4Y MLC"%H2I%$@BJ,B2UA*H423&HRI'$%*I2)($`&E&2(:DE5*5(BD%5CBQ,T5>5 M(@D$51F26*)_XA39H6W3I(E*^J>#\:OZI]INU=A([54MFL#NV?!D]92L',$6 M;"U%EM)X3YJ=]4ZUIS!R?X)%)MZ;MH!FJA/I>"]C["[HF1\C>_W@[&`IFESD MV:VJ>[V`).MO[#LCC[`24\$?.MFZUH:Y=/T<@>5X131*SA;UC8WY/<_@F]N- M'M((`IL[JC&@KE,,TEU`4HA@Y*I6$TR2RC&1^2&'I0*8EG2 M`I_!M-N0Q]M(CLO)_R'F-=<5C[=A67"WTN4Y)F0I@+#!R$_`O&M-T[YFHZL= MJS)BM/[^.G(/(.OU-@(Z(@ZE8VDT5?ELV:"(\BD[N4#3J!YJ+[9A1*"D*D<) MVN+6>;RURD%65GFO@87F2N=0`^16EL0JF0$6:,?457`:B=318,C\2$O MZ$"ML%29!1O[O+_P6(333QLTE;7@6TR&]=%5&4=2]`&\ZXPCA3GV+3,WK9>5 M]PPYS&NN![]*C&O2,O$4:85J$+<^TL;#P<)?P]L;DTH8 MZL%.70/BU+@;K4PFSQ98RJ=//A0$$S;5K.B,3^:3%J#+X8E5[$T^)5;\J9:U M85TF$9Z4G$GQB`<=>Q11;="A^X#!2K:%[DTLE=F<(CO2::5KZD@\39[.+?%? M$>,R#4F#7[H>Q8%6])DK4FL]4)',>BJW_*7H83O<7;+T7/X?66TGJFO%/; MD$@J'/UT$RE!2?/&ZV`>FP6/3-+U.80O=(2R1;HJ>(/F%5ZOO"G["J,&2Z[2 MA//_VV:P`I<),=$6%PQ):?&Z'PCJWBRS(]M&6>!"D45P45J% M'4%S1,8^B-R65F%',!RE!2*WI578$1`26B8P:4NKL"-8@=("=VM+*[>CB;%> MZ'X@J/NK4COROHI[GD1P45J%'7E?[0OZ*J55V)'W512Y+:["CD"5Z,N$#]K2 M*NS(YPE3,$]0&0L[\KH?".I^/Z/R'F\(>GQ"I;`=O",ZPOE-1$<)E<)JO)?W M!;T\H5+8B_=O4]"_$RJ%I8`>DZ+K0%B0"85-`B-*3LWC69G"+=DZ(CP><1D4(W>_6GAW8 M<1B]:+B/+R?'&WT@2.X/89CKB*=@P*$(H#_"CQC`[R-HH)=$0[P/XW6[-F3R M6.#5TQ.T6(8&1B=H>/_#I6T;-#`Z(<,G5:R?1,A\"-;;W$)\+L6I6X3$1S=X M=I:\Y_`:QLM/(I0^.=LXLG/_XT/*$%3,)[RQ/Z?!IXCDL<394PC2^O,3W,>? M*1'W.)+8P1I:!/B?MS%1(XXB1/#ZO0B1!S>&AYUD0B M_WP_'8[O[BWC8M2=CB[,OC.X&`^F=Q<#Y5[YO7&@U\FB5)A4_"?BW,3G1PD\-E#60`V7&_,A.AL\M]LN?TO M````__\#`%!+`P04``8`"````"$`5=N'.K8#``":#0``&````'AL+W=OV_/^,X!-N!*MP`@3?O/)[Q.,/J\;TL@C78H::6,B:`%4<`O]ZR6)[I36YT#N^?$OP?)_6$4AVU`G13;?:$$S17.H'`IT13:;3%H3>&]-<#24)#2K:A+V3!19 MKP0_!K!=@5O61&]^O`3CRUF!=&CMDQ;'Z![J%B,)I7E;CU?A&R0_:Q6)4=NR$TBJFEF+F*]#.%0P@F-N'G9%H<(UA]5Y&Y&SHZ1]R=G$:0,,Y\7PQ#5JC\XK6=)J'#RO M6](+FFM\^A`>7%ALCFS[",%>'R:MYG,^XV-KKO'IPWHXGSG:;;[(;U=L-';L MR._7"YIK?/JH'LYG#G:'SV]9W#_\(Z][T@N::WRP3IMOV#,,Z[OEN'URT_-"3VT^GQ<\:34V7^2W\07-V<;E MN^FI`:-OCZ_7Q_V'0M3KX[[&YS.3KQGD2BIV-*5%(8.,'_0DBR'UW;?=:-[. MS-T/,.369$?_)6+'*AD4=`NWCD?WD&5AQF1SH7C=C(D;KF"\;3[NX3\0A;%K M/`+QEG-UNM!#7?>O:OT;``#__P,`4$L#!!0`!@`(````(0!GF!S4>P(``#,& M```9````>&PO=V]R:W-H965T<\!%M?/RUV4CWI MAC&#P*'3!6Z,Z>>$Z+)A@NI`]JR#F5HJ00T,U8;H7C%:N46B)7$83HF@O,/> M8:XN\9!US4MV)\NM8)WQ)HJUU`"_;GBO#VZBO,1.4/6T[:]**7JP6/.6FU=G MBI$HYP^;3BJZ;B'W2S2AY<';#<[L!2^5U+(V`=@1#WJ>>49F!)R6BXI#`EMV MI%A=X)MHODHQ62YH;[Q@4&]ID&["6\LE*'RK["A:3 ML]7WK@'?%:I83;>M^2%W7QG?-`:ZG4(@FVM>O=XQ74)!P2:('48I6P"`7R2X MW1E0$/KB_G>\,DV!DVF09F$2@1RMF3;WW%IB5&ZUD>*/%T46:C")]R8)T._G MXR#.TRB=_M^%>"(7\(X:NEPHN4.P:>";NJ=V"T9S<+;))A\F`QJ[YL8N,SG2C!2K?RE.V.!#E[-9<8'!^XTMCT9L7I.[LD;0VF0D6)T(LG`R M'0Q.P"#=Y6!6/`8;=]1KI@YL.IO-QES'\UF8?\0%N^MR+BL>G`K@9K(D7Y%D^>YOW!?/GWA^+GF[8(U4;WFG4LAKZ%`89&"A_ZOW` MR-YM_[4T<%K=8P.7,X.S$08@KJ4TAX&]5X;K?OD7``#__P,`4$L#!!0`!@`( M````(0!H!7!ADP(``!0'```9````>&PO=V]R:W-H965TU\_?M=XP1E M::>R%\!P[CGW'E]?EG<'59,=&"MUD]$X&E$"C="Y;,J,_ORQOIE38AUO-X%J9HEH]&4*2X;&A@69@B'+@HIX%&+K8+&!1(#-7>8OZUD:\]L2@RA4]R\ M;-L;H56+%!M92W?L2"E18O%4-MKP38UU'^()%V?N;O&*7DEAM-6%BY".A41? MUWS+;ADRK9:YQ`J\[<1`D='[>/$PIVRU[/SY)6%O+YZ)K?3^LY'Y5]D`FHW; MY#=@H_6+AS[E_A4&LU?1ZVX#OAF20\&WM?NN]U]`EI7#W4ZQ(%_7(C\^@A5H M*-)$2>J9A*XQ`;P2)7UGH"'\T-WW,G=51L=32C9@W5IZ*DK$UCJM?H>/\8DB M!">G8+R?@N,TFB3I;!ZCV#LL+&32%?;('5\MC=X3;!;4M"WWK1*O`A$RO$`/QG:X8$W2><\; ME`-F@#*VPW!E#[ZN^?9*.6#2;LO'\VGZ#Z^QF8?K>O"5[G1TI1LP`RK&GARN M[,'O>1TP`Y3]:!]\@#SXJN;TVNN`.7D]&T_&O2>AN\)T"H=8@2GA$]2U)4)O M_>2)<8_ZM_U0O$^ZN=9_P*'4\A*>N2EE8TD-!8:.HAGNLPEC+2R<;KL1L=$. MQU+W6.'?!_`$CB($%UJ[\\(/SOY_MOH#``#__P,`4$L#!!0`!@`(````(0!= M,!'6G@8``/T<```8````>&PO=V]R:W-H965T&ULK)G;CJ,X M$(;O5]IW0-Q/".1$4))1)YRU*ZU6L[O7-"$)ZA`BH*=GWG[*V`;;Q=(']4W3 M^2C_=E79IC";KS^*J_8]J^J\O&UUR6EL?\=M[J_WSSO]BZ5C?)[9A< MRUNVU7]FM?YU]_MOFY>R>JHO6=9HH'"KM_JE:>Z.8=3I)2N2>E+>LQO<.955 MD33PLSH;];W*DF/;J+@:UG2Z-(HDO^E4P:G>HE&>3GF:N67Z7&2WAHI4V35I M8/SU);_77*U(WR)7)-73\_U+6A9WD'C,KWGSLQ75M2)UHO.MK)+'*_C]PYPG M*==N?R#Y(D^KLBY/S03D##I0[//:6!N@M-L<<_"`A%VKLM-6?S"=V)KJQF[3 M!NC?/'NIA?^U^E*^!%5^_"._91!MR!/)P&-9/A'3Z$@0-#90:[_-P%^5=LQ. MR?.U^;M\";/\?&D@W0OPB#CF''^Z69U"1$%F8BV(4EI>80#P5RMR,C4@(LF/ M]OJ2'YO+5I^9$\M>F(LEV&N/6=WX.='4M?2Y;LKB/VIE,BVJ8C$5N'*5Y62Q MFLY,(C+2<,8:PI4UG+^IW9RU@RMK-]X/W&W=A"NS-]>C`UNR!JNNP=L&!NNJ M[0BN;QH8C**UARL?V'(RMQ8K^[70F3!7:.K(I*%9&1VC05/?SB0W:9+=IBI? M-%B>D-OZGI#%;CI$E<\AFK=N5OW?I(+91%0>B,Q6AX#!=*EA)7S?F:OYQO@. MLS=E-OL!&]GBP"W(5"6RK@H\%?@J"%00JB!202P``\+2Q09F]&?$ALB0V'"O M]ASTP;*40'`+WL15@:<"7P6!"D(51"J(!2`%`E;H9P2"R,`>(TV2A>SYGMI8 MXDQ23`Z=21<=1#Q$?$0"1$)$(D1BD4A!@NWH,X)$9&`QPIP<64K4:#1*G4D7 M)40\1'Q$`D1"1")$8I%(48)-6(K2\+.*;RO$N@T&=V)/"7C.R0$1%Q$/$1^1 M`)$0D0B16"22H_`0D1S]X,9*9.0(4&+!0T:8($MY&1TZ(QXF%Q$/$1^1`)$0 MD0B16"124&!92T$9SSZQEGVG1,P^(BXB'B(^(@$B(2(1(K%()$=)B?T)CU4B M(T>`$FGEFZN5DOW.J,L^(AXB/B(!(B$B$2*Q2*2@0)TC!64\^\1:]IT2,?N( MN(AXB/B(!(B$B$2(Q"*1'"6%U#L\;:U,B"1XWP&%S+5EYOQ2/N,]3W%W1$ M5%+Z"WLEPROU%O17O+^[4@<@1)362&-&!R,$;=!*?.VAE*^\E'K."0XWV%0^."69*=_Z@D-I=\":K<-!*'52D M#&HUG2O54#RH(XQ)S@LIZ<2\?&RFT\)02A>K%<4\V#,U6]0(&5A MT&I3BC0K0"UA6^W0B/^NR:QF74,/(Y^C7C[HT8A\R*UZ^0BCF*-67HX,J3?% MR'QL:M*J50H80_).HAS@'$Q6[HY.#Y=9D3.V?@JKB];C6G0GL6;6PE(V&W]0 M2%BU[2,EX$*C@PH'M=1!15R+#LI>V6ME3/&@CC`F.5VD$AY+U[?R#F7?JV=K MM*"6\D61U<_`@]DA(>S"R-B!&K.BQ\'DC,WC#7OD<]3+!ST:D0^Y5:\5811S M-##!24DM1NR5I4\K<"DR%`D5XX',1+(W]F<&+D8>1CY&`48A1A%&L82D60(/ M4]EGLJAG`-]Y!-OJR&\1#('G0M)L]3RMM^(;NHN1AY&/48!1B%&$$?E.TB>) MQH=^]Z"GU456G;-#=KW66EH^DV\:L!)WFP[3#RY[:\J_N*AW5@Z\K(-_*K<= M>%\=X&L'7N\&N`D]P$O0T!WXVD-GHMJ'"6*0?]P&JEB'U*CX#M2;#JDF\1WX MJ/30+AS4"W0R8+^W("1#?.;`6>:`_AST!QV<.W"LAQOL%PZ<@@WPI0,'0<"- M;J3P\>F>G+,_D^J=(65%I*1(O1C6>.8]SB/Y MY-E]?2L+[Y4*R7BU]Z-%Z'NTRGC.JM/>__>?IR]WOB<5J7)2\(KN_7\IA7\Q2F0M:`DUT5E M$<1AF`8E895O$+9B#@8_'EE&'WEV*6FE#(B@!5&P?GEFM;RAE=D-E#1#/K&#J78/Z7IEMOYTJ+LAS`7V_12N2W;#U0P^^9)G@DA_5`N`"L]!^ MSYM@$P#289_+,K[\+EO_)*@IJ MPS[A#CQS_H*IWW(,07'0JW[2._"7\')Z))="_P`/CT2H9'`Q0A;WL_!F*6J_/>7Z:+9!TN(TCWGJE43PPA M?2^[2,7+GR8ITHLR6'IICT21PT[PJP?[#=FR)GAZHBT`#Z\%%H&Y]YB\]]>^ M!S02!'P]1*O-+GB%IK,FY\'DP.='3IL1`&G+#&SSF3$9F5$57,J#"71IXF&: MI4V#HB]AZSYO%(L@K]M$$K;X9@4F9]7)2=H,JU%(F=\H)L->=!OK:VR29E## MN9A/C3^_*SK;)KN%;&G3X2;QK'?99FNK"QUBQ(*0W>9ZA!B6UR6>:!.S';8F M9+=Y-\*&?N$X"=EM?CBQ93^1XS^H;[R"T@G:UHE:.]!( MKKKIAR_:M&@>G7XGV!JKT2\KXZ_X:C1["0NPH1VOF8#NFTPTY#+IB+%%CLUH M_9)DQBW4E<[.-:9C[5PZXF^1XSH3??:]1@/``JP#FHY87#3@-LMU..UQNM!I M<\ANTA&7BQV[T0*'JQD"ZTJ;^1:R!1XQNMBQGL\%UMD.6^,WML`C1A>C771N MA#:Z67:N*QUF!(.0W>>(T\60Y3+'\Q3&2H>Y"=G,(ZX7.^8SH7#?,3J\'^PVV>T@=()VK[Y:"17WO6(U<6.'_V/C>U[DP;K,8]X4^QXTT2?C?ET M3%8#N/*N1_P(AJ.>O)O)_]*Z"BBZK$-_@M:N+YE!RDPK)14G^ALM"NEE_()# M4@SS1QMM![C[&$<$-[[:WIO!+FA_@<&J)B?ZG8@3JZ17T"-@AMISA!G-S(/B M-:P=QBNN8*327\\P0E.80;0U'CE7MP=\3[5#^>$_````__\#`%!+`P04``8` M"````"$`%"B)/+P"``"L!P``&````'AL+W=O(PF&'$:Z8R41+$;T43"NC9"L)F,=M^V'?BI4<9S>JCL+W7\QD516FCW`APY8TGV=,,- M@XH"31`M'!-3%20`5R2%.QI0$?K8WH\BLV6*HS!8+Q;Q.+R+-&)!>XGEODR6*QF\Q!$WR$A/J/6X`VU=+O1ZHC@U("D::@[ M@V$"Q*\[`BL.NW/@%*\P@EP-M.%A&\;QACQ`Z=@)<^TQ<'W&=`@"HITRJ$U7 M=F"G[&KK4KGV@;Y,]+K,_",R#IQBN#XG'R\Z7J_L,7$/\XP8&`3(=(,.##WH M&QK7UH,F2,-YF"[MP*UT5UP?B=MOHM^RY4=H'7A(>XK`Y]1?B?">/6ZD\NAY-M*#CQ4\I&Q M$YAW(RO1ZETK[;:APBDT-+-^8<;/1C\Z)-<%_\*KRB"F#F[N13`,NF@WDW>1 M.T$OXW&R\[.:=&]@5C:TX#^H+D1M4,5SX)P%;C9J/VW]PJH&4H=9IRP,R?:Q MA+\BAX$P"P"<*V7/"U`FW7]V^Q\``/__`P!02P,$%``&``@````A`$<_]..0 M"P``94,``!@```!X;"]W;W)KX`]P&*Q>\ZUXRB)4=L*;+=IWWY)S5CBC.VAG%ZT M3?QI-#\YG)^2;-__]G.SGOQH=OM5NWV8JMMD.FFVR_9YM7U]F/[OOU]ORNED M?UALGQ?K=ML\3'\U^^EOCW__V_U'N_NV?VN:P\1%V.X?IF^'P_O=;+9?OC6; MQ?ZV?6^V[I67=K=9'-R/N]?9_GW7+)Z[@S;KF4X2,]LL5MLI1+C;C8G1OKRL MEHUME]\WS?8`07;->G%P^>_?5N_[8[3-UT_U398GF,W?UP$GZS6N[:??MRN'7A9I#HJ>;Y;#YS MD1[OGU=.@1_VR:YY>9A^47>V3*>SQ_MN@/Y<-1_[X/^3_5O[\8_=ZOE?JVWC M1MO-DY^!I[;]YM'?G_VOW,&SDZ._=C/P[]WDN7E9?%\?_M-^_+-9O;X=W'3G M3I$7=O?\RS;[I1M1%^96YS[2LEV[!-S?D\W*EX8;D<7/[M^/U?/A[6&:FMN\ M2%+E\,E3LS]\7?F0T\GR^_[0;OX"2&$H"*(Q2.JRQ]?UK2YSE9LKHF08Q?U[ MC%*,364&LKI1LHO#XO%^UWY,7.FYQ/?O"U_(ZLX%/@X/B.D'[-)XN8'R0;[X M*`_38CIQ0[%WD_SCL7>:\(2Z;7R M68@25B*("$-%R,E[F,U"P9('Q'2S,#>:+=TZ?%EE2YBES92P0(#T+$_*6#$P8\B%J.`@"R[G+^WMO'Y@Q&2_%DWK!0PQS,;[D8U M`H)`2V+D19$/)Z&C[X)DS%ZH4,$)R-2(@\$;KDM6?I4"6FN+2RO6. M-G[PP?_<\/8>.F<]I?);=R=13#^*6#$*G0#O;>,5@!.2\AF&!GL/<4NC5G,;GSQ8(4F>.ZX*[;+(#9N>FKQ^DV>&:;,4<&U5 M#>V!#KRWM?&Y@PF2TF&C5JFHE=9QQ(H(5>#];;P"<,-P]!5OZY4*+5,E\]1H M5EXU06Z*U%E7W]BQ]8=!=)'D1;#*B`)]E?%V-.T^V3"Y4/S(0&M166:"O4I' MU)1(YHI-HR6`W^OKH3W1[*_R77WJNRKA^P:$L#,:9_H9&]V:(LJHN;MB83/` MF$(9;;+A7%2%JXCQ5:0]3:]45#*,#TX"0%(/Q3@"8D6$2O"&.7HA:+!7NA!. MZ@B@HT6E)1=98YB>,"R$I4#F[N<$5YXT?S<,5^3O:3X%@[WC%``DC&^MHX@5 M$2J!&?&XRUY_;XKM)U3".GJ%$`RTIE=0N*3CADR"Y'GBK&6H6JKD*D/6IX:L M$F9:%4+B9(26?*-.=]P6@V"]"9<#^BI3[FC:5!7O)Q5"H@`P;@&Q&`44E*90 M138T+CH'5WFS!M^E"YIO+!`2\JL1@?P4'>&NT"PATE(KE5Y2P+QYY'HXY]', MGRH-D*@D=&!W1XMYB,40J%29`"#SX&]`A(UIG(KN*%92?)-0(22IB",6$1"B M=3KT8*J#.?5('6<<6PTN"HTV!0@S.->="*$*:=[`:P^`T%9G*3_9]B(0560XBJ00'73$+GN;K@1MV"A`DR(8/ M)R$DW'TXH[*A2#K$2D&H@$_9=0H^ZP:[OWY6:IAEG(NH&=<8Q^GIX[`H5D2H ME*O\.CWCU_R^8H50!L^93JY!^Y>%]$,[+]UJZ3?H-/>KK#H%BZ7#/T3&X8_Z M<(UQQ.&7HE`)S*I'MM8SEJVX9:<`2:T5"%&)$(0*.>/8)OK@)@6GI7/"EF6% MD)!F'4>LB!`IV:=LNSN*M2D]-$`H+X0D*7'$(H(SJ^8F'^:>*OF4<6=GC%MS MXT9(5`)Q!,3V4?PC:1T,%Y7!7-LODLSU2?E.?7;&O8-[$3@A``DYUAA'0"PB M,"%*IX4.+F>I%&^UHS<@F:=Y30V;-)0`D)!?C7$$Q"*"->6?2`RU2Q6X**&" M<1TK\T=Q)=S$$1+2K..([1%?4\$VA:KXE(/[HCM1P;RW0DA4$35Y*T:A4JYR M\`RLE71/DIW4%D%`T=19%K(@0 M"?FGG+P[BO6&Q9"H@2((R!6C$(E>,\-)(Q;YCDX-5WF)X4%D)!GC7$$ MQ"("A96Y9PSFTB/LW(7YA!1_%"LL_JRHZD++#X/CB!41.BO,U".%!28<*:RH M4]=Y%+$B0B4P,Q]96&#&I+!2OF//HXY=QQ&+"!26NW_KWC84G(EJ^92KYV=< M/65WU"J$A!50QQ$K(E0*L_5(98$-D\H*[JV"G>=1KZ[CB!41*N$J.\_!AFE% M\?TZ0N(LQ.T,)'@[R=)K/`B\H`Y`H(8I8C(*;JKF9#YV0"O!.&PCP MO39^6\'XH[@0?@&%D"@$X@B(%:-0*2Y,*"4R%YYFC\!/^I,!2,BOCB-61*@$ M9M[CG,^`^;JBZ.^%AP\5H=4B)$J)FSA&P2U5Z3XG-%RA426?\G!SSL.',Z"2 MN(=C'$&L%1$JA5EXI*[`NB-M"B`AO]I$$2LB5,)5UFW`E6D]G;2IN'5C'$&E M103J*2VRR[?<#+/ND4OCG(7S:[\NM+Q%CR-61,AL%,S"Y8+JZ%BC0D@8ZCJ. M6!&A$JZR[@(L5RXHA$0)<>O&*,>"2M)LL"6JP'OHU<97^*.8\?&WUU4(B4H@ MCH!8,0J5PCP\4D_@N7*#*@`2\JOCB!41*L&=B<^&?V-&1(H_BLU&\)P4[*(` M2)0212Q&@;I215FH9.B(5,JG/+PXX^'!VRU12M2@:XPCJ+4B0J4P$X_,!OAR MI+#BYEU$$2LB5,)5YEV`Z48:5=29:XPCS@)$@8+JWBAVX:9GP;Q[G/%U1[&E MP=^34R$DI%G'$2LB=#*8AT?J";P[4D\`B1*BB"TDA$@HK_+NCF:SD`Y]`U8U M0I*$.&(1@4^INL_H9<-IJ`#FW.,N^,HS#G[RQGF$1"%Q!Q>C4"G,PN5R*L%R MY7)"2)00MVXQ"I7@?9;M0N*^Y[Z+(.Y["(E2((Z`^*\]\*?"-G6NKN!;#>#S M^IMF]]K4S7J]GRS;[_X;"[1[`U3_V_[;%+YH_\%V]OM*W;F/U[O?S_H7W)<< MO"]>FS\6N]?5=C]9-R\N9'+K'6P'7Y,`/QS:]^Y;`I[:@_MZ@^Z_;^[K+!KW M`?WDUL$O;7LX_N!/T']!QN/_`0``__\#`%!+`P04``8`"````"$`Z:2,S#D$ M``#=$```&0```'AL+W=O? M]QC;)YMOKV5AO."&YJ3:FFAFFP:N4I+EU6EK_O-W_'5I&K1-JBPI2(6WYANF MYK?=;U\V5](\TS/&K0$*%=V:Y[:MUY9%TS,N$SHC-:[@SI$T9=+"97.R:-W@ M).LZE87EV+9OE4E>F5QAW3RB08['/,4A22\EKEHNTN`B:6'\])S7=%`KTT?D MRJ1YOM1?4U+6(''(B[Q]ZT1-HTS7/T\5:9)#`7&_HGF2#MK=Q42^S-.&4')L M9R!G\8%.8UY9*PN4=ILLAPB8[4:#CUOS":UCY)K6;M,9]&^.K_3NNT'/Y/J] MR;/?\PJ#VY`GEH$#(<\,_9FQ)NAL37K'70;^;(P,'Y-+T?Y%KC]P?CJWD&X/ M(F*!K;.W$-,4'`69F>,QI904,`#X-,J<30UP)'GM_E_SK#UO3=>?>0O;18`; M!TS;.&>2II%>:$O*_SB$>BDNXO0B/HR^O^_,G*6'/%^O8O$1=0&&29OL-@VY M&C!KX)FT3M@<1&M0'B+CXQAC_2A4B)&)/#&5K;DP#8B"0GY>=HZ/-M8+>)KV M3#!EO)6([`>$.=!3&.@8)]]X&^G[HA'@:S>`;5 M@#>`]BU`:>Q30G8@G"*.*!)-"5DDGB*N/:H($;MBQ"RU+DQ]=>2L$W!W@2+O MIM]E)>#,_([QQA%TQ%Y+A%HBTA*QBA"<@*'>Y_XQ)UBGK0EVWU+N2_D*.+/D M,]YUO(7G21-TSQ'X'&4DLT*]2*05B041>[YRG,5R3(I@!JPXGS>#=9+-<$=] M/BTXHXATKR5"3OB=H9[=_8E/B;0:L8H0G(#U[O-.L$ZR$W-QC`%G5$YHB9`3 MW`G8)I@5XE,BK4:L(@0G8.7^O!.LD^R$-+<#SJB#/<^G@\J0O``P5XI3X@YK"WJ_;/K);L@G7." M'E+9H$?"'N%+A.\B=RFMR)%>)%8BHA_L9/7I%P3Q\YBPC2ZDMSCH(1[)?(6\ MI31O]CVA<"S4BD1ZD5B)B':P@]B='9IIP8]MH@W242%`'.+'"=>77_!]?U]I M@EHBTDO$2D2T@!W`'K>`']=$"^0#%51Q;!'IMST?V8NY-YD+`N/9"]@=I3GO*+EM1= MB7<@+925W=)W2\```#__P,`4$L#!!0`!@`( M````(0`WLD.@N0(``*L'```8````>&PO=V]R:W-H965T&UL ME%7;;IPP$'VOU'^P_!X,[!TM&VT:I:W42E75R[/7&+"",;*]V>3O.\8;`F&5 MDA?`P_$Y,U4)NHBQ;]_W5VM,3*6UAFM5,U3 M_,0-OMY]_+`]*7UO2LXM`H;:I+BTMDD(,:SDDII`-;R&-[G2DEI8ZH*81G.: MM9MD1>(P7!))18T]0Z*G<*@\%XS?*G:4O+:>1/.*6LC?E*(QSVR23:&35-\? MFRNF9`,4!U$)^]228B19\K6HE::'"GP_1G/*GKG;Q8A>"J:54;D-@([X1,>> M-V1#@&FWS00X<&5'FNFS%MDW47.H-O3) M=>"@U+V#?LU<"#:3T>Z[M@,_-,IX3H^5_:E.7[@H2@OM7H`C9RS)GFZY85!1 MH`GBA6-BJH($X(JD<$<#*D(?V_M)9+9,<3P+XO4B6BP!CP[0^SZ!`#@P"9;M"!H0=]0^/: M>M`$:3A4TZ4=N)7NBNLC\_:;Z+=L^1Y:!Q[2GB/P^?7*N[YG>P*AL:,&_4UV(VJ"*Y\`9!BOHB_;#UB^L:B!UF)?*PHQL'TOX*7*8 M!V$`X%PI^[P`9=+]9G?_````__\#`%!+`P04``8`"````"$`0,A`W><"``"0 M"```&0```'AL+W=O M=,6Y(<#0ZHQ6QG1I$.B\X@W3(]GQ%KZ44C7,P*O:!+I3G!7V4%,'<1A.@X:) MECJ&5%W#(S`-@6BX* M`1%@VHGB949747H?Q318+FR"_@B^TX-GHBNY^ZQ$\4VT'+(-=<(*K*5\0NC7 M`DUP.#@Y_6@K\$.1@I=L6YN?%BTUEH-P3B`@#2XO7!ZYSR"C0C.(),N6R M!@?@ES0"6P,RPEXR&H.P*$R5T60ZFLS")`(X67-M'@524I)OM9'-7P>*K%.. MR[KVP`Q;+I3<$:@WH'7'L'NB%(C/^P).(':%X(S.*`$9#0E\7L;Q;!$\0]#Y M'G/O,/#;8Z(>$8!HKPQJURLC&)4Q*^C*O3,,9>+S,HDO@TE/H'27`\5#@!L$ M$<>W/;_SP&'&`\RD1WB!`N3Z0!$,M?`".\FQ`UTA#7UQO32"K72?Y+T%N:]Z.4`$^U+.$L_M"!A>O@BNP#"JF'RXG`\FKU;,WOR2!G)P.3G;_R&,LZ)H[)%D^0:93QYI+PW M^F-J+5I.8E<(8V'.4VBGLQL@/?82M(`YO`/E:P^3F,SA![MI32'%YP9_7_ M)9;_````__\#`%!+`P04``8`"````"$`[@R]3>(+``!./0``&0```'AL+W=O MNQTE,3JV`MM]>OLIBJ3(XJ]6[*#G8MSY5%4D?Q8IDI)N__RQ>QU] MJP_';;._&WN3V7A4[S?-XW;_?#?^[U_)'\OQZ'A:[Q_7K\V^OAO_K(_C/^__ M^8_;[\WAR_&EKD\CBK`_WHU?3J>WF^GTN'FI=^OCI'FK]W3EJ3GLUB?Z\_`\ M/;X=ZO5CZ[1[G?JSV=5TM][NQS+"S>&<&,W3TW931\WFZZ[>GV200_VZ/E'] MCR_;MZ..MMN<$VZW/GSY^O;'IMF]48C/V]?MZ6<;=#S:;6[RYWUS6']^I7;_ M\.;KC8[=_@'A=]O-H3DV3Z<)A9O*BF*;5]/5E"+=WSYNJ05"]M&A?KH;?_)N MJKD_GM[?M@+];UM_/UK_'AU?FN_I8?M8;?/K^DJT(.1YMOAY/S>[_ MTLA3H6007P6AWYX@`XZ!A-EHO%_&IY3:4/.,Z5(_UJ1W\R]Q?7R[;> M`YX4MVTP_2K/E6GO@-^5\J-?7:(WN?9FJ^"=JEXK1_K5CN>UD89H6U/ZU8ZS MLZJZ4H[TJQP7$W^Y\!97HD\'VNA1^LEL$'FH>MH[JTRO2R3ZAW(]3UA/9X_X MARYT-MB94YG$[9B(UJ?U_>VA^3ZBB8;*/KZMQ;3EW8AP>C3(-G?CXU?#@\:% MB/))A+D;4X=1YA]I3'^[]Q?^[?0;C<.-LGE`&X];A-I"##H1-G)![(+$!:D+ M,A?D+BA<4+J@LL"4A.O4(\%^AWHBC%!/M_M!`TM.1RIMH5TB%\0N2%R0NB!S M0>Z"P@6E"RH+,*EHPOH=4HDP-.-:B>:MW$23-KZ=C0M'OLZDTP](#"0!D@+) M@.1`"B`ED,HF3$B:P'^'D"(,#7K*;&O(!ERF!VDTJ&1GTBD))`:2`$F!9$!R M(`60$DAE$Z8D3>U,R?X5@)[BA'4KF&[H@R2DCB8AD`A(#"0!D@+)@.1`"B`E MD,HF3`RZ2S,Q/G@C$&&X2I*P'/)6USS1PLY(2QD!B8$D0%(@&9`<2`&D!%+9 MA`E'TPP3;CB+A#771Q([BX!$0&(@"9`42`8D!U(`*8%4-F%BB$V2O9P8%D-8 M9FN@42`8F!)$!2(!F0'$AA$]Y4L5RT M1\$'YU)Q!91&3AM77.98 M!2&NH] M2J:>*3N@'9W:Y\EE*5-4(EM134S=>U)2&OEVUO@S9T<8>YV5;F&BD"DO[9F)9*S\F;-UR(V5+J_HHH.B8F%I*]JC'!T?=-+)=2B33B&Z@W0CQY\YB_#0 M4U8TM796/7IV5KKFL7+T9^V&/%A>+>9S)X62LX*G9UEEO59+D%A6-+AJ:S6; M!'.>U45O&&M$\JE"+&@OZ`2Y_F6=H);$EKK^S*E3*`X(VVECL`NTD>D!20*[ MZ_R9LQE-S@F>GF.4=4:Z!KDBPS4H.K_^YG'%Q4KX`L7EPIDIKA!/^RN>!J&G MK&SM>M*^L])-CI4C)9AI38_HG:.Q@O#I697(C)6N1'Y6)0KCV%\)+KQ8==O" MRV7%I3.X7+NS_E#+>::7NT/SI!$-WJ%)2!MI'6+E-IQ_R3G!TW.,LLY(UR`_ MJP9%Y]??/-X18L5O=\0[$[_<(##%)?+;QQSMG37T.M1?`W4@JJR";H41:T># M$HU,^-2@@?"9L3+R=?72J&!67!FQ_+>5^5B*BBC.VE\AJDR7?O[,66.&GK3R MWTE2%6ME::@=%217I*S,TC?6?IY962LW:_:$2^DJ MIA26M1WJKYF<<+6CG;7*T:!$6]E9>T[X#!US1`5#7#&Q/[(5&[X5^7([Q911 M.RSK%%M96:<%$:(848(H190ARA$5B$I$%4-<&;'-L)7YX"&,N)G(FY%)$W_A M[`\>E!5)9JR([^24W'"R_ M)+*2*13#TLTO0#%:)8A21!FB'%&!J$14,<25$0OQ"Y21ZW:FC%K*FV$6^H`B M1#&B!%&**$.4(RH0E8@JAK@R8F5\@3)J(6T/,(E(?#TH0A]0A"A&E"!*$66( M MMC8/<&VND!$N!!)I-RZ3<^@>@U_2[^?L'5/PR_K]G&[)P:_H\_-6SCZX!+^J MS\].`RZYN^A_9X!W:WL][3\$"G$YG>5^J*Q,QT2]?O`X"_R27C_/6=JEX)?U M^SEGZ#GX%;U^;CU+\*MZ_3Q3'N\&=Y/PH6/``/<.&M'BK9LV?:L6\BA56=F] MHT)Q/^>(.P:_I+\\Y]@Q!;^LW\_)HAS\BGX_&"2R-:9]5;^?*8_W#N7V)5.\ M,'<6!1(MF)R^\V@Q%`]@A*,YY(P4HE,X<5JTFOE7[C/M&+T2A>A'>"TF"^@` M*"E3/O.E.I=RSXIS+*=0:*!V)7I5`R5QV<6.XX([JS!W9%>(NM]DO^],O6$@ MK4QV1(K025S[8O;LVE^ZSX%C\$H442=[BXDS6E+PR+C';.(Y+CFX%(H,5:T$ MKVJ@("ZYNV7ZV#R$.ZE`HH54%'I`.=B)+Y%*K>5J1O_Q@])8Q;2&2Z(099CH MN"4\*D_1)^,^3M5R="@44E6;>P']QZM6HE?UJV*X_I=MS,1#0C?EU2[,'*R& MRHK.1/5-.]+(/`*+-3)6":(4488H1U1H9$HL-3(E5@PQ9>;NQNQ#F=E&X7.$ M0F;TAXK0)K'32R/UU*#OQ9!8VQBW1"%JE4C'*_I"AN=)BCX9]\&W/7+T*30: M>*A1:AM3O%\E.J77UXKL/Z]?4XVC1?Q:>#=+YY?]MA^5WCP^J&WHZE,>AR M/[@1SS'PRB=_?O.)RL8K]+R!?-I!#M$6=*7M:+AR15?:5Q/ARC5=:<^^X,J2 MKBQ[:T#-D7.*ZS/W]0>)%>OD`^D M5J]8I%6O5*14KU"D4Z],I%*?2/3>[8UXT18[D%Z:O1&OQ.*5R//)IZ_9]%(H M^?1=B;R`?/HDH=<>R:>],NW4I:]9W];/];_6A^?M_CAZK9\H96?MD^Z#_!Y6 M_G%2[PA\;D[T'2O=9^CS0/INN:9']_19Y7CTU#0G_0&ULK)E;CYLX%,??5]KO@'AO".0"04FJ(=RU*ZU6W=UGAI`$ M30@1,)WVV_<88[!]6"93]:4TOQS_[7.Q.?%L/W\KKLK7K*KS\K93]=E<5;); M6A[SVWFG_O/%_V2I2MTDMV-R+6_93OV>U>KG_>^_;=_*ZJ6^9%FC@,*MWJF7 MIKG;FE:GEZQ(ZEEYSV[PS:FLBJ2!C]59J^]5EAS;0<55,^;SM58D^4VE"G;U MB$9Y.N5IYI;I:Y'=&BI29=>D@?77E_Q>,[4B?42N2*J7U_NGM"SN(/&<7_/F M>RNJ*D5J1^=;627/5_#[F[Y,4J;=?D#R19Y695V>FAG(:72AV.>-MM%`:;\] MYN`!";M29:>=^J3;L6ZJVG[;!NC?/'NKN?\K]:5\"ZK\^$=^RR#:D">2@>>R M?"&FT9$@&*RAT7Z;@;\JY9B=DM=K\W?Y%F;Y^=)`NE?@$7',/GYWLSJ%B(+, MS%@1I;2\P@+@7Z7(26E`1))O[?,M/S:7G;I8J,IS5C=^3J14)7VMF[+XCWZI M=Q)TL-$-AF;+6+AU:K0V'1/),*ZW+Y\'HU6C1M#;I)D^RW5?FFP,:&\JCO"3DF=)M, MP:J/NM#7X_^5(]0A47DB,CL5(@D55\,>^KHW5O.M]A7J/NUL'&RCBQ8'9D&* MG,BZ,O!DX,L@D$$H@T@&,0BY0VT,OI(DDT-OTD<'$0\1 M'Y$`D1"1")&8)T*08-__BB`1&=B,4)/<5I(VBD.-)J/4F_110L1#Q$+X.A/'JQ$1HP`)4+N==,4M]&A-V)AP3:]%W2OCL(^(BXB'B(Q(@$B(2(1+S1'"4-.?\:W7:46(M.DH)[R@B+B(> M(CXB`2(A(A$B,4\$1Z&/^8"CQ%ITE!+>441<1#Q$?$0"1$)$(D1BG@B.DN;H M`YZVYJ*K'5H.1Q(CXB`2(A(A$B,4]$5TE#Q%M:0MI6P9N,G4$.>:M!_OD(,#*\[733$@\SMQMFP+'2OQ-U8,5F\]'\P4]X96D^<)!B;.RI'8V&JS8?'&O#D2,*.FL^(B.1`Y^K?2AHXT8 MR#%I1^\0;,0A!I;4%QR8%53Q8(7CV6D)5I8AQY-:&?.VG=?A]^!"FLY_:+K@ M(:MPU$I>5-19L469\^5:7'8\JL.%0,P+Z>;XO/Q4$A7UR;R>;`6XE(/ M.C6"7FDJ6]D9L]DB^5@]ZC"?]=9K7H!WH8^0P-\L&`)N1#9C7(1QC% M#+7R8F1(9\E'YN=*D_:G0L`Z))XD2[DVJ94!H9PJSD[KG9.DTZ(GB;$P5H9T MV/CDPHMT!H(0MVO;5TK064TO*AS5PB>)L"C+M#;2FN)1'6Y-8KI(SSN5KB_E M'?Q[]QZ%MLY"OKIN>JC`@]ZCR>1T5O32D-RG>&S@@'R&!OE@0!/R(;,:M"*, M8H9&"IPTSWS$WMGZM-<6(L.WWVV%'."BEM01UT^Z&'D8^1@%&(4811B1V^)A M$;1*Z.TOO7DKLNJ<';+KM5;2\I7<[,(IL-_VF%X[.Z8-/R_@V)6Y94,W/L(W M-C2O(UP'(5@1_@;Z*IMT3?@;Z(!LTM_@;^`R_*E-I;PJR;-@',D'_!Y?] M#P```/__`P!02P,$%``&``@````A``*M)BPI#```)3X``!D```!X;"]W;W)K M&ULK)M=;]LZ$H;O%]C_8/C^V)9DQQ](_/T.1%,EY9<4NVHNZ?30SI%Z.J"$EW?[Y8_\Z^%8= MCKOZ[6[HC2;#0?6VK1]W;\]WP__^%?^Q&`Z.I\W;X^:U?JONAC^KX_#/^W_^ MX_9[??AR?*FJTX`BO!WOAB^GT_MJ/#YN7ZK]YCBJWZLW.O)4'_:;$_WW\#P^ MOA^JS6/CM'\=^Y/)S7B_V;T-9835X9(8]=/3;EN%]?;KOGH[R2"'ZG5SHOX? M7W;O1QUMO[TDW'YS^/+U_8]MO7^G$)]WK[O3SR;H<+#?KK+GM_JP^?Q*Y_W# MFVZV.G;S'PB_WVT/];%^.HTHW%AV%,]Y.5Z.*=+][>..SD#(/CA43W?#3]ZJ MG/K#\?UM(]#_=M7WH_7OP?&E_IX<=H_E[JTBM6F,SDB]*L\O>EEG?4H!65&B%Q4*7$SND@BK\TF^H?VG8^\Z>0C<3V= M0N(?VK/_7,WA_K[@&8;:OOXOA%SE[<2X?0E(4>HO4C.72-T M<8@HGT28NR&-&:7_D2[L;_?>TKL=?Z.+<:ML'CIL7(NUMA!7G@@;0@XB#F(.$@ MY2#C(.>@X*"T@",5S5J_0RH1YFY(?UN)QK1YD#:^G8TS)E]KTNH')`(2`TF` MI$`R(#F0`DAI$T=(FL5_AY`B#%WTE-F6DOR2E4:]2K8FK9)`(B`QD`1("B0# MD@,I@)0V<92D&Y&C9'<9H*2U5OIL8H6LX4D,ZFDQ-;&,%>V_ MN2UFQDJWF)OPH)\H+6W]K%GH]++;?GFH::CHLNJ8D@):):NULRQ0'5E5S6K+ MVB+3?0]EE593JEG:)/$GK*R/O-9*GV2LD"/K)2VF)I;=(EN29<9*MY@[+;II M24GAR-HA'^T_M?H):<=IL],1 M+&YFTRE+I%C;D/?YX(FVZNU"VFFU`(U51^=-KR:C@)7:N0YSKDON((BRU\[M M#P9!5LE.$DL44)'3*N!/6*?6GG+L52`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`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`:Z(H_77VB`<&&'^C\.D^/SJ[SY&Y6]!U#1YSYBE[2[^"D19<4 M])+K2KS5BA[T?NI*O'V*1T(O()^NTZ-W,LFGZTCH3)Z1VQJWJ M])'N^^:Y^M?F\+Q[.PY>JR=*S$GS0.D@/_.5_SFIQ_&?ZQ-]GML\F7^AS[$K M>N5[(K[;>*KKD_Z/:*#]P/O^;P```/__`P!02P,$%``&``@````A`&"@,YZJ M!0``"AH``!D```!X;"]W;W)K&ULE%E;C^HV$'ZO MU/\0Y?T0[%Q8$'#$=K7MD5JIJGIYS@8#T9(8)=G;O^^,;1+;<0AY62V3\7R> MF<]?!K/^_EFLHW_ MQ6K_^_;GG]8?O'JM3XPU'D0HZXU_:IK+*@CJ[,2*M)[Q"ROAR8%71=K`Q^H8 MU)>*I7NQJ#@'=#Y/@B+-2U]&6%7WQ."'0YZQ)YZ]%:QL9)"*G=,&]E^?\DM] MC59D]X0KTNKU[?(MX\4%0KSDY[SY$D%]K\A6/XXEK]*7,^3]2:(TN\86'WKA MBSRK>,T/S0S"!7*C_9R7P3*`2-OU/H<,L.Q>Q0X;?T=6CW'H!]NU*-"_.?NH MM?^]^L0_?JWR_>]YR:#:T"?LP`OGK^CZ8X\F6!ST5C^+#OQ9>7MV2-_.S5_\ MXS>6'T\-M#N&C#"QU?[KB=495!3"S&B,D3)^A@W`7Z_(D1I0D?1SXU,`SO?- M:>.'R2Q>S$,"[MX+JYOG'$/Z7O96-[SX3SH1L2D92VSM*6W2[;KB'Q[T&[SK M2XKL(2L([-X+;`)]=^B\\1>^!S`U%/!]2Z/Y.GB'I#/E\RA]X&_K0UJ/`$!; M9$"['QF=$1FK@EMYE`8=AKIA0A,&BQY"ZVXGBHO`3T\BMA.5/I'F$[MW`"[W M)XK.T`LCL:BKH$Q>.MT!#;RX'QJ=!71;9&F)!('TUB53PJ*S&599H`L=1^+0 M73P@V_T9H+,))2W]#%!3-=HC*X#*8[3`569\:=$[0>+(G-M`+',1%`F,YD!3B-!==01,/068%W':=0=6,EJ$7/CZ_A#Z).T M@RBM$$*HH*3)44U++D;RDAH`&V^/#%$FD]R)FQ($2Y\M+Q M.Q<3'7SN5PV*WE8UINGX0ZR8I!JTKQK* MU*\FCLLZW^09&Y,,L3U*-L%6- M5@65R9&'I0AX;LER5`7#OC0HD]X5DG2M,_+!;U$Z%V]73WB;+%>F?CZ1I0B8 M#QUGN5AF05REH:,B20:FL@H;>%)DT.5E@Z(%@Q_E4^Z@N",ADL M7PQ,@-$DC1#>5C[7P0+.L7E^+#VX\]1&?6%0)C.?@5DLLK1BA`VM1.@L[UJO M6"Z]=/P!EL>3-$-XF]54ICX[8DLS;N%MHUW'" M9@7<2QOG1[`"OX*-)"1/O_Z&%Y%,[2$+>P:3=]CRHKA@U9']PL[GVLOX&]Y/ M+^'JM[6JN_,P7NU`:6'?]I.(PI,'YY/E:BF1_I-4Q+VOOS`Y0B?EL`;I4 MR;M\^:'A%^@IW,?S!N[@Q;\G^,V%P:7U'+]H'SAOKA\0H/T59_L_````__\# M`%!+`P04``8`"````"$`*JR!=)D"``#=!@``&0```'AL+W=OTL\_>]Q@DBDU'+O`"^')]S-U\OGLZR0D>NC5!UBL-@A!&OFU-R;A$PU";%I;5-0HAA)9?4!*KA-?S) ME9;4PE(7Q#2:TZS=)"L2C493(JFHL6=(]!`.E>>"\8UB!\EKZTDTKZ@%_TTI M&G-EDVP(G:1Z?V@>F)(-4.Q$)>Q+2XJ19,ES42M-=Q7$?0['E%VYV\4=O11, M*Z-R&P`=\8[>Q_Q('@DP+1>9@`A8I78;*>8[)09\S9X+-Y&[WMBW`=XTRGM-#97^HTQ%5ZX/$MT88'WE64:3&:C./P_"?$>M0%NJ*7+A58G!$T# MDJ:AK@7#!(C?C@A"<=B5`Z=XAA'X:J`*QV443Q?D"*EC%\S:8^#98<(.04"T M4P:UX=;Q>V6/&/M``:6BJX=(.W$IWR?66<7LF^B6;OH?6@6]I+Q8X?EUO1/'\ M[>1!DPV/P(%OI;SE/@(WD'OMWA[D"!SZ=]^[7;?\WM*O1!0_OHK$CQ-_VB37 M!?_$J\H@I@YN5$1P?CIK-\56D4OZ:_LX6;73C70_8+HTM.#?J"Y$;5#%UV`,.DNIN5?````__\# M`%!+`P04``8`"````"$`\Q=#\8$"``!M!P``$``(`61O8U!R;W!S+V%P<"YX M;6P@H@0!**```0`````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````````````````````"<55M/ MVS`4?I^T_Q#E'5*Z:IJ0&\0*$Y,V5BV%/5H'YZ2U<.S,=BK*K]]QLD(ZW&KP M9OOC-$$M3"GU++X1"NVFZ\KXYS3(G5EB#.R:Q)DEE;`V>KG:9F:J2`B^, M:&O4/AN/1A\S?/"H2RR/FB>':>_Q=.W?ZK0T(N!SMXM-0X!S=MXT2@KPE&7^ M70IKG*E\.\`N609<\/[`HAD#8' M:5W.UOYTC<(;FSCY2+2-T^0.'`8XTW0-5H+V!"NH]9?NK!KG;?[+V'NW0O2. M9:30/W;'H>[P+"?Y>-)IT&E7,WCHD9!@%^-">H7N1S4'ZV.0)T/,'8H><0]H M6T5.O<$OM2>^^%?=5UN:(?*G'&:&"JT=EIQ.SBA9@J?+9U"@!;'YI!AXZ:,< M-CEYC4WA*5K]JC!_3>)A?M@E:/G8]5041R&76E+#4ZGYN1"F)9+TDL\I<2'C M.$C-MAT_-4V/V^_[VGAT?`X;N%-Q5X4WXGYE5$FSS2]_MU2?*,J9J6OIPSRZ MKI3$>(!)2X!&.VKQ$U6H6VB;#5]8()PB#%9<^S`+<6IC-/!%2'5/C)>Y'E(? M5HY?@[7$\QKY!7J0:D^$@[4<1WF*9E'0=BQ;A3QJLE/6%]"B)I$Z#PS_VZ1H MZQKLAIOJ#2;Q*A[LK'C^>UNK2VF(;&>O_;/)ODE][VZ:A;F@/MVNZMU'5JS` M8DE+;"M_?F!7M*6M"DYF*Z!1*+&UL(*($`2B@``$````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````G)%!3\,@&(;O)OZ'AGM+:1>CI&6)FIU<8N*,BS>$;QNQ4`)HMW\O[;HZ MHR>/Y'UY>+Z/:K[73?()SJO6U(AD.4K`B%8JLZW1\VJ17J/$!VXD;UH#-3J` M1W-V>5$)2T7KX-&U%EQ0X)-(,IX*6Z-=")9B[,4.-/=9;)@8;EJG>8A'M\66 MBW>^!5SD^176$+CD@>,>F-J)B$:D%!/2?KAF`$B!H0$-)GA,,H*_NP&<]G]> M&)*SIE;A8.-,H^XY6XIC.+7W7DW%KNNRKAPTHC_!Z^7#TS!JJDR_*P&(]?MI MN`_+N,J-`GE[8/LWUR3>[RK\.ZND&.RH<,`#R"2^1X]VI^2EO+M?+1`K&PO7W)E;',O=V]R:V)O;VLN M>&UL+G)E;'-02P$"+0`4``8`"````"$`'.&4!L\"``!5"```#P`````````` M``````#V"0``>&PO=V]R:V)O;VLN>&UL4$L!`BT`%``&``@````A`*K28BM] M!@``/QL``!@`````````````````\@P``'AL+W=O&UL4$L!`BT`%``&``@````A M`#@Z\?]C`P``A`L``!D`````````````````L!@``'AL+W=O,X)``"]/@``&0`````` M``````````!*'```>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`),QW44/!```I0\` M`!D`````````````````]RD``'AL+W=O&PO=V]R:W-H965T&UL M4$L!`BT`%``&``@````A`&%V16R%!```K1```!@`````````````````%3@` M`'AL+W=O&PO M:78+``#Y90``#0````````````````#N:P``>&POP``>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`%TP M$=:>!@``_1P``!@`````````````````]X```'AL+W=O&PO=V]R:W-H965T M&UL4$L!`BT`%``&``@````A`$<_]..0"P``94,``!@````` M`````````````X\``'AL+W=O&UL4$L!`BT`%``&``@````A`#>R0Z"Y`@``JP<` M`!@`````````````````.9\``'AL+W=O&UL4$L!`BT`%``&``@````A`.X,O4WB M"P``3CT``!D`````````````````1J4``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`&"@,YZJ!0``"AH``!D````` M````````````&<0``'AL+W=O&PO=V]R M:W-H965T&UL4$L!`BT`%``& M``@````A`-?C@O(R`0``0`(``!$`````````````````@=```&1O8U!R;W!S ?+V-O&UL4$L%!@`````A`"$`V0@``.K2```````` ` end XML 14 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Statements of Operations (Unaudited) (USD $)
 3 Months Ended 9 Months Ended 138 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Condensed Consolidated Statements of Operations [Abstract]          
Grant revenues     $ 12,286 $ 7,229 $ 1,102,545
License fees and other revenues 12,000   12,000   294,900
Total operating revenues 12,000   24,286 7,229 1,397,445
Cost of revenues 4,800   4,800   4,800
Gross profit 7,200   19,486 7,229 1,392,645
Operating expenses:          
Research and development 1,371,644 283,141 1,642,591 764,810 12,615,483
General and administrative 326,649 317,961 1,078,239 1,049,249 10,197,474
Total operating expenses 1,698,293 601,102 2,720,830 1,814,059 22,812,957
Operating loss (1,691,093) (601,102) (2,701,344) (1,806,830) (21,420,312)
Other income (expense):          
Interest income   1,023   3,212 187,616
Interest expense (66,158) (2,136) (66,808) (5,580) (2,178,222)
Other income, net 991 769 2,879 2,130 153,367
Total other income (expense), net (65,167) (344) (63,929) (238) (1,837,239)
Loss before provision for income taxes (1,756,260) (601,446) (2,765,273) (1,807,068) (23,257,551)
Provision for income taxes               
Net loss $ (1,756,260) $ (601,446) $ (2,765,273) $ (1,807,068) $ (23,257,551)
Weighted average number of common shares outstanding - basic and diluted (in Shares) 24,839,007 24,685,193 24,807,040 24,679,417  
Net loss per common share - basic and diluted (in Dollars per Share) $ (0.07) $ (0.02) $ (0.11) $ (0.07)  

XML 15 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stockholders' Equity
 9 Months Ended
Sep. 30, 2013
Stockholders' Equity [Abstract]  
Stockholders' Equity

5. Stockholders’ Equity

Common Stock

During the nine months ended September 30, 2013, the Company issued 75,001 shares of its common stock with an estimated fair value of $75,001 to an investor and public relations firm in lieu of cash for services rendered during the period. In September 2013, the Company issued 100,000 shares of its common stock with an estimated fair value of $100,000 related to a licensing agreement with a collaborative partner. As of September 30, 2013, 24,936,833 shares of common stock are outstanding.

Stock Options

The following summarizes the outstanding common stock options and related activity for the nine months ended September 30, 2013:

 

                 
            Weighted  
     Number of      Average Exercise  
     Options      Price Per Share  

Outstanding as of December 31, 2012

      3,865,440       $ 0.34   

Granted

      —           —     

Exercised

      —           —     

Forfeited

      —           —     
    

 

 

           

Outstanding as of September 30, 2013

      3,865,440         0.34   
    

 

 

           

Exercisable as of September 30, 2013

      3,388,773         0.25   
    

 

 

           

On December 18, 2012, the Board of Directors approved, subject to stockholder approval, the addition of 3,000,000 shares to the 2011 Equity Incentive Compensation Plan (the Plan). On May 6, 2013, stockholders representing 69% of the issued and outstanding voting common stock of the Company accepted the Board of Directors’ recommendation and provided their written consent to approve these additional 3,000,000 shares of common stock of the Company to the pool of shares reserved for issuance under the Plan, increasing the number of shares from 1,877,529 to 4,877,529 shares. As of September 30, 2013, options to purchase 3,987,529 shares of common stock under the Plan were available for future grant. The following summarizes information about stock options outstanding as of September 30, 2013:

 

                     
        Weighted            
        Average   Weighted       Weighted
    Numbers of   Remaining   Average   Number of   Average
Exercise   Options   Contractual   Price   Options   Price

Price

  

Outstanding

  

Life (Years)

  

Exercise

  

Exercisable

  

Exercise

$0.06 – $0.08   902,600   5.58   $0.08   902,600   $0.08
$0.15 – $0.19   2,072,840   5.70   0.17   2,072,840   0.17
$1.00   890,000   8.34   1.00   413,333   1.00
   

 

          

 

    
    3,865,440   6.28   0.34   3,388,773   0.25
   

 

          

 

    

As of September 30, 2013, the aggregate intrinsic value of outstanding and exercisable stock options was $2,549,625.

Stock-based compensation for the three months ended September 30, 2013 and 2012 was $25,439 and $40,445, respectively. Stock-based compensation for the nine months ended September 30, 2013 and 2012 was $76,316 and $95,912, respectively. As of September 30, 2013, the Company had $219,439 of unrecognized stock-based compensation expense related to non-vested awards that will be recognized over a weighted-average period of 2.3 years.

Warrants

In October 2012, the Company entered into a service agreement with an investor relations and public advisory firm. As part of the agreement, the service provider was entitled to receive up to 250,000 warrants to purchase common stock at prices ranging from $1.25 to $2.75 per share with a term of two years. The warrants are immediately exercisable upon issuance. On January 1, 2013, the first tranche of 62,500 warrants was issued with an exercise price of $1.25. On April 1, 2013, the second tranche of 62,500 warrants were issued with an exercise price of $1.75. On July 1, 2013, the third tranche of 62,500 warrants were issued with an exercise price of $2.25.

As of September 30, 2013, 12,242,018 warrants to purchase common stock had been issued with exercise prices ranging from $.046 to $2.25 per share and terms ranging from two to seven years. The weighted average warrant exercise price is $1.40 and the weighted average remaining life is 4.7 years.
XML 16 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 17 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8
Related-Party Transactions (Narrative) (Details) (Officer and Affiliate [Member], Bridge Financing [Member], USD $)
 9 Months Ended
Sep. 30, 2013
Related Party Transaction [Line Items]  
Related party transaction, cash proceeds received $ 250,000
Minimum [Member]
  
Related Party Transaction [Line Items]  
Related party transaction, date (in Date) Aug. 12, 2013
Maximum [Member]
  
Related Party Transaction [Line Items]  
Related party transaction, date (in Date) Sep. 30, 2013
XML 18 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8
Accrued Compensation (Schedule of Accrued Compensation) (Details) (USD $)
Sep. 30, 2013
Dec. 31, 2012
Accrued Compensation [Abstract]    
Accrued wages $ 162,531 $ 17,046
Accrued vacation 69,991 70,846
Total accrued compensation $ 232,522 $ 87,892
XML 19 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
Organization
 9 Months Ended
Sep. 30, 2013
Organization [Abstract]  
Organization

1. Organization

Q Therapeutics, Inc. (Q) conducts its operations through its wholly owned subsidiary, Q Therapeutic Products, Inc. (Q Products) and its wholly owned subsidiary, NeuroQ Research, Inc (collectively, Q Therapeutics or the Company). Q Therapeutics is a Salt Lake City, Utah-based biopharmaceutical company that is developing human cell-based therapies intended to treat degenerative diseases of the brain and spinal cord, the primary components of the central nervous system (CNS). Q Products was incorporated in the state of Delaware on March 28, 2002, and merged with Q Acquisition, Inc., a Delaware corporation and a wholly owned subsidiary of Grace 2, Inc., on October 13, 2011. Grace 2, Inc. was incorporated on October 27, 2005. On November 2, 2011, Grace 2 changed its name to Q Holdings, Inc., and on December 10, 2012, it changed its name to Q Therapeutics, Inc.

The technology upon which these potential therapies is based was developed by Q’s co-founder Mahendra Rao, M.D., Ph.D., a leader in glial stem cell biology, during his tenure at the University of Utah and as Head of the Stem Cell Section at the National Institutes of Health (NIH). Dr. Rao was one of the first scientists to identify and seek patent coverage on stem cells and their progeny cells found in the CNS. After licensing Dr. Rao’s technology from the University of Utah and NIH, Q commenced operations in the spring of 2004 to develop cell-based therapeutic products that can be sold as “off-the-shelf” pharmaceuticals.
XML 20 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8
Accrued Compensation
 9 Months Ended
Sep. 30, 2013
Accrued Compensation [Abstract]  
Accrued Compensation

3. Accrued Compensation

Accrued compensation consists of the following:

 

     September 30, 2013      December 31, 2012  

Accrued wages

    $ 162,531       $ 17,046   

Accrued vacation

      69,991         70,846   
  

 

 

     

 

 

  

Total accrued compensation

    $ 232,522       $ 87,892   
  

 

 

     

 

 

  

Starting in March 2013, certain of the Company’s executives agreed to defer part, if not all, of their salaries until additional funding is obtained.
XML 21 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

6. Commitments and Contingencies

Supplier Agreements

In March 2010, the Company entered into a service agreement with an outside research firm to support the Company’s preclinical Good Laboratory Practice (GLP) safety studies.

In November 2012, the Company and the supplier amended the terms of their original agreement via a Letter of Understanding and increased the total purchase commitment with the supplier to approximately $2,600,000 with an expected completion by year-end 2013. Upon conclusion of the supplier’s final project report, any outstanding balance will be converted into a note payable accruing interest at 8% until July 31, 2015. Any outstanding amounts thereafter shall accumulate interest at 10% through March 31, 2016. Should the Company be successful in obtaining additional financing, the amendment calls for a percentage of the funds raised to immediately pay down the outstanding balance. As of September 30, 2013, the amount owed under this agreement totaled $2,136,730 and is included in accounts payable. The supplier also was granted, upon successful completion of the clinical study, a right of first negotiation on any future preclinical GLP safety to toxicology studies.

 

Advisory Agreements

In February 2013, the Company entered into an agreement to engage a financial advisory firm for a minimum term of six months. The agreement was revised in May 2013. The financial advisory firm is entitled to a commission equal to 7% of the total proceeds raised by the Company from its financing efforts payable in cash; and if warrants are issued as part of the placement of securities, an issuance of warrants equivalent to 1% of the aggregate number of warrants purchased in the offering, collectively not to exceed 8%. Additionally, the Company shall reimburse reasonable out-of-pocket expenses. To date, no placement of securities has occurred.

In July 2013, the Company entered into a business consulting services agreement effective through December 31, 2015. Under the agreement, the Company issued an initial payment of a warrant to purchase 75,000 shares of common stock at a strike price of $1.01 per share, with a five-year life and a cashless exercise option. The business consulting firm is entitled to receive additional warrants for up to 100,000 shares of common stock with similar terms.
XML 22 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8
Notes Payable
 9 Months Ended
Sep. 30, 2013
Notes Payable [Abstract]  
Notes Payable

4. Notes Payable

Between August 12 and September 30, 2013, the Company received $250,000 in cash proceeds resulting from a bridge financing by a group of note holders, some of which are also stockholders that are considered affiliates, as evidenced by promissory notes (Notes). The Notes were issued at 50% of face value, bear interest at the rate of 8% per annum, and are due in full beginning February 5, 2014. Notes payable as of September 30, 2013 are $500,000. To date, the Company has recorded interest relating to the note of $65,942, of which almost all pertains to the amortization of the debt discount with an additional $188,333 of debt discount costs to be amortized over the remaining term of the note. As of September 30, 2013, no payments towards principal or interest had been made.

The effective interest rate related to this financing is approximately156%.
EXCEL 23 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\R.#$X9#,P9%]F8V$X7S1D-3E?8C4P.%\W.3$T M-S)D-S0V,6(B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?4W1A=&5M M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T;V-K:&]L9&5R#I%>&-E;%=OF%T:6]N M7TYA#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO=&5S7U!A>6%B;&5?3F%R#I.86UE/@T*("`@(#QX.E=O#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/E-T;V-K:&]L9&5R5]O9CPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T M;V-K:&]L9&5R5]O9C$\+W@Z3F%M93X-"B`@("`\ M>#I7;W)K#I7;W)K#I7;W)K#I3='EL97-H965T($A2968],T0B5V]R:W-H M965T&-E;"!84"!O M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\R.#$X9#,P9%]F8V$X7S1D-3E?8C4P.%\W.3$T-S)D-S0V,6(- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C@Q.&0S,&1?9F-A.%\T M9#4Y7V(U,#A?-SDQ-#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2!);F9O2!);F9O'0^)SQS<&%N/CPO'0^)U$@5&AE'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)V9A;'-E/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO M'0^)RTM,3(M,S$\2!6;VQU;G1A2!#=7)R96YT(%)E<&]R=&EN9R!3=&%T M=7,\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)U$S M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO2`H9&5F:6-I M="DZ/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M)SQS<&%N/CPO3PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^ M)SQS<&%N/CPOF5D M("AI;B!3:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ M,#`L,#`P+#`P,#QS<&%N/CPO'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)R9N8G-P.R9N8G-P M.SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO2!A;F0@97%U:7!M96YT/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,RPX,#(I/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO6%B M;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2P@=F%L=64\+W1D/@T*("`@("`@("`\=&0@ M8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3PO=&0^#0H@("`@("`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`@("`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`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAAF4Z(#$P<'0[)SX\8CXR+B!3 M:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/"]B/CPO<#X-"CQP('-T M>6QE/3-$)VUAF4Z(#$P<'0[)SX\8CY4:&4@9F]L;&]W:6YG('-I9VYI9FEC86YT M(&%C8V]U;G1I;F<@<&]L:6-I97,@87)E(&9O;&QO=V5D(&)Y('1H92!#;VUP M86YY(&EN('!R97!A6QE/3-$)VUA MF4Z M(#$P<'0[)SY4:&4@86-C;VUP86YY:6YG('5N875D:71E9"!C;VYD96YS960@ M8V]NF4Z(#$P<'0[)SY4:&4@86-C;VUP M86YY:6YG('5N875D:71E9"!C;VYD96YS960@8V]NF4Z(#$P<'0[)SX\8CY"87-I6QE/3-$)VUAF4Z(#$P<'0[)SY4 M:&4@86-C;VUP86YY:6YG('5N875D:71E9"!C;VYD96YS960@8V]N2P@42!02!O=VYE9"!S=6)S M:61I87)Y+"!.975R;U$@4F5S96%R8V@@26YC+B!4:&4@0V]M<&%N>2!IF%T:6]N(&]F('!R;V1U8W1S(&%S('!O=&5N=&EA;"!T2!I2P@=&AE($-O;7!A;GD@:&%S(&)E96X@9&5P96YD96YT(&]N(&=O=F5R M;FUE;G0@9W)A;G1S(&%N9"!D96)T(&%N9"!E<75I='D@2!T M:&4@9&5V96QO<&UE;G0@;V8@:71S('!R;V1U8W0@8V%N9&ED871E2!H87,@;F]T(&=E;F5R871E9"!R979E;G5E2!H860@86X@86-C=6UU;&%T960@ M9&5F:6-I="!O9B`D,C,L,C4W+#4U,2X\+W`^#0H\<"!S='EL93TS1"=M87)G M:6XM=&]P.B`Q,G!T.R!M87)G:6XM8F]T=&]M.B`P<'0[(&9O;G0M&-H86YG M92!#;VUM:7-S:6]N(')E9VES=&5R:6YG('1H92!O9F9E6QE/3-$)VUAF4Z(#$P<'0[)SX\8CY56QE/3-$)VUAF4Z(#$P<'0[)SY4:&4@<')E<&%R M871I;VX@;V8@9FEN86YC:6%L('-T871E;65N=',@:6X@8V]N9F]R;6ET>2!W M:71H(%53)B,Q-C`[1T%!4"!R97%U:7)E'!E;G-E2P@86-T=6%L(')E2!A;F0@97%U:7!M96YT+"!V86QU871I;VX@86QL M;W=A;F-E6QE/3-$)VUAF4Z(#$P<'0[)SY4:&4@0V]M<&%N M>2!P97)I;V1I8V%L;'D@87!P;&EE'!E;G-E7,@;V8@=&AE(&EN=F]I M8V4@9&%T92P@86QT:&]U9V@@8V5R=&%I;B!I;G-T:71U=&EO;G,@8W5S=&]M M87)I;'D@9&\@;F]T('!A>2!W:71H:6X@,S`@9&%Y2!M86YA9V5M96YT(&)A6UE;G0@ M6UE;G0@:7,@F4Z(#$P<'0[)SY);B!$96-E;6)E2!W87,@;F]T:69I960@;V8@82!S=6(M87=A2`H2DA5*2!F65A'!E M;G-E'1E;G-I;VXN M/"]P/@T*/'`@F4Z(#$P<'0[)SX\8CY3=&]C:RU"87-E9"!# M;VUP96YS871I;VX\+V(^/"]P/@T*/'`@2!O=F5R('1H92!V97-T:6YG('!E65EF4Z(#$P<'0[)SY4:&4@=F]L871I;&ET>2!A2!S96=M96YT(&%S('1H92!#;VUP M86YY+B!4:&4@97AP96-T960@;&EV97,@;V8@=&AE(&]P=&EO;G,@86YD('=A M'!E8W1E9"!T;R!B92!O M=71S=&%N9&EN9RX@5&AE(')I2!R871E('1H870@8V]R2!T:&4@=V5I M9VAT960@879E6QE/3-$)VUA2!H87,@ M:6YC=7)R960@;F5T(&QOF4Z(#$P<'0[)SX\8CY296-E;G0@06-C;W5N=&EN9R!0 M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A6QE/3-$ M)V-O;&]R.B!R9V(H,"P@,"P@,"D[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W M(%)O;6%N)SL@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F M;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[ M('=O'0MF4Z(#$P<'0[)SX\8CXS+B!!8V-R=65D($-O;7!E;G-A=&EO;CPO M8CX\+W`^#0H\<"!S='EL93TS1"=C;VQO3H@)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M3H@ M)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US M<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE M.R!W:61O=W,Z(&%U=&\[('=O'0M6QE/3-$)V)O6QE/3-$)VUA'0M:6YD96YT.B`M,65M M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O M;6%N)SLG/D%C8W)U960@=V%G97,\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT^)B,Q-C`[)B,Q-C`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M)#PO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$3H@)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M6QE/3-$)VUA'0M:6YD96YT.B`M,65M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/D%C8W)U960@=F%C871I M;VX\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[)B,Q-C`[ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV.2PY.3$\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3XF(S$V,#LF(S$V,#L\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;3XF(S$V,#LF(S$V,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;3XF(S$V,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/CF4Z(#%P M>#LG/@T*/'1D('9A;&EG;CTS1&)O='1O;2\^#0H\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C,38P.R8C,38P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M/'`@6QE.B!S;VQI9#L@8F]R9&5R+71O<"UC;VQO6QE.B!S;VQI9#L@8F]R9&5R+71O<"UC;VQOF4Z(#$P<'0[)SX-"CQT9"!V86QI M9VX],T1T;W`^#0H\<"!S='EL93TS1"=M87)G:6XM;&5F=#H@,V5M.R!T97AT M+6EN9&5N=#H@+3%E;3L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@ M)U1I;65S($YE=R!2;VUA;B<[)SY4;W1A;"!A8V-R=65D(&-O;7!E;G-A=&EO M;CPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=F;VYT+7-I>F4Z(#AP=#LG/B8C,38P.R8C,38P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XR,S(L-3(R/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT^)B,Q-C`[)B,Q-C`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)V9O;G0M6QE.B!D;W5B;&4[(&)O6QE.B!D;W5B;&4[ M(&)O6QE/3-$)V)O#L@8F]R9&5R+71O<"US='EL93H@9&]U8FQE.R!B M;W)D97(M=&]P+6-O;&]R.B!R9V(H,"P@,"P@,"D[)SXF(S$V,#L\+W`^/"]T M9#X-"CQT9#XF(S$V,#L\+W1D/CPO='(^/"]T86)L93X-"CQP('-T>6QE/3-$ M)V-O;&]R.B!R9V(H,"P@,"P@,"D[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W M(%)O;6%N)SL@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F M;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[ M('=O'0M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M6QE/3-$)V-O;&]R.B!R9V(H,"P@,"P@ M,"D[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SL@9F]N="US='EL M93H@;F]R;6%L.R!F;VYT+79A'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US M<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M'0M86QI M9VXZ('-T87)T.R!T97AT+6EN9&5N=#H@,'!X.R!T97AT+71R86YS9F]R;3H@ M;F]N93L@=VAI=&4M#L@+7=E8FMI="UT97AT+7-T2!P6QE/3-$)V-O;&]R.B!R9V(H,"P@ M,"P@,"D[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SL@9F]N="US M='EL93H@;F]R;6%L.R!F;VYT+79A'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET M92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M3$U-B4N/"]P/@T*/"$M+45N M9$9R86=M96YT+2T^#0H\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!;06)S=')A M8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^)SQP('-T>6QE/3-$)VUAF4Z(#$P<'0[)R!W:61T:#TS1#6QE/3-$)V9O;G0MF4Z(#AP=#LG/@T* M/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;3XF(S$V,#LF(S$V,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1&-E;G1EF4Z(#AP M=#LG/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;3XF(S$V,#LF(S$V,#L\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M+7=I9'1H.B`Q<'0[(&)O M6QE/3-$)V)O6QE/3-$)V9O;G0M M6QE/3-$ M)VUA'0M:6YD96YT.B`M,65M.R!F;VYT+7-I M>F4Z(#$P<'0[)SY'6QE/3-$)V9O;G0M6QE/3-$)VUA'0M:6YD96YT.B`M,65M.R!F;VYT+7-I>F4Z(#$P M<'0[)SY%>&5R8VES960\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M)B,Q-C`[)B,Q-C`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(S@R M,3([)B,Q-C`[)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M/B8C,38P.R8C,38P.SPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C,38P.R8C,38P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C,38P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4Z M(#%P>#LG/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3XF(S$V,#LF(S$V,#L\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)V)O#L@8F]R9&5R+71O<"US='EL93H@6QE/3-$)V)O#L@ M8F]R9&5R+71O<"US='EL93H@F4Z(#$P<'0[)SX-"CQT9"!V86QI9VX],T1T;W`^#0H\<"!S='EL93TS M1"=M87)G:6XM;&5F=#H@,65M.R!T97AT+6EN9&5N=#H@+3%E;3L@9F]N="US M:7IE.B`Q,'!T.R<^3W5T6QE M/3-$)V9O;G0M6QE/3-$)V9O;G0M M6QE.B!D;W5B;&4[ M(&)OF4Z(#$P<'0[)SX-"CQT9"!V86QI9VX],T1T;W`^#0H\<"!S='EL M93TS1"=M87)G:6XM;&5F=#H@,65M.R!T97AT+6EN9&5N=#H@+3%E;3L@9F]N M="US:7IE.B`Q,'!T.R<^17AE6QE/3-$)V9O;G0M6QE/3-$)V9O M;G0M6QE.B!D;W5B M;&4[(&)OF4Z(#$P<'0[)SY/;B!$96-E;6)EF4Z(#AP=#LG('=I9'1H/3-$,3`P)2!B;W)D97(],T0P(&-E;&QS M<&%C:6YG/3-$,"!A;&EG;CTS1&-E;G1EF4Z(#AP=#LG/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF M(S$V,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E M6QE M/3-$)VUAF4Z(#AP=#LG(&%L:6=N/3-$8V5N=&5R/CQB/E!R:6-E/"]B/CPO<#X\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M+7=I9'1H.B`Q M<'0[(&)O6QE/3-$)VUAF4Z(#AP=#LG(&%L:6=N/3-$8V5N=&5R/CQB/D]U='-T86YD:6YG M/"]B/CPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M M+7=I9'1H.B`Q<'0[(&)O6QE/3-$)VUAF4Z(#AP=#LG(&%L:6=N/3-$8V5N=&5R/CQB/DQI M9F4@*%EE87)S*3PO8CX\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M)B,Q-C`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@&5R8VES93PO8CX\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@&5R8VES86)L93PO8CX\+W`^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT@6QE.B!S;VQI9#L@8F]R9&5R+6)O='1O;2UC;VQO&5R8VES93PO8CX\+W`^/"]T9#X\ M+W1R/@T*/'1R(&)G8V]L;W(],T0C8V-E969F('-T>6QE/3-$)V9O;G0M6QE/3-$)V9O;G0MF4Z(#AP=#LG/B8C,38P.SPO M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C,L.#8U+#0T,#PO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE.B!D;W5B;&4[ M(&)O6QE/3-$)V)O#L@8F]R9&5R+71O<"US='EL93H@9&]U8FQE.R!B;W)D97(M=&]P+6-O;&]R M.B!R9V(H,"P@,"P@,"D[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B,Q M-C`[/"]T9#X\+W1R/CPO=&%B;&4^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P M.B`Q,G!T.R!M87)G:6XM8F]T=&]M.B`P<'0[(&9O;G0MF5D(&]V97(@82!W96EG:'1E9"UA=F5R86=E('!E65AF4Z(#$P<'0[)SX\ M8CY787)R86YT2!E;G1E&5R8VES92!P28C,38P M.S$L(#(P,3,L('1H92!T:&ER9"!T6QE/3-$)VUA65A7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^)SQS<&%N/CPO6QE/3-$)VUA MF4Z M(#$P<'0[)SX\8CY3=7!P;&EE6QE/3-$)VUAF4Z(#$P<'0[)SY);B!-87)C:"`R,#$P+"!T:&4@0V]M<&%N>2!E M;G1E2!S='5D:65S+CPO<#X-"CQP('-T>6QE/3-$)VUA'!E M8W1E9"!C;VUP;&5T:6]N(&)Y('EE87(M96YD(#(P,3,N(%5P;VX@8V]N8VQU M2!O=71S=&%N9&EN9R!A M;6]U;G1S('1H97)E869T97(@2!D M;W=N('1H92!O=71S=&%N9&EN9R!B86QA;F-E+B!!2!S M='5D:65S+CPO<#X-"CQP('-T>6QE/3-$)VUAF4Z(#AP=#LG/B8C,38P.SPO<#X- M"CQP('-T>6QE/3-$)VUAF4Z(#$P<'0[)SX\8CY!9'9I2!!9W)E96UE;G1S M/"]B/CPO<#X-"CQP('-T>6QE/3-$)VUAF4Z(#$P<'0[)SY);B!&96)R=6%R>2`R M,#$S+"!T:&4@0V]M<&%N>2!E;G1E2!F:7)M(&9O2`R,#$S+B!4:&4@9FEN86YC:6%L(&%D=FES;W)Y(&9I2!S:&%L M;"!R96EM8G5RF4Z(#$P<'0[)SY);B!*=6QY(#(P M,3,L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A(&)U6UE;G0@;V8@82!W87)R M86YT('1O('!U65A7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)V-O;&]R.B!R9V(H,"P@,"P@,"D[(&9O;G0M9F%M:6QY.B`G5&EM M97,@3F5W(%)O;6%N)SL@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A'0M:6YD96YT.B`P<'@[('1E>'0M M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z M(&%U=&\[('=O'0M2!4 M6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E M:6=H=#H@;F]R;6%L.R!L971T97(M#L@=&5X="UT#L@;6%R9VEN M+71O<#H@-G!T.R!M87)G:6XM8F]T=&]M.B`P<'0[(&9O;G0M2!R96-E:79E9"`D,C4P+#`P,"!I;B!C M87-H('!R;V-E961S(')E2!A(&=R;W5P(&]F(&YO=&4@:&]L9&5R3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R.#$X9#,P M9%]F8V$X7S1D-3E?8C4P.%\W.3$T-S)D-S0V,6(-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO,C@Q.&0S,&1?9F-A.%\T9#4Y7V(U,#A?-SDQ-#'0O:'1M;#L@8VAA3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SPA+2U3=&%R M=$9R86=M96YT+2T^#0H\<"!S='EL93TS1"=C;VQO3H@)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M6QE/3-$)V-O M;&]R.B!R9V(H,"P@,"P@,"D[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O M;6%N)SL@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O M'0MF4Z(#$P<'0[)SY4:&4@86-C;VUP86YY:6YG('5N875D:71E9"!C;VYD M96YS960@8V]N6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H M=#H@;F]R;6%L.R!L971T97(M#L@=&5X="UT#L@;6%R9VEN+71O M<#H@,3)P=#L@;6%R9VEN+6)O='1O;3H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[ M)SY4:&4@86-C;VUP86YY:6YG('5N875D:71E9"!C;VYD96YS960@8V]N3PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^)SPA+2U3=&%R=$9R86=M96YT+2T^#0H\<"!S='EL M93TS1"=C;VQO3H@)U1I;65S M($YE=R!2;VUA;B<[(&9O;G0M'0M86QI9VXZ('-T87)T.R!T97AT+6EN9&5N=#H@,'!X.R!T97AT+71R M86YS9F]R;3H@;F]N93L@=VAI=&4M#L@+7=E8FMI="UT97AT+7-T6QE.B!N M;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R M;6%L.R!L971T97(M#L@=&5X="UT#L@;6%R9VEN+71O<#H@-G!T M.R!M87)G:6XM8F]T=&]M.B`P<'0[(&9O;G0M2!O=VYE9"!S=6)S:61I87)Y+"!1(%!R;V1U8W1S M+"!A;F0@42!02!E;F=A9V5D(&EN('1H92!D:7-C;W9E M2!A;6]U;G1S(&AA M=F4@8F5E;B!E;&EM:6YA=&5D+CPO<#X-"CPA+2U%;F1&6QE.B!N;W)M86P[ M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L M971T97(M#L@=&5X="UT#L@;6%R9VEN+71O<#H@,3AP=#L@;6%R M9VEN+6)O='1O;3H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[)SX\8CY$979E;&]P M;65N="!3=&%G92!A;F0@3&EQ=6ED:71Y/"]B/CPO<#X-"CQP('-T>6QE/3-$ M)V-O;&]R.B!R9V(H,"P@,"P@,"D[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W M(%)O;6%N)SL@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A'0M:6YD96YT.B`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`P<'0[(&9O;G0M6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@ M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M#L@=&5X="UT#L@;6%R9VEN+71O<#H@-G!T.R!M87)G:6XM8F]T=&]M.B`P<'0[ M(&9O;G0M2!E"!A2!B87-E6QE/3-$)V-O;&]R.B!R9V(H,"P@,"P@,"D[(&9O;G0M9F%M:6QY M.B`G5&EM97,@3F5W(%)O;6%N)SL@9F]N="US='EL93H@;F]R;6%L.R!F;VYT M+79A'0M:6YD96YT.B`P<'@[ M('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W M:61O=W,Z(&%U=&\[('=O'0M M6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N M=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M#L@=&5X="UT M#L@;6%R9VEN+71O<#H@-G!T.R!M87)G:6XM8F]T=&]M.B`P M<'0[(&9O;G0M2!A<'!L:65S(&9O2!G;W9E2!R M96-O3H@)U1I;65S($YE M=R!2;VUA;B<[(&9O;G0M'0M86QI9VXZ('-T87)T.R!T97AT+6EN9&5N=#H@,'!X.R!T97AT+71R86YS M9F]R;3H@;F]N93L@=VAI=&4M#L@+7=E8FMI="UT97AT+7-T7-I6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H M=#H@;F]R;6%L.R!L971T97(M#L@=&5X="UT#L@;6%R9VEN+71O M<#H@,3AP=#L@;6%R9VEN+6)O='1O;3H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[ M)SX\8CY3=&]C:RU"87-E9"!#;VUP96YS871I;VX\+V(^/"]P/@T*/'`@6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N M=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M#L@=&5X="UT M#L@;6%R9VEN+71O<#H@-G!T.R!M87)G:6XM8F]T=&]M.B`P M<'0[(&9O;G0M2!O M=F5R('1H92!V97-T:6YG('!E65E6QE.B!N M;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R M;6%L.R!L971T97(M#L@=&5X="UT#L@;6%R9VEN+71O<#H@,3)P M=#L@;6%R9VEN+6)O='1O;3H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[)SY4:&4@ M=F]L871I;&ET>2!A'!E8W1E9"!T;R!B92!O=71S=&%N9&EN9RX@5&AE M(')I6QE/3-$)V-O;&]R.B!R9V(H,"P@,"P@,"D[(&9O;G0M9F%M:6QY.B`G5&EM M97,@3F5W(%)O;6%N)SL@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A'0M:6YD96YT.B`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`G5&EM97,@3F5W M(%)O;6%N)SL@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F M;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[ M('=O'0MF4Z(#$P<'0[)SY4:&4@0V]M<&%N>2!H87,@28C.#(Q-SMS(&9I;F%N8VEA;"!P;W-I=&EO;BP@2X\+W`^#0H\(2TM16YD1G)A M9VUE;G0M+3X-"CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)V-O;&]R.B!R9V(H,"P@,"P@,"D[(&9O;G0M9F%M M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SL@9F]N="US='EL93H@;F]R;6%L.R!F M;VYT+79A'0M:6YD96YT.B`P M<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L M.R!W:61O=W,Z(&%U=&\[('=O'0MF4Z(#$P<'0[)SY!8V-R=65D(&-O;7!E M;G-A=&EO;B!C;VYS:7-T6QE/3-$)V-O;&]R.B!R9V(H,"P@,"P@,"D[(&9O;G0M9F%M:6QY.B`G5&EM M97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.B`Q,G!T.R!F;VYT+7-T>6QE.B!N M;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R M;6%L.R!L971T97(M#L@=&5X="UT#L@;6%R9VEN+71O<#H@,'!T M.R!M87)G:6XM8F]T=&]M.B`P<'0[)SXF(S$V,#L\+W`^#0H\=&%B;&4@8V5L M;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W M(%)O;6%N)SL@;&5T=&5R+7-P86-I;F#L@=&5X="UT6QE M/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE M.B`X<'0[)SX-"CQT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[)B,Q-C`[/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT@6QE.B!S;VQI9#L@8F]R9&5R+6)O='1O;2UC M;VQO6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SL@ M9F]N="US:7IE.B`Q,'!T.R<^#0H\=&0@=F%L:6=N/3-$=&]P/@T*/'`@6QE/3-$)V9O;G0M9F%M M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^#0H\ M=&0@=F%L:6=N/3-$=&]P/@T*/'`@6QE/3-$)V9O;G0M6QE/3-$)V)O#L@8F]R9&5R+71O M<"US='EL93H@6QE/3-$)V)O#L@8F]R9&5R+71O<"US M='EL93H@6QE/3-$)VUA'0M:6YD M96YT.B`M,65M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM M97,@3F5W(%)O;6%N)SLG/E1O=&%L(&%C8W)U960@8V]M<&5N6QE/3-$)V9O M;G0MF4Z(#AP=#LG/B8C,38P.R8C,38P.SPO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX-RPX.3(\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;3XF(S$V,#LF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)V)O#L@8F]R9&5R+71O<"US='EL93H@9&]U8FQE.R!B;W)D97(M=&]P M+6-O;&]R.B!R9V(H,"P@,"P@,"D[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=B;W)D97(M=&]P+7=I9'1H M.B`S<'@[(&)O6QE.B!D;W5B;&4[(&)O7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2`H5&%B;&5S*3QB6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F M;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M#L@=&5X="UT#L@ M;6%R9VEN+71O<#H@-G!T.R!M87)G:6XM8F]T=&]M.B`P<'0[(&9O;G0M'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O M'0M'0M:6YD96YT.B`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`M,65M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/D]U='-T86YD:6YG(&%S(&]F($1E M8V5M8F5R(#,Q+"`R,#$R/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C,38P.R8C,38P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P M.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$3H@)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M6QE/3-$)VUA'0M:6YD96YT.B`M,65M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/D=R86YT960\+W`^/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[)B,Q-C`[/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XF(S@R,3([)B,Q-C`[)B,Q-C`[/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[)B,Q-C`[/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT^)B,Q-C`[)B,Q-C`[/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XF(S@R,3([)B,Q-C`[)B,Q-C`[/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^)B,Q-C`[)B,Q-C`[/"]T9#X\+W1R/@T*/'1R(&)G8V]L M;W(],T0C8V-E969F('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W M(%)O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^#0H\=&0@=F%L:6=N/3-$=&]P M/@T*/'`@3H@ M)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M6QE/3-$)VUA'0M:6YD96YT.B`M,65M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B`G5&EM97,@3F5W(%)O;6%N)SLG/D9O6QE/3-$)V)O#L@ M8F]R9&5R+71O<"US='EL93H@6QE/3-$)V)O#L@8F]R M9&5R+71O<"US='EL93H@3H@)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M M6QE/3-$ M)VUA'0M:6YD96YT.B`M,65M.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SLG/D]U M='-T86YD:6YG(&%S(&]F(%-E<'1E;6)EF4Z M(#AP=#LG/B8C,38P.R8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C,L.#8U+#0T,#PO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C,38P.R8C,38P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)V9O;G0M6QE.B!D;W5B;&4[(&)O6QE/3-$)V)O#L@8F]R9&5R+71O<"US='EL93H@9&]U8FQE.R!B;W)D97(M=&]P M+6-O;&]R.B!R9V(H,"P@,"P@,"D[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9#XF M(S$V,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#LF(S$V,#L\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2\^#0H\=&0@=F%L:6=N/3-$8F]T M=&]M+SX-"CQT9"!V86QI9VX],T1B;W1T;VTO/CPO='(^#0H\='(@F4Z M(#$P<'0[)SX-"CQT9"!V86QI9VX],T1T;W`^#0H\<"!S='EL93TS1"=M87)G M:6XM;&5F=#H@,65M.R!T97AT+6EN9&5N=#H@+3%E;3L@9F]N="US:7IE.B`Q M,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<[)SY%>&5R8VES M86)L92!AF4Z(#AP=#LG/B8C,38P.R8C,38P.SPO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N,C4\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;3XF(S$V,#LF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)V)O#L@8F]R9&5R+71O<"US='EL93H@9&]U8FQE.R!B;W)D97(M=&]P+6-O M;&]R.B!R9V(H,"P@,"P@,"D[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=B;W)D97(M=&]P+7=I9'1H.B`S M<'@[(&)O6QE.B!N M;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R M;6%L.R!L971T97(M#L@=&5X="UT#L@;6%R9VEN+71O<#H@,'!T M.R!M87)G:6XM8F]T=&]M.B`P<'0[(&9O;G0M6QE/3-$)V-O;&]R.B!R9V(H,"P@,"P@,"D[(&9O M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.B`Q,G!T M.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F M;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M#L@=&5X="UT#L@ M;6%R9VEN+71O<#H@,'!T.R!M87)G:6XM8F]T=&]M.B`P<'0[)SXF(S$V,#L\ M+W`^#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0M9F%M M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SL@;&5T=&5R+7-P86-I;F#L@=&5X="UT#L@8F]R9&5R+6-O;&QA M<'-E.B!C;VQL87!S93L@9F]N="US:7IE.B`X<'0[)R!W:61T:#TS1#$P,"4@ M8F]R9&5R/3-$,"!C96QL6QE/3-$)V9O;G0M9F%M M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.B`X<'0[)SX-"CQT M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^/&(^5V5I9VAT960\+V(^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^)B,Q-C`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)V9O M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.B`X<'0[ M)SX-"CQT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M)B,Q-C`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^/&(^079EF4Z(#AP=#LG/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1&-E;G1E3H@)U1I;65S($YE=R!2 M;VUA;B<[(&9O;G0MF4Z(#AP=#LG/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D M97(M8F]T=&]M+7=I9'1H.B`Q<'0[(&)O6QE/3-$)VUA6QE/3-$)V)O3H@)U1I;65S($YE M=R!2;VUA;B<[)R!A;&EG;CTS1&-E;G1E6QE/3-$ M)VUAF4Z(#AP=#L@9F]N="UF86UI;'DZ("=4:6UE6QE/3-$)V)O3H@)U1I;65S($YE=R!2;VUA;B<[)R!A;&EG;CTS M1&-E;G1E&5R8VES93PO8CX\+W`^/"]T9#X\+W1R/@T*/'1R(&)G M8V]L;W(],T0C8V-E969F('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@ M3F5W(%)O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$8V5N=&5R/B0P+C`V)B,Q-C`[)B,X,C$Q.R8C,38P M.R0P+C`X/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XY,#(L-C`P/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+C4X/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XD,"XP.#PO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C,38P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4Z(#$P<'0[)SX-"CQT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1C96YT97(^)#`N,34F(S$V,#LF(S@R,3$[)B,Q-C`[ M)#`N,3D\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L,#6QE/3-$)V9O M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.B`Q,'!T M.R<^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/B0Q+C`P M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX.3`L,#`P/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XX+C,T/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT^)B,Q-C`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XQ+C`P/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT,3,L M,S,S/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+C`P/"]T9#X\+W1R M/@T*/'1R('-T>6QE/3-$)V9O;G0M6QE.B!S;VQI9#L@ M8F]R9&5R+71O<"UC;VQO6QE/3-$)V9O;G0M9F%M:6QY M.B`G5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^#0H\=&0@ M=F%L:6=N/3-$8F]T=&]M+SX-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4Z(#AP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C8N,C@\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP=#LG/B8C,38P M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C`N,S0\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=F;VYT+7-I>F4Z(#AP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L,S@X+#6QE/3-$)V9O;G0MF4Z(#%P>#LG/@T*/'1D('9A;&EG;CTS1&)O='1O;2\^#0H\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*/'`@6QE.B!D;W5B;&4[(&)O3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R.#$X9#,P9%]F8V$X7S1D M-3E?8C4P.%\W.3$T-S)D-S0V,6(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO,C@Q.&0S,&1?9F-A.%\T9#4Y7V(U,#A?-SDQ-#'0O:'1M M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^36%R(#(X+`T*"0DR M,#`R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R M.#$X9#,P9%]F8V$X7S1D-3E?8C4P.%\W.3$T-S)D-S0V,6(-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C@Q.&0S,&1?9F-A.%\T9#4Y7V(U,#A? M-SDQ-#'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&EM=6T@'0^)SQS<&%N/CPO'0^)S,P M(&1A>7,\'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R M.#$X9#,P9%]F8V$X7S1D-3E?8C4P.%\W.3$T-S)D-S0V,6(-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C@Q.&0S,&1?9F-A.%\T9#4Y7V(U,#A? M-SDQ-#'0O:'1M;#L@8VAA6%B;&4@6T%B'0^)SQS<&%N/CPO6%B M;&4L(&%N;G5A;"!I;G1E2!D871E("AI;B!$871E*3PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^1F5B(#4L#0H)"3(P,30\'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA2`H3F%R'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)S(@>65A M'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5R8VES92!P'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5R8VES92!P'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M&5R8VES92!P'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO&5R8VES92!P'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!);F-E;G1I=F4@0V]M<&5N'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF5D(&9O'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!3:&%R M92U"87-E9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO'0^)SQS<&%N/CPO&5R8VES960@*&EN(%-H87)E&5R8VES M960@*&EN($1O;&QA'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO&5R8VES92!0&5R8VES92!0'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2`H4W5M;6%R>2!O9B!3=&]C:R!/<'1I;VYS($]U='-T86YD M:6YG*2`H1&5T86EL7,\'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)S4@>65A&5R8VES92P@97AE&5R8VES86)L92P@97AE'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO&5R8VES92!P&5R8VES92!P&5R8VES92!P&5R8VES86)L M92`H:6X@1&]L;&%R&5R8VES92!07,\&5R8VES92!P&5R8VES86)L92`H:6X@1&]L;&%R'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO6%B;&4@8W)E871E9"!T:')O=6=H M(&-O;G9E6%B;&4@ M:6YT97)E6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA2!!9W)E96UE;G1S(%M-96UB97)=/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)SQS<&%N/CPO2!F:7)M(&5N=&ET;&5D('1O("AI;B!097)C96YT M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO&EM=6T@6TUE M;6)E'0^ M)SQS<&%N/CPO&5R8VES92!O<'1I M;VXL(&YU;6)E2!W87)R86YT("AI;B!3:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XW-2PP,#`\&5R M8VES92!O<'1I;VXL(&-O;6UO;B!S=&]C:R!C86QL960@9F]R+"!S=')I:V4@ M<')I8V4@*&EN($1O;&QA3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\R.#$X9#,P9%]F8V$X7S1D-3E?8C4P.%\W.3$T-S)D M-S0V,6(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C@Q.&0S,&1? M9F-A.%\T9#4Y7V(U,#A?-SDQ-#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M2!42!4&EM=6T@6TUE;6)E2!4 XML 24 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 65 167 1 false 37 0 false 5 false false R1.htm 000010 - Document - Document and Entity Information Sheet http://qholdings.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 000100 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://qholdings.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets (Unaudited) false false R3.htm 000105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) Sheet http://qholdings.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) false false R4.htm 000200 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://qholdings.com/role/CondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) false false R5.htm 000400 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://qholdings.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) false false R6.htm 010100 - Disclosure - Organization Sheet http://qholdings.com/role/Organization Organization false false R7.htm 010200 - Disclosure - Significant Accounting Policies Sheet http://qholdings.com/role/SignificantAccountingPolicies Significant Accounting Policies false false R8.htm 010400 - Disclosure - Accrued Compensation Sheet http://qholdings.com/role/AccruedCompensation Accrued Compensation false false R9.htm 010500 - Disclosure - Notes Payable Notes http://qholdings.com/role/NotePayable Notes Payable false false R10.htm 010700 - Disclosure - Stockholders' Equity Sheet http://qholdings.com/role/StockholdersEquity Stockholders' Equity false false R11.htm 010900 - Disclosure - Commitments and Contingencies Sheet http://qholdings.com/role/CommitmentsAndContingencies Commitments and Contingencies false false R12.htm 011100 - Disclosure - Related-Party Transactions Sheet http://qholdings.com/role/RelatedPartyTransactions Related-Party Transactions false false R13.htm 020200 - Disclosure - Significant Accounting Policies (Policies) Sheet http://qholdings.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) false false R14.htm 030400 - Disclosure - Accrued Compensation (Tables) Sheet http://qholdings.com/role/AccruedCompensationTables Accrued Compensation (Tables) false false R15.htm 030700 - Disclosure - Stockholders' Equity (Tables) Sheet http://qholdings.com/role/StockholdersEquityTables Stockholders' Equity (Tables) false false R16.htm 040100 - Disclosure - Organization (Narrative) (Details) Sheet http://qholdings.com/role/OrganizationNarrativeDetails Organization (Narrative) (Details) false false R17.htm 040200 - Disclosure - Significant Accounting Policies (Narrative) (Details) Sheet http://qholdings.com/role/SignificantAccountingPoliciesNarrativeDetails Significant Accounting Policies (Narrative) (Details) false false R18.htm 040401 - Disclosure - Accrued Compensation (Schedule of Accrued Compensation) (Details) Sheet http://qholdings.com/role/AccruedCompensationScheduleOfAccruedCompensationDetails Accrued Compensation (Schedule of Accrued Compensation) (Details) false false R19.htm 040500 - Disclosure - Notes Payable (Narrative) (Details) Notes http://qholdings.com/role/NotePayableNarrativeDetails Notes Payable (Narrative) (Details) false false R20.htm 040700 - Disclosure - Stockholders' Equity (Narrative) (Details) Sheet http://qholdings.com/role/StockholdersEquityNarrativeDetails Stockholders' Equity (Narrative) (Details) false false R21.htm 040701 - Disclosure - Stockholders' Equity (Summary of Outstanding Common Stock Options and Related Activity) (Details) Sheet http://qholdings.com/role/StockholdersEquityOutstandingCommonStockOptionsActivityDetails Stockholders' Equity (Summary of Outstanding Common Stock Options and Related Activity) (Details) false false R22.htm 040703 - Disclosure - Stockholders' Equity (Summary of Stock Options Outstanding) (Details) Sheet http://qholdings.com/role/StockholdersEquitySummaryOfStockOptionsOutstandingDetails Stockholders' Equity (Summary of Stock Options Outstanding) (Details) false false R23.htm 040900 - Disclosure - Commitments and Contingencies (Narrative) (Details) Sheet http://qholdings.com/role/CommitmentsAndContingenciesNarrativeDetails Commitments and Contingencies (Narrative) (Details) false false R24.htm 041100 - Disclosure - Related-Party Transactions (Narrative) (Details) Sheet http://qholdings.com/role/RelatedPartyTransactionsNarrativeDetails Related-Party Transactions (Narrative) (Details) false false All Reports Book All Reports Element us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights had a mix of decimals attribute values: 2 3. Process Flow-Through: 000100 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Process Flow-Through: Removing column 'Sep. 30, 2012' Process Flow-Through: Removing column 'Dec. 31, 2011' Process Flow-Through: Removing column 'Mar. 28, 2002' Process Flow-Through: 000105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) Process Flow-Through: 000200 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Process Flow-Through: 000400 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) qhoi-20130930.xml qhoi-20130930.xsd qhoi-20130930_cal.xml qhoi-20130930_def.xml qhoi-20130930_lab.xml qhoi-20130930_pre.xml true true XML 25 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) (USD $)
Sep. 30, 2013
Dec. 31, 2012
Condensed Consolidated Balance Sheets [Abstract]    
Receivables, allowance for doubtful accounts $ 28,800 $ 28,800
Common stock, par value (in Dollars per Share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in Shares) 100,000,000 100,000,000
Common stock, shares outstanding (in Shares) 24,936,833 24,761,832
XML 26 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8
Accrued Compensation (Tables)
 9 Months Ended
Sep. 30, 2013
Accrued Compensation [Abstract]  
Schedule of Accrued Compensation

Accrued compensation consists of the following:

 

     September 30, 2013      December 31, 2012  

Accrued wages

    $ 162,531       $ 17,046   

Accrued vacation

      69,991         70,846   
  

 

 

     

 

 

  

Total accrued compensation

    $ 232,522       $ 87,892   
  

 

 

     

 

 

  
XML 27 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)
 9 Months Ended 138 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Cash flows from operating activities:      
Net loss $ (2,765,273) $ (1,807,068) $ (23,257,551)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 9,624 14,088 401,271
Original debt discount     450,000
Accretion of debt costs and beneficial conversion feature 61,667   1,298,930
Stock-based compensation 76,316 95,912 508,117
Debt issued for services   110,360 90,000
Common stock issued for services 175,000 10,000 331,750
Preferred stock issued for services     44,750
Warrants issued for services 44,668   57,754
Provision for losses on receivables   (2,282) (43,677)
Decrease (increase) in:      
Receivables 462,135 26,839 28,010
Prepaid expenses and other assets 7,566 (5,465) (10,313)
Increase (decrease) in:      
Accounts payable and other liabilities 1,093,627 (73,110) 2,705,796
Accrued compensation 144,630 10,919 232,522
Net cash used in operating activities (690,040) (1,619,807) (17,162,641)
Cash flows from investing activities:      
Purchase of property and equipment (23,802) (2,363) (431,273)
Cash flows from financing activities:      
Proceeds from issuance of notes payable 250,000   5,507,562
Payments on short-term note payable   (15,000) (90,000)
Issuance of preferred stock for cash     8,671,747
Issuance of common stock for cash   190,000 3,821,137
Proceeds from exercise of common stock options   1,800 11,600
Proceeds from exercise of preferred stock warrants     2,233
Net cash provided by financing activities 250,000 176,800 17,924,279
Net (decrease) increase in cash (463,842) (1,445,370) 330,365
Cash as of beginning of the period 794,207 2,741,519   
Cash as of end of the period 330,365 1,296,149 330,365
Supplemental disclosure of cash flow information:      
Cash paid for interest 866   8,537
Non cash financing activities:      
Debt discount related to bridge financing 250,000   250,000
Supplemental disclosure of noncash investing and financing activities for the period from March 28, 2002 (date of inception) to September 30, 2013:      
Common shares issued in exchange for technology (in Shares)     219,658
Common shares issued in exhange for technology, value     220
Debt discount related to preferred stock warrants issued with debt and the beneficial conversion feature     1,237,263
Common stock retired (in Shares)     200,000
Common stock retired, net impact on equity     19
Series A1 Preferred stock converted to common stock [Member]
      
Conversion Of Stock [Line Items]      
Conversion of stock, shares converted (in Shares)     250,000
Series A2 Preferred stock converted to common stock [Member]
      
Conversion Of Stock [Line Items]      
Conversion of stock, shares converted (in Shares)     2,022,190
Series B Preferred stock converted to common stock [Member]
      
Conversion Of Stock [Line Items]      
Conversion of stock, shares converted (in Shares)     4,102,654
Common stock issued for preferred stock [Member]
      
Conversion Of Stock [Line Items]      
Conversion of stock, shares issued (in Shares)     13,791,231
Notes payable converted to Series A2 preferred stock [Member]
      
Debt Conversion [Line Items]      
Debt conversion, original debt amount     1,050,000
Accrued interest converted to Series A2 preferred stock [Member]
      
Debt Conversion [Line Items]      
Debt conversion, original debt amount     29,691
Series A2 preferred stock issued for notes payable and accrued interest [Member]
      
Debt Conversion [Line Items]      
Conversion of debt, shares issued (in Shares)     482,008
Notes payable converted to Series B preferred stock [Member]
      
Debt Conversion [Line Items]      
Debt conversion, original debt amount     3,740,000
Accrued interest converted to Series B preferred stock [Member]
      
Debt Conversion [Line Items]      
Debt conversion, original debt amount     370,346
Series B preferred stock issued for notes payable and accrued interest [Member]
      
Debt Conversion [Line Items]      
Conversion of debt, shares issued (in Shares)     1,787,104
Bridge notes payable converted to common stock [Member]
      
Debt Conversion [Line Items]      
Debt conversion, original debt amount     900,000
Accrued interest converted to common stock [Member]
      
Debt Conversion [Line Items]      
Debt conversion, original debt amount     $ 16,644
Common stock issued for bridge notes payable and accrued interest [Member]
      
Debt Conversion [Line Items]      
Conversion of debt, shares issued (in Shares)     916,644
XML 28 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Balance Sheets (Unaudited) (USD $)
Sep. 30, 2013
Dec. 31, 2012
Current assets:    
Cash $ 330,365 $ 794,207
Receivables, net of allowance of $28,800 as of September 30, 2013 and December 31, 2012 15,667 477,802
Prepaid financing costs, net 188,333  
Prepaid expenses and other 2,800 10,366
Total current assets 537,165 1,282,375
Property and equipment, net 30,222 16,044
Other assets 7,513 7,513
Total assets 574,900 1,305,932
Current liabilities:    
Accounts payable 2,236,896 1,203,365
Accrued liabilities 69,781 9,685
Accrued compensation 232,522 87,892
Notes payable 500,000  
Total current liabilities 3,039,199 1,300,942
Stockholders' equity (deficit):    
Common stock; $0.0001 par value: 100,000,000 shares authorized; 24,936,833 and 24,761,832 shares outstanding as of September 30, 2013 and December 31, 2012, respectively 2,494 2,476
Additional paid-in capital 20,790,758 20,494,792
Accumulated deficit (23,257,551) (20,492,278)
Total stockholders' equity (deficit) (2,464,299) 4,990
Total liabilities and stockholders' equity (deficit) $ 574,900 $ 1,305,932
XML 29 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8
Commitments and Contingencies (Narrative) (Details) (USD $)
 9 Months Ended
Sep. 30, 2013
Supplier Agreements [Member]
  
Long Term Purchase Commitment [Line Items]  
Purchase commitments entered into $ 2,600,000
Note payable interest rate applicable through July 31, 2015, for note payable created through conversion of any outstanding balance under purchase commitment upon conclusion of supplier's final project report (in Percent) 8.00%
Note payable interest rate applicable after July 31, 2015 through March 31, 2016, for note payable created through conversion of any outstanding balance under purchase commitment upon conclusion of supplier's final project report (in Percent) 10.00%
Amount owed under agreement, included in accounts payable $ 2,136,730
Advisory Agreements [Member]
  
Long Term Purchase Commitment [Line Items]  
Minimum term of agreement (in Duration) P6M
Percentage of proceeds financial advisory firm entitled to (in Percent) 7.00%
Advisory Agreements [Member] | Minimum [Member]
  
Long Term Purchase Commitment [Line Items]  
Percent of warrants purchased to be issued to firm (in Percent) 1.00%
Advisory Agreements [Member] | Maximum [Member]
  
Long Term Purchase Commitment [Line Items]  
Percent of warrants purchased to be issued to firm (in Percent) 8.00%
Business Consulting Services Agreement [Member]
  
Long Term Purchase Commitment [Line Items]  
Warrant issued, cashless exercise option, number of shares of common stock called by warrant (in Shares) 75,000
Warrant issued, cashless exercise option, common stock called for, strike price (in Dollars per Share) $ 1.01
Warrant issued, life of common stock called for, cashless exercise option (in Duration) 5 years
Additional warrants authorized for issuance, maximum number of shares of common stock (in Shares) 100,000
XML 30 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8
Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2013
Significant Accounting Policies [Abstract]  
Basis of Presentation, Policy

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of Q Therapeutics have been prepared in accordance with the instructions to Form 10-Q and, therefore, do not include all information and notes necessary for a complete presentation of financial position, results of operations, and cash flows in conformity with U.S. generally accepted accounting principles (US GAAP). This report on Form 10-Q should be read in conjunction with the Company’s annual report on Form 10-K for the year ended December 31, 2012.

The accompanying unaudited condensed consolidated balance sheets, statements of operations, and statements of cash flows reflect all normal recurring adjustments that are, in the opinion of management, necessary for a fair presentation of the Company’s financial position, results of operations and cash flows. The results of operations for the nine-month period ended September 30, 2013 are not necessarily indicative of the results to be expected for the full year ending December 31, 2013.
Basis of Consolidation, Policy

Basis of Consolidation

The accompanying unaudited condensed consolidated financial statements include the accounts of Q and its wholly owned subsidiary, Q Products, and Q Products’ wholly owned subsidiary, NeuroQ Research Inc. The Company is a development stage company engaged in the discovery, research, development and eventual commercialization of products as potential treatments for debilitating and fatal diseases of the CNS. All significant intercompany amounts have been eliminated.
Development Stage and Liquidity, Policy

Development Stage and Liquidity

For the period from March 28, 2002 (date of inception) through September 30, 2013, the Company has not generated significant revenues and has been developing its products. Therefore, the Company is considered to be in the development stage in accordance with the provisions of Accounting Standards Codification (ASC) Topic 915, Development Stage Entities. Cumulative amounts are presented for the period from March 28, 2002 (date of inception) through September 30, 2013. Historically, the Company has been dependent on government grants and debt and equity raised from investors to sustain its operations. The Company expects to continue to fund its operations through similar sources of capital. There can be no assurance that such capital will be available on favorable terms or at all. If it is unable to raise additional capital, the Company will likely be forced to curtail desired development activities, which will delay the development of its product candidates. The Company’s products have not been approved by the U.S. Food and Drug Administration (FDA) for commercial sale; therefore, the Company has not generated revenues from commercial therapeutic product sales. The Company has incurred losses and used cash for operating activities since inception. As of September 30, 2013, the Company had an accumulated deficit of $23,257,551.

Given the current pace of pre-clinical and clinical development of its product candidates, management believes that the Company has sufficient resources to fund the Company’s operations through at least December 31, 2013. However, the Company will require additional cash resources during the first quarter of 2014. The Company is working to raise capital through the sale of common stock and filed a registration statement on June 20, 2013 with the Securities and Exchange Commission registering the offering and sale of 5,000,000 shares of its common stock with warrants to purchase up to 1,250,000 shares of common stock. The Company has not raised any capital through the sale of common stock during 2013.
Use of Estimates, Policy

Use of Estimates

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Accordingly, actual results could differ from those estimates. Key estimates include allowances for doubtful accounts receivable, useful lives for property and equipment, valuation allowances for net deferred income tax assets, and valuations for stock-based compensation awards. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances.
Revenue Recognition and Grants Receivable, Policy

Revenue Recognition and Grants Receivable

The Company periodically applies for research grants, including as a sub-recipient to grants funded by government agencies through research universities. Grant revenues are recognized as associated expenses are incurred and are billed in conjunction with the terms of the grants. The Company records its grants receivable in accordance with the provisions of the grant agreements. The Company’s grants receivable are considered past due when payment has not been received within 30 days of the invoice date, although certain institutions customarily do not pay within 30 days of the invoice date. The amounts of the specific reserves are estimated by management based on various assumptions including the age of the individual receivable, as well as changes in payment schedules and histories. Grants receivable balances are charged off against the allowance for doubtful accounts when management determines the potential for recovery is remote. Recoveries of receivables previously charged off are recorded when payment is received. For the nine months ended September 30, 2013, revenues were derived from two customers.

In December 2012, the Company was notified of a sub-award as part of grant funding awarded to The Johns Hopkins University (JHU) from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health. The sub-award for the 2012-2013 grant plan year is $631,383. In May 2013, JHU applied for, and was granted a six-month extension for completing the analysis and remitting data and expenses. As of September 30, 2013, $491,588 has been invoiced under the sub-award and $3,667 is included in the grants receivable balance. The balance outstanding is expected to be paid upon the completion of the extension.
Stock-Based Compensation, Policy

Stock-Based Compensation

The Company calculates the estimated fair value of its stock options and warrants on the grant date using the Black-Scholes option-pricing model. The Company recognizes stock-based compensation expense as services are provided, which is generally over the vesting period of the individual equity instruments. Expense related to stock options issued in lieu of cash to non-employees for services performed are measured at the fair value of the options on the date they are earned.

The volatility assumption used in the Black-Scholes option-pricing model is based on the volatility of publicly traded companies in the same industry segment as the Company. The expected lives of the options and warrants granted represent the periods of time that the options granted are expected to be outstanding. The risk free rates for periods within the contractual lives of the options and warrants are based on the U.S. treasury securities constant maturity rate that corresponds to the expected terms in effect at the time of grant. Stock-based compensation is included in general and administrative expense in the statements of operations.
Net Loss Per Common Share, Policy

Net Loss Per Common Share

Basic net income or loss per common share (Basic EPS) is computed by dividing net income or loss by the weighted average number of common shares outstanding. Diluted net income or loss per common share (Diluted EPS) is computed by dividing net income or loss by the sum of the weighted average number of common shares outstanding and the dilutive potential common share equivalents then outstanding. Potential dilutive common share equivalents consist of shares issuable upon the exercise of outstanding stock options and warrants to acquire common stock.

Due to the fact that for all periods presented the Company has incurred net losses, potential dilutive common share equivalents as of September 30, 2013 and 2012, totaling 16,107,458 and 15,072,509, respectively, are not included in the calculation of Diluted EPS because they are anti-dilutive. Therefore, basic net loss per common share is the same as diluted net loss per common share for the three and nine months ended September 30, 2013 and 2012.
Recent Accounting Pronouncements, Policy

Recent Accounting Pronouncements

The Company has reviewed accounting pronouncements that become effective subsequent to September 30, 2013 and does not believe the future adoption of those pronouncements will have a material impact on the Company’s financial position, results of operations or liquidity.
ZIP 31 0001193125-13-442024-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-13-442024-xbrl.zip M4$L#!!0````(`(E\;D.TY-E*T4\``//\`@`1`!P`<6AO:2TR,#$S,#DS,"YX M;6Q55`D``T(TA5)"-(52=7@+``$$)0X```0Y`0``[%UI4^,XWG^_5<]WR,/K M36/Y=E`&'0,>3?#SG[WPXG?7T/V0R?AUTFKRLAS^95H3JNFB^U/R^Z#>)\-=X->`P&D"ESP:>%/DVM!;/_ZL>T\A@>1.^,J4`U,!)"_9 MEO.?E,`T5\(QN?VD>S!Y',%GYM/R,;Z;/.@$B^('31\=^ZLE/,9/0&09ZQ=< MI\8[KC/-O!?JS2]4NA0IU5^3@',"#J8`VC'1TG'\&*76N:XO"[5*;A0H->K+ M4B!0K1/)BCLMO,-HWRKI-0J>X?.6YXH\4,K>B)Y8O^"\0B^C5`\:G^;NZW%T MKX`K$UK%;^`;14+DH!>/-:!IVG%X]P@/T%)ALPT&1SA6#J.VHD&N^%B@_#F3RP,A)GWZ#X_DFT1#Z7P MP?6CT/$M?Q5?6U^U3'+]V8)H$C(%4T(D0I]=_GITPF&S('PGW3+52G(IU@%++>>/VM70M((E1_XY M'K@G"=2X=?.;>YF7H&-2K]"J3.YLJTH*80`\`G$0NDPA#(`I$+M&V%HM_"/^ MAXW"P-3"3_$_`70_\(3!#SSE,`9>HDI^J*KDFZN2[TN5VN!5V=0=]*9*(*B# M'N(X3:@-P,W.!"$"$'SSG>-_YRY.&1%.*2_=\_E;1F6'_$X,2W\7)0`QTG'YT@FT0D)AS\W5\R7XT)>-C(<%PGQ_K'%C]@J MQE8#Q8S8*L36Z0BM0F@UT,N(K`RR*`U=>EX`S;0N/Q2::NEB1%`&03]<'WHW M^DI_LB$U](JM_K#Q=`Z?_`VFRL'40BTCM#+0FAD&PL,PG*&!GC^B:XVN=IH9 M`=;$=IU^5'`UU\H(K(:6Z\-BJY5B1GAEX'6*+',.&>/TW22#37#53",CH&K; MJP^)I@;J&*%4JPX:)=3T^,SH^..`:RL%C7"K4QH=T59>(AW!U@YLN0IA/NSX ML$!KJYL/#S(M;<^")\\R+9V,VF&"QX36Y^]PKMO?0DXCB"2(RHNWC_X_S`6` M,0#("+H.1]@B4.W);X;;D\*KWJSP']Q MD?5?:#XX)D04.&YLW?%.5REMW.K.'%*A(%-5[]#4%\,#2!S01GC4@0>EJH\" M#\!Q(S9J8&.MI_<#C&Q8,7J5X7B5`XU4RB$U>J)#]D1#A-3HO0[4>PT$3'?! M$JL!HMD<04@$'FB=,X'3=]>9WT.TN`F0\8)110KAED^:.UV=807.7;2Z?K[T MX?H)DYZ?86AC!$UZ@8+Y:GE8D2-HPO4)#&V,H*D%FL&0 M`>;MT#,+D*Z034I)P#MOD$PE^Z(M4AEQ'WM'0 M9B8/1I#L#R3[F"RJ(__[2&+ZZOTAIBF'B[3WD'\<*M+VD6'L?I[SG[H3Z&@% MR*4851<6\OQ[I#L8(,.&5KBDBKA^"EMY@;L$TF8*XQ?7-;V98_YP';A8VNX* MPCN(7BT#>D2WGF[XX=+M=9UYPV*^`SYXX)4KR"R19=.0O8/X7A M(7=_(>4>DN-<-L7W#[&%-F( MKWU[M`.M?.5JM:,7/`BS-"YEKSF=,$+T(WG.@4#T!G>GXY,U/[JS&B8T2T]: M*Y!O1$`*`9?AEXI==!,\86W<0CM<^>5=6&C@2]TZJ2E5:F=$4PI-W[%2<3\X M\W45[@_+?SES;5M_D[$(W@^MQ461\<:_FY[\!>I6<>TP7@Z?V+ MA9*9L#CB\*)C68>-OL)Y\;0R#KXZ7]DY[[?&,>)VQ.V[M=)9L)\&V,-!SSO# M85-@^]C;)9I_)_.DVVWIKJV>$58%'_^YL!P\#K'28DMZ_?R,58=F^(=M8;+# M1E:8;D"3Q(`KRDSE/OB3T4*GY91B%KS3%7V'XJBX!T;PAN`M+%U_""3O<"73 M.&K>Z:A)5=,_ZJCI:P76.&H&/&H"QXJ&S,/=>0;L"ZA[`8(GEN>*/%`^XR>2 MAI);=..DI<*6HX,A&8W'0H>/M&H=)XFAPA5=9$MO_^@+;]J^/^=.XP'ET'FF$E"953 M^N'2_<=H(DOI=]<.'.R65A>6#9'7A$+FU1P&(UEOX=)%80'#U_V@@L"?Q#Y6 M-9$E%))/2BKE[=\M=!L_/%FW.(GG@&FJJ?;R:(TZ+P+F>Z]S!R3_"!'C[SJ-A;%F_EG.D(K M_/3ONAW`6OQ%BMGP%T8_@L`)LO3EN!&Y-(?7/K;(M]"`^.DG&WH_H!\#M#U; M0))E9<,5FT2:E1L$E[IE?GLC9[)`+$?XXLSSH.]MS1.ON2&18 M%S19I.PMM*R(&MW;A30,P\6&?OWM\*WQQ6,SH,42:404DDM MS=TY?(6V&QH)'+G,X3?R;=>>!PA[G>P;VV%)D20* MW]MSDY8N%/C%M4T<^T6'A;7G=LJ+LLC3>,NWS@0[-L9=\I(UB564^@ECXJ]D MYMR")F)<[B^,8;`E*HK*\?N*8QA,`1SQR3L,9%AL\"HO*#N)9%@PIEF'W+":FTHN]0AL&')JO27B(9!C^JHFH[#F38L."P MS>PUD&&0YD5%WFD@P^*#PQ&50O?'008R)=SSO*(>6"##AFJHS[1&KZA;:'1;0/+@M5V0^7V0_4M4)E4L@$7/Q?(6]9 M4EWRE-=8+SPUK?BR%+6I^-8AU2E3;$T1MPM4VO;59RK:>D&2@V2YY2UV'4Y9 M%'#^*%R5&#D<(::320:!-!_QQ9)PN!G9I+TL%0_JR"`)).4AXP2I/6E2N*7S MC5(R:8Y^@0Y$NHV?G)D+RPEG.,E^EVUY$GA9%JGJ0@6=3!:T)+/,&"OQW2UZ M1=947J.SH6S3#,J7CN$NX'?7:T][BHD#KI#XIO4T^4L26$%O:T3(,J#+:)EF M"U+.'Z[CIIG;E@5-`YDY03XE;@7 MR8(H^.PB&#UWK[]![\IRL#L@A_A'"L=P3[<2A7Y7$+L-,]K22$;F-AA3))F7 M.;JO=\9UIM^@W\F@R0J4:C=-\@]HS5]PQ#)[Q;+-8;3\YOHY=#F4QSG5/0 MZ]1E\:Q,1``BV(_'8K`D`$63P>X\%H,-F0,@5=CMP6$Q2$^9M*O\570_M/*M MJ6/*0MYE42UOZ2I92`2"O"-/R>!`D;6=>TH6`@0ZC!RBGRR!MBC*PW.3=>79 M@Y?,L[;QDK(J`3KR/0@O6:C+M)?D6WO),-TC*/@EW(A:ICZM/(_D53F71VX: M[B!]KJ#?5_I<2I87B\3N*GTNEU@6>4G;>3!2SA.GJ+RPD_RYO%L4GE,%KJ]P MI)3VE%?P/=HA=9D_EY*6997K/W\NU[RJ[#(L*.\)6=!X;:B!017(9(E7A"%% M!@T%VFEHP.*-2J`YA1.Y@PD-2I29"@T`V%UHP$H4>'H05D0&]3UR$VK=.F1F M0B2J@-N//V8FIZ+&[Z:>7RZ[:[JQ24"6]H"EB@?1=!2=5Y'D9 M2*(J[#I`J6*+`U@MBKB+&*4*&KP*>$U2^@I3*LA/>2#RG`!ZG,FHZ@M5D4'! MM$(7T4J5[H&BIK;1]12R5&E`$H3NYWLX:CG%=I@LDR;KO;'2$#EMYP+J?H"VJ%""G=T9K1^/=NN'*U&CRQ8 MVPMI0&B&GOZ'Z\,$/^WYDM+KYUD$:G7N^L"[#CHWRUA]DG7V'D=N)(ON]DC$ MHT:E-]0UH5J<9I!-:*WY4>6"S(:TV(Y6112H2H)2AURW7<$LJHDBYH?KHB^Z M8KA"?_6.X:G#\!81-FLV0^14M7:(W5.PR)SQZ2I6#*U*&'QO=JXE'GJ+0CRO MIL_*8=+H/A)D353(*IU@'TH@R-*@),JE8>OA1((L"10!@-)X:M^!('-L::`4 M*/N(`YDF7P::2E?]#R$09(U`01:VCP-O,>ZC-Z^?F\6!K/Z6,GOCBMMG1Z.; MS+?6_OPJ=C1V6%I(J;_XE,6A(JM=Q*>M7'9%0"%BKA70V&O/%N3\Q_^&CUV' M=:ISRPNM$[:S"RM8;,-2)IROI-5;S:YRZDA3-9("[ZEN5\&>Q*F`GI(M*]V% M$A"V&X5<%0S$`Y/==D^18&4,34J'6P6#H4@8?5$L0370#8>B&#)8ATI/A'^1=17OF2,M]QU<5^)%`3(OB^!0XNLJ0RN`U.+J7=9:JTRLQ)&]TTW+ MK6VB_7INO(MX/^W,L#ZC"Q#?K$P"JBJ+L@(44:G*`ZHXZ#!KJ0I#5!X`H9)A M9N)"/Q[>OEZ&ZP"^O4%D6%[Y@K[*%6DR*Z4J),7F+`X$DB>W6X=$GY131J2/ M#*]*8XK&BSR]R:?U+,0Z38C#J6B197096WC0@$OR#51R8AE(PW[=UKU+P2O^ MJE/!ZDXI>W!2!8?]"\1O)Q#'\T`[*(E.MQ)(!!PO2V+7`D791B-I*&ZCM]-R M,27`EE`#O``J18AYHO*P'ZY#!EI,F7H(!T=OQ@OYVA>.^N^A\>*XMCM?51Q+ M6<,.);E9*\I;3?=ZD@WV5881%)Y4 M2KOEB-E/Y'VLE6=H5:R:K^);*^R%5/,4$]3M6^CCV#15K>@$&AQ5L*E#+EN> M)%6O]:!%UAR[.IMDS5P&`*5=M!I'6$$11Q._]24B!/H8SSV*5#T74E&+Y7%%)N<[^"[IE(, M(*=.4MQ*BC7=2\?S4?BEJ-914O&8CQJBNRPC.CO^4['M5EF"5G&^6ZE/NQ(: M**H".&;W'HK4N8@X/S+K2JR5XKF>P*%S#W>5;V/MOS7Y_Z1FEE@1D""*DLBO8^CO?9XJ97!P'DN)1=:!>*E6;PF3W]V? M$$6_60O+9ZLL$]D^IIKB.)GCU"K-<96[L;L1HD=U/2R7NU.7VI.Z,D(] MX#J[>7'4=TM]MXG.#T?9A^3,#B]ZK^7E#EB%AQ"]#UR'9=&["`1!>%>15CX` M+C,HIW!N.4YXU+A-=E0--4;84NIWV!_[C2'&_CB@&&/LC)(T,3=1>2"R[5/K MMW"A6X29,ZQ2I!M^H-OW$"WXEM-/)S?2G_(5KYWO2]5,@8:N9=K*$RVK5X`? MM=RQEC>V^^1&_5.\&C6\O8:Q*N4_A2L`#EV7WUUG3B[?!,AXP;R1#0M6^"F` MANMT'^^"Y=*V()K-$0P7;GB,;6QR9GM1%0NIO9@^C+=-)/LE;G4?S@AE@UR] M?T%N,'_Y9V"O!("9DRY<1+UTAF"X(31ZBMYD/'-6J2\3A5XJ[(L\6P_+<+^% M80?Q!N58\CNRO=^^0>Z_H8$%7KJHP81J#?5%"=?129AG#%,?3?IR]HRO;CB/ MF;PB7^<)K\COLF\!5[=O#UT_],E\X4"^_AF;M[4>+IUH[7KN$*8>S`X09&5S M7E]3ANI:S7MK46,#U>/,?+4\%ZUR7&._<57'-&[H4&J.CQ?1[5SS^%$#_\!^ M@9R"$^V/6H.+[#^O#V8FZT6&*OFNR1:<-98OV=Z?*,V\=T_CL_RVE_+Q"CO5 M1;`HD1DTDKF$VT.37'^KD%SM5O+U82"%YYS/_#/L5 MTIR00)>]M)_CZJQ#Z40:^I3/"*[7SQ$LR86(@U.8PQ3OIXW&JC&7G7+)I$#CGS#'=%=*Z[(,FEJ/ZK*RM+-EFZ&#Q2Y MU%=8BUNG#&-K(?-[7LC!FIL91)SJ(,OQ+*.NQZRY_23@QF9E!U\C(]>7H=>C/F9!_PGF9[Y7WO?VIRV MDBWZ_5;=_Z";D\Q)JH0W#X-Q4GM7><=Y[IU-T5VD0MT3\OLA MY#.,D0+K!<:G[[3/V2PK,/*7$V9./$.O1T>BY:T?)RE.XX[%0I3T$">;8V0Q MZ'L]#>NN?I<'_R%V_V(:^X&Y>A@J"KU?8_/77'QQ[Q^6%6YC[R5$BW7_=OL4 M'J^\!WA0^]Q92[@O6K:YO2>%&A2/3*;766![9[QK39U0V0ZJ\E9"_0^^CIUP MY17O16&Z9`VJ_^/ZM#(R?BA+V8;=H':.3]Z6KJP7T/C/]D(V>=J\K]50'_PB M2;XI\J7J^:\BZM\.X^%4R=_8C>@J2O]7P-K<:!2B_6U6`XBN_PN=:RX-3<^CZX[J->0']RSV@J!+>6FV76'I>B3OZ M::/2?$H`=^<\M[6F-'B&%`Q%]TBA-\)K)PBPR+XZ9?DS'P(W2B>1C'1SJ63PH.%KU:$7`>)[_E4 MRTJ1=;O9;#>:G48;-*WZTVP5K&L'2UKAH7#"F0%7M]%J-K#+^KIP*?06ZNC> MMSI9MW0<*@:?:S843<17YX=LK\15RU/K1^*_#/W@]R<@J<4Z]1M_V]KXU<[$ M;8R_C/*W-_[NX%]>_;TT`_+N3T-9-W3CJIRG_6*;#F/,#:=;RGZV/]VJ=DUU M)US?-;ZT@>=Y][S5KN<:K^+':W?G6=Y-M+]!:Q[=@U&USN0BQ+H9C=DR86-Z M*(C-FI-M%[Q5G3ON!Z!2`5YG20K\($XD[5V"]G++U3 M;\YEL/X/]@(!=0$UA.79OO#YM($:4'<1#.9890'#T$GY@J]M7@N[>WY:Z!@X M-_1B3K5YK^CU--1Z/>06[^";X5!@^RQ123BG:Q-.ZZ3;JT,Y%?.N84RMU2*V MJ-A^(-,OBJ^S0>"[U-0&N?Q;/UXJ:73MJS7OYJOBBK:UEK2L<^^N M-^HC/!XF&!)6P;A_^.GX=10$SH`L"Z`=)TY#$2_V5Z]C+3_,QMUCE;(U3ZTE MUMK(AX@U9L&L&&\IQE\;7\=^K.(O1;_?3QZ*VB9F"M<8#\;1+_5K[K;P(61" M?1='2;*&.5NGEO%O:S"L:@MCM_#<$X&RQ5F&/$QB<;<`RTYPR)=FQL'A:P!` M3,9W]3E!R7"05/]I.`02C"_@G\"'21=E(Y4;Z]8&L-;*%JJLE>'$M5:"RFZG MT>PW3+-X"1C;@;<0'=P$WO-&9S6^UTAGJE?Z@9-Q(!)]`ID\ MZSN.UR"[#(0OS/0:#E(68$JO$@FK,N'N5\6^[X>*E09Y3V#GJ3(I'X:*MQ!KRZ53=4(>1OZ*5%1WMAW!N2RCY/"` M79(=\L?UV;V`K:W5)&OIA4N3%+:D[9A\:ET=;=5J%,`_S8(JM,X'7E*]:V-+ MX%`V6+/]SV;GG^W^\D`362K7<33T-^JEQEZ8MJFV&B-N--728,=9V[Q7<=^I M5C5D[IRW>^8=B.TL;6'[Y]-^;\E<.DBQ@9]F4>BHU>STS/C'"M_*%37"_C3\ M-!4<%%^:DO;DC[\%Z:O_UVC!YT[;P?R]>64,8NC%T)GXP>VG]-]YN3JPK<6=]B29.^-_R=QK@ MI15&,2!`?G?KQ#YPW=*W=W2N\R\#D:8B;B13!^T%XWO001KCTL-1/!V#1?#2 MF7ADAM.X(_"E[`$6)W\R@\]@1,WIS_D-RD:$D,8!<<*Q2OK;NRG@F8U MP+[SO>A.CWX7Q5X.%XT%T`^^^S`.2$_G]H;_'[WP;JB=^F MQVW;[;;UUMJUS];7,1S"J3J`-@8HA27S=EZ^-1"C8HVUYH!;`&P#OD.`=Q(X?$D*2 M*9:^@%ECSZ:?IC$PZ'A&<``]84*:?`G#1C$\"Z/>1EEB);,D%1/K^>NK&UJX MPK1UYR!`*B,)@(*Y<(`$HY'_AH7PL,],*WW46;31"`,HNZ$AM-0R\\LE-(U!];I_1,KK`J$+K*KHEMVU=`6Z/DAKA3I,W0F`O?Q ML_4^"C!5.=&K#6FV2^&6QFLU:4`8%L1Z]5CSA_#(+`]0QL$V`:CN.(0]&,VL M#,X@`NF.\00E<#RC%._XPC$T#G]B,3]`TI3\`GG+S/K,)-)OM\Y>H0;4&$89 MEHR!4S<&?A$[UATS\.[(6#S\"I'04X$QUS9#O(KA`LV_+( MD6^-86J`!U0M"U@.GO%OH4^E>5(Z9LCI^#`FUGL85;&2&QSQ-8YX(]AO+5^_ M$]L)K+^"0G?5@`K1NV4XT^Q/MC5N+ZB*D$ M3@$<`!])P1_.F.D)\=V:.HA)0`I;3WBP]$(3>@S&\F-@B!%PTIG\GA"H&!IP MOA.+*AD!G*^1C$4PU-^W7EE% M897,\1#0H=^$7EF#-A)&Y_3RDID,A]@?PMA@_'(-(XP718!=(/2O<-S^#-!1 MMU*7U[RL^10!NJ"C@LLF2:O!7?$I8\>52F]D@54[`0@;GY$/D%86"Q!:`MAN!$(J1?4# M"WU9#C!0/T1YEJL](28E@8X&)G&"R@[\"BP=UPT`(T*@?5.D MO?(^%7\U=@TH":T9(AW6=^`K-XN)$SC>O[(DY==(0CA(=%+8H`TBB08T/H>] MEO8`_+$UY2`][_0-TF1IJUE] M[A#/Q`.F%@7*+BS?\UTVH^1*U+QP5($PQ8\I(!3Y@IQXF`%N%6F11K"(MCHU M:6M#N:69Z6M-2(^$FRH&E\KA,LUB5QKQGPT?`#Z<_VU07FT?`)M\7TW1B1:] M5+,06`1[)+39+L*1,\I-7@_3M$&[FQ%=2[>"^3:"B$G2>-^4=;T8D2$]6[AF MK;.!BF9H_VCD,[*0[CPQ\`,?#QP>8QASZ*3P5-GN9X45R--4'M!W$"OX'<[9 M,*27"/P)[!'LU6ZI]=+`R@WA%-?QT0>;'PAHME.R?2N/KF04I)HO<$Q8SSWI MQ0`B%10T>:$]54MXBUU0P,:PFX/7J/$R)TSG$=Q$ MK\\O;EZ_L+X"E*YUWNK:.1YPI_SJ?:9K;4J+IF=.K-?9)`N8ZRJ21.8L!8O! M;7>X92?6>Q^3?-'40=]?>0/EKDP%^1E0Q1CA60]I:2.^S(D[Z&%2/!UTOC09 M.Y3D1B#[,I&8I$D"TA<=$GP>9I(Q5OA/$SC``8BC M),IB5TB-@.KH2=I1EF`8`9-)LIAH@!2`)`,>*!\&JD`7`&R(JNZ%2QXZMU%, M?Z1T\Q^5`%(O3JP/0W1'`1F"$*`'(EXZZ!DJZT&-740N313XWP6PZ`%:,;'+ M%`R*"B`(^)I(_)CR7@U.BCY:HB-;>DQH&$\$SFR.Z)$6\C.$Z_=('A617=!5 M-!\FUHB'E_;?D26%E(E%.O#;"$@2=_PRSD;6A0<,%"A).B>?O[V\>$'TF_-[ M*W$"\A;`)VD) M18I&+E`34H<^22!/B*+68'V(&N0V?,1I&X&!^+0K3]L=N]T]L[O=UDX4[W?` M49@'NO(R+/K^6,Z*AAO`1J$7GM1-]4)+/$ZMTSG-Z"Z*O],;ZJ0KUJ%`)J^5$Q#"74IG@3U%CP[I+'Z`QB(` M,,I/B]8*D=G\E87"X.]*;=?B*L\@IP'?_&!?N$6EIQ.48W)PH1<6#8?\!YE- M$K2NW6PV\3\PMS#W1FU[`62:]4[=VH))-INH0HYBD6UG2J$0_!>[\1)L[\+R0 M.D3@.Z3A*])6Q@7P[DS3%JEF)`L7O*@-`6)9N;^\8N5JDBJX"OJIX.MY!6[! M+Y&_A]0SD#X7I%W"5ZA)<7T=;4B[Y.0!-1*.HO*+1XF!O1/K[V)F(--P@$5W MJ*U(*RC*!BF8W[G-&`-G]&]1^[!1MN%O@7\K'PL$F72H M%<BMU?DATL[VI7^97Z(!*3[QKWNAVJ!1*D0<,R%9#1I,O M%1X=:RV4D!W[&`]0P4`,KV$T-D+)7T%AL5#22-D`6"8Y8HV,@T$D#?T8Y#$6 M1X+%[M;04[?IC<(NM!A.0,2OY9;MG`,HO#.1LIJ/"EW@RPU7-KO4YFU)>"0N MT`^09(,&D)@_]>6AEUH_2G)6"0V+`'A#2)YYQ<_UZ)F*`/E(ZES\-S]C,6Z9 M*HM#\R9)Y/JD.>G#AT]IA8YX#6Z\CRG<"[VF4F%G)L"0%^D1IT43#RE2KBP_ M4/5,1CTT+%^5Y%^L8\]/PI%];<5.4=WQ@'CNQNA8YS1)+3M)(>>79=8`P-AI M`K>;:6#`X(HH`Q_P!R^&*F$TO&7?DE#&ZQ\YN0.EZAREK#,PK-#@F M1^N`4D#QHWV/;^6FJ9-.U&*JD,0RC`-N'NV<#,E#-A(Y$![HZ1XSUYSU`7[N M,-H*_[)&1))-H2]QQ\++`N5O8&ZC*;&P'=(+S:##4)2>`2H4P.`@ZA@>Q347 M,&7:.V.IGD!*Q(1Z)B#MY.(CR`XTBR($DPB1^X6_\X641@H\U,O%+6(+-JP` MG3Q#,9[*`NGXB288--MRU[%%KN-DM=/8SH_J'=K2'A<[D'+L+I)4!.=[)P;- MASP?1*:`%!1]/AE`=H0)R;)(]I`_T8G)I.$3BER+6!O^S.("R?BO:`PD]SZ: M@FJ?F-'JYW^]__8BCV//Q^YQ:'*H!M&(Q-2V`?22V=,X M++X1830$62*)_T.&$,2/%./[Z/!@PQW#:?H``K@S]+7C"$"D?DH_`2=P"BI2 M+5OYZ>EYR^[V^[F+27(6SQ#7QB["^$\[=J]WADN5BI'V/\\S5'F"&9$JJ!3E M=1%Q%!W28(5AZO@>9Z*0IB#7GD=V-&YVJS=0FGJ#\N,M,XE^;VH"4+!+'@OF M4SGGIIC7+:6[2T.1[;)HF@>OM*$8&3M#PL+*$D5(?P8.+/'&'4?(S/CUQA14 M/WQ@$GDBF!?0I!5Z77($Q*/JKJ/0$[%4:.Y[<="?D9%#I*IC03H'X`?&9B!%K MH8DI()B<]'EGVZB$OP+U*MX(%AZ[X@TG/+_I3T3N]E)C:)8:BS)W,7B/#.OZ MR7>0*@(^T5DC4TU.(%4OYD.Z4&L-N$D=-I%)?EJ,H@$5(7:TXPBUS13/YD06 MO2$P9,94!/IU`IS0(X=/:N*.M6D`3K!1+S%`^%`B]L2Z671,2\Q;'D56Y0W_ M\:W0!]K,JJU(!-@M,[X"4_@CE@ZX!D;!%],LNB6T4VZ,$6V7S'!I?0-IH/<: MZ4.[Q!`*ZSD_^N8:%`L*A$VFF52RB77A*:L81SKQ[^3-*LN1R8$AW18V'6_2 MI6<2[Z4?T!RUX%,/;P@A\!1%[YL`:_B0``RDJESK+L`I\IM=^'Q87/&U?DF/ ML_!MLN(24C?J+CC[)HBS[_;5]CMO*01?;P/MJ%#JKM$="C;0"L,@NXJ[5LUO- M,_NTVZ=?6UV[>=:VN\US2DF8YE<;5/)+68=4:H_4^`S"!?;M.B#4S":Q.%G-$X M"N&SRSQ[;\HK$B`:Q^*NG)!G@L,D#=N*+$>HFF&4(0.$*)UEOVF_@7A16XV?&(B+C<^>&JW7>?;DM\(/MW(`WA,];:M=>K#F M']L:C^B@L(:X[JX;J.PK`EL$7@7QI=X:+ZSSJH)?4@%_J^BCA<>C^(MD(I1E M7?ZMBE>5:0&I"R@EQ/)411]LI>IGIN2T.B61MQ92?@TL5N9K%9#8W@X2JX[" M8$2P__[DOUQ7@(I?FR562M`YD(!C&S^4C9A`#(%1ML2DQ#H;]%5YAE4BM"## M[YR13!J:;H:V=:GP:1V2DW_&*'WIK58/C.].:_?@[7]E9W;SM+<=Z+;#PP^1 M3&\=-S<,]D2IZW')N8WMG=OGYX=-L?=2#8Y$+@QSE1._KI2$^$.E&%RDEC\ZZ/:IG!S6R@\;NL>F[W2V*4BH>QYZ M<.<\%^N+%/@%IZS@3_T*^[J(<7QXC;DVTRG:'="6VNT]")"#1T7_S.Z?;PD3 M/X.,ZE1S&TPWQ*M4#\T,]P?>P4FIX\ZL(:?X(Z6[SP-_#`T\7"4N"KM10J0L M4B?S,U6F^)*R%N*'<"D"GG#6N\>EF?!V"V;/\6H7=26U M,.(8F-?R5&(N5G,8X.05F6NK*B]M&*&<[VMU#&,^#FK?,&'A],2BOF:6)!2B MLV,`\T`#F'^*]`Y3Q"^R49:D1D'(-F?8U[V4K2_-/%5W5O'2$.;D3E7S2LZF M0#9$&?^.-:`^)BKS`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`*N?R[#1"?1]`:^8@J>91)<:VQ42C0]_1FHBZ4K>IMH.I!UR)[!.6CZTZ MAOVZ-'`H&8'56L8!D=BA((J;V^&ETZK;IGM+D]QK?AD-],F\O)EP%QU9]D-5 M*E\[5/9P"5<=N]_KVJ>GS:JWP^@N=J:_/^%_GQQ.EMEF@?OF2>=T-\NLQW'W ME+Q"`[WC>_Z/B!*UBZ1=&XB#I<_'B(H'XKUK4;72DXYT?:3KQ\N;90?A(Q4? MJ7C?B8+[-%4JSLPQD7H!=/O>EP=ZX7':=WE\1_GGUV?[M[Y.R'R3H/'+Q? MC[/SQP679NZ1=O@IK.BEU.K;1F7U/R.LNDUU$&/A4N]'0Z)T_TR6=98XT=A4Q3)';*)U//"K6A]0+.(;Q0<<;P0.>O7;K9:Q??A,?Y?*3![O/6^V[5ZS,MMI^Y-U3[I[6M;/ MBL'RNNKIF=LBW%9W->&VSO>#B3;UC^M7)^KM@G3/]C03H/#LIT1A:6%;Y,(U MB+=ULJ\CVC^G8/">)EN0B+G]F?:'P--6!PMW/[/@UXO M.##?_7%+]AMU6\VF-X,H6"N5$@==(X%RS?L`!P!?[Z1=6\_=,VB++@D<`&A+ M-F'V`(7&<4\>2V)NC61(2JT=C6(QPB*A?IC&?H@MQV]5 M)<-"/F+HJ6;SE/U7S%R\ZSQ;;F:WS$#.)1R$5$$X6+47\P,^%@K%A%#:P*"=F.G.)8"HZ34W' M!\(R1J6RQ(YU)[-+&@Y'WF4!3@2B?=*Q9AC%V&T9RG\X,2;B[K8"Y8?0^N2F MD2PFVBYBGZQY+BZ-M3]E?=*YRI]&P=.\RJE1^M3Q;GTJUHV53XD$L#BH2M+6 MH_'<:A*9'AX386'6>AKP3LJ*Y58VQ;]4U?([B:Q"2G2QA&B*5:&IO*H3CG0Y M\Z+:_LF#1PM*Q'V]CKO;)CKAR#;8$AZ-] MVK:;K7X-8M.5QLTU%1=4IL.3YFE/TF';I$,\2$B$I>>1'O&VB;B%64S"E'S+ M4GQ+`EM&IY_@UITV>?RJ%_.R[`$&;N&%TY.S.<:7U\^N71J[6%$;2T;[*95O MOP@]S+*!*47H5KK*&XR:;3P`>*N%"\^ M:6XH$E#I`OY-MVQH+"I[C10+BXGB=&$/G2DP^`#HSG4"ZUT$$O4G`F/3Q]M+.:YN?0=P^)%*_^.#W_"&3D%5E;>/U(C4`;#`<9@R&>L%2-3] M*542'_7:GKPUE7-8U,RD]A0(TIT&,SKB#<&*7>?$^H92#(Z=&V2)T0]"S538 MO"&M$*:EVW"QP)W&KAFS@A(^<`*Z:Z6T+Q@<>$Z:DQ4UK=#-,K!=$?=CRGMU M])_);DE%J2,K(H)`NBC-Z4RH"Q*"#A@=ILQ?`VJHF$VR0-H.>H)6\QFJXE$V M&O-AF)L$>,/-.,H"KT`2`\2,"^P]&68!EGGGQDT$@M'82;4ND.8+D@UM)%!] MD)`N[J`,P(`*\F*)<^P'A7+`3U@7,A4/0!=8CW?A7.UPB>W:NC=CRHKN8`YU M9\Q/#+(E,J26,7:KT[//.BQ$?+P9!D3"[4@0KXQQN8\LGO*3@EU@4)\9<>5` MF[4E`W<&4W]R0K6\J;#=BJ(B+!`0_#A" MNG;424"^:)H)\@A,8,LFV41KX8G_0]JF3$Z&W*%N.+=T,JAQVTRR+[K&N&`2 MOVA:.,Q2$V)SXM\9/`_?GNFKLI+_ZL9(?`Z!8YK+)NT,NRWD[4G$$%:3GP35 M8ND5'YMAR9B0]W&+5M(T<%Q>*&)!N%E,C=MLLK[4W=7(&`K`]V_AF#*Z6\]R M=KB)/Q`1P(N!MVC>%LR*9,!< M-A;^9)#%9)0["3R'>``NU8B&C2GH=2)55GMBM#O"UC[5"Z?N1Q&P[CBNZ(FW M)E6'CF!YEUME%B9OW&>BZ]O^K)NR3XN-?H@ MXQLP@G3)39`03X[6^DT+A7J4++PSC2VXX&/L?R]:=\U6;HS8RBH>PCH:J">P M;4!ML8BF`T2$-C78K\9GL`I-58=0V?>&M-3TB4R![?[Y!B?SS4T2?^('`"(I M8I4FRWJV1]%N^<+.I6LXI+.OV%<)55-8VK%-XN/H2[6A17AV8LF=MVCK+7/O M:TC;XR8>>R:NZIG(_?FT,@TK8Y-Z.`2VS%VE4)]2'1*9OZI?43`"IP7^S1LB M4$*"-A_"T&-_:K;7D^VJ\H'*5+NJ9=H:/+#(//]T$C_Y-)2]:0$?UU'@NS/^ M_R/?_&F.G&:;M.%(>]=C)5K&A0/\"6JQL M84HO`WD(-&&R1T$M9AHEI(G:DJW3FB)0BCG4Q5UAN8M?`)M%TB"BR;&*$RWF MV\G-B06:);P#!E)>.VW&^O=Q<4U-;3U$^E'0X]&CH"$74\4 MNW0\.>>_LI"0E6.PRL.*O6R=H&+4O^L@,*GV[,I<:*6TCQU4#[6#ZGK'5KEC MD[$0*;9L+AS>,J$7?S7('HXB>@CH[#$B4%,"`YU]G_\"G4LVZ97MGFWM99B" M#EF9JG[23)%HD!M*90742)2(2>?2 MBX)3`,OW?)?;9O>/S/V0F?M;J1!*]9.?(W:D%?(A6)YS_ M%SH$M48B;D+J*]NP*"U,OA4CW\P$Z]+X*+$KR5PI=0.#BY)[$A-7=GLQI$7R M"+,^.10T$)IYSW'Y!1X#2AM-N`SMT,J5623QT*/$W]>11W`35W]^J#\@;#52K[BYXYL5YS$@E%KB3C=F+M53!T^!UNV8GUWL1WQE26TGMZB2IPET19[,KHGC,%F1I(VH$_0Z2. M,`)1#!**:(#,RB0#34$^K/.+\BK'F.?NW$8Q_2$3M&(*?08P]@=`>(IDF'%\ M&J.1N'0S%BG'+B*7)@K\[Q@;'U`M99%AW@4P+'E&WEY>O"#ZS;4B*W'PFDI:?9+GN87F$$1$QCAI[AG4J\.Q M2U2$(\)AH'"_!5I)(IE-1EHL6>\`GZ0E5+PTX@.*&1)X;;"`S$ M3SDGN6.WNV=VM]LZ^L,.T1_VSL<,:4H?0^J!LX2PL3HO&CHIC+Q`ZH]:)\\V MG%5PM`(?7I+.K?)92#(,SOF"1*7B:HH)+O)@53!&&#H`*R)=YO>QWD=W`$E< MP:%BY.=QB9W!TYSEA",?CIG@,%>?J!3*FB M3B#F\TW0-/(QZ<,!`$8YN]'&)W+KO[+0Z%O?5MXT+>]O\HP@'/#-#Q?H>"0X M:YL3N7APH1>FES+,T9))2NN)7 MM9$G]VDC1]\R`Z]H"GY+Q*?AFR2E%.+D:/P='B_<,%'T6T(DI;?V:.P=LK'W ME>P:C)16!"<+KKKYN.--SCPQHJA$0&+*+N!<$^>[L(0^Z91A`HKU1/49H8@- M)3#*,`6&#I%I3;1#$)X7TGX(?(=\8(HK*_<;,QO)%F6N7;KP1>TJ(VFK4^"K M5JXFJ8*K8)NJ'%-3T/%+%((ETPQ;L)!E"5^A%<4U?W5HQJ6X*YB0($7D5:QQ ME!C8.['^+F8&,HV8='2'EHKT$T;9(,4\=^U5Y;PBM#QLU&OQM\"_E8^#_@'@ MI3-METTY2(:WG&6,NSA^*%+44SG]!V"()F#0.#\DNMDCJU_F5Q9>J.4KLT7Q M-2!O)LK(?*GPZ%A;H(3L&)0>EUU+\",>^RB#YU#KKZ"P6"A%2MG_1K9PWK_& M]6/0Q?&"@UN1K;]*_A6E6CFIDXCE"U\'/D:U'@4WW=0#*C?;,G:;"/4=ZW=? M]'$\BL=#%X^**3$'9_\7>CH"7W)#?0V1W5RVY,JR196#@:<&\%]_ZDN)*-UA M:*&QK\1PE3DR1USKZ7KT+`2&'2"\21*Y/KD4M&2B.R#* MTT&"&+DBF&]B<9:/>=500EYDUC@M^CZ17G:,9ZNB-DG&0*+3S,6+VX&4FG"616%XSRM4),LFF0"E@T*L6/ZM[['FD>L%#MZ5QUN+L":R=$GM4^A+ MW+'PLD`YXED4:THL;(=,^F'08:@80Z5@&@,,#J*.X5$JQ0*-A?;.6*HGD!+Q MFH=LN*=BI'P$.?YJ44;;)$+D?N'O?"%5-04>70.^16S!AA6@DV@1`J$1^^KX]4Y%85OCC*`<>SM/W(6_B67%7^XY9"YQ; M(B7)\TFS-2_;,8M#MD^R`7]F913YP%_1&,[L^VCZ'8Z(]4TQ^YGU_*_WWUXH M:T!85XYTKWV03(B.-24T!-&(E.-+O(9(C3GI[@$APGI^]>'J\N:%X@'SP]`Q M>2^0V:G[M&H-*KZ$*V^0DXR7,L5FCY0SAB4?>IV6W>EW3JP/^1U)VP+HI;2D M<=@X,"[G(K+\'S+E#38.))4J&:1NZ2H.!N#.,%D(1X!3[J?T$[!2IV"`U?+" M/ST];]G=?C\/7DG6[!G&@+&+6':H8_=Z9^6[R+E8K&"!\GJ:3((T;T[CS325 M@L?FR-3Q/;ZH3';(W`UEC9L-KE*LL#R*ALH-.AC_1,EB]H;E_BP7H:=;QV*K MSX1'.IHN!\CA-C1=N(H7[7^A.?#14GDLE@K(`)>BB:PJY,N66?&?@0,TDKSK&NUN7INVN)<=N!*JHA1)@YD/O9*C1=F6_`USZDA?%FOIA;$2'R M)C2P>9!?F4Y*ET7?!+#H:":D&:B!!A"04@2;5Q/AH&?2LV3LKK@'G*(N>QN' MVB6)'V:L^3MQN.P6^O'(/>QUB-L(,W,")*W<]N+4`:D=0J!SM_2P18./Y* M/=.]W8T,(W[3GX@\)*W&T%I=+,H*CJ'^R)L0?O(=%%L!GXA9D2]:3B#-9U:% M='>\&G"32\-$)B6A8"(M',.96>8!/08I,C=@COC=C,#@)8$5B,4E(ZR)(UN\ MYZLACP@`QV47U,$F?"@M?TDQS)+^*'D9NV.,Y)A;H3FBVN8%=V?6U@[(2+$C$\5(5)5WUE8:3*X!1K4"_1Y[$@@\M)6H7$H>/Q/4#5 M\I(SF=E@H,P(T#+HJFH0:!TI3P`O)P7J(`^>"TYIM0W"74V#SBH/FJ[.;7/I M,B2^5L]N-<_LTVZ??FUUJ255MWE>K-1MZPNK93^:,EREU\LX^:`_N@YHU;EA M!+3D-]1""GG_`\W[JCF*G^1:,ZS3,YA1]0O%\NETWW^C0N9K*VHK]*RB4@:G MT+A@&T22D2P%%9.V1EK9RYB^%)<56`B`RU$T5"^),>!_S MW,&OJ(<=>>A/<_;D#A==-%(#SQ-#(TQ60'!VP3X9HG8.XG%/Z^:BKRB`3$V# M+%<$P13OI82CWY\TBUU(EVS.(F16X:T.DNZ+#]FV"8OE.M,$,*T^55"V12_^ M_N2L]^R)?)&6CJB0L]+?B[IZ%]J3>6JT7N?9D]\*/Y1[G\D'6^W2@S7_V-9X M1`=+6JS5.Y*ZPO:NNET=D;NZV9]BCQ&+E M);L"$MO;06+545C>F+FFO%K<$10X=E6?.LF^`S$$1MD2DQ+K;-!7Y1E6B="" M#+]S1O*^T8;]ZM:EPJ=U2&Z^2S%V*.JT=@_>_E=V9C=/>]N!;CL\_!#)]-9Q M\X2:/5'J/1MK]\[M\_/#IMA[KO"L:??W1;HU.[PN58WNB:W#;FU].-#M4SDY MK)4?-G2/3=_I;%.0?*5>,4Z%YV)]D1*LU0M[XZ[8F^L4[0YH2^WV'@3(P:.B M?V;WS[>$B9]!1CULG^L#`N_@I-1Q9]:04_Q1]3?'OP:QY09.DOS^Y&(Z#42# M:W?2G;Q&*.[0G:M.7LV,O]H1C461$$IGY!3!Y$L4!&^C&"_&',,AA^XZ7S\4 MJ:,=F#N%%UO_(R\2F(E&A9)!9KZ1RJ675=)F.GMBK9R)8Z#E&&CY=0,M9^5X MQZ+`2'^[<98UA]N.B^ZPPBQEA_U.W5#W`;1FH.$?,N>5AMQ)-.&Q[WA-1%ZI M7.'M8/(!5W+!V<_YV&]D,O&11@X];"@5\,,EP4-!U#5UF<4[*U6758ZQU(6^ MQ4_FU0=*@-)U+U1OKK7M\8>+ZG3L?J]KGYXV]PKI?H*MS9/.Z7Y\@8_/0_Z. M;Z$^(DK56;+MAX^?_HQ+/U#>O56J5WKZ/=/_S\O:W43P4_I&['ZF\/I4_ MAFCF,;,CV'SX& MSGW,=O@Y>/?CYM32^N."V+\DI^[T^_;96>?(J0N+_G"D1*W0HDJ`7"GA/@K M'(6-U_C3$/(R#'#&;++SE-EE,'P1$\?'&IH/!\*#G[8]92YOBH,]G85EX&TW M`7H3"/:2V+L,@->1;K+P<$"0P^,7WH3%Z]_7(=ES_G8.2SE`LM":;I4\*_TZ M\9%UD;YA5E&-W?\%$6RD$!S1O#LT?_2'PGK^O\*)DQ='/.\.SPN4A2..MX_C M10W2CVC>*RE7*1\[SG-;K"P];9XT>^5(9+_=:AG;C<_T=ZF\Y?'U\V;;[C4W MR`[;9++N27=/R_I9,5A>UW;TZDT)N=5=3YH) M4'CV4Z*PM+##XM*MDWT=Z?YYTV[N;;*-$E\WF6E_"#QM=>Q.9X.TN2TL:Q7_ MW4%26;UEKLS5>M#K&MO+OWK@T7Y&5.]+IUB]$\%:::H(]AK)J5NX*[%G^'HG M[=HZ[9Y!6^="Q=YW=4Q M%_.F+\508+O2M]0=3KR.DC1YC0U,PQ3[3WO"]2=.D'!FH)$`?9'\,QJ:&=!6 M%OK\T[>;RR=_M/I]4&SS=2V?YP]$P8]!'/@O\?_AS_\/4$L#!!0````(`(E\ M;D,691T':`H``(N"```5`!P`<6AO:2TR,#$S,#DS,%]C86PN>&UL550)``-" M-(520C2%4G5X"P`!!"4.```$.0$``.U=2W/;.!*^;]7^!X[FLGN0)=F95.R* M=\K/E*L<6V4G,W.;@DC(P@Y)*``HV_OKI\&7^0()4E)(I/9B6V*CT=U?H]$- M@/#'7U\\U]I@Q@GU3T>S@^G(PKY-'>(_G8Z^?KD>?QC]^I]__N/C3^.Q]0G[ MF"&!'6OQ:ET'_R6"!]:-+Z"U0$_8^N-WY#O6^73VX=@:CV4KE_A_G<@?"\2Q M!5WY_.2%D]/12HCUR63R_/Q\\'QT0-G3Y'`ZG4W^^'S[:*^PA\;$!YZ^C4<6 MT)_P\,M;:B,1RIEI_K)@;L+@:)+VI:20G\8)V5A^-9X=CH]F!R_<&<4BRL<: MG23D+R7Z6*?9\?'Q)'R:D@(C4L,Z51NL9UF1_1AU\0->6O+WUX>;M/6W%74E M3OS`IMY$/IU<4COPL"_.?.?*%T2\WOA+RKS0:B!"R$Z\KO'IB!-O[>+DNQ7# MR],1,"1@D=G1]/AH*NWQY-WCAC8:(4%L9&['^'S7>Q2DT3^0O''?N_S[&24:7774[)X](9_\ MKW/LS+7O;%W/(R)4#T(PZ"W@._.PFH MQ7@?4M\A)L/Y!E]B@8B[>^E+'>Q^%.U"AS;L=SS*=B&^-N\=C<*=N$T3SXZR M@@^R0$XPWAIFFC!TRWK$"5Q\OZQXN(4*7;O*:@:SFQVXX>-;^)R3`K\(#/.E MD\@A]=M16DZ$9#6=3@^ML95.P/!WRL/*,K%B+E;$QOK75Q\%#H$G_X[*G$0= ME]HY%5Q9[U&6MV2L05@V+1%?A+53P,=/"*TGTL(3[`J>?!/:?#R=Q07>S_'7 M?YYQGM'(10OLAOW]*8&*'T[Z%>XB8#*+J94QH>%')-P;0O*3]DE&O9+.D,ZJ2U`HX=$G7DIU,`]>,4`;Y,_C3R*(, M$NK3T6PZE>L0SY@\K01\[`\)F5'*F`Z_9)J_06X8Y<4%Q)M7&#^_(3?`"H3T MV@X%N8*W90'4-()1P,X97B/B7+W(^(I!NWLH%YC.P--I:0"H6@;0@/1H,)"& M"CQ@&X.'+ES(O;"H1K*9,)[A:@@'C+"V>AFI3ZP<.TM0JXY-.IQG.>SA0V_H M7^(E!NF<:^++7.."\E0;D+S@`7K$L9D:B`?L":W4K/>&)E9I-#@IZM&&#\<5ABO3<^S%$,&):>)45/I M+4$+XA)!L%S14*^I%X!I;-:;0MHJ-`K=AXOIPI%UOBHJHS)TN:I&_5"-VBJK M2-8_7'H`E?4S"IXSQR&1I',H(V[\"[0F`KD9K50+%\T-38%0QP9&S;V7>(-= M&B8.C_)$QY4\VP$BN MG=LLE]F7^X[2^^W[3+.87%$X[K4&R,R<]:LZ%83]^TF7>5^M<94W-/4@?:.* MHU94FPTDJL4;BWR.7N5*1L.Z>C7QH)RA9EE/I:M9N46T^Z4]>-7T!L&FTMBH M!.+*6[OT%>-X3[D106WZ.'@UTP\=\;8:J\)U9FU.@Z6&$[T;T&+N'16X/ES7 M4,2&JZ(8NG,T:Z7A#I5,4I`5Z[,?)T63W,+G[WG4H.$<:GKFX)W>F8,W=A9= M6F\,!W'ZX`Z+&Q_,@6\I5ZURYFEZ&XIO,ER#(T>'FP*`\\VBYWA)&8[HOJ`7 MS#\3/XPNX9L!F,OUZ#R7*+?\C,6*PI,-D'C9XWD%0WQ/"?H/$)6ND4T5OBL@ M1J6-L07\I\:Q5479/_0]#+7<=D65^D(I^V#C5Z&G4%"4/ M&]XOJS&J?!;'D/RSP47`.M'KPE^A70+7<#9=[ZA/\[-I?5ZHIN]_?/58 MTJ@AG-BBWA&*5/W#W^C*^96Y@I)F5>;A<=6V8[>AD6$(-IG`J$.\B3M&.H2J M%4"LH8CGH2H*0S!M5BXWR2IYRBFWDE?U>:=>9]YT%HIE/\<^+A?V*JK^@>UI MMFTP6Y6[?$=)(P=42%A=`1\6S^`-W?+--NLG[OLLFK^1GA0P'LS:BD5_^3X64D*H4#8$_./\]2L`=>.G*VIGMB";\)2" M>JM;ET'_,:H+K+F4OH6UC%I6V?900T^[[2U=MP"EL7NE9QYE(KZ=ZGYYB1?B MDO#P[.B<88\$G@+!YG:FHZIA&:/J@,<58O@<\?QU,@IX%<2F8ZJR@=:YR*$` M69Q=0/O"._KJ$U1-#4T'6,'AK0?M@!M.7KWN0WX8LM M6/9-P[PBO$4#^4Y4S=M$OCKJQW=Q7V,D`J8J##LP,AW7+K;3R\B',I+#U^]N M.`^2=RRCHC)\.SSZ&EPZV)CN$RTMIN,.NZC0%*-?NJTNCM6TIN.E ML(`.+KO8RU3@`DE!E`YDW*D9H:96IF/5:!4=U(93!9=S0?5K<^7]DM9-T_VS M%DU-]9@M[)/?@M/N/=X2:=&KGK.^&\Y.'HPW>=%:_*\&H$+Y75YQ##EL9@S> MLPL7$:_DKUW:)@[;JJVQ'KN%A;9QV7;=ZOGL+\/QV=*(+-Q&((_,EUYT;PRV M;9@HPZX6$V/=>1KZ6*`U](J=(NN4=UB;[R*0?].LZ>]\4IK&77^%32R,7;" M8S[9^QG4"[35Y/U#W-ZA"XNS"CL8M7G^@-?H-3[%I`&GDMQT.-5V,.OH<]8M MWY+T_`H(Q+7H"RS_(4K-!9<=F9GN"UUM:-19BFHEFR\];6[W8\+?]BK4X1RV MR.H35^E7+YC91'VM1&V3'PG?LCV,.EJ1525TS?M0<)[HXVC@6]WN1P)981FS MSD;$VF9#/<*P\O\DJ"#79]`_]MM67VVLU7[6[N__%VCV=>OK M(W(14^I;3Q0KJ2#J;X3JHT0U5SL(R6V.M5\RWM%XP?RQP+F(_CF;U!+`P04````"`")?&Y# M8(C/PP\<``#DRP$`%0`<`'%H;VDM,C`Q,S`Y,S!?9&5F+GAM;%54"0`#0C2% M4D(TA5)U>`L``00E#@``!#D!``#M75ESV[B6?I^J^0^^OL^.[632TTEUYI;L M)%V>2D<>V^G<^]1%4Y#$&XI0/:`X"7#T[OC\Q=GQ$8I\O`BBU;OC+W"AW]\ZL7+8XNSLY_?G-TG;X\.SL__>=OGV[]-=IX M)T%$:$8^.CXBY=\F^8^?L.^EN9RUZH_W<5@1>'6ZY\4L0?]W4A4[H3^=G+\\ M>77^XC%9')-.!( ML;<0,?3146'J&(?H!BV/Z-]?;J[VM?]`P6%#P77@A5?MVC5":Z$@J0=6:O-=>3&RT1FG@ M>Z$=X9LL3&IRFY(_J8^3^7*^I4T!\:TY%S#(V]+@-L7^-UJ/-%\?_LP(8JUH M`K"QI=&EEZP_AOB['9<K[PH^$N[[6S4U[;N9A.DN7JD M"29ZI^0[ZF#@U=68)5%"P)'DEGZOLXRTU_35!,C5_]K26@%&$;4G_V8MJ9"?&E:1N*0B.P$='4E/4ZQF2,DN[H>)=TZUOJ M5.+>+8Z*'@;ZWD.-/NQL1/27!"VS\!.Q(V$^2Q(R\+05VQQ6FII=D1GN!MUY MCV:BFD=.U_:=4>,\2^E\CY:CK0B.\B+S;1Z`,Q*'#Z10'Q?TXVA,S]MLL_'B M73EP+KG51#&JHBPS8]H9:='$5"UYXROE$_6+=$46!D;D)FS.I5>7T8O]2LSR MGW5)]RLX092>+H+-:5GF=$UDB?WL'IV07\G,16HBP5@:JA:2Z.+6ZUQZB+H! MH??$3A9XXP4F)>Z0-B%N3NED@S;W*#8I:X.N`4&]4&+2*RT>I69`J`BG,Z-R ME03-XA`MO2Q,[0"QI%T7F/P61`%M%#Z1_S:XHL<410NTJ/A222WV^+E0E5@A M]ANRA'3A',>@"7+UEUYRG]L@2TY6GK<]I8W?*0K3I/HE;PY/SL[+E?*_ES__ M<;OV8G3AY4LMFRTQ5=Y$SF@COLH76RYVAR+7WBY?(O[NQ0MB,'25HLV^.0Z] M>Q2^.S9',`U2:G(#!$\G9]WN4.9S5F_V^AJ;2;]IJD-\S.*FT4CL5K*48:S9 M@"]CO#&*&FS#+$U('LSR]JB_Y$]LQ$"RBP1(R]'C1$Z M8KA*D@PMWFK#B0^/9((0)(?A2A4"Z@2>!L*U#6#S MU93;\(\X7J(@S8@%JL@TW(9#')X&PNV9WMDV')19(D;^:\HQ4C8'WGV(K,P! MF/3[SK^8])_C3\+L[D4?(+%$[/TTY=BK3:N^HF"U3M%B]H!B;X6J3OHZ#GQD M;U;.Y?H<1^HN`1FOD-&I"K[YYCLX31WHU)9(9D] MJ#.G`U-^3CS@!%&1J_F%G.?@M^,B]Z:ETGK(A/JX>VG^&BVR$,V7^NW@';5# M.YA-TZW"U1A=FP%9RW6S$H:6C&LAT,Q)*A%*9R]>$XWR7+>W/HY2])A^"'/B M[XX3M*+_&"_2"ET(E]ECT,[)`+^53FE^LXE:3KINB6+CN,-\W1N`-,6S8D9B$[U-)A875N!T9"CWXR&Q_\Y1JPX]H^73RA*FHGJ(X1)QYHN!?'-67H8.B7TY;=R1#\VU#G.60/&[K5+>2_ M)K,L79/8_`LMOA`CQ#4-J".2QES^ACJR,QOC=@RFF'`[AMY,'.NP=?7!WU%< M:K8)4JO^@5E9\5*+E5,-K3%X,\<"5APD;K7[*L8>6IA2:)IC<4WMOVRW0X5V MF]5SO/5PT'3CK:.0\R=B3&I?I+'.E[5!7#FLLQEZ8JXV.E@.U^?8-^JV"38# M/-TF<0;IWI`AN@9H[7K>((KG_$A_E,:>GV9>>(?BS4NHQ7!'JGJ+XH!43[O% M<<#`H[5(+N@^B1-A@QFJ4>4"K8*(6JV\(JM MF,@`$DW9Z]&;,M.CT%K.V8#3,397F],Q@.O3;EL&=]N$IV.0;I,XP: M@-=^6AW,:(IB8_"B*LK3;E#<LJY8:L`B>L6.?2?7S`Y.)U$;R@.^\TL))VC MDI_?3Z^>LPFV/C]4*H5"5K,1#C;6"$;/^[<95J;7`X2'!RPH8WSB/^T3"(Z' MJN3Y@TD$*W3\8'K1RCW#\"3BM?=!B.Y3)O27/QJBG)W]=';V,WC"05BN-#R[ MW%-8/.H>>)"UB[79W>'<`T<4>]V`%*S.7Y^=OY&`%5`.A%6]W(\`*[9=!H=5 M0Q1[.9XRL#H_.Q-CJE,(`M2AT`^`)I9%AH9230ZES,`ACVXIO30ZUACZ$D<^ MHJE+5.>;(/G66VF[A%V+!8H3M#4T8B+86%`'P1);U.WI=[!CW MRDB49(&D5G+4Y7(!)B#4,)7D0F>_S,RE-[UF@W`$UY(D2C(;D$/)\99A9=P. MMBDL-;GH.!"'6Y8:T1\"(IU%*@=``BW_]4<)=SG."DY!; M0^1*5XO,@M*NC%:!Q@*KZLKO=?8,\F58$6&EMF74>T&QLX4)YO>WL*M[V-V]BF7IJKQ5J, M9Q?8HZA3P,WG@XO?/^+X%L4/@8^ZFNI4KL>2?.6Q`HWM3-$;PB(#-&*HPT;X M'C!`WHWP`&7^W0LSI(DG?ET^G!AUIX0F*?6UP<2B;F67O]QTFB\+AJ39KQU_ M_AW33=A+;QND7IA+>X=GVVV,'U".^*O(CQ'I0EJ@,4JSM*89FDZ"S(:YQ.`S MQ-69RX1XPQW6:*U@^4%"9/S`D`T'!^]'4=?RP0M"NFM/1G'Y.[66HH+%QG!P M=-@\Z1@1&'6X4.D*XLR%(3K:E9<6U,::5U%*YCY)X.?S'E,Q(LO'T#.+;#Y/ M*TH4S6HQ3,22P#W+N)==4%4Z5X%TM;UG:%N[_:.IK=PM.B89<>_(,<+(W<@9 MPK"2H6-)%#AV?C:Z]&0P]&?1@JF-O1Y%AJOY_H7+U=V8&=SD@_8]?+G M*CBDL#PEZ!E""C/S9-37T3]LMB'>(51N',"B?\;1`TKHK6$4S\D=3KVP_OT2 M)^EGG/X+I3?(QZN(SM7K+VBU<#,HS^I4X2`\G43U&.86!\E`4C%B;M0M5FNJ M%SN"9.Y?_D3+MF_F@,D0W4D]DBPEK0IM#^$E@6]IPYL'-8UVA>]2= MN,O02Y+Y\BL]K!.E\_B&7G7I48&CD^`>WM06EQA59*IB9?RM+1U- MB_.85U&2QEE^-F&>KE%\M_:B[C*KY'-BQ";`C M/:.?U=S:,WR`!WRS`?S8/K@SQIL(@J,#'+%ES@8TJT_AXI^]S`5R*=S)](,` M%[J97Z9LV\E@V7%ORX>]C-44!.%PN%>>3\F%(T8MR<#SRMPRU6HR6&;$N]2E MG(CEE`.]#!'.%VUA@I-V=N<\]*CN!F_C[N5O_LW8FAYW[L0VD7"#HWQ/#CRQ MS?R^OXFI_7VD02<_9K%8D[I[06+%'4L=(BX$<76X&^B:H4_5*;SZ)T<[7H[X M_'ZV6=&%4./>_\&]A<69JVA`;V"!]'4_U0G4O>12CZC@ITX?X<[=*'*NXG9R M(F<-\,9".6FF9UN#!U2?HTABZB.B/U;.Q;1'14A1Q(5EU%UBUOMXKKPYQW2*U,MN'8>PWT]SX;1M+AW8$`%? M2GWK7\;KS,$GAMA"UYW4>,ZG4<6%#ES*)9V>;P2G0/VVR"O<'IOM%^@;Y5W&M\<\PY' M;IYWFM5<:.!4,X,N=M5=O]Q7=?L0TTP':Q%S=-QBU$2"[8&>K-RZ<4$R*[/4 M0'`Q:A]BNHFX36(N/`/;"X$ZR;H\>\+75.J(J)7-VQ)MBDVS1>QSKO]U&?W\ M=U7'A;_D:ZEC!8#]!;E2B-DJ1GF_!=_RRRU4@1$N-/I]O[U:12RI?!_8-%GG ML&&PM/(^Z<<@3E(JCK^&Y]CL`J7R0(')>UVHM%F/0^PLQ;N/HP7/W9P2^TCO MEIB\P\5JFXYQ@%^_Q6B&RZ_RHX,XOL[NP\"_06&^^I\0R,'+`=+E2[N(RT\> M'*HF,0L5">ZU_$-SP/E$)"-CN&BU[XB^!NGZ$H<$*+AXGN?:B],(Q2".=*N7 M-E2N/GF4]3286="I"[/'X$\6QZ520:SG)I35;)79TE MOI$?'NG'X!^SQV@5(CH,!(O1\K6K"$%J!? M#IT45-_*HMZ,N#QD>X/UN8J0]F?W/"'00."';FT[49&%O)"`OU;QT/KJG@OX M\HLBH5VYL_0UX/O#]!!(D.:'>,G(DQ[*)=]1Y`8A8G&.:-/^K-Q1U]+V M(+&?,RF?,RF?,RF?,RD[F91PNOAS8J63B94.OOO]"4M'&=1;[:R]!AX[_ M$^-M6H4:U;Z%1`T'#3#;X*SS!I)L<:'J9?&18*[B1*RL=3TB)#CEFRM"#D9/ M*3&F)Y]QBJZ]77DE/HI1DM[0902ZM.K37^_6,\]7\ZB7>WVFPLOI%=R?B%#\KBK\9V=!MWZU]:!RLT7Q*L^P@MDGV,7GK)N@4N`Y3V*>OZE*8! M.'.VTH!>+^9&'P;MADKXY-%[2BB5MYLUK')%,/H< MIZG+7K'_K9#O?1:3<4CQ&E#Q7DKQ.QG/5)EU+33K5=Y?!ZM4>1HX[641#5"J M\G/W"4N%)]5GBT50Q%#YK$^6KG%,G[)JX],^I[[7OTMPF@CR![.U3IC8%,[% MUT/9=KD+-JAH)*3W<+I5A/LXM2K3@*^&]D;W<^I<7'P:4SN"/GI!G+^?/".] MT:;Q9+G9EW:D&?5MLL6,I@'YP2P]9(,M(9N+#UMR&@9@\4RRM+B5'OZU#7/- MLIG%+R&#*;S8P5;B8G?II6A%9JOS)=5Y/RT%,D1[4A&BC4]EU.-+LC#C(E+% M2G)(W1^%TF8ZJ=PJAB;@X9V>5(1@Y5,9+^.X+_RX"%8QG1R"N4+QD2T0YAG9 M32J=I&;'L0TE;H\';FY*N`/P'N""K^I*LFI5.X'O21`4JR97K&+.38WDVCPL MK;D<<+A<\PD0DYO1AH^UN]_>XH#!("I6[=6SBDT7#)*:&P(#FYO1@PX,,%QD M"9DQ)+Y_'*BX*_ M\G5.PX>)$^2_6.&'TP4*BLD,^4=[#D-^^N-#E.9O`"UQO/%*I<##3N*"U?-* M[((]9VFJ.ODXWN;7D>&('C`GH5'_B:&?7*66KH)*8[V2*'89UE2\\7XBDTW^ MR)0D>>;DY\SD1%\)0@%*H)5X\%L=$/MO@ZZR*WB;(;RB4P]4)'PWP%JZK&\_ MH947%OI!*^+PUVJ!I?5UU'X3]B46Z=!QS&=7^#- MUHMVX&R-4Z(T"%1BU$%1=QHF5J+;/1YF5V#M88*Q1WY/=I\$B\"+20?`6/AE M%=@O^78*..96H0H\KT*5)9QJ=BF.3-E]])*,EE^`/F)]+M7K?';,/P+Q>=[I M5AWWGC!2.LJ3EZ($A\&"G@#<7W":S)?T`,O'$'\?[YJP]^@^/1Q&9$WT!:5* MQ[!*C=:8-06:Q\&*GI*DOQ9GW*+)&_L+JN]:ACD*<4S2.*/!63\YP8>);&40,\+*4P&0HA6TT"3FX<+8N"DSM%C$ M*0&"9(2%(V7_B]:.I)T\H73+IN`7NR]1\&>&WJ/$CX-\,`@L)2G5`='`JC/J MLA,/#!VLR&G-1L]^84J2K'L=SF=O`]]%+BH&(J)6;+R%+#47=S#!5)4-`P:/ M+C#JM)\`%CI+2V.C`5HF,P8'[D*:`4#8SZBCE\!4=Q;LAS!W^!;1)839RVM2 M%\4QG1AB_QLXG^]!H79QDBH%)X:>0+N`31B$C:(#Q^H:(&5.=G+Q?#_.Z-BW MN(Q(#TG]B%1Y?'I$',:3$;/(0DJ7V?"-TT7?MHE+0*9I@@DXC*3>YC#2,#$8 M6;D55@1G&1#UHB'9*DT.2B:,8JI-X@/*;"+H11PL5HB!;YJXAR,VDO0J5^G& M:I4=QDXO,\B"1I6)G0L(F<@5046CIK"IF11(]`W0OUEAP\/L98+PD*I8,*XC MMR4IO/5M@E:U2]Z+EL.@,FDD69CUY&GEQD"PW^R#NWZD&K#3).4\ZHR82`UT MNBS[W?G'P%RM42T$Z?;0,GCK2Z8TI#89AW%FR#2R&--GY\(%?_5+KG,=/C'2 M2\0%]Y!B%G1'RV)/>C_6:6$``4D\B@9F`<'(ZE:0C+3.#0*(D"R9.Y)0H.QT" MBE1FB2PG$"VNY9<8`4@G[\(!B$"))H8QPDTW,8:2`:YQ*I;$SIO+$PJKX_H$ MFBN<*@1<&;%R5S;U+<*%$KBBJ<3+2M8)O+2JCB,-`MR5\NGC2-\BZCA2XF6Q M/;KH"2.-^KR%[\F#2-\>RAA28F4ET:2S&"J16*)4A[5N[5+BB"0\=/16@(0D M^4YZR(!G+^DY742&9E'ZX8$>MC1\EU*_$]8UP3K+);5SUKQBM=/68+%13Y#7 M#4]O]N'KUB@"ZU44&2GFA*[`4BK5XXM%LCIAWB5E9W379%6LBNP?*INM5C%: M$>[Y0PI\'TI5A7W;JGI%8A]EY=GHPYM5LVCQX9&^`($2TM@\!#A+0GJ%5$9; MG1:[Z>!$Q6R:^!&PL'2),$\$XM5JN[+I1>&:'&QJ][FG!(`9,V@BP<.?2MIN^U!#C"C(+W^-8IS603C1[G* MC)%EA8:B9HW4;1H'W\9]R4MGY*ED#-TQJ8B)G5Q>MA#MT"Y?9]QN8_Q0=%]$ M2B_JOC)GD"0#7^QZTP25KET,0$V!M9V<7@.B-1ZA4V_?S/!A0-45`_*=>(5@9$Z0IZ3!K1$.4X*J)A0?E-;/DJK6;TZ3ZM:W8WA)1#KN+G.[NR.PS\7Q*UYT\BLZS7R746,^!'7X? M;?24BP#&!_"E+O80T<`="'>-BGE"UW&_K[I_9,U,?S2@2SI#NA&<`@U315[A M#D79?G'NN9'?O,=@DVU`-X'?2G6;WT;J2Z`HP7RY.VXJ2E%'M:HYX1TB*],[ MT+?*.XUOCGF'(S?/.\UJ3C1P<#_>6;^L6CW)XE5#*"KNFM[%*P3)?%G[3]^5#BY$%6W_AHMLA#-EZQQ\L6N\07:]NA# MHUH]TZ(QZ,:)"N),F$05>YH\I[`5(Z<0-(=2KLAO`:&*X^[A]`(:NVT46ZBQ M)*`C!:>]!+F[T%S6I0+W"]@%`&"-OBVDX7PLH:-$RP6P:./!I>TB#;]WY]JC M>1Z<,YLMEX*-X1OX*`\(?G/[Q"Y6:,PHY,$#NKOE**<1R MY6&YET7&M9BMC\6E1PGRPX*G.PX8N.-O]/2C+@8Q!!0V_LRR?`2Y.A3@=0`B M525Z`JCI!\@ZW)RH`X([,!@-$@IC!"5,Z(P/)%%A?VQ0W%+Z,8B\R&?M"'/+ M-.[C;Y=Q8&#`#F$LIYF$-]OW['<(,J-[&UL550)``-"-(520C2%4G5X"P`!!"4.```$.0$``.V]Z7+D1I8F M^O^:W7?PJRFS5IDQI5RZ:THU73$6)#-EG*&2;)*2IDTV)@,C/()H@?`0%F92 M3W]]P>(`?(4[`@ZF?E0I&3A^CB_?=WP__N__\_-C`IY@EL=7;[YY_16` MZ09MXW3_SZ]^O/OPZN]?_<_5__O__/O_]^H5^!ZF,(L*N`7WS^!#^5]QD9?@ M(BUPZB+:0_!_?H[2+3A]_>;OWX%7KTBJ)$Y_^P?YO_LHAP";2O-_?,[C?W[U M4!2'?WS[[:=/G[[Y].X;E.V_??OZ]9MO_\\/E[>;!_@8O8I3K#/=P*\`EO]' M3G^\1)NHH/GDDG^^SY):P;MO&UM2"?+7JUKL%?GIU9NWK]Z]^>9SOOVJRB+Y M;&"D%O\\D*_*].:[[[[[EGYM1+&B6*&Z*3:N/0!8_64H@3=P!\A_?[RYD*;^ M[ELB\6T*]Z2-+J-[F&"S5$7Q?(#__"J/'P\)K'][R.!.K"O)LHXJ4DO?D5IZ M\S=22_^M8^%;YYQ>PRQ&V_?I$;+<,^4K[[=%E!7'RCUGS#W_=ZB(DNESSIEQ MS_-'>(2Z;HQXJ&/L'^$1ZK@UP^_O"*_O'K]IO+( M_ZWZ^==;C'V8KZ^Q2IAE$+,`;7[[`3[>P\8<+>D_OS))\6VW&"1AIR`9S%&9 M;:"]ZE^3^\2J4BM==9LFRC9UMO`_-3FK)+[=(-P5'8I7"0_>788>S6JYS@"RJ+DRQQE#!]+- M1_C/`_9X65P\__,K/#!!V19F;)#R[6PX+##7'F%:O/^]Q/DZ0X\'E.(_\_7G M.)?!19G&%8LJY;[0R'2#5CGXA:@/!8,F;=)!H;[.@LGUC@4I_""0Z%JSS@\700,E&[0I3B7S:9\+!.R8G,.=_$F+L[++$[WY_`))NA`9B6W9#5= M[6WLE+CBU\J:+W]$316`,PZ86<#9!=1P:,`>U<0=I(^H\="!?P.+*$[A]GV4 MI;@HN1+@$F%'((NU>@5L;(;8,("J;A(>D*J:.TXG*LF!]]Z3;[RJ0QC84M8Y#RU%W82.JQ^B MS_%C^:C$4U?&$4<=9;[P4RD-S#<)ZY;'C:`N0L?+#:YVJ-C=:;^[]G"U(E\8 MH0J#VJD9U&6GN^J6/W1<_!"G>C_2D7'U([PR;WZ$*0W-CXCJMN-'AG41.EZN M<;U_C!Y5KJ0CXH@67IOMW"F/DI_(^^>\(__
P/W,FIG>8?5"MJX M\]D!*[P>[ST943H_+D0U6<-A6/PP4="G&^BY#]AE,F=B534`2$RG=Y.@S']@!D`Q$)`;D57^36* MU+44%J#82.IGF"3_.T6?TEL8Y2B%VXL\+P<+?GIYY^&N1+'G82^Q\NHW8@;4 M=@`S-#_(C!JD.PY65EJ(0L^P:K0#JCX4 M+$EJNXLA8G.%>>X\R^7I/5\H951UUGL%$=8-:>2@0$E9S%SF"2@D1 M,-Q-@-N'"#?U55F0.`C44^J&1YJ;ZU>Y#G$;I)L9T M0'FL.#A@E=17\`&%#7_7(=,M3'.XQ1UJFJ,DWM)#VJ=10@(FX7X50AJ7((Q# M!&,:4!BB0%NSH4-XG>>X831@[0FY7ECJ:/.V7$^UA@$K<:5VKA`)ZF`94*FF MPT:(Z\5_(@:^4=(0))4^1!/PJH)'59G4?ZP3K?D/R3@RU.4T%@O MQ5F49<]XJO)3E)32^_U&:5V#")@8\09#;"4,[%FU2R>R@'E]'>=RFEF&K.^J M'8;1!46MB3T*0#MP#_=Q2BYZD3^*!PA8\B^BK9WNM$W3VN_&M387!U/1UC#= M?H&M_&X9_P%Z$]ZN"S!3`#); M.3WXC8BY,-!JT4Z=^P2F-1@Z3DT0Z15[3B@K^%"U?:C1`+-@TQEAAP$R+9R\ M`<>M-;R%K6)J3^H=VD6VPD*NR%]G"/?^Q3.YX40OG>"NDP:9^`CE/8PBB7/7 M(M?MKT]A-FA?`FL#)R"%@2#-I$VZO8FNTJ;U!O0_1KDVDU M-HBW1@E7^/_`/4*_@27 MG"I?SHJJ#&HT(JA1WAD-ZB!TA"C!X0<7XR!A,%H-"1=R2+BC862%>QZ0@E_. MX2XJDP+05@ED>U!;[PL9B5[&T7V';#R%O\%5%'UOZ[BC/TU#$C:-B4/6KOZ71"HS?8D%0G\`7?BWT09,<"[LV"`IFZ"'M94U10ZW&B4 M2"-')I+T$;YS&A=&5(?EOA0U/0C;Z<]QV:TQ*O+H86E1K%V^HBB2KZ*R+JEE MM57;7344"+:+A08DG'/P;3PT]C_8GG"O,K@.RJQG\MLE>6@A;\M%G.[`-C%' MM\Q2%I%0NK^#V2/OAV0`$(FZ@DJ@TV^X[Z`Z%E5M=_`DK9;@\=0R0>]'/+JD M"7J+D'L)C1.:J5^8I$-87-TOQ/.3B\1Q\4C/?*;;,Y22,`@PW,6-"+G"C^'^`OK[]Y_?KU&SP`SM@9 MK7^`-Z]?G[QF_P,YBXD1E<4#;I0_X/9_@+?_>O+=N[^=_/W=.^H@\9___6]O M\)]O:V'4AIJH[D3<8CS1]P#`N]@33O,N)V=A@K=5#]7;JIL%O*TJ:"2#]S@' M]1MZXF03GPN==D673E.6T$F;MI[-D="9EH?%>9EB MS9@]=T7UO^!67-!"P">8EO`#+OSWY`U9 MV3F:H9PC_@8*?2&/:@,94Q_((1EI+?,XDM3(,:Y<2//GX<*%2+?\NL50NMN@ M@%0LR,O[5]&G*-N>@#C=).46NQ;IZRRT*%795;3Z?GJZZ8X\(W8$`H/[,-"4;]F!1W=44]\-S:]+=W?+*^^ M%[+X?E5CN@J=JGL40B[O&NI+IMA;X*^&O77LVT#.U&J;H!,-3%U-H.0;6LF#/P9M4G7QVGK[#@3 M*8-\>YE4J>VH)EBJE%)8U`YJ8?"P:)7^%$N1A)]N*36'[OJ^AREVW0G._7K[ M&*E2.;H_C7IOZT3,#`5ZU#$4!L8-VX9W@D8U%SHF!Z,)T\&9 M]]'>I-.U>L`7!MBDE:X0BK!J@.#T[#"A8#J5\V1>XWP'M<8:[J^D.Y/VW6*H/P[YI*"QV+%RF>8L-@5]%45^@HM`7@9-CS!CN3 M10WAZ"8@+%K!6JWA?1@[7R.G-YBH;%*7)CV ME.PIW*$,,KF[Z#/,?XA36H:ZS\:C\:X6=NON!U@\(/SE"8O0P[?2P=#Q*[ZB$U\K!G'\8KE M<3;#+9>Q,[AMSOES_!6TJQ`*+$>`R]))W=70@IW@V5&11;ARXS3*GL%%`1_Q MC]B5DTB'.$<)ZYQ8L?]DQ3SP64;'B8M:=?BG,(6[6'V?9BCMA=8#M1[?LUU` M7R%M@R&")345.M8^PD*[7]65<9T)\,J\#D7(`[#A[$X)*[8SOA]6Q)'F8AW# M_N9?2Z[^A?0,/\-X_U#`[?H)=XY[^+$D`3ZO=O3>*'=M]#3*XPTYPA4G92&] MF#Y2F2/ZQEGU!=+:.HB8>9!2^^3RYJ:Z:3R\8OP*W)/22O+A^NQ$(A]6Q&-138>09[^%FG&/,.,8@#F_,9Q1? MQFM0&?/&CAZ8MPX=+?785/4)X)0ONEV<@D4?.<@_"W)V M7F8XX]>4'C0.)/OY`\K.HOQ!VH6;IO<1#]O$T!2AQ>K0=F0Q>H-M!(),V[8; M!,LVK\^%XI@/XC<*R"(%TR!98.D84`ZP([1N2@-<2VMWH<#N\K2.1N/B.QL= MQW#4M;&I$9Y7=L#7?WE#UZGR@-:I1C6MM0_O5O41'Z\PSICUF+\3+<`6"E]D MVQ]EED#_,ZYD)JW^!+-[I(H286M9'C7"3A-[3Z7&&NY.DQB6=,^(]*\O"'L. M#=P--V&EH@T_X=2/S=YE]X8@X_ILF9*CC$EG[K6K`,]!DTC3R/8CU6-VWTJ6 M:4KF(WP4/_KVV.,7*9'/BZ' M^>CE2R=!V^BST&#>\H-J\V:S0RU?F(N`K MF>C2;UT]0!ZE:(I5T]FA?W"ANRN'-#6^*S;'ZK<6>^!].:4@]/UH9^Q,4_6H/WS=6AT&O=F3G^D."/NGBR"F3^#JW*]!]U!?5B'5`S0?WHII) MDPG/^TKK-'20?H0%R3F]NKN%V]/G'W'K7:1-`,?UIHB?V%O9:NB.4.1^Y]'2 MHC>8TT4VBN`R9^MO;9B:J#$;2.S$\4W-D!&&9[N$K"]GG89>$P>0N\+UMO_*JNP&G?H!I+6C!/8N51]A_ST M%I.8#8_ MHJR(_Z#Q=JYVY_"^.(_S#2K3XCJ#CW'Y**.!-ITKSW0&O$4=S>)]C!L';+$- ML*V,!()_T];I@-FLYJ9#YN\/**9X>_W=N]<4;>277]>;30:).40S=8;R(H_2 M+0N:LXFC!,\&G_`H"DM\@%%19GUHC-4R$HDCS7ESYK5E,ANFV-P0X_2J_GUC M'O]8VP<[EH%YH>O8U`3(3A4_[4QB;-:V:&.#"2Q>DMZ(NU(F%?5P#'6CU=W=M"WO4G-]PZ/ M"66Y0V(274(*W@UD&M]Q^J8;2NB0N`-+H]C:J@%D,Z?'AV#-=?9&,Z^`V[(:1AQCV,)?66Y(-*7=J7AQ*KUNF.-S6) MVH&G5GOH$^4FACC.]3DJ[XM=F:PW=(U3=O!;F<1QTJS2/4W8=+*90V+5IB"J M[)#='A@_D>"$8O<')!36&O'Z,K-2^"A0S#T_& M#E&\/:^F9-530NMT2S/-O+JQCS)2YMTSFECU-P^BMNK=([;GS=YMC:BA4+EA MT\YJEVI>W0OL_^OAS&4)R2E12R73#68%UCR^6EB-:+=P22-:12L:#FNE ME;H\;-=3R^OH6?&*ASZ==P3W#'B^K]C,NP],?:B@E32/&J?"JCO:\ZN:S/A\ M-+5R/^><^P%-RUY_`2V[D/NDPH)D)=QRCM0&4/VD4X"V9\.__R$&0-):"!BH MDJ;28E58AS,ZHGY^CN"+:"M??E&MO!"G9'X/3@(Q"P5'NR_L_0E;[:VL,`!M MWYCC;@@?^65\BZO@F-H"^MK9GC(Y@4,+IHB.HC5M'1U"I&T1'>+%@ M=&UNH^@("CW:Z`C*/(3>%UQ'S]4U\O7F]S+.("X=[MF*YVN,U6*=;M_C7P]$ M1':6S%R!ZZDU8TO&/O\[QO84[DE$)]E8]QIGZB%BD>T.E4VZC0-K@V'PS+XM M.^?9+*OW.`-=BUQY&^C6-@GS*ZN@-GL"J.$3VO[OO]#V7_8X]T.<1NG&PSA7 MI6B:<:["X@3C7#JNV-4F%S.N,&A?@T&NMJI#1S\NT`;";?X!U]E'5$#--IY4 MW/VLN5"OQW/F5'\U"L[SDCRQ3+KJE%@+:Q-/UR:]\^6*BCO2V7)E;OV<*Y>9 M4)XI%R=:D;_J%C]AZY.'2G@Y`#"K_,'Y<:%TY^RX$;^/YZ!NX*$:MZ/752]_=6N>T,03U;8#Q!_I+\8#$XLE'D<$IE;];8? MS0V1^A?0PWI4WJVI96,IVQI?)B'8"SOVV.?330)SSL`4B-[T7A8*'LZ"AM(C M=U")QYX.*//O>5X@LV4V01"G7MU&R0`O9,9PB(LH`5E$GF18(&PL6TH^B1`F M$\\F)!:6Y#=MWO31I_/H-R=]L:>[=`(7\6R5<:O)G.B"GZ7BB_%SE&516M0E M4$21D"?QB-.^[NDAVA^Z?F(Y"!"FLJ:2(51 M09#K-O1AM_[A=PG^K%0X8MW&EG<_U[GV6=U_B-.`)N-C&I.'MWWM'L?#6>7+ MFX^C_HV39*Z MQGPWL.$M5BMGBSZVDJ"\S-@DN3XI@SW;#F6/-#!H($=C;%JP$RC>N&I#Q_!% M6D",H^(ZBF4K.1T1YSN%K2ZO7I4&#R$+V7%E(0R`B:JW>QNP7Q^A`Z:&^T=< M>/S/]E1WNA4,6L\;5Z!QB,YJ/0P(7.P?P9&F+&O\%08\E!#-C"D1B@<(#FQ4 M05>%?L"P?0!O_WX"<"[>XJ%G5%"U,04QAMM?R;KU+?XWI`]1OWM-)-^\"\15 M^\)=?U#BWNA'#P>/LTMR7FTCT+>R6;#?B_3]Y\T#AA/\@+([N'E(48+VSS]% M22D,_3U.D4NP\5$6?7'K#C."/,D1I<]U0.FW;[X[^=N__1WD-"N#-?V8/&?" MLL4XU60,/)&<;4%4@+^\??LZ@+JAH`ID[--`18M6/RYWG"/8X$Z^H(ZZA MPK!3(4H'F6^^<*@<+1*^4R%]7'X<:5]Q_W&4QM69%*8BE)XPF+X$E'K`0>]6 MY!A5W,5(']WM$<<-3,2''ZXT'=/U,Q%O&'^WP^28( M<'!092^4T0$37.+PP"]/*`$YR0GZ]G%,SDDKEOT52=R7>Y5:O?Z MU&=EY5\`LP-^J:W\WS#6"LQ:I[.@:U!YH6.2$"UFK]V3G1:4DJ4,F&ZLEN&L M=+BNN=D8\]F35T;95AQO%K1V@P/UJ.;MK';95_>+@/P=_%R<)O(3_I9*C@'Z MQMI14+\@?`_:TAK@O:H-'>$W,"'7):^CK'B^RZ(T)ZO\*-7M+VN3.=\F5.OW M=Z>0V@'4$.`M!>>?35NJ>\O0I!J7BE%S%VRC82+D3NA\*Y.OAB`.&[F&;M>Z M1D/'\VUYG\/?2]R/O'\R.LLC$7<^OR/6ZV^KN=8/F('@7*JN(;I'TAG08WE$W"-DGCS'`863=J'AZ.^`D-'Y(\YO-J]SXOX$8\D9#>? M>D*.J.MJ\X6S']FMNT9O6,`25S,/)5&MA`X>NF]P&N5P2P[W0#S^)%EE=U?7 M*3E=CED?/T$2H#%GS2'K_$9H0T?_ M^RA+XW1/KE+0,K*\Z_IS72I'5&O4^[PS>(GRG-R>`=46/;47%H0-FXB'JU$% MA@Y-,>?6Y-KVGAYQ/GUN1:K`;^M/4;:MX@[\!/,";DE(W<\'N,'_O$/DIZNR MR`L\?&,'=:O[WR0VUQW]/]W,:=Y,3=)='"OW7GL>4&4)<,;#X&L8N-7W7L=M M]M"]S6F9QRG,WJ(!O"%VLJ3WQ[-" M">N\J'9DOH\\>`LWTF@DDYVHS0(]]U9]#>3BJD]8\)3TUQZA$^L2/L$,YW9[ M6CZCLKCZE,(L?X@/=_"//F?>NEN` M<)9HB(O_`' MPDV9T?MB[S]ODG(+MR18$>FV2W9F]&K7']RO'\F+M!(H^]'MR"0![;(G1>D>B35SLZ6_A8DDNI^(_..6)NNUDV8;)1 MX3HYL[#E;<$YC0O<:^`.@]WRQ6WX1"[V'I)H0V<&E!E4*A!BC&G4SES(NI9# MA[DL[#)MR>NZ(26@,TP\42SNKA6?ZWJ'3DC#`:S#P+)=RYF$VA95:.CX/8?W M15V&,Y07LCG`4,X1E0.%WD-E;[!6>E%G`,!`SBU(ZYX'FZ2>0L<5%R?YC$6< M9H[^!N8P>\)C'91]*(LR@W79%$>N[?1X..-M9=";XZ0=(C_[Q!U_'"7)^@T&+WXVQT>K9^B."'KNK@:OB>1C, MS;7UH$H[)XP##ZHUKZR2H(AC=/G1I=7K8QC)HP=![C*3K,<^J>^`F+ M;`M=(NVZ,R]6.Q$)ZH8B,1#H0F@8F->T1&(_C09/7C(3#1%'F3!RWR;VUU.QAB\01YN4,L(5DFQELW`))W,VUPI`E* ML(CN63T*]#GTFV*\Q[35W1ANS'O(SH-DH;P+IAO@+6]4]_[QD*!G"&_QC#+> M0#%Q/B*ZA0ZWE",Y'7?PW\DRX$=4_"ZYSF:DRYF]S+FMT M5A%%[^EQ^PV7@3!H,CFH.I.J:1LN=`*/[NKJ$V5YD97L;>+B`69W#U%UD2'G M#G3^#./]`ZD]=MSF!CY&,3D(0,)BD'NQ993

Q1ME<35A[GF@Y.41A?SJ5Z M_RP_`9\JRR!BID%6VP9)O&,#XO,RHX5>^I!X2@IXF7M.!YD7Z]:&%7.!RQ^G M>;P1A2Z?WM[,ES2D&?/E.C@#W<=+3T"TWV=P3W:ZX]IT"`&!CX8QG[.Q(4W?CP1"G]PW M;]V7[@8X+\B6ZJ;O-2L[X73C+$.V;&:O]]P6459<2HC='O@1W*8\`?=PS^8! M]U'RPM;&=>B:J"/G6_(X3U7ZS[SU>Y8,B._3[4@80C;4_!.$D[3C4F'XSO^I M1P'Z_D2;W^9ZZ<,5>J"L&;5]GZ'<^Q*IPM+,)!5D:3*2G@!J[46=B=1CR"=' MI:WUTCGZ`64[&).3W$WI)R*$R-+,'!5D:4*.5M9>(DL5*/+)4FE[O726RC&)1N!Z9"QN#J@LDO\%BK%@%ZQ<_`GUV:"^U`4/9:&\+8/H,/XG M>&<%[TM9/\FM9J53C/P\YF!J'^$OJ\?R$EQ/R*_/+-9Q^(>KE?/P#8`7[SX& M&^=S>!"[3,SM1*QR.X,?J;^\<$\R"KE>G5Q8L+,^U^&&>15\NH]9>G6,]4#_QU)@*,(CR$9'G9:'#MDV_2.:?QR2\ M6KH]-N\[=D-D/9]![YS?5LK!3-'['YX?X)2(@9D!`3 M(?/9+Z;T5/;9:/.%0_);:Y-%1O*63=L@29X,#TC5N_+)<6R!4VG_U#L>9$V" M*_FQJ(NSY*M<7]20X,?#X=A#@K[)D(8$O;Q--20HB9D7.R208&JR(8&PT18W M))#46FA#@F$VCS0DZ!O6#0DXCGTY0P(%]8X'V0F'!#V+$PT)!N5:Q)#@7K]8 M="5AK@WC^;Q1]<9'SHF/`<1QL^Q]JW$8-6O3FF01M)XA]GX!N;QYX#H8 MA,S1\(MP)P['2;F*F31H>2/!/CSU-X=9D9#^'5Y27X@GKB&>ZOFEH/ MI]<.X'S@R8ONVH]]L\FJ;17LBACU!"PZLF>A;30FS M$P:G177,=Z/#2CD.:G*X^6:/GKZ-Z3L8##/LWWVTL%]_O:#_(95(V>EO`K%-]1(EW=CZ5!F?%W!VS40@:%.+H;NR]6:#2ISU&[B! M\1-QS:=QDM!7F2]1NB=+O/6*;WZ576=HGT72YTE&*G-TC^.L^GT[LMZ;8%`/ MPX.Z-2WO:UUJ.'0"7*1XLH!YC,*J%1]GI_A+B077^H237_7Z(T_BQ M?*Q&V/EY61=0@B)+)8Z8M;/F[?&4VBI(J%FPHW;!(S-08%^K2^, M!3>X&.3:%Y[U?H2&OKZ7QB^ZN\I](9GJ!I#I!24YWP90#]U!8E?/0?3I'+&I->#MX`HV!++&0!A0-&X6'HZ&518Z M)'_$_,&#>K@]A_<:%`I%'8$GTNGOJ>)*-T@)Z@YL.A,&Y%35SJ-,7C^A`XMD MN'TRM)Y3DIO6MP7^OVUUISW:RZ!AH<`1A.:6O*T7I"DYB%LO%P#?IV M%]?&YK(\]`\1GO?A[)W+@[TH$GCUP+QFKP//AAV/E06PK6E!;`7)"5&[R%WN ML.I"1R'E#Q'I`"6RR98-F(?] MBZDIQ1$J(PVK1HPF>(3))R)X#,+"V& ML&=)E.=56=:?X_XRLE:N3\R!G!\RRLQ[(J!`O0'I!JDXHM%OX*JB&^87_AX* MMZ1M.>23IMG['.J+"W@SU!@Z5QBWR8$_E.("G"-R#[`'5Z5,55EB&2=^*,VZ M<4.F6LX+<8I5U<,TOX-?V)>9V:!N,614PUT6"$5;!D@TA8Y^GJ]"Z,L%JNH1 M"#B!7F[0#?%"O7*X"\17?:\?!-(5#83T==K%^%"N!;A(1^CH;M?\\P^XLK@A MW0]0<,G95+RJ-*VX$P],,^/&"@,KUYF<;IG$=MI7-=KC/*'*(=7NW6>P\&=@C%)FYF) M15+'R8I])EWG+U8655,:"T6K,_X(>TQ3T:/M!=P\I"A!^^>Y)SHCT()=8/Y([%?VH8[;)JJHW M3N:\#VV3.3>Z6UA3;S\;*5FU4F2?(*4C\V:W+4XW24GO0T=!W9.PA@L:VY;# MC6>3U-UM9S-[BV$'T\./A)`Y\U40-.5_1X>%%^C9#MT77&-=,,O@EHY>6.9OR_M\D\7W M<'M:%C^F##YT(M,CVKC$54-8)G;R!>,RZN8+K&W*?8&EJE7UC:*..^D-_O+V MFW>O:?`3ZAGF]0(CP8/QTM%[`UO8"O0"/H?X,WU1_I#9Z%R`>$C_$0_6:VV#1*9 M++.UB:9;7QMD;,*%-=[6R!6U5L7J:H=11N?1Z1;D$>8H'FYWHL($PU%+:)@M MH;U&R[ZX70MIWF7^VJB7Z,QV2WY#)@ M7,16=#;694!SO:[)Z&]8V(!SN\W.<$C-B_1:CNAIY]L+" ML8!Q4?X0KB\QQZ61C[&%N8'OT:HT\TD&.5NHKV)#)4_.RE*9R71B'G=E69`) MIQ^3."Q3U6,]UD(F,?[RT_Q\5#6_(/D-RM[#L"WVJKQO6FULF_^2ZO#M)/Z0;*X9VB=\2CJ>#6=92^M+>'VD^KW95#*[AKHQ@N"K*Y@U[.)H6PDH1>L%PKD@FY3 M?VT&'"?S*OV*Z;D\V>HVWJI-I`I%"BYFA5+OHHA$SBK&VS@B6S17V57Q`+/V M?:Z\%85;VA%C*59>%>-<=8JH.5JG/PZ[%LLCV1VR8N@51EM8_0"S/GD'4/1&6;'-1:=WHPJ&)TN]:H2`9P,/(CBC(;IS\[C M_(#R*+G:D9>Z+^,GN&41M-1D=E%1-<0H%4XD=\FT&^%'6I:3?Y3"59N*S&&) M]"LJ#IA\&![!"5K(1UMW/<483:W7&)>/T#T(?9]4[2%4(E4%"T6<&*XRZL9@ MB68Y0X4)V..U@1!-V4+(I$J[1!%)MD00ZPD=Z.3PQ2.\BSYKND.-6-WER<3< MNC6-<<>N2ZY=T3W)$JW8%X`_A4(#;=LATXKN]1L2::YOD.I;#"U^Q-6:%5&< M2G=,343[]!")^J&((A.>:"*V8$`54<)5\R-A#*9+3I<,0F..JFF'[-$#H<\@ M00H!BX1Z0V?2#O5=2"B+%,WRICZ%XP*G<997V3S#:YVSVSD9EUO(5F;U5Q1\U6V8IL5O0.T7:2A4'S MT3A"KHW;NQEGJ86[-V=M/W370$X2P=]+XM.>3/V!59HZZH=1&K?@'C;99BROHZ6?RV+&V9F(E$97Q_2I)6@*JKY%IDQG0;SF7RJ1% M.(_S38+R,H/6':0BJ8Z3HJ33T%.1R8F8*K8X@K0B11+^!DI:%4+T_-7C2T=E M@08#5@OMAD[P]X^'!#U#>`,38SDKLPS2$G[$35C](>YSW934 M$13&*7&+J."4<<<("V-M*R(NC%.Y6E=OSY%[:##-PXK,X@@NY*>M>T$:1NGB M@C:,S$OHWJ1:LLNOV?N&N!05M+@2ZD<.CEJZX1^LM?B(#3$VZUX"1XPPKHTJ M8:U3Z%."""XQ&E;]R!..^*Q+WU=>/TW"*[A!4_GOX0&#(Y_"=)U#DL&,XXW:L M4B00'/D2:5T@;[3'BO6C$*6H;^I,=<38=E"K3-AA3W"4,3EF;#SV5*50LF9! MW4W;=;[?[>"FB)]@4Z`;//DF-VK3#>Y+Z;#$<%PY7M5@I#E"E:>QY_A"^!J- MCLJ!R?ATA.+.B+5U`>"4/C=0@#IQE3J4\:L#$@4C6F=<#\:X]AI%H]XQ^5J. M8SJO7KO`Q6+W^O`D9<6+_@M@P@$\^68%"#2ZL00/N9DD M[[W99F8Q>`(WGHF^.'<:Y7!['3W3@T2?HFQ+BWI%\Y^31S79JPUY7CZRWPS' M#SZ5#X857I1[&FWX+*BO08BG/)F,3;R8Z@Q9:%K`$@.J+3\!C1+`:0EEY.(5 MZX(!S01<&HQS?-@0#7_\Y'V)3I7?GV*/>Z[+X@'G^P^X_3'%>>8J@9S^RD^? MZW=S:_NBT?'Z/LN>_+ M?J]=FK[";> M/Q2Y@81W]`CZ)(Z&+-D`W^B2>;)?9AESI>WT%HS<0X:)>UL M]XJ[@$J%P;I['XXFF/FDC35.!%[`"F$#TJM3BSBNLQ%2!!?_U- M"I^*I08)#2Z[\586RTU2A'/T&,7])X`M4FBC.[0I)@KO,,C25/$=>$-C`CRT MZ=7<9,1DHJ%24P`$@]`.,O3HJ-DF-`GNP%D)G9IW+M&C([=H5WR*,LPI]GUF3NG; M$AG7>Y<_4O&6-0J-H7.%1L(FT^"+QT.&GE@P-"%;#"3Y4.H22?>(ZNHL>`BL M+C6@B:\N2;=J/@+^:R"\,6E59%'_@BCLX@2]8.PRK:'SYVJWBS=0W<\H9:H* M$\LXL45IUHTG,M5RAHA3K-C/W#"-="T?RBR-BS*8OD7=?LBHOKN\$(JVC)!H M"IT+TL'C99S"BP(^&J]6#!+H)D1M@FGF0X,,330=XNV,F`VUR=63H5^((*"2 MH8(1P\7/@@T[O\8S\O.2/5W\UT#I*0"$GI]2%.D(VB8T M8"AO9;$4_3Y#N7%WV1'6$9,)3\/)3D8FHF-M8P036=)NV+J&=B=@3SX'RK=N M$^NI)H*$CF4TC0'!*MVA!7RK;2-+^5'K&FK*:^&<8T_YRHTR&)4?(ZM+B.D3M>K`EM-'G4W$ M*9H];I5?%*.I(#2(;.5%>R?4E:?\ANX0M0$">R[!6-XTV.;$<37].!T3,P[1 M,ML@=IM@(E>9-[1YX$LQ?;7)+,)9CB6<9]3]^M8&=P4JHN1R+O#AO*[N2`Y( M-_4%@+!MF_!@.$.0IVYLB^;GZCFT*BC)NO@`<9ZCY+:(BA)GZ;D3'Z-'DDET M]\-(>='M)^Z4SV)Z"E3E*4L&D:V\6%I5GT',XN$4T6<0%2"OI4&&I4*)D>45 MU<.@6A.0IO)P7DT(PG;YR?E"/2XDM)XT,[*_7C4RM]G[2U%/X-UU6 M)_%@"J/6/DJJ:T6_+-`':=&C\S*&\%/[$9D2K:>06U^H+\`_G&5P&Q=Y_=:L MF1>0IU/S7Y!N"N;+LS<)YX7FK-DNT-)]0'G+/:"\89)!DEP!#AV]M;A2$WN8 M7$MID<6%DOGL@5PSOD@'T;K:Z!1)@CY%Z8!,_A2JZ6^C<`J_,*)`DS@,NWQ8 M>Q(;]2LFC,<2X*F)3Q/5GX/T+V-@J7,\XZ&N]D@6>K6NRBJ/"_5A5\4#S)J? MTKWHX-V8I&J_)$XZA0=29G(27R.S:.U5Q(I6].<@_80:$#J/8`(G-?>%&K0L ME]A=#)^[BRAGB#Q77^)R7!T@.Q0FI;-YRCZ;#5+Z(;-Y%CUQV1[O MX@T;?8C?K!F=OFH(^_1.7!^=73?&CS$KY[V]ME7U^1_SDGT\6)!S`W:);ZVF MI?^('"S.">!_U+]53HZLGV1/,*^?VXN2?D_OID3F#LR4^/4)5AGW[!A,;5MX M!S.5J_I?=#4RJR0"\Q=VD)([C3'0E'D.(UT*]V&8E\7YD.&ZA?@HGWU"F:^0 M)_3K'[09].P35/8L_(!]VC)PJF*A1S!:T*[],%TTS[GS$86+:;-&@5KBY1NG]5P.PQP)F#,7J4 MDP=+#"KF#SI-ZBF$/A^+4N01%2K^> M0)]%SPY`:=""]PH]*XQ#@.KO("%W[C:\Q`G^K7((@?D#`\3(W8`QW&3LERM0 MD%YE=7%<-[VB:)]0QO2)KAG:9]`SS\==%;10LSI7W?T+E^(6%_U&HTQ&<(/+ M>C8V%T?OYB!5QT])CA6.3*U8`E2E]K[V9Y!5_XM^:J-VJWTJ78-#A[TSA^'2 MWQ!$RD4_EG7JA;YC-R=?Z M.B:=EOLX3:N?1.M\H5+?""XVBWU2M)FO][4JK);\>,N+HWQGF<)J?<]J)6_* M-;MCK,XYK,/5=Z"W]:O8_"T@*AXN2\4-;KCX-F:9S71!;9E,,]PM&TKJ3]9, M=H9F\M,R8\_%#'C%$RK,[2U!PYJ<@K$^[V)TLB5\"NE>]EN3U[/V+(+SZ;/X MT5?U(U2>]!H^5VJN=])72:V+-^WCHS;9&?_&J+F5SDM95!!02<"K`[P^\A(/ M+UCI9.](A_:>EB_(&[\Q.I9-E9OSIM[\Q5"+'(?N0EE>Q:]W";_5\0$[W]R" M_(G,.$;JZZE4A-OK2*X8(X-Y-4O<`DA9<[T`=;P(%V6NFS)TE(ZG85O0=$L6 MY3]&C^+GL*8T47?_4YAP&PE,6&C'0<$T.5.,#Z8PN/(P/.!<$HF:3RP`8B*0 MU\,FY0TZ!E![PXD)+'$CBTG*$;S[[CYSS)Y5SV]0DGQ@>R)TL&3XYKAI:O%+ MX]K4/M\7-\VJM_F3H5'CM\2UNO@7Q*_*(B^B=$N.$6%T/V(OQQX5K[30W<$>AV+PYC/C&F61COE?J,1^XKX9\KP1#OI/:8YYT M?.HOQ`JHS(0^ZG/CD/FXSP=734=^HVQ9C/U&EN7%.O5+R3MM_A2Z.NM+/^^\ M^2O03$[XTNB=.`_JW9UK0(_-><2QN\.4<)$6$#N20A#X_&CV7%VFL;UY/*IM=/Y*JK"S1Q_",;1M-G)&&8$M%8`-=-9+*;;7'1CK+8%J#%` MK2WCR(PGTAF?H_%**RI?:\N&RQOP[X*)H?OOCPV(:D=/?8,D-> M/+:\%%^4Q[;;G/1E9`J_/>DFIJ^"!^2]738[G4U.Z,,#WQ?U1J%I7/FH_5-7 M6Q,Y],7OLXXL]\?R\1YF5SONI$UU]F9*)Z^W.H775U@-IQO05TU`_8(RLT?J M*!1Y6+%O]*1V=2";DSH!L.X4#K13H%MU=)^6927(;=KI&#=-)V%,]2EZ#;GQ MB;H156D7T:_<>ZJ(807\#./]0P&WZR>817MX`\D,"G\F#PJ1R+]EE-S![/&M MJ-\))U=\OQ1`KMS[K0`*X:]?"Z(PFGXO@#RN:DE0B8)&%G#"X#+>X?[P/V&4 MY7^E_>)YR5[\"J%G#*`>Q3UG0!D;]JSS9Z[7\\Z?H3][YFY%=9*P)R MNAZ*JID/XB[8T4X=)0GNX<&!K)R2@GU1O;NA2YFIB[=R>+/T\^H`56PUOCE5=-@&N\PLP>>8U7D`?!&B\G]46N M\2H8-^T:KY;J4Z[Q#HU/O,8K*NTB^A5?O?"P`E2]\*0SQY%9F6*F:)N5<&:& M(RLQH)F@?0F.-/.SS=C8F5X]QX.MO9<_QQM+_FGF=&ZN:(HYG&6.)IJS6=?+ M='WI[P\HICWDZ^_>O:;](_GEUTX&7K_^V^O7?_\!DKZ^YWJUTMYJM5?7G_S^F_@%2#__3OXA?T\\WD[?1,BX^KN,ESB/F!>9]8KZKWA3S?"J"^3?_QC#_YKL@,2]J0@GF MY:TMQ#PG+L-\1^.\F'_S^K4>\`,A$=I;(7]0'QCVB'->MR'(VR2K^O=J8/H7 MW$2O0P3ZL.G$*)KS>_EW$>DWR>1P6\VG$_ MK/<9I"%,^E/X<8FKBK5,[,2I<1EUXYJU33D'+56MR$>R(!K5O]$XQ`<21AW_ M^@BS/V[K+=3D?K!6QM+]`[O-_M(`ED M#0<%,_`.!HGEWD&5V+=W,,BH=^^@MFGE'52J5LU'L*W]1/L]5!=@@AR5"S!' MGMP%*'0H78#2=N@NX"S*'\B3[D]10MYJ6+.'G>-T3V.6]?AD)EQ5M$;8B=)F M&7&CL-:&G+*:I"OR'H32/L1D2XR\OSDMX#7$6^O'X[1)5-668R(DW=AESXX^Q+3F/#%6LV']) M5Y_/I(FO8<-#[YYR=!O(1`R^(\W[+O.T`;";?X!USTM M$\KZIP55(E4E"D6<"*TRZM8=233+*2I,L+HM[U]%-.I^PS\,C@>8',"N3+?@ M,4K+';E]DI'SUW1=)H.O-C@_\29*0![M8/$,\J+MT>262;%DDUC/7V.X)IB7$[;H6O*RD$NF.V[HB/GHUH5$O8[*^9FT_ MU4VP^KX:6=&?09P^H7B#B5#2Z"QYS9`@^A-QR_5[#U7[=GN*CN2@7^CI.>(0 MJ&-YH@&/&VS(8,8,.&&,1$8@1S/*.`)VCKAP1"J0W+0D.20![451W-5"]4*1 M6,AM@4AIV'%A2*9;L2`D3K+J_`[(AS`"@6O:#9E5T4B[W6\QRXKC%12M$<4M$4W: MU54*02T4R/DXT_9%EJW0N\*@3L3=,M!I#YU=@XQ?2@(EZP5EG=.EGX#%^@QX M[IHNC0('*Y()9T"7H83M-6A0>;[H6+/C#)UQ5?Y#=05Q`B&']0/<=MO`))NA`]PH/N-@/40[S M@)ZI-&IU.;WD&)$1C$NAH%A';^@DNW@\1'$&M^L\AT5^AT[A>9P?4`ZW5[O3 MYQ]@\8"V5\4#S.X>HO0V2N#Z$95I<;5C"0DV+E'>[\<\:ZV:Q9=6)Y9[+IJ; M0_"7&;GO\&5CU?Y-/,TA0P>8%<_4TY"3;(?F'#HBVD""TOVKA.Z/1M3TO,[& M-Z311(#JNC!/REMOYRVWP3O&=(,>X5WT^?WGZ#%.J7<_A_DFBP_\+E?M\,RD M:T>FD79S4&99<70\6B,*AZ))N\*?P#.)*4LV]/X+;@H"OQW$F(@2ZB#R@KZL MC,5@JR*(@^FF.$"6K=5CM3H1QU:=]M!9>`[O"^Q@-@G*RPRN[W,:F+6'>[50 M5742(2>JJ0V[,4RJ6TXL29+51U3@<%A5+&\MY.IRNSX.Z8J M,V-V9E6<>M7\#%+\.SE-S@(I%JB(DG`.H:I;7'@BU00D% M#:SN#.3D,7J4%20N/O$C/:!KY:I*E,LY,4QKWHU9*O5R1LE3K9I/9$&D[-** MS',RF$0DQ%N<%A`7O)B77/K&1<8-T2635+PED4)CZ.2Y.D"R.)SNR<('O8VX M0QDYHME?-=4+5M6F$'3BCSX#;@12ZI,`6?56--2N)?T5`GDK.EP!N!^B;4LT6^:FY)`:)B6)M( MPS->>^ALNZF.#@IO#(@_-JN!G8^.2X`B0Z[K?CV=JL6^CNCJAC]/>XM+HX+XF MJ7S8=1G*"7[#EE;W$C)DJ#J)R^%I?IWN15*,'1`TFKUT))7S%R8YP0RFDX4I MYC"U`=M9#$M'";5AA.*7WDY`1`4"Y%*O5353&1$$E),9FD`WG:FT+I(_ZM5P MFR0J1GE=`[?)U`0_S>!M' MV?-51J+1%M71^(OT">8%A.1D_-6.OHEU^CP4KL5$J^%3J&YN:GM4[7BMVW\A M7>^`>\V1ZL*X1T.K5@!<98")`*80U**`J`17.T"5DL`HPE2->!![")/0`$V) MO_[M=W\6^*OR/O.]'"_+E4NP%Z*5&_B_OIPG9R8Q[\LS#=6;N)E^*MYG=#U# M")LA^K84D%C=[`-&]L1%]!IH#)XK;8;)JO+5[BZ+TCS:T$&5:#_$/$'-'GT" M-QH99\B13R9V%,32)U]U:44W1?!?G&`@>R06&$#VS=2CGS8=QT,#&Z$3\CJ+ MG_!DYCJ)-O2U)^&^B5JHN;<@%'*\K*`R['I#0:);=2U!F&15_0Z:#X%LK&C: M#9E5<__*@4B6OV<@UA4Z$>CCS^)=P^&7>LN0^^*V7S@TX;A9V%&HV"GDY%;T MCT!\OJC2D:*Z>KN!K0"W%8`-'-;.0[?9HA/W/,089F6"B<6FT M#ZA)JIAR7(:R$6C8U.K9APP:JBG(Y7`C4*<[>(ZUN:X?0&'ADZH7,:Y2;D`G MGY>8IQU.40S2^IJMF&?3V\3%R*31',9`TVJ]WV=P3\9AA^JNXPE((;W5MB6W MN.(\+R-,++!!^=QQ?,;!1S2[L4;?<**C5R&<\YA8#MT%7&-=,,O@EI;H]B'" M;%J7Q0/.Y1^P_XB*F7`S'5(*.TZ+3#+B.CW2V%!-DY1)5\UWD!.!$Y!3$1`U M,C2\'TLX\S:E89LCNZ;I3ZE4:?BIE5KW$LEV@9VR$=&Z@@J258+>"=;-@']R M-?KMB%4EDY(JIM_#)E2O;95D$N)`020FKR91K3-T`N$>]PEF17R?0'DQ?CR@ ME`GFPV&K@X8V`MF.S[!SG=H1A9?A;:WVK]M\L7&6/Y!OT^(@_!XHW,+_* MSI(H'BRSCDI;!UNU2NL6>G5,-AT#L5J:5(1EM=*TJC_671]YB#:OI&:.P3H* M+,BI$7OQ66U4<-%:[2R'3OC3,H]3F.?KS>]EG,SU=>0W>%%^DF@QB'YY#]]R)=;S;D MSE$=`A+[>OQ+A@MS&4?W<8*K8G"5QTU)&WI^C!+7B/0.&7<.5#_.MC)^_1B5 MJUJJCIC*OW71RLT>O]X%8\A/DP^BW8_0U0F"/RHORW,J[Q\/"7J&\(;%#;5Q M)?JD4@>B2.K9;>@SZ=M9*"W:N`B%(C*&.<`T9]<$(X;$T-R``3X4Y#=&EY3R M<@TJHJOLCJ/W=!#^]:T-B/'P*(>782$9EV!5.5*R/-Y@^DO!#C=>;QV-TTN[Y]-IU!\^_JIMOFM)X MNV0"O?N30-;06!*!CC>LKJ9;IRC%/65^5F89',124\I4U2J6-Q;#J1_JC5XN9#CI55N4LZ3@Y6/Z99\X4-75_=$RO=A<'* MZS4/'#XNY=`LD.XZ[*.8;OW_D4KZQ78GUQ`7=?L!9=5/ M1.[-L?H5I?&I.QBQ\3![&F5%!=KER/(\0]\CSHK'3N@$?(+Q_@'_\"IZ@AG9 M[SQ0FVSWJC%*KT.=ERR2U,P7HF9B]?1]F(E7F;HS$^;A"+V:I.RA=V_B"EB3 MV[A[>H_P]+D5J5;T:*W4]]/6VVW,2J<);78$2_7ZQ826W!9!IJ\"QY6423.H M6(Z9T.Z*_B+J7Z)6/[A_9A%N*KD#L\$ZF1.04C.D2XD:0R&'E#L&U]`14=U; MN9K.(+?\-66ICG':=\(">#T&_`)]#CTX_*>C.**CD)T__E)=Q1$#!B91GE_M MJ@`N5]D-F8V)GO/3"];A_^2";E'^M!EP#.:GTJ^(V2=/MJ+?2(SXZBMYI(Y^ M#^-I.H,F1>:UWPNE)Y7G(N8I="Z2-X(GW;1R*M:X/^FF-3\!9[1/NLE3J1@3 MP)MN^L94\T7^IIM47,.69;SI)LRZ\&2.@:2*,#[.[!AD80+2&)SF4:53$2>( MHSXF#:LFC^H0D"*!AD!+.1XDS/Q56>1%E&[C=&_"(X&XBDR\N']&"3(S`:VZ M5BRYQ2=NXDB>`-3^',Y,T+C!U2230T3%-"Z5AFX=_8ODW*7DA2TS817?+OV\ ML&66D0FX=FGTPI8FJ:HCNPSEB2W#ME93388-%=$NAT]LZ70'3S)^S27=WL`B MSNBJRWF<;Q*4EQE*#!/Z?@R@74675\DL#&H>HG`7,_J M%*9P%Q?T*':.)VK5A[E).@(>R*'A^D\)&"O@GQ"PL!HZL:]Q25@YKDCLR&N$ M,]X4J(),WA;L#GXN3G%V?NL1R55-?:MCK!JW^Q^.F7>\*3+>NN).R5BE73FUH[A`W7L")_&*D']C&12YG64D5B8=.(6[V)<>&&8@Q$IJR:R2>GD?$9DT:A^1CG(`)[W-]F48(39T4Z=_R=,7A"#BW= M]1<6"EKG8&4U=$_`%>"9>P'Y!O_8(Y>!9%6Y*DDG9AMDP8W):@-RYJK2K:J/ ME&_/("7HJ8E[@BG*GNH`&7D`G"S<7T-<_+28>>7>I+611;MT>:=(T/),J35T M7IV7\`.NR*Y_^(CK6]BK&DK7(WN-M-O0W2PKCF-SK1'%X%N3EO6,&7W7G7:. M!-#@,4XI0-C%H`>48(C,/-TW;71DV32](;$Z$3?FU6D/G7+7&=I`N,U)*]FSV"9L71(T3.KXK:IM!U]=&+>RIWB`U5K.J M91E;LT&7R1'Z!&.VB)*YWRRUQ@P:WYS]]TU-T_.OGIK;/`[1<[CY9H^>OMW" MF'$<_Z-/;?S3K^]37/KGZ_(^B3"[VZ5@F3G'>[L"M8JK MM0/I%?L)L-\`_7'F"ZG2=D':NNQ=Z^R+<3B-R5NC2KH@`(!*@%@&M3!BGWTW;&UFV M2I=1FD0MO[3:E\NVT^"\O*,6+3O56B9BK5'6IV*S MSO@8EJMU:MA_^@SJU.2<%TG?R&V#..?O"D(#EV JTK42HS<3&:W"S7]4B* M);Q[X*A%ZWK46B9R/499G\KUZ(R/<3UJG1K7H_([05R3<,6@@>>Q`;/6\RB5 MF7@>36Y"]SPW,(>X61_6Z99[;(6[._P#)'>$!QL\5JF:S1ZS5(X;/U99<]T$ M,C6FVA`RT[&J!>F^+2<*.%GP"Y.>V0O8X@.-;+W^5I%18G[;R-!:Z"R6NZ=+ MR6T/BQ3:<<&EGWL?%EF:JK^_-+H!8I)>MX!P&IN):4/LYFFF9F*CH:G*_4)EXU]-LTGW(`Z5F*+3E3@4+EG^PT MI"5$M,SKGVC4ZP^=<[>;![@M$WBU(_M7T3TB83>?(->QY[C+)QO6DL_<&9)< MM-0^G8$ZA*!_`V[!O"8KL&/`P"GRI8C9Y=_=5A;%!,R!(T/3![@;R\V^'B=TU0AM!=]!TV<+7CRB#82E'*5,TCEG'R=4JS M;NY*IEKN<<0I5N1GXC`Z4_\`-A[438:,JKA+/*%HRQV)IM#A/^1V)*:S3\`.9>P.>:U@PPK0R&^:(M#7^-+G3C3U>U8,4))R"'OL M$A>%**G*0I3D56G^)0<[4A[<%=`"X=Z=E"B@2"_+0\-@++'<(@RB42VJ&-V8 M6(O*^G&>2UQ3/RI76=W_S977YIW:7L(<[% M%>0+[#"G7-M8[_"O;0U5E?$#N?U%?_G;['5FM]:QE/*8KGT$7YYI!W?!%_\X M:R,+J`:'(5_PI3,<`$:D'-WA7S/(HZ6I?_Y;D*/")2VH!`\9^Q'C8HID-WX, MO5@6X\G0BQ+(@DSHU73T!9K0*^1E]][F"S@+[[]#7]4)'2@OL,\>O>H3>L'^ M[+7=5H72LRA_J`-:5_'J[]`U3@2S#&YO283_^F%L]KC<)HZ2MC8^X$HJ,UD4 M>'>%O>CP#@J]1(UW+Y"?:/).^=!'F7=0O[I[@,VC22S0/`D^7X>DQ[W77]Z< MO'WWWT_>_NT="U"_A?=%$Z4>T_E0VV3O2X!/E54:UJMX@'$&[F'*[/.]ZX[E M((Q8]AZ0/XAQ[XU-]0EB9[W#F/@N>3S&I,4]G[YG#<%3FHR;NT]*C&,LE%)V MY@%KF)R5#=F^1-9Z'Z>84!>/%G-XJ5BK]YX=>?A'E2ST^&?.78^V2#S(U02NWC"=<.QL,[ M.P:2S;:I7-*'QU%EP76K3V5`ZQ"$Z59WGU#G43:R.L6^G33GO_(\&O<+\'7W=OD5HX[%% M&'TA8'LW$=AFN\I\&N5Q?K5;;^BP.T[WURB)-\_L_^_@Y^(4&_^MAUV[1%55 M&29RHI-=QMQ&2,:VY.PR5+&BU2.^5RS9E6)"\A/LHH3E\%KV<)_Y:1[KO?74+;"\VY1C'?J!4$;:^)[NB M/U3/EP81R576&DA3A[VH\UTA+LA\/W582&4Y$[ZR)OK4>3_8QWMH(B,^7@TV M>+FL(UB_%1S&XV+"JD>J.A.]#MQ_VZN;+O380==X=D_CB)#)OSBJEERB/FX@ MD'#;=I2;=#P0(%2LV`X4R*_^`]P]P"PZP+*(-_D)N$@WWX02/4O15LB@=GM[ M9T-!;C-,I"5TM-^6]WF\C:,,#VF$8)<+U%&MA@)NL:JD!ATC4(GT*N)*#<6[ M."<;J=MR4X2%=T5S(7T-]X(X#>2XT$P"'2&.,"[2'Z7S\4A*Q62_8&7T( M!3V,1509\#$RD>C7C5.$R>I1"_-,(1R??'.V*=H?<'W],- MW1MZ[DZPKB'[7%72X+,3+V3&W-@@T"KGP$!XQ7ZI3B:2GTY`7MZ_BCY%VGT+$''`V1OM#R9/6[4 M/6&90G?EU6$SX215^*UJGNXW)Q\G-./FEOHJY9ZD*[FJS]X%,N\4MP!2UER7 M/QV1%O*]E$>_XD3N6:7D:.-Z^Q3G*'M>8\]*N59%.(CV\&I7MT9]@6M[AT[A M!3W^VD.2-WU5[;GK^J@3)&8'F>'1]6Y<>0;F']7%I M_,MX/.3P&`?4G+/I^\!FX%0DAS\O.!+BT5)- MO`A3,LHH1\GYST,2;=C[.>3*/-R4&=WX/V$?&VNU>#OD3DO:A9E1/:K*03D_ M\T6F$'DN.S[Z$I@^^;"DOK_1W&LGYQM'#4B4FJR&(F)-1_"!RB(<8_@ARX"K MMQ/K75UW7%1S@WI7Z^RZ'@!36B3*BZ4-/=3HM'1&)E"W;15%M$CS\]O=QZ^?`(=KQEL4N4[N]@]C@,'7,7/T)&U(K8WSU4B33'LP4BCF>T MY49=#VH+-:M.:PL2K-H?P);,JS&)$)YW1^2&"$A($O`U$9V;0ZK&0R:UW3_2 M/93DSW6+](3.@:NZW6CV\P\EB0U0>K8`02.;KTM0P\0M9XVM'7T9J0XG MV(R(98>`U6+-46")F..!8+5QUV/!4NVJP\&21*OZ"V@_!;)#JVU#9%KA_5/" M8FG^K+!,W]'Q/I@!BO&N$ZMJ0"KFA'>=<3>\*[3+\2Y-M*J_A(=W;1LBTPKO MXETFW>)=KB_T81KKGYKN:GV?%UFTZ;^=HY'B)RP"*?_Z?:CR=+1[H( M2S,OMUM!"HUK\RY%3=*V?#7+WS'VG&QJRLWK'P7=XDA,="68"R%Q"WC1( M6YV]V7)?C)LFZ]KWB,NUN$O-VGM>^4=8G)49N=[>7Z'5"M:+LG)!MW58;08< MEUY5^A6KK?)D*^YG%HJ/;`XF"?I$'_(AH2+?_OWD[Z]?D\$,_NL68Y(AY=UK M^FC0.QJA\AQK8;^RIX3>SKP2JP<",F^SWGJK5)Y;8C7&U_%8M*X;]0/*SE%Y M7^S*I)]/,:U&I*R7I"Q2NJU2V6?1<>'*RJ!B+K+4G)HUW;*BV(6-BZ MF6?X8R"#'!JSMRAFKH!;)QN/U>.1N'X+ZB+%,U%(L]?C@T*BJB21A!/Y%";= M2"96+">32'Y5_PAB^NN\O%"U#C*HSR[.!8(MG@V:^7BX/8>'#&YBNJKS$:4' M%JR&6^*I`*65JRI`+N>$9*UY-SRKU,M1+4^UXC_1<5CTB+(B_H/^,"_2]2V) MC&N]BWJI>(M]8W@<<;X=[]-X%V^BM.A%EB7A.R61D^T2U3-SLT1NTW6KC#G. MX4UM*2;V9BI6G!QH!4$M.?.TWPX,:%Q;]18(C-)RJP:CL'<\%O(/7](5#E&X M9+50L[DB%')<9E89=EU8ENA6+24+DZS:W\'5CJTAA1%F6=-PR*R>^VO#(EE^ M-=@$!S,B_/3YQS3^O83G,-]D,5W0$T1CMDTF8X$LF5]>:#+GF2ER:Q;F$Y"+?`XEP;=*N<@))02#C3)M`01,Y8&9DQJ4D6JI>4,:+ M2S_14O49\,R*2Z-HJ8IDXN';92CA4@U:5,X(6>O+"'$Y#)=J#A27@^Z01"I> MO^D^8,E,TY%[*Q'6>KA5"6>PNW/]K2O71RCHJ5VN6^@9<-T![,Y>Q['1PD]E^ MY`5C>=FL=B#O=W(KRX[G.:[`C,54=Y":G_&2VQQ$Z*2^U-%2-J#C[Z8HD,^$ M-<"138C[R13S8AW49F<9BX9H2+&>L)I?M?`4Y.IE9!)FM3:L:54G57*JBB<: M.J'Z;:YCDQ@C:BI5:;0\DD#JF">T[HLV;Z)M<85$9A@%7PMWAM@.%A%)6>]M&266T"VY7NYL]Z9:V3DQ(-U^;V3KC/DEE MN(TM332@3D#[U]I&E-!#MW,MDY:1((0]ZVZ.+B4;UAHI(>HO_6Q5:TS[Q/RE MT2:U+,UP8'49RNZTKODD>)>ULQ#NE\--:4,\.*Q0.\2@6ZSR4JXK>^*C6.^FY+ZJO`X)6ZWAITR[GB!>*QMQ5WB M<2I753KR.">[*;DH7^"(/N0'#+T+R*-T<7>1O9!AJN'`J>MH0*G`9#`@5C#= M6$"9X0F'`C*[(T<"8G4&`X'30+GO@#*S88`)4DU&`4(]AH,`([!/.`8PH;N3 M#L,1P`2D=\KVM/V_/?7':33K_4-U`&ZX,^[[+=S`*%7F/?_4SN`TB[=[*/%' MNN-KXQ)7]6>9V(GWXS+J1GAKFW*F6ZI:,7F0ROOY`,^JC0030XI:*##I90,Z M/-I=]+_*XGV<1@GY=?U((FOT3[89RPLWF43R'K>;%-GQN?$D-F.Z!25*S3:C M-HW,"4"5%-B2+Q&5"VE72M7RDOTI/5B$.U6"9+(]*P-X^8FGSP[2&4Q9K=(, M(^HKTO@*-:[/EK=8XTI31L'&%1JZT<:KPZ$D:&68>IA;MUB-F*J5#I!N1O\4/TF3R1S)Z%N]JQ>WM7.RYG9U&2X)P]_QQE6906_;/?>@5WZ!1> M8\H^1#G<_AP7#WU-5;6Z:'+R&AZ*X.8XW#(@]QTN>E=58MD[@1L*"W#_##Y5 M2<*Y&NL#D\@C.KI^PT%AZSJ62!;?CV8&2!ORQ&9-G%3WU.:00C._G1D*;V0O M;8;&'(=^]QIB@J7%U8YU_.MT>U46>8&'87&Z_PF1"/-GT2$NHJ3*TOIPR-`3 MI-F]2#<9>?:W1U"O.JN:]Z/3R>-X+99;1^TK*W+?X\?"JE)#7$XU\B<#?-2J M`D]4%_9!5%GED3!)(J:/^2SRO!#52/OV2NG,G;M?E*-)4-9U6UY4MP[LI5#2 M]W!@(>0D0P3?])QYW!`R)65CB260TF7#@>@])0,8/+`YP#2GO%F3<

$AZ= M/KAFZK5X&YW..RO/^,BQ?G9$'B(BVR.,WCS4]14O:]PY&MUML8 M1[+JMN-QW*IQW!PY6F85^RA'RL.*:GEU3]20^5EC"D2M+3))8RZ7R1V8/1`1 M@P!5+VGS#IPX=-@:)8NJS"IX(F9GWI@Y,D_13"SH;?<2C8T_=-/S>FGWMGXJ0)F.;S\ETCH/O+]/IN-Q#HT?\KS[![8_I%F9K#'::43Q]3\HM MV:2OGH>M-^][?FQT^OI.FG5ZMYMI8[/K>#]MA%G%+35K;2N6!""._VFJT:[@Y;X!#W/8N9&>QD9C$: M[C//#N;`NVS$/B?B'3HTUI-^3_:VA6=!I=^KT@^_.[%1:LZM0Q&IE7-H*+UB M/P'Z6R!G(N4M@[2UV87N0*R%IK9YCW=M^`8649Q&>W@.#RB/BQY^9)^KH@X^ M.\%49LP-I0*MC$H;!>EJLHO0OE0+4%V[ M.KC&#W&6%W<8^IL'*/2-C0XW2[#)=RJT*J0:.Z"#24< MKWA)3;K>W!(I5EW(&LH+(LJC&10?7W+T$-!/F[35I4'/%)K"3*\ZM= M=1KS*KN)]P]%M?`#KS/%K=045]LVF,"K=;30Z9=KS1-,ZRXC;3 M&(6K6@`.X#BDX80SX:O7=/:80F[HZ2![@? MST7<8C>U+1-8G>NF:\??([3-U^GV(TKAXR%!SQ!6WC\GCBV/-D7_O:BZU_2C MK>YA';6Y]<9^BN+8U0K`U8YMA@"J`U`E`&L!G!I0ZP& M2O,%6N09.KU1AYM2;H3BEU5'=%66V3U]OBT/AR2&F>#1-S_*!NV>E.@? MZ9ZZ.L>[)S69PG5/EY*W"YWUC'1*EW[>/W3._G%=T:71&XKCM8YU0.$\QNB. MQ]%N1P;MD1[G2A.MG6#R!ZG;?]@/*R(7`*!W0U[O>L8,CJ=[CCI-T MQ3ORD$F1'8^C)ZF551.WHKKPRT)WQ=5WNNQ=B\R\W.T?R./'388<&3N$DJEW M&$V9LB]OH#'=7K* M_/CS>@HSJX]-S*3^UON"/9X!D$>[/&.2C/1Y2;#0S::8I=XD9(H,O$3 MY._$$80(3_59I:EJT"R-D\NPRI:;8S`U):>_F885$P.-'.`%&8?#.!QHAPDT MJLVZ9#1*VE)N%`"/-Q"@5TS/HP(*=MF%W^K+F9UO;K?21&8<+U7V5"KND'4D M5_1/0/X.8N-8W`)(67.]JUJ\"'<-2]5\,Z!/N(LJ^=I'H(]]3HDI3R@TV(GL MRW:0&,0NH:PUAFA4[>/UA`2('+_3)AEJ_*\H+:/L^0WY(AQ7R`6JO`L$G-`F M-^@&.*%>.>8$XJOJ-_#F!)"?`^GE%2V$])7:1>!0K@6AOJ%=XBD$5_"0QYTE9!NJKL^;V>%.?X-`WK]@P768QJ M+EG+'MA2"+5/9XF$7!_%4AAV?NY*K%OYD)4HB>#J5!C(U+0;,JOFP0M1`MG. MVT\&,)@CCFN]5,$65G^&9+T";M=/,(OVL'-_0[I-,[E%U_BM%A;G"3UF7R4S MQ6VURN@$L<8L[*_JKR!BG^NMHCJB6'U-+,"K8_$>*'4A#N:(AW[*^QS^7N(LOW_"_R>\#*L0J0=R(A$WIZDPZCA4 M$FM6."-1@E7[*Z`_!W('5-56R*1R>T032'+,,&CV^:",[8DN3*JE)("NI;QB MNF?:+ZQ;Y>;(KM,,P4T^!;$/I&L^*<;%[2R!>24L1[H$#[."77S_3BE$1,3X-+3 M+2V-<:_POS2[8R5+)!C27`9S.4K7B#+HRYI;C/Q+P.=B?C$>L>H5YS7FHTQSA+P^(84WU^3W^=>&50UE0S5H@85(YI*2M$L;'67 M38NN^OH\9?7$+CWF*KXAHD\G>XU>#& MUX>AV>EH[A9'$.><7:`FH^,(O(K9:J)(2N8@,>]]97I^]--7N7KXSW4$F'N! M>";42Q=P9\:]OSXNY]Z/9WT;7=&]AAG-B69@UETBYE3=%EG\FWC3?(P*KP,[ MFTS['?@96C8?&!HI%/1VG0L_7!?';SO3]@^KM[/#FW3T.0*UDM&IB2;YZ#5, MZ$_/.(=1X?=9M(%O+]+--\)[-++/5>D& MGYVH(#/F!GR!5CG,!\(K^@MX>T+"!GP3R"T9::L@755V4=F7:C&H:]@C!O5! M>7&UNR%#@+(/&^&W.N!.YYM;^!R1&<=@.#V5BM`V'A;E#Q_B%'M5\NKXIHB?:'B87LOK!:MR*`2= M0*?/@!L"E?KE<%0D6^%O[.W*7?T51,WG?\R+5(/V1.95W\6P7+X%M#E,'-!] M#N^+\SBG3PV?9O%V#QM[Q'@]L.CAS3)557;35$XDL,R:&R/,C?&G_'6S:Y2`N( MP5V\_TRNN4+2`_4PKI"H*D4DX40HA4DW!RY6+*>)2!Y/7PL(#M$SN?IX`N)* MA`R!4+:=>[%:U5K(H'Z[.!<(MK@V:':G%9@"7K-*KA>WKV%&`HE&>WBU^Q!M MX$]1,ECJLTW6K,X8)G-+0Z-$.D]=F1M_(G(@:CH MGB&HM,T]?+&%#1K;IOTE(;/4_`)12$CU/JXY)F;I",<:M7,/=29'JG30[B0KX?K>#9.V5R[%@/=0Z+;3G*.ION*Z0V M)M4+4N::>FQ.T6-,3OK`6I0;K)$K+A69:RBNV(U&L?S'/^Y M@0<6L">_VA&\Y)6'4AP`TB41'`&2)O%V"$B7*7_'@!26S`X"217TN]]*"N.+ M!@`_9'&ZB0^8PN1L7@6N<`X#:6$A/`YD"*:*ER8IQ4>"3!'H,$>[2)]P@Z#L MNKQ/XLT-V9PBC]]\B+-'X2DA8_EF84$G[[C,8)@=UT4'O1G5$H0N]:H6H>?I MF!QH!`&1#.0\DGG[(^LVZB]<:)+QRQB6(',@S&6,N\*<;.O7081_CHN',W*# M[![A,0GI+J.L2&$FY,_8Y%7=6"=W8M?8S+J1;815.?>LE:V:%*!)`C[A-*"3 M"%2I`J'E:%@AU[;NDM962\MA5V2[/+!1)JK7-<1?ZZE_=WM40FW)\5&.@ M5/&B1D]V17X([$4#67L@32WV7M'H"G%/:*@;U.-K!J_N'N)L2Q[:W#S`[@U! MHX<.C--+WD#0I_?Z/()Q=OV^G&!BUOQ1!;TVP7L+KP!-!0J63/1<;AC4&H\P MZ6L-MB"MZ&FM1O[&@S7,'2A^6N(>#.;Y&1Y]EDF!>[/Z/5WU&R;&Z5Z_?M.K M,*ND3H0>DTDW+EM:E-/82M&JE@:M>`W(G!L4AL'94=!!+FW:9:J-AI:D+J@] MYM9"%C_1H><=S!Y)K)H4^_!-_WB%3JS9,)"(.>X-J(V[;@-(M:M6_"6)5I7[ MK7J]$Y#$N\'-P?K2[PYE)_2.04*HV#P6PEYG9F%;RHQ.]&=?^=XR]?BPH MF%@5+K!$'H#2NU-GKXB[>;<`?O@^G1(`4\B9E2FY,O/IEKD((COS,C=%?'6^ MXNY5WIT*0F6I>E9Y$#BMN'^?X#TDH8$52XYW0@V:TUDZTLVI/LE;>"$$)31& MC9K$VF"#NE0:R19F3J+LH#0_?>Y\$;W_Z:*C M/C$P2H?;J0&7;#N>'!AI6G%Z8)3&59T,7.U`]9D>-WL&?%)P^MS[&L9;IDZX M0UYPT#M+,$85=Y[`!PF.YSO,,BEX8M4^857-%@F=7(-]!MW\@94]N1.P4+.R M8GL`[[J.P`P:WYQ=6ING;[D\'JKS$%CX.*Q<0$!('\_!R@WZ(YC!`[`"\1YA MPGCQ5=$^0O"KWG@=RHG!//>KKA)BF7$W!-8N7YK M7V_DW,/QYERFM(Y=*JLFAV]W+\W&)`2Q[`2&*54D":YOD#>QCBBF/<8@B98L M@?8CEY)7PDW%U:2Y]/-JN&EF)J'.I=$KXMK$*@)=AO*LN'&KZW@DPXF:2I?# MY\9M@>6P\7>UV\4;F*WQ?Y(8&Q7>)U`+5:64"#EQ0&W8#?E2W7*\2Y*LJM_I M;>OF8R`'^C5MA\RJNHMDL6R+7S,HN%R,Z8;"%5^"4^O M2%0K+JH(4ZS8SZ#Y/1"HJEL,&=5P[S:)2)2[-F+2_+./5M:/)/IS?K7C?C.< M!2M2:F;%HI23S)(569QFUBPV:#^+%NEIQCL'.MXIVD_L?-0P/'J00Q\E;K33 M;CWH---P@0+]M-P`L+,S^1S_:#A)YR0U4W0B.9M*]V?CX$@V9V3BI`.S<7`,?E!"$?9^,GF&Y1EM\A>F:1'G^X MP-,76)(CC<+1VMCD]6E!V^1N)YM&9M;Q9*"]5<79)5MEJU[XFBH-@1E-!=A! M&Q"ZD(O&F*O?OQ5S22%24TPBRGJ/ MNZ0]'D2*'EU0)V6=U=6.OFN(LB961[JM7H[(KS/X%*,R3YXOTDV993)S]=/I>*HZU3&U^U%@!Y;*;G^8[)1'+FS5(717V\V&?[%:B3'):\+8C4T$Z6?T'4JLCOEX$EL=JQ+$VDS M\E#L3F']X$G$FCMDWZ1"EZ&ST0/4R'<(U)@Z@_DA?MSN?G*PFW;(0K@'W1=/ M@_=QO>6TB/?7GWV$1?^Y;G'/)1`4=U&\H$^B"C+@M=/IZC*\Q M\?!@Z?Y#/#CQZ4&(UZ`R88UR%NDU#,=8B_8;[K%[\W[(8$&@*1*\O^>(1J:N M6L(VM9.W')E5MY&3O5&Y/[/550=2;1YOPK@\5&DD4=Y.0(%3AO1HQ5B`(<=F M[_H*2R6M!P@9X;Y[^1FQSH4-MD;[S%WLL0$NZP[G@OCQ[LY\GZ$\O\[0+NX_ MX2+X4E4._\6)FP(3;CU+5Z&<2;S(CB+=@UU\4W1(2N\\_]5)I1"R.[ MAN@_FZ9*PS^>-A>`+)T?S'(H=WZ3X8BX2'*E`ARB9Q+2]`2[2B&NJCW\Z!%E M!8V$C6?:&<@@B21$A,A@\"7!3N:%O0*/K[!+_"_\8_T3_K][/`[$O_S_4$L# M!!0````(`(E\;D/Z(K?I?3,``#(Q`P`5`!P`<6AO:2TR,#$S,#DS,%]P&UL550)``-"-(520C2%4G5X"P`!!"4.```$.0$``.U]67,?;V+:T5!M&?/]$_'KP$S4A34?+32Q+\_.8I33<_O7__]>O7=U\_ MOL/QX_L/1T?'[__GU\6=_X36WML@(C0C'[V9D?(_)?F/"^Q[:UL5>TM_>GO\X>W'XWZ*"$4"$C78A/MS6:%_F(UK7_>L(AM5/RSL?K]_3K^S/L M9VL4I?-H>1ZE0;J]C%8X7N=:(RSDY-+M!OW\)@G6FQ!5OSW%:/7S&T(P(!HY M_GCT^>,1U<>_"^F]U^/Q%$=+%"5H2?Z1X#!84D2=>"$5^^X)H331X11`=31^ M;[R8Z.@)I8'OA>,PWV["I"1W*?F3VCBY7EUO:/\FMC5G`@[YL22X2['_)ZU' M?-+Y7QE!["B2,)H92Z)3+WFZ"/'7<4RRHSXZ_^/T$D!3FI)=QX]>%/Q+VW>V MZFMK=[T.TEP\XH*)W"GY3L;G`&G"@4].D\-;%%(S$(VGV_O8BQ+/UW8@7%J: MO-UE#PGZ*R/BGC]3F75XZM'0Y25XC((5P2,93'T?9[GJ;PB*J?*KO[48!!$> M@^LK+Z;N_!F=H=0+0O/<]QHPWXM,R*!"WG`O,\$^F+:A7F@$-C*:$%Z[L^_/ M!;\1>J3Z6'@/"#!,L6B%<=PB15<9G^DJX_A3SGVK!4VMDMX29W0H7&_(F*@] M2+'(F..(KN6668BN5XR/`\ROVY0YR>Z]AU#/7_.):7)W29;K:W3OO>CQTZP^ MG`-]O?2)&)BWF?`U0GJ:/-[$F*R%TBU=5Y/EPX8.'CJ\,>D8Y(FB%$?%[)KU M?8!:AS1G4$(3"`'1-9*@-!EK#BYH2ETR/4FGQ;/R>SXF10: MHO!A+1J3;3,S;!,.&8(V>%S'A.G\@Z<_Z,8N\1$>>=K0N/8E2V M01R8TT.V7GOQMMR:+SUGPZV:%1G8F*9T)RA"JR"]"3V]?=16?0,\F.@30GHC MH>!WVDXT;&ZDV$13DDV,$C*_SKO#@OS0:AZ]I"A:HF7%`!5(^30B2&FEHZ.C M'V=O9V=!XH9[L]V$;U;/L7,1*B%"[+?X#ND9 M/(Z9FV#Y!MC*2Q[R7;`L>?OH>9OW5)_O49@FU2^YAM\>'9>'[O]>_OQ'D^?= M$0_U)='RIJ'+Z]5%$'F1'WCA[O1G_I"DL>?7J^B0;J[]_,8HS5+?9FB^MZ7F M*R\E&&$=]I8ZXQ;_$#OK?\4 MA'6/6<5X;=K`&"!]4[B?9D;:GZ5XQFHW2TA[.!]>Z)'I)@YP3%P0Z?)O9C@F M/JFXL5,ZG?=,KS.60Q*OTVV!N\\*QS'("Y;F%A2TUH7%^P[$DB>D\3\[$JM5 M*J4'5K+6_0%FQ)JBM_LYOR':>:$-E)WV@Y.=MK=K5TTOCK\W.+V8?5?]ZV^O M7F)4*5O#4<[6EN<;($5+285%'?<#"F*J]'XQ6<`@_O?:'UB`R2(@ZYHEW5^L M>S@/)L*BCML>(J:&[<5D`;;_;-/V7Q(RXSQ/TF!-IJ3==4#GH^/V98NB8=$N M(<@D_,BF$6_1,XHR=(M\3$9>N;,'ER^5)R_O.#14!59!"X`V!$`?;0+H[HDH MN+>#6VQKDF7L9>03;03/*-^\*\3KKBTT*#@.F@%*T5E`Z+0&`=:/-H%U[L41 M78#6"&,&!FZ MU:O]2M7JCB-MH#I4H*?>%`2+5D<[XF6#)+\FVI1;@D"U2J6B@94<1YN6Z"H8 M@S8`0-8G6QMKK'O4UD;=]2;$6X3*B_V+P'L(0C(U19.!B,&F%-=V/7I< M4;>DS8W+IW;\Z(-7;S4U;]4+>6EPG!N5>Q*H7+$Z#817G+`;TE:/*<^CPL#$ MG(WPZI?9H\[^!7%K';5_'Q2GB./*8(6K#BDN;,\U,?F23YV4ZPGUX-3T"&A7 MK*^$MOL1MY>[&7@[+GL9;BR"6^`_Z.Y>#UCL?>S\UV2>I4\$-O]"RR_$OG'C M[G2^JWVR/7]!L1\DZ"8.?'3K18^`&;RR*R;.:T.:_@X M>SNK;TN3?]<$9TV*LY+DK*`Y^ZY%U=XMPYKSQMWO&YSDEP0XLP'"S1\T"`54 MU>+%PCI$E:CZ.LZY7?[FA1FJCB@Y`@5X=R_3=20HCM:RHW: MJW$(QNRK`7+&Z981&\&)4"LVJQR.&5N*`-CQ>[?L>)DD6:\C2DK5%[?9I29G M6YBXW9F7O(WB*C>'-F36;Q4J\S#$7^DTB$P4SW#VD*ZR\)I,@N);Y*/@.=\2 M*3>>N^>5ZC6K,TJ%FI.#F;Y:]*"GU%X)N1]L3>U!B:;K>?PQC1\J:S3_22.' MBNJS9GWU+M0/W*:__"'B4C(#!U4=V-D3Y+][Q,_OER@H^CGY1[=[DY_^*!BX M18\!;9?FEEKS)MC,HM:[GHH=FJ,W6W"`*S;@B=6,O1 M;7FZ92=NGI[H>UKB0`U427=/R$HZ>UYDLN9H"[JG-8JJ%?@*`%CJA[T/_;^C,/RO"'^-[I"7X`@M\R5C+)P"\.I,UF82 M54"N;N_=<+_A,"/:C;<708CB;O1K6[)NV8D;JB%VVI7^D`L MU1`?8J=][DX44MUD#V'@7X38Z\67\+Y7H2.][Y.SF4S$]J$&A'H>NMZG"O*H MU@XV("^NU7G1CKMYT1JU\\.-=GV;I\@(_^U;WV8[?7[JK,RCK6K@QVF)==$^05MW?YN,.1 MK*OQRUOO53);-#N00&R7^TKSC0=;B#E##ZET%!(7*KLVIY"UOM#FA]<3)*68 MLCG02R06P5#!.M-*)E4ZD>12LWW)7?0JB1O(.Z0^1;5=961@WV83E*C203%* M.-R/Y`)!^Q"34N,F&1F8PW:7B:9H?#ZYS@REX5`G"(C+B'"!DO3\A0;](:J/#A8$)4J5LDHX M#!2Y0%",,"GU4FM9&M`N(\)HONE4L7GKI:@(LKE!,4V0Z3UV.[YZQ<;`!ZSH M,#2TQ5>9ED$;:`3'[M6Q<"X'-R9N])H"O7F]X_9Z=>'Y*(_=8LPO5*HU)AV@ M:@ZC25-TE>D)C'SO&0VG7-+Y:H7\/%FONE<2U)4Z)E9=A]$T1`G#W1.S#1=2 M\K=9_I6^"D5?%^A?`)079"*F57`R\!"(IX>%-L'JFJ=-PS!%*Y] MA;"PP\!0$A/N,\1$&^_W#)W2[GG;LLQ*>./%Z?8^]J*$2$Q3C5C;L^0QQ-F] MA!:OWS"1%+?X>@N;,_G)@49-B3:<.F$`6Q@/447;$\C:+%Y\46C+]ND$CUEG MCBKR[%KSEZ![)Z[W>P7=^G=[/9:R\"M:/_2"/!A?FFR77^SUJ)Y.L8CG3M>H M*N=]H%FIAW$+-ODUB()UMF9:A?FME+']S:YE.@QB,><,ZQ3EJ'TZ%9VPD/?" MMQ#K6V6AUC?G+"3@7&RA=D47=K2^U1G8+N<>C\>3;>L+8R4^B$8O>:(*C4G, MSTRH1WVFIMFJ"]X2QC!KWJ1<4=(_&17M9>T,YIY_5J%?@HGI._ MPH`TR9R'B0N5XG(*.6'5CGTP4"2^!0N"U%(\0JYUTP;FX,,#?#PXS`%@[QZ_ MY>)=G/5+O3VWK!@_CHX!(JF:Y?6*9Z MSY)9QC53]L<`B&P@(^Y&`PY)KODFY2,Y6Z^F/.*.O`O'[ASN%T&$+E.T!@Z@ MO>)B+[@K/F&8J&EBW/&TT6HO-:H[H&+;M'A>G6?-U_L;H]:KQ&W#*+J@IF<*S:DX900!5&$,4NZW>NS_.O;32TM@S(E]>'58P+-D\2)`WZ[A2R'R>M^31#5]C]I'4>:IQ3X3O$ M;=FZ9:V;BHVOOE%Z0KK_:HV7/-'4%>0O^K#6LQ?2NYOS]-2+XRWQE:Q(CCK[ M!:BN(\;CX*^5S0.F"^I6DC=%GF:8M4KPSCU0OOQUAM$9L3THRNY+>XO` M>PC"(`T0S9;8?]-9LC<`KFX=`KH[.W`%[2E+NA%;PW9^!!6LVU,5N!R;ZNT. MV9UW^7Z^;2_,'%9[/G9AE\P'F9QQ1-Y7BO1!QHHS,D?LBDJPAYR:G70---5-'T!.='@&[:D96R@\Q.HF7N#1M]WY>A/B+4+E<;:T MEX++5R\?2,M/Q-ZJ@K=7-/PV\E<0Y+1!#M[J4OC@4J^JX4,U#:L8$:)4K,Q!(>FW>+63>9FI'Z8H).Q.TNC9;+ MH&#OQ@N6E]&IMPG(_+`A"F^-)*\X,?-!5`$QJ-VU;E]FL*NP!W-,7I.4Y`2"6ER[57@!^G< M][-UEB\+SK*8+"V[-7IG3*8(UN=0@PE.!)'&5=<):>$R49QL#6^\'K)4]C(/E[B89H.D]MISF+@J(\=%V9C+IHIVXLRL<^<)CH6%$H'LL M;"*O>T[[]T@#[3UX'TJO?7-[5#K)_1T8IDOW<^>%7LR%J;A0:0Y.H0D#$B2V M*13R&H/LFCAP9OF;Y^JR_?)->K MZPV*\Z8887S?P\+X=N1F>#7;$70BH.\R(KI`-8N276->:8NQO<\HRA#-&_]+ M[$7<"[[]1R.]^A$'GG6/N/D.[E'4;P8#7-%5/4(AME%8@_.-%6SWS M"D>X[9'$9I94FJ#596J`@,!NLA!5&QZ4^09:;JI1)KO9`]UB+`(M,J*"W5[U M"5KA&!7E[KT7E/P:1+G\E9LC"FY3*>YA_(K2)TR^/),B^1:X<&-Y/QQ,$)=[ M-1`$Z9\FC72BH%+K)V01NPK$QQW]TI-%$$-PB+7M+M.O4"I=RK7+3-`^'2'! MT6T3[(._H^#QB3VBJXPF<+]>W3T1M5YG:9)Z$3VE/?&2P*<;A$&8 MI;L3W8[A-8E-$"&Z:G,_M.+VC$\%WGPTPR]]/@F12R'1/09YL&)Q&[#W@`X,7WI-Z9<%03>;RQWE'8DKIHJ^-#E7'/$DUD/!4('Z!VA#= MWJO40^G:ZRGCXA^/I_Q.IQI%CO9+V8/Y=SY2(^>5M,)X'97YK8K+:'USX-DV M4TC#8KEY[[8-;#Z/U6@WZSIR]"7>"1HM:?[X*V^-F`^LCMD$=!JDTX2U[L!& M+F3.,UR3G9S&34Y`$QPM#ISO)+M5&_.=6>[WYCJH]=W=:<,0"&&Y*A0'?PUN MG+ATN.O!F<1QC4\XM3#!*_.KS3-+1>*<[[Q M=FU*^NZZ>CATS>ZWM!5O=E6X:#YW.@+/P*F*XL[U!A$Z-#HZ3FVGNYQ:__KC MPVL/XZOFL/K8<>LA=*T^=A[9OL\]5&%%G/IE=)/+DY^=&>YCK!9>^YA,^0[W M,2;7SL_TZ!KN,DFR*G=01Y8/9,7? MN>A;.9J;./![)\][:O6U/^D8R>$^!I8$DHKC=2?!T7[[NNN@KK!OH>\>MW/$ M'>H6!?FC$I>*UU1K?'7WCC` M9"YW2$6!(/FS)MTG&8OP??9*U>9?^^4@L[G<,Y5%@N0_<[IOPEP5O4\SRN$U ME[ZA:)X^_6^E]PY4O(N+40;/D.R[[WZ8Y"NKYI2UQ\TBQ5;-]_+7D7LL(SGN M$0:/TTK/K?$8Y]"PV&Y+)UG/%GDB@QT M/3(N6+)&86]WI>ND^]LO'<^\<"#(5^Z.>6*`?7"#@!,GCJ*+\\7O%SBN7D54 M"8+@5F[.)^&5[8."O8$X1`4)3CB_[R!V'7)S)=KPIFR<*^<2OS M-TS?#SGU-D'JA;FD]WB^V<3X&>6][3+R8^3U7E0Q2K.TA1F:CH)T#(5!P&NH MW49HF+M;ZKP]K2K]_'RY#(J]T&(@F6?I$XZ#?_7C',=O:>C)):`E1WO"_I0+ MV;Z6`N="MH9])(6W%(G>G9"T*ZVB8S MT/R:_DA]BM>,X:[5:^;`>YA$K?OL:'U6&A&3T^LF_?"SRR@E:[7[[1S:#U%4;&C=A4Y+^RQR7ZDTX-LOC-J0\W.,TY# M+O>>?:@6W'U&8H;=?S3/"#C;8`:[?_[T%4>:\4862*OFQQEAJR[WF[TK?<]C MD)BS1O#0P2R/0%T+U!.F!5QC..,Y6KO/,)ZO-R'>(E0>H;!9O\+YL\^HN*"8 MW-.'R9K?Z6-U5SC]7Y3>(A\_1G3/H)D"K7NM9I]M5M=T]M*FH\BVH7!(1]D3 M7YQ^9_?ZV5BB%^>C%S@N?Z+ENJL&.XV/W1/9C7]K71)B`JM]D\,@IY,ZDIW_ M%XR7"9GT$8%16S')/9D^)IY/&2^W\XI#7"HB/??U(D&@IB&ZO?G64+J.]IJQ M%*";[#J MQ@"XJ/$*X7:?'`^])+E>_4ZC:J/T.KZE0<:MV.+Z8U)^[2Y5AI"HKH[KD'`4 MGP;4`4&B7C.<&83F&9KICAG;947@[M,Z]!P..Z@;&X9\SWEH-+FH$K17KKX9DW:F=J*BC"(:(IS+/ M$I+C7:#]WN!TJCU`W>.;+/:?"'Q+=E8-#BGJ.B;4K%UJ2+6VHY@8I@0(3)1; MJ%S!]S8#^ZL$&HPX?M:G*@ZF^9!^K494\PK+[.=$NGTHP18_>[@R;I,0TT1Z,> M/[[#KBF8CHCQI92X^<6:H?KFP"*>VU:J*]<&2?(+E&IB%)@, MDCCVQP"QAZ&CW3!%!ZO!42Q^AWP<+44F%Y2H/`VCQ`$872ZX::LS6QPV!>.: M/6=G_ABC?$SF6%Y4J#8^L]!!V!\@OGD(L!MU(?-O>:S!Q`KS6_O!X@\O\4CJ.;[*',/!O49ASGY!!B+TN!I6IJEIC[=YRO M75O9WF%CVP3+^&<\"E41:5EKU!VJ__2BS(NWQ_0+TXOS"Y1B,`K8MT3?L4KE MX)ACYPI9%$:QR7P3!R'?(KS/5;?H?G;1&A(9I+;HUQ]E6^<_LU#4-=A?JW[1 M^>JB&<02R'M$MWIO-6W]1VFLTOBXC4WAL;9]JEOY M\;>1F7/^O4VS4@LO@QAO01AF-JP%>_UJ/[V%&WAFTC"=SCBJ9/Q0M($2'7`/ M[HNL\*JTD1:&]V!N"P[L^YGO5\.Z+=`:D(>#!XDSL*_RQ1BOK_(B5IJL'!U] M.CKZD1VE(BM71:9PRTT1SE*\8;AFC(&2QU0>"\-GQC*TCG\X.OX,@!:C'!-: MS7+?!K3XFK$`K18S`&B9W<%J\7)\="3'5:\0"U2[0M\$HG@ZV3^<&IP`L.1( M?C<#ZECP'ML=M9$QYJR[1EX7GF;,,Z&UIU"H\08'%SLT_HKB4@/K`/9TE=FF M1NG0UWN!*^1;A_K@[=ZSB@8HM>R07I`5[+:KJL_2JJ5>4$/081 MU=J)%])7-6`OH]IES8K_DK#VZL1L0.`P/9E,!0!W9C7EW"BST<8[H7MSL["Q(_Q$D6(_*?Z_C1BX)_Y,^`M$-?$TK2LPP5;_=V(*56J50GL)+C M0-,2705)T`8`4+'Z+M--C'V$E@G%?BX3CGN/L@B*5*]^L(HX#A&`6"J`8).# M>`JS=^9+8#ZC*$-WV4,>G<[V"\PB;2_0+N*X00%B:?3P#CF(0:U>1B2>B#YC M$NXQ?K+M/@_#@T._)`\3 MC9+6@"$Q.0L47`';R&!39J*B2='U>-F^6*1%9MPKH"376^Q*NH,,AMV9/H,G MI00>._)LS]$@ZSI&JI1W/2'8.0UAI:LM2DEI=_#"``)6E5;F4NHF\BTW&6G7 M<=-CO+>9RG,M_5U7CF=9V(\4TAAR>.)ICSB+Z43(]'@GRV/Z@_?8.TF!%.4! MHUG4'6@P3Q,4Q)0`9-%^.%A$UG7?<4966R'>T.2<=Y3E\RA%,>$R06=H12;F M=*\]6V>AEZ+E61;G:PM(4!@HZOGXRK3&6M9:)QUT&>[RLDNZU# MUN8,XW-S8Z;YV7$X2<11WI!ID8)MQIC,05\^6U?=FBB.0EL/;9]Z88B6)]LJ M!W3'O'("]_@$50]Y+VF"\RZE]L.`6I0=#ZG1L";J`D>/-!JU M6I#NV&;=^`"6KAZ[DY2VAF@]&S6PKZ:'[M:[0J/Y@W6RQD`72:VN"ODBG&Q/ MO10]8OJ("#U_J#=&&/.D@52DJ!13L896*-B$N%314!NODN;%")4TZ_HN.U\P MCEC,ZR\#J4AQ*Z;B(&YA8!3B645S4#P+V1+C7,+.WG->5Q=`ZIWM'QWSY'"2$5PDZ9,6JV"I>L2FC`RB[ M,73PV]M[4O.3+`DBE"0T&B4+Z>RT>LNV9HX)%W"]HZ/NY12EJE.&U0`=&8.: M&@_#\A!Q(%:$[N9'\4PH<;^7NNA_GS(H9-(:LSRC(6Y>%B=4V%O@\+;*E9LNM+$4\_C.* MDSPJ>1YM&PF?RB1.>1*&OM!?-CBB=T+#K*A;367O+@(B^DV,_XG\]!9M<-S= M#9TL_]6!\^3X=[`'][LEGJ)F]7S*HGFQ>H)"CY>C4M?ES5?DUYV&2F7\2A#Z ME/_RR;K.U%S@5.2!ND3GY3D8%^F\IO?A,MU7@NMY,?F68.88@A:7+CML9QM2 M[(Z*E5=.ZV[ZJF7/'6`8X!2J=LA ME*8"-W/:TD+BH.:5DN[M#Z15H$6]-49#,8J+]5I0!=!3`JR(WF'!%JZY$<$K M9,+Y%#V";:Q@S4[EIE)%?H=K5V4JV-20W_`HWFQGO,3(O&/??`IQ_;5,MEKW MBGDX1$5%\=V14A?RY=K--%?%8TU M7RZ#PLUWLUYWT3U^2\+W("GXE$GC)JYPA-:;$&\1 MJH:9>](Q$L^GXI9XWVQB_)P/154D--??&J+;\ZY#Z4X%BV-IM=RYV>QGEUUZ:O`$DJCQI.B2F`E\#^M%"JEZ[O,'[ M[Q9!FF<8R`/LJ=@TX4W$"H^4%:LSI'&*30500#FU0,.G76U,_F#T!*@$8+&N MN\?U=BDS;U7R%**D?KBGN'$*3W35=5LE.04.NEY+@\)4,#9<.WH^2Z?9"IEF M[PJU6&!CCX^UNS0._BR<+`1VC.(BC#6+3QI0?+G-H:?5QLZ)F8UYJA;#U7BZ M6PXW9GR"/E-'10TE5,=-:1.:"J",Z4IO@WQ`ZQ4(/]E*DM1\RZV7%I?D#8JR$&\QOI9#M;]9<@EG[8;',;3]@I&GJ*3I-[B<1 M.A0?"_3HA3F'6U92#/;7ZOB^\]4:2MA&Q3+^V_9N$M&5&J@I*5/E*&27L M=L.NZ3!$#$9/W.XB2YGU7;?N7?:0!,O`BXE+X:3'X!6H$V/T"CAG6JD08LNR MJN\])<$O9*!&'RXC_QW33KS/NVSW[<_.V4@B@-A"_8S(CIN34HK3GT<;W#Q4,P9F5E?KUH_<8P/J]0! M@J22Y3XMM#W6%)W5[UD--:$C:T!I4-Y[8FA2.LHOO%2+.;HW6*W8KE=T\_`B MQ%_[>:&//LW>SNJB>5KHDM:L26Q7))GA5;X9.#Z:._`H"DXQ$\?V5P] MS9?_S)(BC^T]OD4^COP@1"TI[K$9+S!*4P<"FW',`)ELVD7?&L=IN?5[O3I# M#RE-GDRC'6YBM`ZR[ELCM;JD]:SC8LR.U4*.7(60Y!^:,.`=T_I^C&A[..?H M%"=IXD7+$Q3E3_=YX2YB_P)Y:19W3TQJZ=0)?3N6UU`R)(F!58_`OB[/FS:S M"W\S".`I"Q*3:+;#4P#*@KXJKMEEOQFC<50%";:WVS/9T6*_>6&&H*97H_'- M0$)1M0"H_+CW=2/',=Q4+#1DE.-$5NN;0894?0`L?)[H'D*NNGSV@N,SG#VD MJRRL8J&YN!%4^89`(U(<:$MBHI"IG\IT#O3TJI; M[ERKU3UX(`Y19>>=S!$XI>Z8XVL1XF?F,E9.T M7!VYPRMW\."%JF@_0!5P4^W@604>$2]&9`5ZAHJ_FP(E">+>%ZZL":]O'7AF M=GH5%`89J>V>'C"$29]03/"/@F=Z'8(W40-4M&YO96A+S-S3#"@YV51G8CWY MR5)FXP7+LU*2\Q>Z887(R)LKIM`H&"T@8H>&()@&(:CZZ)K7J-2R"+R'((2< M)BH2L8Z%T4K,9,OA339`("[4]6;Z;W)3LOLY?8U,!M+PJ%\:"J@<% M7K"*S$-6U#0(J!^G.!-=9(>#4"]V$SF7TC!(3 MMTM%A*Q#R=#M4J&R(."9[-E0D2@QN<=S_Z\LB!'1#.E`Z?8F]**4S!C.R:\; M6H1W4@0G8!TL^CVE=2JDH#+0Q4$5Z'PNH!.AQWQX=-+SE-'EPSV/B)!U,!GR M/$)E0>!C]^)I]>+%!=$-?5:(DRN]<:+*+F[=G/I8[IP8<]0!,:7=W:1;M"D] MV_4*8$IN\0,Q)5\=$%-^/UFGWH3P[G2W?7^F2"A"?D`T81`C*Q2K/R@0.Q`( MZ:H2`C"[MXO9DO&SA(DUXD0NKWV8OJ4@B)5U;Q>;MW+.=)%#L$XIV,W7SQ*> M7>\`K/9".@TN[M)WM^PYX%$B<2#P45,;`$`?M:X/ M.PN@.5%R'&^)/O.`#"7D=.L>-&1ZBH)@Y5@#*YOBG:K4B]-#1\P?'[XIS!!Q M0:C1N197H.8\LKU3D;\RGF_!>F&U!7L>"K/KUINWD*K6\:*ZQ0Q3"`06MJ\R M%2_;WW@!;XG9*F+?4`I(;-]":PH*,8SNM@\GJO`*YT]4RQ<%\H+EE1!!0?MF M`O8GL+#M^R\B\O2VBXAL;5^S:?Z;:2Q.XF#YB.K6RY$H7^/V@EN4:M6A+K!: MUF``,"O6%;Z-!'Y+12@*L`47LL)62"8B^>2?N[/R:,D0CXH5XB2+$6<`-D6N M\=;(('*3\4F&%:?FN88WSGZCZ^,/9I_T+OM=N>'[W,CI_\9_H2Z$7.+Y' M_E.$0_RX9:TJ!M%H#X**-*QAT1BVL!GUM<$YE+O&T*O*%61&YDA^B%+":O`H M[\_>X_9I8Q6<"T\@99QNE0=^.,%#ZB_&]3M:'S+!*221FEO]JG%R2QS%"M', MN,*!@UF2.3RT2QX2J`&J&-O5=]J&)(>:YD7>72\K4S&PWD\2%ZKFU.Q"!P%, MD`+,8Y+7K!.9:WO,G6R_1,%?&3I#B1\'>6=AO+2D6HV'+EXU>W@38X2%(ICH M'5PQFV&BA4O>B0V"+K=7WAHQ'WD"E.2!I%'2'5S(K,Y""E=D"3@X;3'ATFQC M&$(X]N+`J-%.L4G8YH@)':4Z]2P'4L=UB.A(K@0+8`.-?2-WYL(+ MSKMO\H*\F?#"_KMO&@LDGGC:2Z(&07.OO1DT?''&4#NO8YG]>>5Y,.B5=P<- M?5NS$"$16`*,1?.M-P!M)Q?*S7,H($`ZA<7HJ`I/$QIL40W@HB;L@N,H'ARI M^&3MV0I*-"[>=$L5NQ\J*,?'@PD:LFHU[H`!NP8):Z2-C],W79BZ"QN*8O0G# M7*L.H%`?8*M3<`0N[$7L<)6(P-->SVJU-0J4RFR0U2UT/30-(U)J3Y.(TY@R MHA@XK'2;&V4G5HCQDZ$^2D@`XJ+8!)Q&TV"%&')0G*9&V8B501H"I$$T@-YI M@G`RH19SODD,*LTM70ZHBH@+#L9E)T1ZE4M]*59V&C^#%`$'CFHSU=.K>W)# M,KAHU)2ZG(D!15\%)MP+'R)F`T_84ZQBI[&)W@ZG"A<:%&D)[S9`:3D-+)-J M@D-M8*OU9/N'L:\]#,'>,%*BRQ`'A#PC2E(%GFZC]4S*).YZ!_/]T1J"N:%D M>+?VA:04<^-[8?_>A=+1!T\JC<..A5MW M+=K,7Z16E`9O-G64QD*E)%,A&F4J4_(>97.0@(:BAG MC!A/"!-L>.WV*__QOF<(XC/_++XQ/[6,A%Y2%"UW4=8M,Q'LA4O"4?+.Q^LB MTC07QFA=_Y,DY5=T>A](B6-/ M6HYO:=MW]F2V9)L;<$V/0YAC\U%OYLT?8Y1G4?L]2)]^(^,PCI-[G,\ZB_TT M,EZCC,XUV(>%FM6K$T/5ZBYA@7%N.$P;4I`T3@^56QKELLL-T4V0)#C>YGNM M\W4^D:M7Q4S(*-79)=X"U'$;'#IR*R`"2'Z4ZRDWV4,8^->K%:*+![;5!44J M([.*.&Y3N50J)F12&W8]9)3!OK?_QA[K^]MTS*%^8?^40G%6QQ-,:UJW<.ND MHKOF./-2R>*L582SZ,R+N&)>YO8Q0"BA>5N[Q&QBX^0B:3=UE5&O4;_:UMA# M%!N15>_4"T/ZXD.5'E%L8Q"%*4%`0R7:"(&U-4X"D@Y6&:D+`A_=H#CG2N(* M*EZ+F@U2=VD<_(ER4A)7`2(Q)1SI*$7?U<`:&V4U($!2%\L%PN>;38R?T?(" MQ]5[DQ)\2>MQ0,6O-RDD0<77AX^@A5&6#IWVBPP:^`05\)T_DG4N?6"8E?1< M7+58`9>YX7%\A^)G@OR$/G7_LD%1@I*;&#T'.$O"[67D9_1^&KLY-J3,-SO]5R#;M=^5-M?+BFA+V&]4KH93`S*H_873*U6$*;LR6 M:OQ\&G':CU+.NSCR@ISI?*/@E&S/%U!_+J9N^N#+,E.VXXX[B>V) M[*9O'8B$)#0DH`"@;?6OOP5`2B3%#Y!2*V:DOD0F=A>[^\/'8O'1\Q]?`]]Y MQEP01B\Z@Z-^Q\'491ZATXO.TZ@['%W=WG8<(1'UD,\HONA0UG%^_.'O?SO_ M1[?K_(0IYDABSQDOG)OP=R)%Z-Q2"1(EFF+GU\_`Z%SV!]^?.MVNXA+N#`?( M05)R,@XEOF$\N,83%/KRHA/2KR'RR81@#Q3Q<8"I3!$DBB7B4RSO4(#%'+F@ MV$S*^5FO]W7&?*6_.')9T#ON#T[ZIR=@%UA*Q9+JY>7EZ.7DB/$ID/0'O5\_ M?AAIS2+",P^3)?'KF/M'`KM'4_;<@P(MM=L?=$\&,;E/Z)>4<,T3B3_IJ>(Q M$C@FIXS2,,AG\"3OR<4<]X"H"U28$W?)5\V49@!O$#O7G(6B.T5HOJ2>(#'6 MLJ."'*NA1%4J*4R1RES2MX94)DE)"0*$JD;L+A%X M74,L:@Z#T]/3GB[M0'MUG'-$*9-(0@_1?ZLO\SFA$Q;]"1\4]5F,\2<\<33_ M&>(N9SXNKZ4WYVR.N23@K$0ST0)F'$^@T0.&W1BMW^8<'X$),>2B(7M]#]>*"Q[SB*].G3;<$P MIU4H%;"L.:Y[!<(/??AOT'>Z3BPA^5/-;4:)HM`C4/+=`;NLTQ\0!Q-G6!+0 M>4M`IF56HOJV&:JI6KX[H)Q!9.E1<3^YGZLH'JK;H*L6R*M`]]BVSZ[$.VSB MK"HXX%J"PT@R]XO"#]9C[[^&,%%M!]\V;9M`J^8ZNX-"%;6#8TD1L(;L2;\L)N1COP]0< MXW_/IXB2/^Q7,BF&4J0&44!\383K,Q%R#'\DV??-UU6OI;]J9B_`HG3=202TO1",B5OWZ#YA'TU9,"X(!>/'%&!7/MPM)"Y')1! M3O>(1'6U+"3*243 MF!BI'+HN"_6H\`"3JAH7XG_MT+"25`K1<3\/HI5<9R78B27"]![]VKO9O-3C M=XBK->LSOL82$7\+&*Y)+,7R32,LEW5`F!95LW>PEDS\C4"M(Z\"TKJ!Q0'0 MLG"C$9K6PLJAK!>.''#,"U*:#;%50BIPLPEB#G!53H^;3X=5B[#ZT]^^`?1@ M]H(7:IOT:TCF:A*QPB67L0*.DW4X8C%F9S46M&\H0$/DH.*6S@1_[ZY^I:"%_$C M>K6<`9+T%:Y^M^YJP^UH]GWS=,/-P+I[?8/^?W/FV820?^_I!MXEIB!0/OC( M,J^98JC(I/77?1ZQ.YI_WYQ=&B@^JH%V"P%G)*<4FI-&61>\6"'EA9`VP M2M@K,+*.10_0)'S;:+EM):@BZU4#KL.Z.Q\[%=XS:LX!Y)5O"JFM_$JD![9( MKVI4QPWRJ?:X$93.9$\"3T+_`W03@&LH!)9B:[L4);(K]RO6P*^<.4UMCJ[N MT`[LL@LUIMAB[HH9UC+3L+?S:R*%T&A:+>.OZ&95*8G#))I)5-3H+^M<%?VD M(FFQM_TCXZ=;_>AU)?P0?_J],=C&J2^[D^"C!TH1$#T6;=K%85E5UP/6[/!7@4 M!@'B"WVC9U6_8Q0P/$ZD@H[?H_,03JS/H>6C4A][6HMTDL)K8<3*^)$FC@)50[M)PFF MZ8S1[:ZHVR6ZY89-Q5)Z9:LXJ3VTI,>11)T'^`L!^JR"(UHS"U139B74;QI" M'5?DO'_%W"5"A1%[C'5R'[%14%XJH!S%RHW)0QR>O0;6"*)2`14=K>*:V`&A M@K2I>C#*"WU\/\DIK`->4]D5N+Y9#\/S4ZYQ96H$S:,XP)[T1J/^:2.G$D[+ M#/J>==?S7O(]+O@K_5[7.0GFC$N'KKT45_9(F'FF[@-SM:`2%O57-^;KJD_= MP7'W9'#T*KSH4:,Z&B@#S1-,]32(^>IJ4/Y@6X$.NO[V6Z9'G4C[J5ESYWU]P1ZDM=52R>`[1I'4G..\.HFL>I:AZ#=YMHTDR+ M9BJD`";T&0M9NUTDV*+?&T&B+###.L53E9"R\X3/>8JKP!/1NY<.&@O)D2LO M.A(&^8Z>CM1;;+^5/68VC)@ZVH;RE],2M,3WU2(IKDJ$4$1DJ*A^XBR<7W3T M^XIG1.*@XYB'V\P7$`$SW2U\5T-RQS%?YX`T\QXUG1>:IWJR]JWLP6.IIC6U MF7_)B3?%-X3"<*I2D4C,'CAS,?;$TB1K\N96!8S"Q,D76;O&YHTI,`J/B:QC M;2&:=XSJ=SAB&Z+8/Q,7I]IJ7N&?:`GXU6MHR@/'$\RY M>B2&N5\*C:HF:Z=Y43^*MC=F"()('[$[H\QGT\4OR`]Q MIA/69FYEFTT;HU`$W2>8Z*DLS]XLR3=@535$AJ0IP$ON#49@4TN#$;AP-HDR MGO@!(BW<5T<7OO^(@S'FL9EE!$TL,2]9GWDL0(3^B:8,WO8'IV6FI`E:;,J@ MWR^Q(UFZ$R.62O^DU%/,S537(\S8D"W;R6QF4@JR9+!;GO?3[^W#FN83+"J&\[E/7/7U<0:Z M36<_A_[B9`"KG;

B68KCA6:Y"(:A5MW4^&-'D8('I5]8D"F`\AAX%0X-4+ M$T]S1=?W0\(Y"53_F(Q6L^A"*_XY=\*A:5*W&V6]/\48=$7HA`.I"91LU MV$I_#2?P=>6MR#$?$9BLO[S;O?_L@/\&#-EM0Z#)]6UT%N:1I._38@VV M38&M#`@3P>LG6&R"1=>A6O.:N2@=_EG2[B+86]H390"0/_2>B6!\,9QRK&D> M3/M"4ZQOVV@\EWU-@1R;N9F(739_.\WCUAIW=&C.E]C$\?5<4"YH!XXH#"[C M$6MIADB'ER7E[8J2U_#(&%)2OF-#)L@7*4B`&XOA(#V2FG%3#[&)T28#5A/. M=EI_W-CZ>IRMM/ZRJ?'U&%MFN[XV%(=G*\WS84U;WXRU9?9'^_%Q>%O3!8VY M6^:%4B@O&S>"(LZ665^%8JD#FC*WS`=F6ZX`S<(!L#97RZPN!J_0Y'HL+;,W MH:()C,M:MBUQRVS,'WF-!PV,_X1O9(@#.Y" MI))GZ%?!][EXMX%1F;W8ASMQM,E;U^?=@N17X#_MVB'F4'[B=& M[2'U$DG&7YC4YT_F1")?&_?(AO,Y9\]8@WQ+78[UN;YH#WU+PG:9D=&ZK-_^ M4NUVJDDO%RL2@%:?0U)[*NNW?]3QI-5=#0">$RJ(F]J!_^NJVT4RLVJ_9QBH M\T[W+]C3B>QE#N16I:X]U5FBYU#$\N'**,1HP-BF;&YANLC`JO?LTB-,7D&[ M,ETWA`NIGO-V9SBM>VY)NY0?89=1+U?[_*)VJ6]NC4'K!RKRC)-CB;J0E-F: MMR1NEXD_(QI"'U1[9B=I>W)+VJ7\<,Z)GZ-ZSO=V*1Z=?UL.L&L!;W[I;H.: MQI-J')^:^"5SVSMUHF7C^;M654W<&=]74*Y[HJ0T*JJ:IS/_-X$XTE\_5K;: MGK%GV/Z\7*^QI%6-(M-X6VPXA;:M#K:GH[9Z/.T\.5INQ`WC\5(E6KG8&9_+ M]TTXX`[+[*G\4HHVQ9-%-HF<#!4,*;!0TYVPP,YJK@U6:&:QM\4>*TH2#6:H MB9:9NFV".>8R7*7E=63M]`3%-FQ(S3@UFL?&%>RB)15&.["\,VDORV,H- M>#]S;\&:_D_,)15$386MZU9?TF/\(1S[Q-4GTU0*!U;'0;JYV1"V:YGP`3HU M%2H)%2\%/A,YNV)*26;N;:O_W1?%/&UI`[YV&:Y.=N8M2=<^MTOM[,*M^S@C M/,YQI)VRX14./$+IA[CXI'IKF96M?0#P:'J=)E\;'V^=AG^`.$\$>I` ML=Y['@*UIW*3T1&,0\R\T,- MMK_P%N)YSSP.`C__#U!+`0(>`Q0````(`(E\;D.TY-E*T4\``//\`@`1`!@` M``````$```"D@0````!Q:&]I+3(P,3,P.3,P+GAM;%54!0`#0C2%4G5X"P`! M!"4.```$.0$``%!+`0(>`Q0````(`(E\;D,691T':`H``(N"```5`!@````` M``$```"D@1Q0``!Q:&]I+3(P,3,P.3,P7V-A;"YX;6Q55`4``T(TA5)U>`L` M`00E#@``!#D!``!02P$"'@,4````"`")?&Y#8(C/PP\<``#DRP$`%0`8```` M```!````I('36@``<6AO:2TR,#$S,#DS,%]D968N>&UL550%``-"-(52=7@+ M``$$)0X```0Y`0``4$L!`AX#%`````@`B7QN0V'AO=+"?@``,T4'`!4`&``` M`````0```*2!,7<``'%H;VDM,C`Q,S`Y,S!?;&%B+GAM;%54!0`#0C2%4G5X M"P`!!"4.```$.0$``%!+`0(>`Q0````(`(E\;D/Z(K?I?3,``#(Q`P`5`!@` M``````$```"D@4+V``!Q:&]I+3(P,3,P.3,P7W!R92YX;6Q55`4``T(TA5)U M>`L``00E#@``!#D!``!02P$"'@,4````"`")?&Y#05:J?Q$.``!PEP``$0`8 M```````!````I($.*@$`<6AO:2TR,#$S,#DS,"YX`L` A`00E#@``!#D!``!02P4&``````8`!@`:`@``:C@!```` ` end XML 32 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8
Organization (Narrative) (Details)
 9 Months Ended
Sep. 30, 2013
Q Therapeutics, Inc. [Member]
  
Entity Information [Line Items]  
Date of incorporation (Date) Oct. 27, 2005
Q Therapeutic Products, Inc. [Member]
  
Entity Information [Line Items]  
Date of incorporation (Date) Mar. 28, 2002

XML 33 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8
Related-Party Transactions
 9 Months Ended
Sep. 30, 2013
Related Party Transactions [Abstract]  
Related-Party Transactions

7. Related Party Transactions

Between August 12 and September 30, 2013, the Company received $250,000 in cash proceeds resulting from a bridge financing by a group of note holders, which included both an officer and an affiliate. The officer has since transferred ownership of the note to an affiliate.
XML 34 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8
Significant Accounting Policies
 9 Months Ended
Sep. 30, 2013
Significant Accounting Policies [Abstract]  
Significant Accounting Policies

2. Significant Accounting Policies

The following significant accounting policies are followed by the Company in preparing its consolidated financial statements:

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of Q Therapeutics have been prepared in accordance with the instructions to Form 10-Q and, therefore, do not include all information and notes necessary for a complete presentation of financial position, results of operations, and cash flows in conformity with U.S. generally accepted accounting principles (US GAAP). This report on Form 10-Q should be read in conjunction with the Company’s annual report on Form 10-K for the year ended December 31, 2012.

The accompanying unaudited condensed consolidated balance sheets, statements of operations, and statements of cash flows reflect all normal recurring adjustments that are, in the opinion of management, necessary for a fair presentation of the Company’s financial position, results of operations and cash flows. The results of operations for the nine-month period ended September 30, 2013 are not necessarily indicative of the results to be expected for the full year ending December 31, 2013.

Basis of Consolidation

The accompanying unaudited condensed consolidated financial statements include the accounts of Q and its wholly owned subsidiary, Q Products, and Q Products’ wholly owned subsidiary, NeuroQ Research Inc. The Company is a development stage company engaged in the discovery, research, development and eventual commercialization of products as potential treatments for debilitating and fatal diseases of the CNS. All significant intercompany amounts have been eliminated.

Development Stage and Liquidity

For the period from March 28, 2002 (date of inception) through September 30, 2013, the Company has not generated significant revenues and has been developing its products. Therefore, the Company is considered to be in the development stage in accordance with the provisions of Accounting Standards Codification (ASC) Topic 915, Development Stage Entities. Cumulative amounts are presented for the period from March 28, 2002 (date of inception) through September 30, 2013. Historically, the Company has been dependent on government grants and debt and equity raised from investors to sustain its operations. The Company expects to continue to fund its operations through similar sources of capital. There can be no assurance that such capital will be available on favorable terms or at all. If it is unable to raise additional capital, the Company will likely be forced to curtail desired development activities, which will delay the development of its product candidates. The Company’s products have not been approved by the U.S. Food and Drug Administration (FDA) for commercial sale; therefore, the Company has not generated revenues from commercial therapeutic product sales. The Company has incurred losses and used cash for operating activities since inception. As of September 30, 2013, the Company had an accumulated deficit of $23,257,551.

Given the current pace of pre-clinical and clinical development of its product candidates, management believes that the Company has sufficient resources to fund the Company’s operations through at least December 31, 2013. However, the Company will require additional cash resources during the first quarter of 2014. The Company is working to raise capital through the sale of common stock and filed a registration statement on June 20, 2013 with the Securities and Exchange Commission registering the offering and sale of 5,000,000 shares of its common stock with warrants to purchase up to 1,250,000 shares of common stock. The Company has not raised any capital through the sale of common stock during 2013.

 

Use of Estimates

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Accordingly, actual results could differ from those estimates. Key estimates include allowances for doubtful accounts receivable, useful lives for property and equipment, valuation allowances for net deferred income tax assets, and valuations for stock-based compensation awards. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances.

Revenue Recognition and Grants Receivable

The Company periodically applies for research grants, including as a sub-recipient to grants funded by government agencies through research universities. Grant revenues are recognized as associated expenses are incurred and are billed in conjunction with the terms of the grants. The Company records its grants receivable in accordance with the provisions of the grant agreements. The Company’s grants receivable are considered past due when payment has not been received within 30 days of the invoice date, although certain institutions customarily do not pay within 30 days of the invoice date. The amounts of the specific reserves are estimated by management based on various assumptions including the age of the individual receivable, as well as changes in payment schedules and histories. Grants receivable balances are charged off against the allowance for doubtful accounts when management determines the potential for recovery is remote. Recoveries of receivables previously charged off are recorded when payment is received. For the nine months ended September 30, 2013, revenues were derived from two customers.

In December 2012, the Company was notified of a sub-award as part of grant funding awarded to The Johns Hopkins University (JHU) from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health. The sub-award for the 2012-2013 grant plan year is $631,383. In May 2013, JHU applied for, and was granted a six-month extension for completing the analysis and remitting data and expenses. As of September 30, 2013, $491,588 has been invoiced under the sub-award and $3,667 is included in the grants receivable balance. The balance outstanding is expected to be paid upon the completion of the extension.

Stock-Based Compensation

The Company calculates the estimated fair value of its stock options and warrants on the grant date using the Black-Scholes option-pricing model. The Company recognizes stock-based compensation expense as services are provided, which is generally over the vesting period of the individual equity instruments. Expense related to stock options issued in lieu of cash to non-employees for services performed are measured at the fair value of the options on the date they are earned.

The volatility assumption used in the Black-Scholes option-pricing model is based on the volatility of publicly traded companies in the same industry segment as the Company. The expected lives of the options and warrants granted represent the periods of time that the options granted are expected to be outstanding. The risk free rates for periods within the contractual lives of the options and warrants are based on the U.S. treasury securities constant maturity rate that corresponds to the expected terms in effect at the time of grant. Stock-based compensation is included in general and administrative expense in the statements of operations.

Net Loss Per Common Share

Basic net income or loss per common share (Basic EPS) is computed by dividing net income or loss by the weighted average number of common shares outstanding. Diluted net income or loss per common share (Diluted EPS) is computed by dividing net income or loss by the sum of the weighted average number of common shares outstanding and the dilutive potential common share equivalents then outstanding. Potential dilutive common share equivalents consist of shares issuable upon the exercise of outstanding stock options and warrants to acquire common stock.

Due to the fact that for all periods presented the Company has incurred net losses, potential dilutive common share equivalents as of September 30, 2013 and 2012, totaling 16,107,458 and 15,072,509, respectively, are not included in the calculation of Diluted EPS because they are anti-dilutive. Therefore, basic net loss per common share is the same as diluted net loss per common share for the three and nine months ended September 30, 2013 and 2012.

Recent Accounting Pronouncements

The Company has reviewed accounting pronouncements that become effective subsequent to September 30, 2013 and does not believe the future adoption of those pronouncements will have a material impact on the Company’s financial position, results of operations or liquidity.
XML 35 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 36 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8
Notes Payable (Narrative) (Details) (USD $)
 9 Months Ended 138 Months Ended
Sep. 30, 2013
Sep. 30, 2013
Notes Payable [Abstract]    
Note payable, cash proceeds $ 250,000 $ 5,507,562
Note payable, percentage of face value at issuance (in Percent) 50.00% 50.00%
Note payable, annual interest rate (in Percent) 8.00% 8.00%
Note payable, maturity date (in Date) Feb. 05, 2014  
Notes payable 500,000 500,000
Note payable, interest recorded 65,942  
Note payable, prepaid financing costs to be amortized over remaining term 188,333 188,333
Note payable, payments toward principal or interest $ 0  
Note payable, nominal effective interest rate (in Percent) 156.00% 156.00%
XML 37 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stockholders' Equity (Tables)
 9 Months Ended
Sep. 30, 2013
Stockholders' Equity [Abstract]  
Summary of Outstanding Common Stock Options and Related Activity

The following summarizes the outstanding common stock options and related activity for the nine months ended September 30, 2013:

 

            Weighted  
     Number of      Average Exercise  
     Options      Price Per Share  

Outstanding as of December 31, 2012

      3,865,440       $ 0.34   

Granted

      —           —     

Exercised

      —           —     

Forfeited

      —           —     
  

 

 

     

Outstanding as of September 30, 2013

      3,865,440         0.34   
  

 

 

     

Exercisable as of September 30, 2013

      3,388,773         0.25   
  

 

 

     

Summary of Stock Options Outstanding

The following summarizes information about stock options outstanding as of September 30, 2013:

 

        Weighted            
        Average   Weighted       Weighted
    Numbers of   Remaining   Average   Number of   Average
Exercise   Options   Contractual   Price   Options   Price

Price

  

Outstanding

  

Life (Years)

  

Exercise

  

Exercisable

  

Exercise

$0.06 – $0.08   902,600   5.58   $0.08   902,600   $0.08
$0.15 – $0.19   2,072,840   5.70   0.17   2,072,840   0.17
$1.00   890,000   8.34   1.00   413,333   1.00
 

 

      

 

  
  3,865,440   6.28   0.34   3,388,773   0.25
 

 

      

 

  

XML 38 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stockholders' Equity (Summary of Stock Options Outstanding) (Details) (USD $)
 9 Months Ended
Sep. 30, 2013
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]  
Number of Options Outstanding, exercise price range (in Shares) 3,865,440
Weighted Average Remaining Contractual Life (Years) (in Duration) 6 years 3 months 11 days
Weighted Average Price Exercise, exercise price range, stock options outstanding (in Dollars per Share) $ 0.34
Number of Options Exercisable, exercise price range (in Shares) 3,388,773
Weighted Average Price Exercise, exercise price range, options exercisable (in Dollars per Share) $ 0.25
$0.06 - $0.08 [Member]
  
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]  
Exercise Price, stock options, lower limit (in Dollars per Share) $ 0.06
Exercise Price, stock options, upper limit (in Dollars per Share) $ 0.08
Number of Options Outstanding, exercise price range (in Shares) 902,600
Weighted Average Remaining Contractual Life (Years) (in Duration) 5 years 6 months 29 days
Weighted Average Price Exercise, exercise price range, stock options outstanding (in Dollars per Share) $ 0.08
Number of Options Exercisable, exercise price range (in Shares) 902,600
Weighted Average Price Exercise, exercise price range, options exercisable (in Dollars per Share) $ 0.08
$0.15 - $0.19 [Member]
  
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]  
Exercise Price, stock options, lower limit (in Dollars per Share) $ 0.15
Exercise Price, stock options, upper limit (in Dollars per Share) $ 0.19
Number of Options Outstanding, exercise price range (in Shares) 2,072,840
Weighted Average Remaining Contractual Life (Years) (in Duration) 5 years 8 months 12 days
Weighted Average Price Exercise, exercise price range, stock options outstanding (in Dollars per Share) $ 0.17
Number of Options Exercisable, exercise price range (in Shares) 2,072,840
Weighted Average Price Exercise, exercise price range, options exercisable (in Dollars per Share) $ 0.17
Exercise Price $1.00 [Member]
  
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]  
Exercise Price, stock options, upper limit (in Dollars per Share) $ 1.00
Number of Options Outstanding, exercise price range (in Shares) 890,000
Weighted Average Remaining Contractual Life (Years) (in Duration) 8 years 4 months 2 days
Weighted Average Price Exercise, exercise price range, stock options outstanding (in Dollars per Share) $ 1.00
Number of Options Exercisable, exercise price range (in Shares) 413,333
Weighted Average Price Exercise, exercise price range, options exercisable (in Dollars per Share) $ 1.00
XML 39 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stockholders' Equity (Narrative) (Details) (USD $)
 3 Months Ended 9 Months Ended 138 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Dec. 31, 2012
Stock issued in lieu of cash for services     $ 175,000 $ 10,000 $ 331,750  
Common stock, shares outstanding (in Shares) 24,936,833   24,936,833   24,936,833 24,761,832
Stock-based compensation 25,439 40,445 76,316 95,912 508,117  
Investor and Public Relations Firm [Member]
            
Stock issued in lieu of cash for services (in Shares)     75,001      
Stock issued in lieu of cash for services     75,001      
Licensing Agreement with Collaborative Partner [Member]
            
Stock issued in lieu of cash for services (in Shares)     100,000      
Stock issued in lieu of cash for services     100,000      
Service agreement [Member]
            
Warrants issued to purchase shares of common stock, term (in Duration)     2 years      
Service agreement - First tranche of warrants issued [Member] | January 1, 2013 [Member]
            
Number of warrants issued (in Warrants)     62,500      
Exercise price of warrants (in Dollars per Unit) 1.25   1.25   1.25  
Service agreement - Second tranche of warrants issued [Member] | April 1, 2013 [Member]
            
Number of warrants issued (in Warrants)     62,500      
Exercise price of warrants (in Dollars per Unit) 1.75   1.75   1.75  
Service agreement - Third tranche of warrants issued [Member] | July 1, 2013 [Member]
            
Number of warrants issued (in Warrants)     62,500      
Exercise price of warrants (in Dollars per Unit) 2.25   2.25   2.25  
Warrants [Member]
            
Number of warrants issued (in Warrants)     12,242,018      
Weighted average warrant exercise price (in Dollars per Unit) 1.40   1.40   1.40  
Warrants, weighted average remaining life (in Duration)     4 years 8 months 12 days      
Minimum [Member] | Service agreement [Member]
            
Exercise price of warrants (in Dollars per Unit) 1.25   1.25   1.25  
Minimum [Member] | Warrants [Member]
            
Warrants issued to purchase shares of common stock, term (in Duration)     2 years      
Exercise price of warrants (in Dollars per Unit) 0.046   0.046   0.046  
Maximum [Member] | Service agreement [Member]
            
Warrants approved for issuance (in Warrants)     250,000      
Exercise price of warrants (in Dollars per Unit) 2.75   2.75   2.75  
Maximum [Member] | Warrants [Member]
            
Warrants issued to purchase shares of common stock, term (in Duration)     7 years      
Exercise price of warrants (in Dollars per Unit) 2.25   2.25   2.25  
Stock Options [Member]
            
Aggregate intrinsic value of outstanding and exercisable stock options 2,549,625   2,549,625   2,549,625  
Unrecognized stock-based compensation expense related to non-vested awards $ 219,439   $ 219,439   $ 219,439  
Unrecognized stock-based compensation expense related to non-vested awards, weighted-average period of recognition (in Duration)     2 years 3 months 18 days      
Equity Incentive Compensation Plan [Member]
            
Additional shares authorized (in Shares)     3,000,000      
Percent of issued and outstanding voting capital stock to approve share increase (in Percent)     69.00%      
Common shares authorized and reserved (in Shares) 3,987,529   3,987,529   3,987,529  
Equity Incentive Compensation Plan [Member] | Minimum [Member]
            
Shares authorized for issuance (in Shares) 1,877,529   1,877,529   1,877,529  
Equity Incentive Compensation Plan [Member] | Maximum [Member]
            
Shares authorized for issuance (in Shares) 4,877,529   4,877,529   4,877,529  
XML 40 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8
Document and Entity Information
 9 Months Ended
Sep. 30, 2013
Nov. 14, 2013
Document and Entity Information [Abstract]    
Entity Registrant Name Q Therapeutics, Inc.  
Entity Central Index Key 0001366541  
Document Type 10-Q  
Document Period End Date Sep. 30, 2013  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Entity Well-known Seasoned Issuer No  
Entity Voluntary Filer No  
Entity Current Reporting Status Yes  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   24,936,833
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2013  
XML 41 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stockholders' Equity (Summary of Outstanding Common Stock Options and Related Activity) (Details) (Stock Options [Member], USD $)
 9 Months Ended
Sep. 30, 2013
Stock Options [Member]
  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Number of Options Outstanding, begining balance (in Shares) 3,865,440
Number of Options, Granted (in Shares)   
Number of Options, Exercised (in Shares)   
Number of Options, Forfeited (in Shares)   
Number of Options Outstanding, ending balance (in Shares) 3,865,440
Number of Options, Exercisable, ending balance (in Shares) 3,388,773
Weighted Average Exercise Price Per Share, Outstanding, begining balance (in Dollars per Share) $ 0.34
Weighted Average Exercise Price Per Share, Granted (in Dollars per Share)   
Weighted Average Exercise Price Per Share, Exercised (in Dollars per Share)   
Weighted Average Exercise Price Per Share, Forfeited (in Dollars per Share)   
Weighted Average Exercise Price Per Share, Outstanding, ending balance (in Dollars per Share) $ 0.34
Weighted Average Exercise Price Per Share, Exercisable, ending balance (in Dollars per Share) $ 0.25